

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: US PATENT NO. 6,573,293
ISSUED: JUNE 3, 2003
TO: PENG CHO TANG, ET AL.

FOR: PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS

FROM: US APPLICATION NO. 09/783,264
OF: FEBRUARY 15, 2001
ASSIGNEES SUGEN, INC.
PHARMACIA & UPJOHN COMPANY

Mail Stop Hatch-Waxman PTE
Office of Patent Legal Administration
Room MDW 7D55
600 Dulany Street (Madison Building)
Alexandria, VA 22314

RECEIVED
JUL 17 2009

PATENT EXTENSION
OPLA

Transmittal Letter for Application for Extension of
Patent Term Under 35 U.S.C. § 156

Dear Sir:

Transmitted herewith is the application of Sugen, Inc. and Pharmacia & Upjohn Company LLC, dated July 16, 2009, for extension of the term of United States Patent No. 6,573,293 under 35 U.S.C. § 156, together with four duplicate copies of the papers thereof, certified as such.

Please charge the sum of \$1,120.00 to Deposit Account No. 16-1445 (fee code 1457). Please also charge any additional fees which may be required by the filing of this application for Extension of Patent Term, or credit any overpayment, to Deposit Account No. 16-1445. Four copies of this paper are enclosed.

Dated: July 16, 2009

02/22/2010 RLOGAN 00000001 161445 09783264
Timothy J. Gumbleton
Agent for Applicant
Registration No. 54,143

Patent Department
Pfizer Inc.
7000 Portage Road
Kalamazoo, Michigan 49001
(269) 833-2501

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: US PATENT NO. 6,573,293
ISSUED: JUNE 3, 2003
TO: PENG CHO TANG, ET AL.

FOR: PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS

FROM: US APPLICATION NO. 09/783,264
OF: FEBRUARY 15, 2001
ASSIGNEES SUGEN, INC.
PHARMACIA & UPJOHN COMPANY

Mail Stop Hatch-Waxman PTE
Office of Patent Legal Administration
Room MDW 7D55
600 Dulany Street (Madison Building)
Alexandria, VA 22314

RECEIVED

JUL 17

PATENT EXTENSION
OPLACertification of Copies

Dear Sir:

I hereby certify that attached hereto are four duplicate copies of the application papers of Sugen, Inc. and Pharmacia & Upjohn Company LLC, dated July 16, 2009, for extension of the term of United States Patent No. 6,573,293 under 35 U.S.C. § 156.

Dated:

July 16, 2009

Timothy Gumbleton
Timothy J. Gumbleton
Agent for Applicant
Registration No. 54,143

Patent Department
Pfizer Inc.
7000 Portage
Kalamazoo, Michigan 49001
(269) 833-2501

RECEIVED

JUL 17 2009

PATENT EXTENSION
OPLA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: US PATENT NO. 6,573,293
ISSUED: JUNE 3, 2003
TO: PENG CHO TANG, ET AL.
FOR: PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS
FROM: US APPLICATION NO. 09/783,264
OF: FEBRUARY 15, 2001
ASSIGNEES SUGEN, INC.
PHARMACIA & UPJOHN COMPANY

RECEIVED
JUL 17 2009
PATENT EXTENSION
OPLA

Mail Stop Hatch-Waxman PTE
Office of Patent Legal Administration
Room MDW 7D55
600 Dulany Street (Madison Building)
Alexandria, VA 22314

RECEIVED
JUL 17
PATENT EXTENSION
OPLA

APPLICATION FOR EXTENSION
OF THE TERM OF UNITED STATES
PATENT NO. 6,573,293 UNDER 35 U.S.C. §156

Sir:

Transmitted herewith is the application of Sugen, Inc., a Delaware corporation having its principle place of business at 235 East 42nd Street, New York, NY, 10017, and Pharmacia & Upjohn Company LLC, a Delaware Limited Liability Company having its principle place of business at 7000 Portage Road, Kalamazoo, MI 49001, dated July 16, 2009, for extension of the term of United States Patent No. 6,573,293 under 35 U.S.C. § 156, which is currently set to expire on February 15, 2021, based on the materials provided herein and in the accompanying papers. Pursuant to the provisions of 37 C.F.R. §1.730, an extension of the term of 827 days is applied for. If this extension is granted, such patent would not expire until May 22, 2023. In the materials set forth herein, paragraph numbers correspond to paragraph numbers in 37 C.F.R. § 1.740(a).

(1) The approved product, PALLADIA[®], is comprised of the phosphate salt of the active ingredient, toceranib.

Generic Name: toceranib

Chemical Name: (Z)-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide


This compound is also known by an alternate chemical name:

5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-yldenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide

Molecular Formula: C₂₂H₂₅FN₄O₂H₃O₄P

Molecular Weight: 494.46

Structural Formula of the phosphate salt of the active ingredient, toceranib:



(2) PALLADIA® was subject to regulatory review under subsection 512 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. §360(b)) under INAD Application No. 10-910.

(3) PALLADIA® received permission for commercial marketing or use under subsection 512 of the Food, Drug and Cosmetic Act, 21 U.S.C. §360(b), on May 22, 2009, under New Animal Drug Application (NADA) File No. NADA 141-295.

(4) The active ingredient in PALLADIA® is toceranib, which is present in PALLADIA® as its phosphate salt, and is described above in (1). Neither toceranib phosphate nor any other salt of toceranib nor any esters of toceranib has been previously approved for commercial marketing or use under the Federal Food, Drug and Cosmetic Act, the Public Health Service Act or the Virus-Serum-Toxin Act.

(5) This application is being submitted within the sixty day period permitted for its submission pursuant to 37 C.F.R. § 1.270(f). The last day on which this application could be submitted is July 20, 2009.

(6) The patent for which an extension is being sought is identified as follows:

U.S. Patent No.: 6,573,293

TITLE: PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN
KINASE INHIBITORS

ISSUED: June 3, 2003

EXPIRES: February 15, 2021

INVENTORS: Peng Cho Tang
Todd A. Miller
Xiaoyuan Li
Li Sun
Chung Chen Wei
Shahrzad Shirazian
Congxin Liang
Tomas Vojkovsky
Asaad S. Nematalla
Michael Hawley


(7) A copy of United States Patent No. 6,573,293, the patent for which an extension is being sought, is attached hereto as Exhibit A. A copy of the assignment (Recordation Date: November 15, 2001; Reel/Frame: 012310/0844) is appended hereto as Exhibit B. The assignees of record are Sugen, Inc. and Pharmacia & Upjohn Company. As shown in the certificate of conversion dated August 13, 2004 included in Exhibit C, Pharmacia & Upjohn Company, a Delaware corporation, converted to Pharmacia & Upjohn Company LLC, a Delaware limited liability company. Also included in Exhibit C is a certificate stating that both Sugen, Inc. and Pharmacia & Upjohn Company LLC are indirectly wholly owned subsidiaries of Pfizer Inc.

(8) No certificates of correction, disclaimers, or reexamination certificates have been filed. A maintenance fee for United States Patent No. 6,573,293 was timely paid on November 16, 2006. The maintenance fee statement is appended hereto as Exhibit D. The next maintenance fee payment is due December 3, 2010.

(9) United States Patent No. 6,573,293 claims the active ingredient (toceranib) of the approved product, compositions containing the active ingredient, and methods of using the active ingredient.

Claim 1 of U.S. Patent 6,573,293 reads

“A compound of Formula (I):



wherein:

R¹ is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, -(CO)R¹⁵, -NR¹³R¹⁴, -(CH₂)_rR¹⁶ and -C(O)NR⁸R⁹;

R² is selected from the group consisting of hydrogen, halo, alkyl, trihalomethyl, hydroxy, alkoxy, cyano, -NR¹³R¹⁴, -NR¹³C(O)R¹⁴, -C(O)R¹⁵, aryl, heteroaryl, and -S(O)₂NR¹³R¹⁴;

R³ is selected from the group consisting of hydrogen, halogen, alkyl, trihalomethyl, hydroxy, alkoxy, -(CO)R¹⁵, -NR¹³R¹⁴, aryl, heteroaryl, -NR¹³S(O)₂R¹⁴, -S(O)₂NR¹³R¹⁴, -NR¹³C(O)R¹⁴, -NR¹³C(O)OR¹⁴ and -SO₂R²⁰ (wherein

R²⁰ is alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl);

R⁴ is selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy and -NR¹³R¹⁴;

R⁵ is selected from the group consisting of hydrogen and alkyl;

R⁶ is -C(O)R¹⁰ wherein R¹⁰ is -NR¹¹(CH₂)_nR¹²

wherein:

R^{11} is hydrogen or lower unsubstituted alkyl;
 n is 2 or 3; and
 R^{12} is $-NR^{13}R^{14}$ or $-N^+(O)R^{13}R^{14}$;
 R^7 is selected from the group consisting of hydrogen, alkyl, aryl and heteroaryl;
 R^8 and R^9 are independently selected from the group consisting of hydrogen, alkyl and aryl;
 R^{13} and R^{14} are independently selected from the group consisting of hydrogen, alkyl, lower alkyl substituted with hydroxy, alkylamino, cyanoalkyl, cycloalkyl, aryl and heteroaryl; or
 R^{13} and R^{14} may combine to form a heterocyclo group;
 R^{15} is selected from the group consisting of hydrogen, hydroxy, alkoxy and aryloxy;
 R^{16} is selected from the group consisting of hydroxy, $-C(O)R^{15}$, $-NR^{13}R^{14}$ and $-C(O)NR^{13}R^{14}$; and
 r is 1, 2, 3, or 4;
or a pharmaceutically acceptable salt thereof."

Claim 1 reads on toceranib, including its phosphate salt, wherein

R^1 is hydrogen;
 R^2 is halo (specifically fluorine (F));
 R^3 is hydrogen;
 R^4 is hydrogen;
 R^5 is alkyl (specifically CH_3);
 R^6 is $-C(O)R^{10}$, wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$;
 R^{11} is hydrogen;
 n is 2;
 R^{12} is $-NR^{13}R^{14}$
 R^7 is alkyl (specifically CH_3);
 R^{13} and R^{14} combine to form a heterocyclo group (specifically pyrrolidine); and
the salt is the phosphate salt.

Claim 1 therefore claims the active ingredient (toceranib, including its phosphate salt) of PALLADIA® and reads on the approved product.

Claim 5 reads on toceranib because it specifically shows the chemical structure at column 249, lines 52-65.

Claim 7 of U.S. Patent 6,573,293 claims the compounds of the formula of claim 1 in which the definitions of R¹, R², R³, R⁴, R⁵, and R⁷ are the same as defined for claim 1, but the definitions of R⁶, R¹⁰, R¹¹, n, R¹², R¹³, and R¹⁴ are narrowed. In the narrowed definitions,

R⁶ is $-\text{C}(\text{O})\text{R}^{10}$, wherein R¹⁰ is $-\text{NR}^{11}(\text{CH}_2)_n\text{R}^{12}$;

R¹¹ is hydrogen;

n is 2; and

R¹² is $-\text{NR}^{13}\text{R}^{14}$, wherein R¹³ and R¹⁴ combine to form $-(\text{CH}_2)_4-$.

Claim 7 therefore claims the active ingredient (toceranib, including its phosphate salt) of PALLADIA® and reads on the approved product.

Claim 8 of U.S. Patent 6,573,293 claims the compounds of the formula of claim 1 in which the definitions of R¹, R², R³, R⁴, R⁵, R⁷, R¹⁰, R¹¹, n, R¹², R¹³, and R¹⁴ are the same as defined for claim 1, but the definition of R⁶ is narrowed. In the narrowed definition,

R⁶ is 2-pyrrolidin-1-ylethylamino-carbonyl.

Claim 8 therefore claims the active ingredient (toceranib, including its phosphate salt) of PALLADIA® and reads on the approved product.

Claim 9 of U.S. Patent 6,573,293 claims the compounds of the formula of claim 1 in which the definitions of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R¹⁰, R¹¹, n, R¹², and R¹³ are the same as defined for claim 1, but the definition of R¹⁴ is narrowed. In the narrowed definition,

R¹⁴ is lower alkyl substituted with heteroalicyclic.

Claim 9 therefore claims the active ingredient (toceranib, including its phosphate salt) of PALLADIA® and reads on the approved product.

Claim 10 of U.S. Patent 6,573,293 claims the compounds of the formula of claim 1 in which the definitions of R¹, R², R³, R⁴, R⁵, R⁶, R¹⁰, and R⁷ are the same as defined for claim 1, but the definitions of R¹¹, n, R¹², R¹³, and R¹⁴ are narrowed. In the narrowed definitions,

R¹¹ is hydrogen;

n is 2; and

R¹² is –NR¹³R¹⁴, wherein R¹³ and R¹⁴ combine to form a heterocycle.

Claim 10 therefore claims the active ingredient (toceranib, including its phosphate salt) of PALLADIA® and reads on the approved product.

Claim 14 of U.S. Patent 6,573,293 claims the compounds of the formula of claim 1 in which the definitions of R⁵, R⁶, R⁷, R¹⁰, R¹¹, n, R¹², R¹³, and R¹⁴ are the same as defined for claim 1, but the definitions of R¹, R², R³, and R⁴, are narrowed. In the narrowed definitions,

R¹ is hydrogen;

R² is halo (specifically fluorine (F));

R³ is hydrogen; and

R⁴ is hydrogen.

Claim 14 therefore claims the active ingredient (toceranib, including its phosphate salt) of PALLADIA® and reads on the approved product.

Claim 17 of U.S. Patent 6,573,293 claims the compounds of the formula of claim 1 in which the definitions of R¹, R², R³, R⁴, R⁶, R¹⁰, R¹¹, n, R¹², R¹³, and R¹⁴ are the same as defined for claim 1, but the definitions of R⁵ and R⁷ are narrowed. In the narrowed definitions,

R⁵ is methyl; and

R⁷ is methyl.

Claim 17 therefore claims the active ingredient (toceranib, including its phosphate salt) of PALLADIA® and reads on the approved product.

Claim 18 of U.S. Patent 6,573,293 claims the compounds of the formula of claim 1 in which the definitions of R⁵, R⁶, R⁷, R¹⁰, R¹¹, n, R¹², R¹³, and R¹⁴ are the same as

defined for claim 1, but the definitions of R¹, R², R³, and R⁴, are narrowed. In the narrowed definitions,

R¹ is hydrogen;

R² is fluoro;

R³ is hydrogen; and

R⁴ is hydrogen.

Claim 18 therefore claims the active ingredient (toceranib, including its phosphate salt) of PALLADIA® and reads on the approved product.

Claim 19 of U.S. Patent 6,573,293 claims the compounds of the formula of claim 1 in which the definitions of R⁵, R⁶, R⁷ R¹⁰, R¹¹, n, R¹², R¹³, and R¹⁴ are the same as defined for claim 1, but the definitions of R¹, R², R³, and R⁴, are narrowed. In the narrowed definitions,

R¹ is hydrogen;

R² is fluoro;

R³ is hydrogen; and

R⁴ is hydrogen.

Claim 19 therefore claims the active ingredient (toceranib, including its phosphate salt) of PALLADIA® and reads on the approved product.

Claim 20 of U.S. Patent 6,573,293 claims a pharmaceutical composition which comprises a compound or salt of claim 1 and a pharmaceutically acceptable carrier or excipient. Thus, claim 20 embraces a pharmaceutical composition containing toceranib, including its phosphate salt, and reads on the approved product.

Claim 21 of U.S. Patent 6,573,293 claims a pharmaceutical composition which comprises a compound or salt of claim 5 and a pharmaceutically acceptable carrier or excipient. Thus, claim 21 embraces a pharmaceutical composition containing toceranib, including its phosphate salt, and reads on the approved product.

Claim 22 of U.S. Patent 6,573,293 claims a method for the modulation of the catalytic activity of a protein kinase, comprising contacting said protein kinase with a

compound or salt of claim 1 or 5. Hence, claim 22 embraces the use of toceranib, including its phosphate salt, and reads on an approved use of the product.

Claim 23 of U.S. Patent 6,573,293 claims the method of claim 22 but narrows the definition of a protein kinase. In the narrowed definition the protein kinase is a receptor tyrosine kinase. Hence, claim 23 embraces the use of toceranib, including its phosphate salt, and reads on an approved use of the product.

Claim 24 of U.S. Patent 6,573,293 reads

“A method for treating or preventing a protein kinase related disorder in an organism comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound or salt of claim 20 or claim 21 and, a pharmaceutically acceptable carrier or excipient to said organism.”

Claim 24 encompasses toceranib because it depends from claim 20 or 21. Claims 20 and 21 depend from claim 1 and claim 5, respectively. PALLADIA® Tablets are approved for the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs. This indication is encompassed by the phrase in claim 24 of “a protein kinase related disorder in an organism.” Therefore, claim 24 embraces the use of toceranib, including its phosphate salt, and reads on an approved use of the product.

Claim 25 of U.S. Patent 6,573,293 claims the method of claim 24 but narrows the definition of a protein kinase related disorder. In the narrowed definition the protein kinase related disorder is a receptor tyrosine kinase related disorder. Hence, claim 25 embraces the use of toceranib, including its phosphate salt, and reads on an approved use of the product.

Claim 26 of U.S. Patent 6,573,293 claims the method of claim 24 but narrows the definition of a protein kinase related disorder. In the narrowed definition the protein kinase related disorder is PGDFR related disorder or a flk related disorder. Hence, claim 26 embraces the use of toceranib, including its phosphate salt, and reads on an approved use of the product.

(10) (A) An exemption under subsection (j) of section 512 of the Federal Food, Drug and Cosmetic Act became effective for PALLADIA® on November 23, 2001 following submission of Investigational New Animal Drug (“INAD”) Application No. 10-910 on August 27, 2001.

(B) A New Animal Drug Application (“NADA”) under section 512 of the Federal Food, Drug and Cosmetic Act for PALLADIA® was initially submitted on April 22, 2009 as NADA No. 141-295.

(C) NADA No. 141-295 was approved on May 22, 2009.

(11) A brief description of the significant activities undertaken by or for the marketing applicant during the applicable regulatory review period with respect to the approved product and the significant dates applicable to such activities is attached hereto as Exhibit E.

(12) It is Applicant's opinion that United States Patent No. 6,573,293 is eligible for an extension of its term, under 35 U.S.C. §156. The length of the extension claimed is 827 days. If this extension is granted, the term of such patent, which is currently set to expire on February 15, 2021 (see paragraph 6), would not expire until May 22, 2023.

A) The requirements of 35 U.S.C. § 156(a) and 156(c)(4) have been satisfied as follows:

1. U.S. Patent No. 6,573,293 claims the active ingredient of PALLADIA®, which is toceranib. Toceranib is present in PALLADIA® as its phosphate salt.
2. U.S. Patent No. 6,573,293 is currently set to expire on February 15, 2021 (i.e., the term of the patent has not yet expired).
3. The term of U.S. Patent No. 6,573,293 has never been extended under subsection (e)(1) of 35 U.S.C. § 156.
4. This application for extension is being submitted by Sugen, Inc. and Pharmacia & Upjohn Company LLC, the owners (see Section 7 above) of U.S. Patent No 6,573,293, by their agent, in accordance with the requirements of paragraphs (1) through (4) of 35 U.S.C. § 156(d).
5. The product PALLADIA® (comprising toceranib as its phosphate salt), has been subject to a regulatory review period under section 512 of the Federal Food, Drug and Cosmetic Act before its commercial marketing or use, and permission for said commercial marketing or use is the first permitted commercial marketing or use under section 512 of the Federal Food, Drug and Cosmetic Act.
6. No patent that claims toceranib in its free form or any salt or ester thereof, or a method of making or using toceranib has to this date been extended, nor has any other extension been applied for, under subsection (e)(1) of 35 U.S.C. § 156, for the regulatory review period which forms the basis for this application for the extension of the term of U.S. Patent No. 6,573,293.

B) The length of extension of the term of U.S. Patent No. 6,573,293 of 827 days claimed by Applicant is determined according to the provisions of 37 CFR § 1.778 as follows:

1. According to 37 CFR § 1.778(b), the length of extension is equal to the regulatory review period for the approved product, reduced as appropriate according to paragraphs (d)(1) through (d)(6) 37 CFR § 1.778.
2. According to 37 CFR § 1.778(c), the regulatory review period is the sum of
 - (a) The number of days in the period beginning on the earlier of the date of a major health or environmental effects test on the drug was initiated or the date on which an exemption under subsection (j) of section 512 of the Federal Food, Drug and Cosmetic Act became effective for the approved animal drug and ending on the date the NADA for the approved product was initially submitted under section 512 of the Federal Food, Drug and Cosmetic Act, and
 - (b) The number of days in the period beginning on the date the NADA was initially submitted under subsection (j) of section 512 of the Federal Food, Drug and Cosmetic Act and ending on the date the NADA was approved.

The exemption under subsection (j) of section 512 became effective on November 23, 2001. NADA No. 141-295 was submitted to the FDA on April 22, 2009. As indicated in paragraph 10 (C), NADA No. 141-295 was approved on May 22, 2009. This application for extension of the term of U.S. Patent 6,573,293 is based on the regulatory review period that ended with the approval of NADA No. 141-295 on May 22, 2009. Therefore, the length of the regulatory review period under 37 CFR § 1.778(c) is the sum of the period from November 23, 2001 to April 22, 2009, and from April 22, 2009 to May 22, 2009. This is the sum of 2708 days and 31 days, which is 2739 days.

3. According to 37 CFR § 1.778(d)(1)(i), the number of days in the regulatory review period which were on or before the date on which the patent issued must be subtracted from the number of days in the regulatory review period. U.S. Patent No. 6,573,293 issued on June 3, 2003. The number of days in the regulatory review period was 2739 days. Subtraction of the period on or before the patent issued (558 days) from the regulatory review period (2739 days) leaves a reduced regulatory period of 2181 days. Thus, the length of the regulatory review period under 37 CFR § 1.778(d)(1)(i) is the sum of the period from June 4, 2003 (beginning the day after the date on which the patent issued) to April 22, 2009 and from April 22, 2009 to May 22, 2009. This is the sum of 2150 days and 31 days, which is 2181 days.
4. 37 C.F.R. §1.778(d)(1)(ii) does not apply.
5. Under 37 CFR § 1.778(d)(1)(iii), the regulatory review period must be reduced by one-half of the period determined under 37 CFR § 1.778(c)(1) after that period is reduced in accordance with paragraph (d)(1)(i). One-half of 2150 days is 1075 days. Subtracting this amount (1075 days), ignoring half days in the subtraction if any, from 2181 days (the portion of the regulatory review period that occurred after issuance of the patent) leaves a reduced regulatory review period of 1106 days. (37 CFR § 1.778(d)(1)(iii)).
6. According to 37 CFR § 1.778(d)(2), the reduced regulatory review period of 1106 days is added to the expiration date of U.S. Patent No. 6,573,293 (February 15, 2021) to give an extended expiration date of February 26, 2024 (37 CFR § 1.778(d)(2)).
7. According to 37 CFR § 1.778(d)(3), when 14 years is added to the date of approval of the NADA application under section 512 of the Federal Food, Drug and Cosmetic Act, (May 22, 2009), this gives a date of May 22, 2023 (37 CFR § 1.778(d)(3)).
8. According to 37 CFR § 1.778(d)(4), by comparing the dates for the ends of the periods obtained pursuant to paragraphs (d)(2) and (d)(3)

and selecting the earlier date, the date for extended expiration of U.S. Patent No. 6,573,293 is May 22, 2023.

9. The five-year limitation of 35 U.S.C. §156(g)(6)(A) and 37 CFR § 1.778(d)(5) applies to this application, because U.S. Patent No. 6,573,293 issued after the enactment of the Generic Animal Drug and Patent Term Restoration Act (November 16, 1988). When 5 years is added to the expiration of U.S. Patent No. 6,573,293 (February 15, 2021), this gives a date of February 15, 2026. This date is later than the date obtained according to 37 CFR § 1.778(d)(4).

Therefore, under 37 CFR § 1.778(d)(5), Applicant is entitled to an extension corresponding to the period of from February 15, 2021 to May 22, 2023. This is 827 days, which is the length of extension being claimed. Hence, Applicant is in compliance with 35 U.S.C. §156(g)(6)(A) and 37 CFR § 1.778(d)(5).

(13) Applicant acknowledges a duty to disclose to the Commissioner of Patent and Trademarks and the Secretary of Health and Human Services any information, which is material to the determination of entitlement to the 827-day extension being sought to the term of the United States Patent No. 6,573,293.

(14) The prescribed fee for receiving and acting on this application for extension is to be charged to Deposit Account 16-1445, as authorized in the enclosed transmittal letter. The Office is given authorization to charge Deposit Account No. 16-1445 for any fees necessary with this submission.

(15) Please address all inquiries and correspondence relating to this application for patent term extension to:

Timothy Gumbleton
Patent Department
Pfizer, Inc.
7000 Portage Road
Kalamazoo, Michigan 49001

Phone: (269) 833-2501
Fax: (269) 833-8897

Pursuant to 37 C.F.R. § 1.740(b), two identical copies of this application, with accompanying exhibits, are enclosed herewith. Pursuant to M.P.E.P. § 2753, an additional two copies of this application, with accompanying exhibits, are enclosed herewith. Accordingly, a total of one original application for patent term extension of United States Patent No. 6,573,293 and four copies of these application papers are submitted herewith.

Respectfully submitted,

Dated: July 16, 2009



Timothy J. Gumbleton
Agent for Applicant
Registration No. 54,143

Patent Department
Pfizer, Inc.
7000 Portage Road
Kalamazoo, Michigan 49001
Phone: (269) 833-2501
Fax: (269) 833-8897



US006573293B2

(12) **United States Patent**
Tang et al.

(10) Patent No.: **US 6,573,293 B2**
(45) Date of Patent: **Jun. 3, 2003**

(54) **PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS**

(75) Inventors: Peng Cho Tang, Moraga, CA (US); Todd A. Miller, Bend, OR (US); Xiaoyuan Li, Los Altos, CA (US); Li Sun, Foster City, CA (US); Chung Chen Wei, Foster City, CA (US); Shahrzad Shirazian, Corte Madera, CA (US); Congxin Liang, Sunnyvale, CA (US); Tomas Vojkovsky, San Francisco, CA (US); Asaad S. Nematalia, Concord, CA (US); Michael Hawley, Kalamazoo, MI (US)

(73) Assignees: Sugen, Inc., South San Francisco, CA (US); Pharmacia & Upjohn Co., Kalamazoo, MI (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/783,264**

(22) Filed: **Feb. 15, 2001**

(65) **Prior Publication Data**

US 2002/0156292 A1 Oct. 24, 2002

Related U.S. Application Data

(60) Provisional application No. 60/182,710, filed on Feb. 15, 2000, provisional application No. 60/216,422, filed on Jul. 6, 2000, and provisional application No. 60/243,532, filed on Oct. 27, 2000.

(51) **Int. Cl.⁷** A61K 31/404; A61K 31/496; C07D 403/06; C07D 403/14
(52) **U.S. Cl.** 514/414; 514/397; 514/339; 514/256; 514/212.08; 514/235.2; 514/254.09; 540/524; 544/144; 544/316; 544/373; 546/277.7; 548/468; 548/455; 548/312.1
(58) **Field of Search** 548/468, 455, 548/312.1; 546/227.7; 514/397, 414, 339, 256, 212.08, 235.2, 254.09; 544/373, 316, 144; 540/524

(56) **References Cited****U.S. PATENT DOCUMENTS**

2,622,980 A	12/1952	Copeland
2,872,372 A	2/1959	Hull
2,968,557 A	1/1961	Burgandt et al.
3,140,180 A	7/1964	Fritz
3,308,134 A	3/1967	Plostneiks
3,551,571 A	12/1970	Pachter et al.
3,564,016 A	2/1971	Schoen et al.
3,715,364 A	2/1973	Hoff
3,880,871 A	4/1975	Haugwitz et al.
3,922,163 A	11/1975	Church et al.
4,002,643 A	1/1977	Carson
4,002,749 A	1/1977	Rovnyak
4,053,613 A	10/1977	Rovnyak et al.
4,070,366 A	1/1978	Gregorovich et al.
4,259,345 A	3/1981	Cross et al.
4,259,346 A	3/1981	Stähle et al.

4,343,923 A	8/1982	Lenox et al.
4,376,110 A	3/1983	David et al.
4,436,892 A	3/1984	Zondler et al.
4,489,089 A	12/1984	Wright, Jr. et al.
4,493,642 A	1/1985	Furazawa et al.
4,493,842 A	1/1985	Furazawa et al.
4,560,700 A	12/1985	Schnettler et al.
4,628,105 A	12/1986	Schmid et al.
4,642,309 A	2/1987	Michel et al.
4,678,798 A	7/1987	Rentzea et al.
4,826,847 A	5/1989	Michel et al.
4,853,403 A	8/1989	Shiraishi et al.
4,853,404 A	8/1989	Takamura et al.
4,868,304 A	9/1989	Larock
4,924,000 A	5/1990	Hesse et al.
4,966,849 A	10/1990	Vallee et al.
4,971,996 A	11/1990	Shiraishi et al.
RE35,096 E	1/1991	Taniguchi et al.
4,987,146 A	1/1991	Rohde et al.
5,043,348 A	8/1991	Zoller et al.
5,043,454 A	8/1991	Wriede et al.
5,047,554 A	9/1991	Ehrgott et al.
5,051,417 A	9/1991	Nadler et al.
5,057,538 A	10/1991	Shiraishi et al.
5,082,856 A	1/1992	Taniguchi et al.
5,089,516 A	2/1992	Shiraishi et al.
5,124,347 A	6/1992	Connor et al.
5,145,983 A	9/1992	West
5,153,217 A	10/1992	Taniguchi et al.
5,196,446 A	3/1993	Levitzki et al.
5,202,341 A	4/1993	Shiraishi et al.
5,206,261 A	4/1993	Kawaguchi et al.
5,217,999 A	6/1993	Levitzki et al.
5,258,357 A	11/1993	Muenster et al.

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

AU	286870	5/1967
CA	2012634	9/1991

(List continued on next page.)

OTHER PUBLICATIONS

Fischer, H., "The Pyrroles, Paper 4: Pyrrole Aldehyde (II) and Pyrrole Nitrile," Zerweck, W. *Chemische Berichte*, 1923, pp. 519-527, vol. 55.

Treibs, von Alfred et al., "Über isoindigoide Farbstoffe der Pyrrol-Reihe," *Liebigs Ann. Chem.* 702:112-130 (1967) (With English Translation).

(List continued on next page.)

Primary Examiner—Laura L. Stockton

(74) Attorney, Agent, or Firm—Beth A. Burrous; Foley & Lardner

(57) **ABSTRACT**

The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

29 Claims, No Drawings

U.S. PATENT DOCUMENTS

5,278,184 A	1/1994	Artico et al.
5,290,947 A	3/1994	Zoller et al.
5,302,606 A	4/1994	Spada et al.
5,322,950 A	6/1994	Sircar et al.
5,330,992 A	7/1994	Eissenstat et al.
5,332,736 A	7/1994	Carmosin et al.
5,374,652 A	12/1994	Buzzetti et al.
5,382,593 A	1/1995	Le Baut et al.
5,389,661 A	2/1995	Sircar et al.
5,397,787 A	3/1995	Buzzetti et al.
5,409,930 A	4/1995	Spada et al.
5,409,949 A	4/1995	Buzzetti et al.
5,463,052 A	10/1995	Haga et al.
5,565,324 A	10/1996	Still et al.
5,610,173 A	3/1997	Schwartz et al.
5,723,665 A	3/1998	Kato et al.
5,786,488 A	7/1998	Tang et al.
5,792,783 A	8/1998	Tang et al.
5,834,504 A	11/1998	Tang et al.
5,849,710 A	12/1998	Battistini et al.
5,880,141 A	3/1999	Tang et al.
5,883,113 A	3/1999	Tang et al.
5,883,116 A	3/1999	Tang et al.
5,886,020 A	3/1999	Tang et al.
RE36,256 E	7/1999	Spada et al.
6,130,239 A	* 10/2000	Chen et al. 514/414
6,133,305 A	10/2000	Tang et al.
6,284,894 B1	9/2001	Philion et al.
6,310,217 B1	10/2001	Lehr
6,395,736 B1	5/2002	Parks et al.
6,451,838 B1	9/2002	Moon et al.
6,462,072 B1	10/2002	Hamilton et al.

WO	92/21660	12/1992
WO	93/01182	1/1993
WO	93/23040	11/1993
WO	94/03427	2/1994
WO	94/10202	5/1994
WO	94/14808	7/1994
WO	95/01349	1/1995
WO	95/14667	6/1995
WO	95/17181	6/1995
WO	96/22976	8/1995
WO	95/24190	9/1995
WO	96/00226	1/1996
WO	96/16964	6/1996
WO	96/32380	10/1996
WO	96/40116	12/1996
WO	97/25986	7/1997
WO	97/34920	9/1997
WO	97/36867	10/1997
WO	98/07695	2/1998
WO	98/07835	2/1998
WO	98/24432	6/1998
WO	98/38984	9/1998
WO	98/45708	10/1998
WO	98/50356	11/1998
WO	98/56376	12/1998
WO	99/10325	3/1999
WO	99/19325	4/1999
WO	99/48868	9/1999
WO	99/52869	10/1999
WO	99/61422	12/1999
WO	99/65869	12/1999
WO	00/08202	2/2000
WO	00/35908	6/2000
WO	00/38519	7/2000
WO	00/56709	9/2000
WO	01/37820	5/2001
WO	WO 01/60814 A2	8/2001

FOREIGN PATENT DOCUMENTS

DE	878539	6/1953
DE	2159360	11/1971
DE	2159361	11/1971
DE	2159362	11/1971
DE	2159363	11/1971
DE	2321656	4/1973
DE	3426419	1/1986
EP	0304493	3/1989
EP	0351213	1/1990
EP	0252713	9/1990
EP	0525472	2/1993
EP	0566226	10/1993
EP	0580502	1/1994
EP	0626377	11/1994
EP	0632102	1/1995
EP	0662473	7/1995
EP	0769947	5/1997
EP	0788890	8/1997
EP	0810217	12/1997
EP	0934931	8/1999
FR	1398224	3/1965
FR	1599772	8/1970
FR	2689397	10/1993
GB	809691	3/1959
GB	835473	5/1960
JP	6239564	2/1987
JP	6229570	7/1987
JP	63141955	6/1988
JP	558894	3/1993
WO	88/07035	9/1988
WO	91/13055	9/1991
WO	91/15495	10/1991
WO	92/03736	3/1992
WO	92/07830	5/1992
WO	92/20642	11/1992

OTHER PUBLICATIONS

Abramovitch and Hey, "Internuclear cyclisation. Part VIII. Naphth[3:2:1-cd]oxindoles," *J. Chem. Soc.* 1697-1703 (1954).

Abramovitch et al., "A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement," *Chemistry and Industry* 44:1871 (1967) © Laporte Industries Limited.

J. Chem. Soc., Beilstein Reg. No. 236050, year not available.

Akbasak and Sunar-Akbasak, "Oncogenes: cause or consequence in the development of glial tumors," *J. Neurol. Sci.* 111:119-133 (1992) © Elsevier Science Publishers.

Andreani et al., "Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolymethylene)1,3-Dihydroindol-2-Ones," *Anticancer Research* 16:3585-3588 (1996) © Elsevier, Paris.

Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," *Eur. J. Med. Chem.* 25:187-190 (1990).

Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups," *Eur. J. Med. Chem.* 28:653-657 (1993) © Elsevier, Paris.

Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," *Chemical Abstracts*, vol. 113, abstract No. 78106 (1990).

Andreani et al., "Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones," *Eur. J. Med. Chem.* 27:167-170 (1992) © Elsevier, Paris.

Andreani et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones," *Eur. J. Med. Chem.* 32:919-924 (1997) © Elsevier, Paris.

Andreani et al., "Synthesis of lactams with potential cardiotonic activity," *Eur. J. Med. Chem.* 28:825-829 (1993).

Andreani et al., "In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones," *Arzneimittel-Forschung Drug Research* 48:727-729 (1998) ©..

Arteaga et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," *J. Clin. Invest.* 84:1418-1423 (1989) copyright The American Society for Clinical investigation, Inc.

Arvidsson et al., "Tyr-716 in the Platelet-Derived Growth Factor β -Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," *Molecular and Cellular Biology* 14:6715-6726 (1994) © The American Society for Microbiology.

Autrey and Tahk, "The Synthesis and Stereochemistry of Some Isatylideneacetic Acid Derivatives," *Tetrahedron* 23:901-917 (1967) ©Pergamon Press.

Bahner and Brotherton, "9-(4-Aminobenzylidene)fluorennes," *J. Med. Chem.* 12:722-723 (1969).

Bahner et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," *J. Med. Chem.* 12:721-722 (1969).

Bamfield et al., "Diels-Alder Reactions of Oxindolylidene-acetone," *J. Chem. Soc. (C)* 1028-1030 (1966) ©.

Barbier, et al., "Synthesis of Isobrassilexin, A Biologically Active Isomer of Brassilexin, a Cruciferae Phytoalexin," *Synthetic Communications* 23(22):3109-3117 (1993) © Marcel Dekker, Inc.

Baserga, "Oncogenes and the Strategy of Growth Factors," *Cell* 79:927-930 (1994) © Cell Press.

Baserga, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" *Cancer Research* 55:249-252 (1995).

Beilstein Reg. No. 233511 (1997).

Beilstein Reg. No. 235647 (1997).

Beilstein Reg. No. 252929 (1998).

Benzies, et al., "2-Formyl-3-Methoxymethylindole, 3-Ethoxymethyl-2-Formylindoline and 2-Formyl-3-Methylindole," *Synthetic Communications*: 16(14), 1799-1807 (1996) © Marcel Dekker, Inc.

Blake and Jaques, "Anistropic Effects in α -Substituted Methoxystilbenes," *J. Chem. Soc. Perkin II*: 1660-1663 (1973) © Pergamon, Oxford.

Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," *FASEB J.* 6:3403-3409 (1992).

Bolen, "Nonreceptor tyrosine protein kinases," *Oncogene* 8:2025-2031 (1993) copyright MacMillan Press Ltd.

Bonner et al., "Structure and Biological Activity of Human Homologs of the raf/mil Oncogene," *Molecular and Cellular Biology* 5:1400-1407 (1985) © The American Society for Microbiology.

Borsche et al., "Über vielkernige kondensierte Systeme mit heterocyclischen Ringen. XIII.," *Liebigs Ann. Chem.* 550:160-174 (1941).

Buzzetti et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," *II Farmaco* 48:615-636 (1993).

Cance et al., "Novel Protein Kinases Expressed in Human Breast Cancer," *Int. J. Cancer* 54:571-577 (1993) © Wiley-Liss, Inc.

Canoira and Rodriguez, "Synthesis of Oxindole Derivatives from N-Alkenyl- α -Chloroanilides with Zero-Valent Nickel Complex," *J. Heterocyclic Chem.* 22:1511-1518 (1985).

Carpenedo et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs," *Analytical Biochemistry* 244:74-79 (1997) © Academic Press, Inc.

Chao, "Growth Factor Signaling: Where Is the Specificity?" *Cell* 68:995-997 (1992) copyright Cell Press.

Chatten et al., "Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted trans-3-Benzylideneindol-2(3H)-ones," *J. Chem. Soc. Perkins II*: 469-473 (1973).

Chatterjee, et al., "Acylation of Indoles by Duff Reaction and Vilsmeier-Haack Formylation and Conformation of N-Formylindoles," *J. Org. Chem.*, 38:4002-4004 ©The American Chemical Society, 1973.

Chen et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ -Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron," *Chinese Journal of Physiology* 40:149-156 (1997).

Claesson-Welsh, "Signal Transduction by the PDGF Receptors," *Progress in Growth Factor Research* 5:37-54 (1994) © Elsevier Science Ltd.

Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration Conformation and Infrared Carbonyl Stretching Frequencies," *J. Chem. Soc. Perkin Trans. II*: 615-619 (1984).

Coda et al., "3-(4-methylbenzylidene)-1,3-dihydroindol-2-one," *Journal of the Chemical Society, Perkin Transactions 2* 4:615-620 (1984) Database Crossfire, Beilstein Reference No. 6-21.

Coppola et al., "A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," *Molecular and Cellular Biology* 14:4588-4595 (1994) © The American Society for Microbiology.

Daisley and Walker, "Thin-layer chromatographic separation of some substituted 3-benzylidene-indol-2(3H)-ones," *J. Chromatography* 100:240-242 (1974) © Elsevier Scientific Publishing Company.

Damiani et al., "Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," *Biochemical Pharmacology* 48: 1155-1161 (1994) copyright Elsevier Science Ltd.

Dati et al., "Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells," *Oncogene* 5:1001-1006 (1990).

Davis et al., "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," *Journal of Medicinal Chemistry* 16:1043-1045 (1973) ©American Chemical Society.

De Vries et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," *Science* 255:989-991 (1992).

Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," *J. Immunol. Methods* 15:61-69 (1988) copyright Elsevier.

Decodts et al., "Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams," *Eur. J. Med. Chem.* 18:107-111 (1983).

Desimoni et al., "Catalysis with Inorganic Cations. V¹ Intramolecular Hetero Diels-Alder versus Ene Reactions: Effect of Magnesium perchlorate on Chemoselectivity," *Tetrahedron* 52(36) 12009-12018 (1996) © Pergamon.

Dickson et al., "13. Tyrosine kinase receptor—nuclear protooncogene interactions in breast cancer," *Cancer Treatment Res.* 61:249-273 (1992) © Kluwer Academic Publishers.

Elliott and Rivers, "Reduction of Some Oxindolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride," *J. Med. Chem.* 29:2438-2440 (1964).

Elliott et al., "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," *Journal of Organic Chemistry* 29:2438-2440 (1964) Database Crossfire, Beilstein Reference No. 5-24.

Fantl et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," *Cell* 69:413-423 (1992) © Cell Press.

Fendly et al., Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product, *Cancer Research* 50:1550-1558 (1990).

Ferrara and Henzel, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," *Biochemical and Biophysical Research Communications* 161:851-858 (1989) © Academic Press, Inc.

Fingl and Woodbury, "Chapter 1—General Principles," in *The Pharmacological Basis of Therapeutics* 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975) © MacMillan Publishing Co. Inc.

Floege et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo," *Kidney International* 43:S47-S54 (1993) © International Society of Nephrology.

Floege et al., "Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis," *Kidney International* 43:369-380 (1993) © International Society of Nephrology.

Folkman and Shing, "Angiogenesis," *J. Biol. Chem.* 267:10931-10934 (1992) © The American Society for Biochemistry and Molecular Biology.

Folkman, "Ch. 24. Angiogenesis," *Congress of Thrombosis and Haemostasis* (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987).

Folkman, "Tumor Angiogenesis: Therapeutic Implications," *New England J. Medicine* 285:1182-1186 (1971).

Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?" *Journal of the National Cancer Institute* 82:4-6 (1990).

Folkman, "Angiogenesis in Psoriasis: Therapeutic Implications," *J. Invest. Dermatol.* 59:40-43 (1973) copyright The Williams & Wilkins Co.

Gazit et al., "Tyrphostins. 2. Heterocyclic and α -Substituted Benzylidene malononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," *J. Med. Chem.* 34:1896-1907 (1991) copyright Am. Chem. Soc.

Gennaro (editor), *Remington's Pharmaceutical Sciences* (1990) (Table of Contents Only).

Goldring and Goldring, "Cytokines and Cell Growth Control," *Critical Reviews in Eukaryotic Gene Expression* 1:301-326 (1991).

Gottardis et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumorostatic Action of Tamoxifen," *J. Steroid Biochem.* 30:311-314 (1988) © Pergamon Press.

Graziani et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger," *The Journal of Biological Chemistry* 268:9165-9168 (1993) © American Society for Biochemistry and Molecular Biology.

Hayler et al., Development of Large-Scale Syntheses of Ropinirole in the Pursuit if a Manufacturing Process, *Organic Process Research & Development* 2(1) 3-9 (1988) © The American Chemical Society and Royal Society of Chemistry.

Hewgill and Stewart, "Phenanthrene-4,5-quinones: a Synthesis of Morphenol," *J. Chem. Soc. Perkin Trans. I*:1305-1311 (1988).

Hirao et al., "Rhodium-Catalyzed Carbonylation of 2-Alkynylaniline: Syntheses of 1,3-Dihydroindol-2-ones," *Tetrahedron Letters* 36(35), 1995 ©Pergamon.

Hodges et al., "Chemical and biological properties of some oxindolylidyl-3-methines," *Canadian J. Chemistry* 46:2189-2194 (1968).

Honegger et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," *Cell* 51:199-209 (1987) © Cell Press.

Houck et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," *J. Biol. Chem.* 267:26031-26037 (1992) © American Society for Biochemistry and Molecular Biology, Inc.

Howard, Harry R., "Lactam Derivatives," U.S. Provisional patent application Ser. No. 60/015134, 1996.

Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone-to and oxindole-1-acetic acids," *Eur. J. Med. Chem.* 27:779-789 (1992) © Elsevier, Paris.

Hu et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," *Molecular and Cellular Biology* 12:981-990 (1992) copyright Am. Soc. Microbiol.

Ijaz et al., "The Conversion of α,β -Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," *J. Chem. Res. (S)*: 116 (1990).

Jellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," *Biochemistry* 33:10450-10456 (1994) © American Chemical Society.

Kashishian and Cooper, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase C γ 1," *Molecular Biology of the Cell* 4:49-57 (1993) © The American Society for Cell Biology.

Kashishian et al., "Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo," *The EMBO Journal* 11:1373-1382 (1992).

Kato et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," *Journal of Chromatography* 616:67-71 (1993) ©Elsevier Science.

Katritzky et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," *J. Heterocyclic Chem.* 25:1287-1292 (1988).

Kazlauskas et al., "The 64-kDa protein that associates with the platelet-derived growth factor receptor β subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp," *Proc. Natl. Acad. Sci. USA* 90:6939-6942 (1993).

Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," *Proc. Natl. Acad. Sci. USA* 90:10705-10709 (1993).

Khalil and Abdel-Rahman, "Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes," *J. Indian Chem. Soc.* 54:904-907 (1977) ©The Indian Chemical Society.

Kikumoto et al., "The Reactions of Oxindoles and Isatin with Nitrobenzyl Chlorides," *Tetrahedron* 22:3337-3343 (1966) ©Pergamon Press Ltd.

Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," *Nature* 362:841-844 (1993).

Kinsella et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," *Exp. Cell Research* 199:56-62 (1992) © Academic Press, Inc.

Klagsbrun and Soker, "VEGF/VPF: the angiogenesis factor found?" *Current Biology* 3:699-702 (1993) ©Current Biology.

Kobayashi et al., "Anti-tumor Activity of Indole Derivatives," *Yakugaku Zasshi* 97:1033-1039 (1977).

Koch et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," *Science* 252:668-674 (1991).

Kohler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined specificity," *Nature* 256:495-497 (1975).

Komada and Kitamura, "The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," *Oncogene* 8:2381-2390 (1993).

Korc et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor Transforming Growth Factor Alpha," *J. Clin. Invest.* 90:1352-1360 (1992) copyright The American Society for Clinical Investigation, Inc.

Korzeniew and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity," *J. Immunol. Methods* 64:313-320 (1983) © Elsevier Science Publishers.

Kovac and Stetinova, "Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoindoles," *Chem. rvesu* 30:484-492 (1976).

Krueger and Saito, "A human transmembrane protein-tyrosine-phosphatase, PTP β , is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases," *Proc. Natl. Acad. Sci. USA* 89:7417-7421 (1992).

Kumabe et al., "Amplification of α -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," *Oncogene* 7:627-633 (1992).

Lal et al., "Novel Diuretic Agents: Syntheses of Substituted Isatylidene & 3-Alkyl or 3-Arylalkyl-2-oxindoles," *Indian Journal of Chemistry* 13:898-903 (1975).

Larock and Babu, "Synthesis of Nitrogen Heterocycles via Palladium-catalyzed Intramolecular Cyclization," *Tetrahedron Letters* 28:5291-5294 (1987) copyright Pergamon Journals Ltd.

Lee and Donoghue, "Intracellular Retention of Membrane-anchored v-sis Protein Abrogates Autocrine Signal Transduction," *Journal of Cell Biology* 118:1057-1070 (1992) copyright The Rockefeller University Press.

Levitzki and Gazit, "Tyrosine Kinase Inhibition: An Approach to Drug Development," *Science* 267:1782-1788 (1995).

Maass et al., "Viral Resistance to the Thiazolo-Iso-Indolones, a New Class of Nonnucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," *Antimicrobial Agents and Chemotherapy* 37:2612-2617 (1993) ©American Society for Microbiology.

Macaulay et al., "Autocrine Function for Insulin-like Growth Factor I in Human Small Cell Lung Cancer Cell Lines and Fresh Tumor Cells," *Cancer Research* 50:2511-2517 (1990).

Mariani et al., "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," *Experimental Therapeutics—Proceedings of the American Association for Cancer Research* 35:381 at abstract No. 2268 (Mar. 1994).

Martin-Leon et al., "On the Cyclization to the Elusive Amino-4H-pyran Ring Some New Facts," *Liebigs Ann. Chem.* 101-104 (1990) copyright VCH Verlaxs of Sellschaft mbH ©VCH.

Mel'nikova TV et al., "Indole chemistry. XXXVIII. Cleavage of a carbon-carbon bond during the reaction of 2-aminoindoles with difunctional compounds," *Chemical Abstract* 80 (1974) Abstract No. 003413.

Millauer et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," *Cell* 72:835-846 (1993) © Cell Press.

Mohammadi et al., "Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors," *Science* 276:955-960 (1997) © American Association for the Advancement of Science.

Moreto et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric Diester of 3,3 Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (DAN-603) in the Rat," *European Journal of Pharmacology* 36:221-226 (1976) ©North-Holland Publishing Company.

Moreto et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," *Arzneimittel-Forschung Drug Research* 29:1561-1564 (1979).

Morrison et al., "Signal Transduction From Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increase Raf-1 Phosphorylation and Associated Protein Kinase Activity," *Proc. Natl. Acad. Sci. USA* 85:8855-8859 (1988).

Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," *J. Immunol. Methods* 65:55-63 (1983) copyright Elsevier Publishers B.V.

Neber and Röcker, "On the action of benzaldehydes on the free o-aminophenylacetic acid (II)," *Chem. Ber.* 56:1710-1716 (1923) (German and English Translation).

Nishimura et al., "Two Signaling Molecules Share a Phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," *Molecular and Cellular Biology* 13:6889-6896 (1993).

Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," *J. Med. Chem.* 14:921-925 (1971).

Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 3. Halogen-containing 9-phenanthrenemethanols," *Chemical Abstracts*, vol. 83, abstract No. 188214 (1975).

Osborne et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," *Cancer Research* 45:584-590 (1985).

O'Sullivan and Rothery, "The Preparation and Possible Clinical Significance of 4'-Dialkylaminoisindogenides," *Clinica Chimica Acta* 62:181-182 (1975) ©Elsevier Scientific Publishing Company.

Ozzello and Sordat, "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," *Eur. J. Cancer* 16:553-559 (1980).

Pavlenko et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," *Dopov. Akad. Nauk Ukr. Rsr, Ser. B: Geol., Khim. Biol. Nauki* 7:64-66 (1980) We should add that we are Sub. Abstract.

Perkin et al., "Harmine and Harmaline. Part II. The Synthesis of isoHarman," *J. Chem. Soc.* 103:1973-1985 (1913).

Plate et al., "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas in vivo," *Nature* 359:845-848 (1992).

Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," *DN&P* 7:334-339 (1994).

Quallich et al., "General Oxindole Synthesis, *J. Synthetic Organic Chemistry*: 51-51 (1993).

Quinn et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," *Proc. Natl. Acad. Sci. USA* 90:7533-7537 (1993).

Rozakis-Adcock et al., "Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases," *Nature* 360:689-692 (1992).

Ruveda and Gonzalez, "Geometric isomerism in benzylidene-neoxindoles," *Spectrochimica Acta* 26A:1275-1277 (1970).

Rygaard and Povlsen, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," *Acta Path. Microbiol. Scand.* 77:758-760 (1969).

Sainsbury et al., "Electrochemical Oxidation of Aromatic Ethers. Part 5. Further Studies of the Coupling Reactions of Alkoxylation Aralkyl- and Aryl-amides," *J.C.S. Perkin I* 108-114, year not available.

Saito and Streuli, "Molecular Characterization of Protein Tyrosine Phosphatases," *Cell Growth & Differentiation* 2:59-65 (1991) ©Molecular Biology Journal of the American Association for Cancer Research.

Sandberg-Nordqvist et al., "Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," *Cancer Research* 53:2475-2478 (1993).

Schindler et al., "Über Dibenz[b,f]-azocin-Derivate," *Helvetica Chimica Acta* 49:985-989 (1966).

Schlessinger and Ullrich, "Growth Factor Signalling by Receptor Tyrosine Kinases," *Neuron* 9:383-391 (1992) © Cell Press.

Schuchter et al., "Successful Treatment of Murine Melanoma with Bryostatin 1," *Cancer Research* 51:682-687 (1991).

Seibert et al., "Clonal Variation of MCF-7 Breast Cancer Cells in Vitro and in Athymic Nude Mice," *Cancer Research* 43:2223-2234 (1983).

Shafie and Grantham, "Role of Hormones in the Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted Into Athymic Nude Mice," *J. Natl. Cancer Institute* 67:51-56 (1981).

Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family," *Oncogene* 5:519-524 (1990).

Shiraishi et al., "Specific Inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4-Hydroxycinnamamide Derivatives," *Biochemical and Biophysical Research Communications* 147:322-328 (1987) © Academic Press.

Shiraishi et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4-Hydroxycinnamamide Derivatives in Vitro," *Cancer Research* 49:2374-2378 (1989).

Shweiki et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," *Nature* 359:843-845 (1992).

Singh et al., "Indolinone Derivatives as Potential Antimicrobial Agents," *Zentralbl. Mikrobiol.* 144:105-109 (1989) copyright VEB Gustav Fischer Verlag Jena.

Singh et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxospiro (Azetidin-3', 4-Indol-2'Ones)," *Bollettino Chimico Farmaceutico* 133:76-79 (1994).

Skehan et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," *J. Natl. Cancer Inst.* 82:1107-1112 (1990).

Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer," *Science* 244:707-712 (1989).

Soldi et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125^{PAK}) in Human Endothelial Cells," *Oncogene* 13:515-525 (1996) copyright Stockton Press.

Songyang et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," *Cell* 72:767-778 (1993) © Cell Press.

Songyang et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," *Molecular and Cellular Biology* 14:2777-2785 (1994) © American Society for Microbiology.

Spada, et al., "Small molecule inhibitors of tyrosine kinase activity," *Expert Opinion on Therapeutic Patents* 5:805-817 (1995) © Ashley Publications.

Stetinova et al., "Stereosechemistry and Photoisomerisation of Furfurylideneoxindoles," *Collection Czechoslov. Chem. Commun.* 42:2201-2206 (1977).

Stolle, Beilstein Reg. No. 273650, *J. Prakt. Chem.*, vol. 2, p. 128 (1930).

Stolle, Beilstein Reg. No. 305045, *J. Prakt. Chem.*, vol. 2, p. 128 (1930).

Sumpter and Miller, "Chapter IV—Oxindole," in *Heterocyclic Compounds With Indole and Carbazole Systems*, © Interscience Publishers, Inc., New York, pp. 134-153 (1954).

Sun et al., "Design, Synthesis, and Evaluations of Substituted 3-[3- or 4-Carboxyethylpyrrol-2-yl)methylidene] indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases," *Journal of Medicinal Chemistry* 42:5120-5130 (1999) ©American Chemical Society.

Sun et al., "Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases," *J. Med. Chem.* 41:2588-2603 (1998) ©The American Chemistry Society.

Superti-Furga et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," *Nature Biotech.* 14:600-605 (1996).

Superti-Furga et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," *EMBO J.* 12:2625-2634 (1993) © Oxford University Press.

Tacconi and Marinone, "Preparazione e caratteristiche di alcuni 3-ossindolidenderivati," *Ricerca Scientifica* 38:1239-1244 (1968).

Tacconi et al., "(Z)- and (E)-3-Alkylidene-1,3-dihydroindol-2-ones: Influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," *J.C.S. Perkin II* 150-154 (1976).

Takano et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits Protein Kinase C," *Mol. Bio. Cell* 4:358A at abstract No. 2076 (1993).

Terrett et al., "Combinatorial Synthesis—The Design of Compound Libraries and their Application to Drug Discovery," *Tetrahedron* 51(30):8135-8173 (1995) copyright Pergamon! all even pages missing!

Thio et al., "The Interconversion of 2-(2-Aminophenyl)-3-piperolidinone and 3-(2-piperidylmethyl)-2-indolinone: A Reversible N=N'Transacylation," *Notes* (1971) 479-482.

Thompson et al., "Facile Dimerisation of 3-Benzylidene-indoline-2-thiones," *J. Chem. Soc. Perkin Trans. (I)* 1835-1837 (1993).

Torp et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain Metastases," *APMIS* 100:713-719 (1992).

Traxler, "Protein tyrosine kinase inhibitors in cancer treatment," *Expert Opinion on Therapeutic Patents* 7(6):571-588 (1997) © Ashley Publications Ltd.

Tsai et al., "The Effect of 3,3-Di-Pyridyl Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," *Neuropharmacology* 31:943-947 (1992) ©Pergamon Press.

Tuzi et al., "Expression of growth factor receptors in human brain tumours," *Br. J. Cancer* 63:227-233 (1991).

Twamley-Stein et al., "The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells," *Proc. Natl. Acad. Sci. USA* 90:7696-7700 (1993).

Ullrich and Schlessinger, "Signal Transduction by Receptors with Tyrosine Kinase Activity," *Cell* 61:203-212 (1990) copyright Cell Press.

Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," *J. Biol. Chem.* 265:19461-19466 (1990) © The American Society for Biochemistry and Molecular Biology.

Varma and Gupta, "Nucleophilic Reactions of 2-Methyl-3-(4'-carbomethoxyphenyl)-4-quinazolinones with 2-Indolinones," *J. Indian Chem. Soc.* 66:804-805 (1989) © The Indian Chemical Society.

Voller et al., "Ch. 45—Enzyme-Linked Immunosorbent Assay," in *Manual of Clinical Immunology*, 2nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980).

Wahl et al., "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," *Ann. Chim.* 350 (1926), Database Crossfire, Beilstein Reference No. 2-21-00-00290.

Wahl et al., "Chimie Organique—Sur les iso-indogenides," *C.R. Hebd. Séances Acad. Sci.* 149:132-134 (1909).

Walh, Beilstein Reg. No. 191439, *Bull. Soc. Chim. Fr.*, p. 1038 (1909).

Wahl, Beilstein Reg. No. 231732, *Bull. Soc. Chim. Fr.*, pp. 1035-1038 (1909).

Walker, "Synthesis of a α -(p-Aminophenyl)-and α -(p-Chlorophenyl)- β -aryl-propionitriles by Catalytic Reduction of Stilbenenitriles," *J. Med. Chem.* 8:583-588 (1965).

Walker et al., "Synthesis of New 3-(Pyridylmethylen)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)-, and 3-(β -Alkylaminooethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," *J. Med. Chem.* 8:626-637 (1965).

Warri et al., "Estrogen Suppression of erbB2 Expression is Associated with Increased Growth Rate of ZR-75-1 Human Breast Cancer Cells In Vitro and in Nude Mice," *Int. J. Cancer* 49:616-623 (1991) © Wiley-Leiss, Inc.

Weidner et al., "Tumor Angiogenesis and Metastasis—Correlation in Invasive Breast Carcinoma," *New England J. Medicine* 324:1-7 (1991) © Massachusetts Medical Society.

Winkelmann et al., "Chemotherapeutically Active Nitro Compounds: 4, 5-Nitroimidazoles (Part I)," *Arzneim.-Forsch./Drug Res.* 27:2251-2263 (1977).

Wright et al., "Cyclic Hydroxamic Acids Derived from Indole," *J. Am. Chem. Soc.* 78:221-224 (1956).

Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," *J. Cellular Physiology* 152:448-457 (1992).

Young and Babbitt, "2-(2-Methyl-3-indolyl)-1,4-benzoquinone, a Reversible Redox Substrate at the Carbon-Paste Electrode in Acidic Aqueous-Ethanol Media," *J. Org. Chem.* 47:1571-1572 (1982) copyright Am. Chem. Soc.

Zaman et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β -Receptor (β -PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," *Biochemical Pharmacology* 57:57-64 (1999) ©Elsevier Science Inc.

Zhang et al., "Microtubule Effects of Welvistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," *Molecular Pharmacology* 49:228-234 (1996) copyright The American Society for Pharmacology and Experimental Pharmacetics.

Zhungietu et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," *Chemical Abstracts*, vol. 78, abstract No. 111201 1973.

English Translation of French Patent No. 1398224, 1965.

English Translation of Hungarian Patent No. 3899/92, 1992.

English Translation of German Patent No. 2159360 (Ref. No. A85), 1973.

English Translation of German Patent No. 2159361 (Ref. No. A86), 1973.

English Translation of German Patent No. 2159363 (Ref. No. A88), 1973.

English Translation of German Patent No. 2321656 (Ref. No. A89), 1974.

English Translation of German Patent No. 3426419 (Ref. No. A90), 1986.
English Translation of European Patent No. 580502 (Ref. No. A96), 1994.
English Translation of European Patent No. 632102 (Ref. No. A98), 1995.
English Translation of French Patent No. 2689397 (Ref. No. A107), 1993.
English Translation of Japanese Patent No. 6229570 (Ref. No. A110), 1987.
English Translation of Japanese Patent No. 6239564 (Ref. No. A111), 1987.

English Translation of Japanese Patent No. 63141955 (Ref. No. A 112), 1988.
English Translation of Japanese Patent No. 558894 (Ref. No. A113), 1993.
English Translation of German Patent No. 878539 (Ref No. A84), 1953.
English Translation of French Patent No. 1398224 (Ref. No. A105), 1965.
English Translation of French Patent No. 1599772 (Ref. No. A106), Year Not Available.

* cited by examiner

PYRROLE SUBSTITUTED 2-INDOLINONE
PROTEIN KINASE INHIBITORS

CROSS-REFERENCE INFORMATION

This application claims priority under 35 U.S.C. 119(e) to U.S. Provisional applications Ser. Nos. 60/182,710, filed Feb. 15, 2000, No. 60/216,422 filed on Jul. 6, 2000 and Ser. No. 60/243,532, filed Oct. 27, 2000, the disclosures of which are incorporated by reference herein in their entirety.

BACKGROUND OF THE INVENTION

1. Field of Invention

The present invention relates to certain 3-pyrrole substituted 2-indolinone compounds which modulate the activity of protein kinases ("PKs"). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

2. State of the Art

The following is offered as background information only and is not admitted to be prior art to the present invention.

PKs are enzymes that catalyze the phosphorylation of hydroxy groups on tyrosine, serine and threonine residues of proteins. The consequences of this seemingly simple activity are staggering; cell growth, differentiation and proliferation, i.e., virtually all aspects of cell life in one way or another depend on PK activity. Furthermore, abnormal PK activity has been related to a host of disorders, ranging from relatively non-life threatening diseases such as psoriasis to extremely virulent diseases such as glioblastoma (brain cancer).

The PKs can be conveniently broken down into two classes, the protein tyrosine kinases (PTKs) and the serine-threonine kinases (STKs).

One of the prime aspects of PTK activity is their involvement with growth factor receptors. Growth factor receptors are cell-surface proteins. When bound by a growth factor ligand, growth factor receptors are converted to an active form which interacts with proteins on the inner surface of a cell membrane. This leads to phosphorylation on tyrosine residues of the receptor and other proteins and to the formation inside the cell of complexes with a variety of cytoplasmic signaling molecules that, in turn, effect numerous cellular responses such as cell division (proliferation), cell differentiation, cell growth, expression of metabolic effects to the extracellular microenvironment, etc. For a more complete discussion, see Schlessinger and Ullrich, *Neuron*, 9:303-391 (1992) which is incorporated by reference, including any drawings, as if fully set forth herein.

Growth factor receptors with PTK activity are known as receptor tyrosine kinases ("RTKs"). They comprise a large family of transmembrane receptors with diverse biological activity. At present, at least nineteen (19) distinct subfamilies of RTKs have been identified. An example of these is the subfamily designated the "HER" RTKs, which include EGFR (epithelial growth factor receptor), HER2, HER3 and HER4. These RTKs consist of an extracellular glycosylated ligand binding domain, a transmembrane domain and an intracellular cytoplasmic catalytic domain that can phosphorylate tyrosine residues on proteins.

Another RTK subfamily consists of insulin receptor (IR), insulin-like growth factor I receptor (IGF-1R) and insulin receptor related receptor (IRR). IR and IGF-1R interact with insulin, IGF-I and IGF-II to form a heterotetramer of two

entirely extracellular glycosylated α subunits and two β subunits which cross the cell membrane and which contain the tyrosine kinase domain.

A third RTK subfamily is referred to as the platelet derived growth factor receptor ("PDGFR") group, which includes PDGFR α , PDGFR β , CSFIR, c-kit and c-fms. These receptors consist of glycosylated extracellular domains composed of variable numbers of immunoglobulin-like loops and an intracellular domain wherein the tyrosine kinase domain is interrupted by unrelated amino acid sequences.

Another group which, because of its similarity to the PDGFR subfamily, is sometimes subsumed into the later group is the fetus liver kinase ("flk") receptor subfamily. This group is believed to be made up of kinase insert domain-receptor fetal liver kinase-1 (KDR/FLK-1, VEGFR2), flk-1R, flk-4 and fms-like tyrosine kinase 1 (flt-1).

A further member of the tyrosine kinase growth factor receptor family is the fibroblast growth factor ("FGF") receptor subgroup. This group consists of four receptors, FGFR1-4, and seven ligands, FGF1-7. While not yet well defined, it appears that the receptors consist of a glycosylated extracellular domain containing a variable number of immunoglobulin-like loops and an intracellular domain in which the tyrosine kinase sequence is interrupted by regions of unrelated amino acid sequences.

Still another member of the tyrosine kinase growth factor receptor family is the vascular endothelial growth factor ("VEGF") receptor subgroup. VEGF is a dimeric glycoprotein similar to PDGF but has different biological functions and target cell specificity *in vivo*. In particular, VEGF is presently thought to play an essential role in vasculogenesis and angiogenesis.

A more complete listing of the known RTK subfamilies is described in Plowman et al., *DN&P*, 7(6):334-339 (1994) which is incorporated by reference, including any drawings, as if fully set forth herein.

In addition to the RTKs, there also exists a family of entirely intracellular PTKs called "non-receptor tyrosine kinases" or "cellular tyrosine kinases." This latter designation, abbreviated "CTK," will be used herein. CTKs do not contain extracellular and transmembrane domains. At present, over 24 CTKs in 11 subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes, Fps, Fak, Jak and Ack) have been identified. The Src subfamily appear so far to be the largest group of CTKs and includes Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. For a more detailed discussion of CTKs, see Bolen, *Oncogene*, 8:2025-2031 (1993), which is incorporated by reference, including any drawings, as if fully set forth herein.

The serine/threonine kinases, STKs, like the CTKs, are predominantly intracellular although there are a few receptor kinases of the STK type. STKs are the most common of the cytosolic kinases; i.e., kinases that perform their function in that part of the cytoplasm other than the cytoplasmic organelles and cytoskeleton. The cytosol is the region within the cell where much of the cell's intermediary metabolic and biosynthetic activity occurs; e.g., it is in the cytosol that proteins are synthesized on ribosomes.

RTKs, CTKs and STKs have all been implicated in a host of pathogenic conditions including, significantly, cancer. Other pathogenic conditions which have been associated with PTKs include, without limitation, psoriasis, hepatic cirrhosis, diabetes, angiogenesis, restenosis, ocular diseases, rheumatoid arthritis and other inflammatory disorders, immunological disorders such as autoimmune disease, cardiovascular disease such as atherosclerosis and a variety of renal disorders.

R^6 and R^7 may combine to form a group selected from the group consisting of $-(CH_2)_4-$, $-(CH_2)_5-$ and $-(CH_2)_6-$; with the proviso that at least one of R^5 , R^6 or R^7 must be $-C(O)R^{10}$;

R^8 and R^9 are independently selected from the group consisting of hydrogen, alkyl and aryl;

R^{10} is selected from the group consisting of hydroxy, alkoxy, aryloxy, $-N(R^{11})(CH_2)_nR^{12}$ and $-NR^{13}R^{14}$;

R^{11} is selected from the group consisting of hydrogen and alkyl;

R^{12} is selected from the group consisting of $-NR^{13}R^{14}$, hydroxy, $-C(O)R^{15}$, aryl and heteroaryl;

R^{13} and R^{14} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl and heteroaryl;

R^{13} and R^{14} may combine to form a group selected from the group consisting of $-(CH_2)_4-$, $-(CH_2)_5-$, $-(CH_2)_2O(CH_2)_2-$, and $-(CH_2)_2N(CH_3)(CH_2)_2-$;

R^{15} is selected from the group consisting of hydrogen, hydroxy, alkoxy and aryloxy;

R^{16} is selected from the group consisting of hydroxy, $-C(O)R^{15}$, $-NR^{13}R^{14}$ and $-C(O)NR^{13}R^{14}$;

R^{17} is selected from the group consisting of alkyl, cycloalkyl, aryl and heteroaryl; and

n and r are independently 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.


In a second aspect this invention is directed to a pharmaceutical composition comprising one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

In a third aspect, this invention is directed to a method of treating diseases mediated by abnormal protein kinase activity, in particular, receptor tyrosine kinases (RTKs), non-receptor protein tyrosine kinases (CTKs) and serine/threonine protein kinases (STKs), in an organism, in particular humans, which method comprises administering to said organism a pharmaceutical composition comprising a compound of Formula (I). Such diseases include by way of example and not limitation, cancer, diabetes, hepatic cirrhosis, cardiovascular disease such as atherosclerosis, angiogenesis, immunological disease such as autoimmune disease and renal disease.

In a fourth aspect, this invention is directed to a method of modulating of the catalytic activity of PKs, in particular, receptor tyrosine kinases (RTKs), non-receptor protein tyrosine kinases (CTKs) and serine/threonine protein kinases (STKs), using a compound of this invention which may be carried out in vitro or in vivo. In particular, the receptor protein kinase whose catalytic activity is modulated by a compound of this invention is selected from the group consisting of EGF, HER2, HER3, HER4, IR, IGF-1R, IRR, PDGFR α , PDGFR β , CSF1R, C-Kit, C-fms, Flk-1R, Flk4, KDR/Flk-1, Flt-1, FGFR-1R, FGFR-2R, FGFR-3R and FGFR-4R. The cellular tyrosine kinase whose catalytic activity is modulated by a compound of this invention is selected from the group consisting of Src, Frk, Btk, Csk, Abl, ZAP70, Fes/Fps, Fak, Jak, Ack, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. The serine-threonine protein kinase whose catalytic activity is modulated by a compound of this invention is selected from the group consisting of CDK2 and Raf.

In a fifth aspect, this invention is directed to the use of a compound of Formula (I) in the preparation of a medicament which is useful in the treatment of a disease mediated by abnormal PK activity.

In a sixth aspect, this invention is directed to an intermediate of Formula (II):



10 wherein:

R^5 is selected from the group consisting of hydrogen, alkyl and $-C(O)R^{10}$;

R^6 is selected from the group consisting of hydrogen, alkyl and $-C(O)R^{10}$;

15 R^7 is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, $-C(O)R^{17}$ and $-C(O)R^{10}$;

R^6 and R^7 may combine to form a group selected from the group consisting of $-(CH_2)_4-$, $-(CH_2)_5-$ and $-(CH_2)_6-$; with the proviso that at least one of R^5 , R^6 or R^7 must be $-C(O)R^{10}$;

20 R^{10} is selected from the group consisting of hydroxy, alkoxy, aryloxy, $-N(R^{11})(CH_2)_nR^{12}$ and $-NR^{13}R^{14}$;

R^{11} is selected from the group consisting of hydrogen and alkyl;

25 R^{12} is selected from the group consisting of $-NR^{13}R^{14}$, hydroxy, $-C(O)R^{15}$, aryl and heteroaryl;

R^{13} and R^{14} are independently selected from the group consisting of hydrogen, alkyl, cyanoalkyl, cycloalkyl, aryl and heteroaryl; or

R^{13} and R^{14} may combine to form a heterocyclo group;

30 R^{15} is selected from the group consisting of hydrogen, hydroxy, alkoxy and aryloxy;

R^{17} is selected from the group consisting of alkyl, cycloalkyl, aryl and heteroaryl; and

35 n is 1, 2, 3, or 4.

Preferably, R^5 or R^6 , in the compound of formula II, is $-C(O)R^{10}$;

40 R^6 is selected from the group consisting of hydrogen, and alkyl, more preferably hydrogen or methyl;

R^5 is selected from the group consisting of hydrogen, and alkyl, more preferably hydrogen or methyl when R^6 is $-COR^{10}$;

45 R^6 is selected from the group consisting of hydrogen, and alkyl, more preferably hydrogen or methyl when R^5 is $-COR^{10}$;

R^7 is selected from the group consisting of hydrogen, alkyl, and aryl, more preferably hydrogen, methyl or phenyl;

50 R^{10} is selected from the group consisting of hydroxy, alkoxy, $-N(R^{11})(CH_2)_nR^{12}$ and $-NR^{13}R^{14}$;

R^{11} is selected from the group consisting of hydrogen and alkyl, more preferably hydrogen or methyl;

55 R^{12} is selected from the group consisting of $-NR^{13}R^{14}$;

R^{13} and R^{14} are independently selected from the group consisting of hydrogen, or alkyl; or

R^{13} and R^{14} may combine to form a heterocyclo group; and

60 n is 1, 2 or 3.

Within the above preferred groups, more preferred groups of intermediate compounds are those wherein R^5 , R^6 , R^{11} , R^{12} , R^{13} or R^{14} are independently groups described in the section titled "preferred embodiments" herein below.

In a seventh aspect, this invention is directed to methods of preparing compounds of Formula (I).

Lastly, this invention is also directed to identifying a chemical compound that modulates the catalytic activity of a protein kinase by contacting cells expressing said protein kinase with a compound or a salt of the present invention and then monitoring said cells for an effect.

DETAILED DESCRIPTION OF THE
INVENTION

Definitions

Unless otherwise stated the following terms used in the specification and claims have the meanings discussed below:

"Alkyl" refers to a saturated aliphatic hydrocarbon radical including straight chain and branched chain groups of 1 to 20 carbon atoms (whenever a numerical range; e.g. "1-20", is stated herein, it means that the group, in this case the alkyl group, may contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc. up to and including 20 carbon atoms). Alkyl groups containing from 1 to 4 carbon atoms are referred to as lower alkyl groups. When said lower alkyl groups lack substituents, they are referred to as unsubstituted lower alkyl groups. More preferably, an alkyl group is a medium size alkyl having 1 to 10 carbon atoms e.g., methyl, ethyl, propyl, 2-propyl, n-butyl, iso-butyl, tert-butyl, pentyl, and the like. Most preferably, it is a lower alkyl having 1 to 4 carbon atoms e.g., methyl, ethyl, propyl, 2-propyl, n-butyl, iso-butyl, or tert-butyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent group(s) is preferably one or more, more preferably one to three, even more preferably one or two substituent(s) independently selected from the group consisting of halo, hydroxy, unsubstituted lower alkoxy, aryl optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, aryloxy optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, 6-member heteroaryl having from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, the carbon and the nitrogen atoms in the group being optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, 5- or 6-member heteroalicyclic group having from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, the carbon and the nitrogen atoms in the group being optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, mercapto, (unsubstituted lower alkyl)thio, arylthio optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, cyano, acyl, thioacyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, nitro, N-sulfonamido, S-sulfonamido, $R^{18}S(O)-$, $R^{18}S(O)_2-$, $-C(O)OR^{18}$, $R^{18}C(O)O-$, and $-NR^{18}R^{19}$, wherein R^{18} and R^{19} are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl, trihalomethyl, unsubstituted (C_3-C_6)cycloalkyl, unsubstituted lower alkenyl, unsubstituted lower alkynyl and aryl optionally substituted with one or more, groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups.

Preferably, the alkyl group is substituted with one or two substituents independently selected from the group consisting of hydroxy, 5- or 6-member heteroalicyclic group having from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, the carbon and nitrogen (if present) atoms in the group being optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkoxy groups, 5-member heteroaryl having from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, the carbon and the nitrogen atoms in the group being optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, 6-member heteroaryl having from 1 to 3 nitrogen atoms in the ring, the carbons in the ring being optionally substituted with one or more groups, preferably one, two or three groups which are independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, or $-NR^{18}R^{19}$, wherein R^{18} and R^{19} are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl. Even more preferably the alkyl group is substituted with one or two substituents which are independently of each other hydroxy, dimethylamino, ethylamino, diethylamino, dipropylamino, pyrrolidino, piperidino, morpholino, piperazino, 4-lower alkylpiperazino, phenyl, imidazolyl, pyridinyl, pyridazinyl, pyrimidinyl, oxazolyl, triazinyl, and the like.

"Cycloalkyl" refers to a 3 to 8 member all-carbon monocyclic ring, an all-carbon 5-member/6-member or 6-member/6-member fused bicyclic ring or a multicyclic fused ring (a "fused" ring system means that each ring in the system shares an adjacent pair of carbon atoms with each other ring in the system) group wherein one or more of the rings may contain one or more double bonds but none of the rings has a completely conjugated pi-electron system.

Examples, without limitation, of cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexadiene, adamantane, cycloheptane, cycloheptatriene, and the like. A cycloalkyl group may be substituted or unsubstituted. When substituted, the substituent group(s) is preferably one or more, more preferably one or two substituents, independently selected from the group consisting of unsubstituted lower alkyl, trihaloalkyl, halo, hydroxy, unsubstituted lower alkoxy, aryl optionally substituted with one or more, preferably one or two groups independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, aryloxy optionally substituted with one or more, preferably one or two groups independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, 6-member heteroaryl having from 1 to 3 nitrogen atoms in the ring, the carbons in the ring being optionally substituted with one or more, preferably one or two groups independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, 5-member heteroaryl having from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, the carbon and nitrogen atoms of the group being optionally substituted with one or more, preferably one or two groups independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, 5- or 6-member heteroalicyclic group having from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, the carbon and nitrogen (if present) atoms in the group

being optionally substituted with one or more, preferably one or two groups independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, mercapto,(unsubstituted lower alkyl)thio, arylthio optionally substituted with one or more, preferably one or two groups independently of each other halo, hydroxy, unsubstituted lower alkyl or unsubstituted lower alkoxy groups, cyano, acyl, thioacyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, nitro, N-sulfonamido, S-sulfonamido, $R^{18}S(O)_{-}$, $R^{18}S(O)_{2-}$, $-C(O)OR^{18}$, $R^{18}C(O)O-$, and $-NR^{18}R^{19}$ are as defined above.

"Alkenyl" refers to a lower alkyl group, as defined herein, consisting of at least two carbon atoms and at least one carbon—carbon double bond. Representative examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, and the like.

"Alkynyl" refers to a lower alkyl group, as defined herein, consisting of at least two carbon atoms and at least one carbon—carbon triple bond. Representative examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-, 2-, or 3-butynyl, and the like.

"Aryl" refers to an all-carbon monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups of 1 to 12 carbon atoms having a completely conjugated pi-electron system. Examples, without limitation, of aryl groups are phenyl, naphthalenyl and anthracenyl. The aryl group may be substituted or unsubstituted. When substituted, the substituted group(s) is preferably one or more, more preferably one, two or three, even more preferably one or two, independently selected from the group consisting of unsubstituted lower alkyl, trihaloalkyl, halo, hydroxy, unsubstituted lower alkoxy, mercapto, (unsubstituted lower alkyl)thio, cyano, acyl, thioacyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, nitro, N-sulfonamido, S-sulfonamido, $R^{18}S(O)_{-}$, $R^{18}S(O)_{2-}$, $-C(O)OR^{18}$, $R^{18}C(O)O-$, and $-NR^{18}R^{19}$, with R^{18} and R^{19} as defined above. Preferably, the aryl group is optionally substituted with one or two substituents independently selected from halo, unsubstituted lower alkyl, trihaloalkyl, hydroxy, mercapto, cyano, N-amido, mono or dialkylamino, carboxy, or N-sulfonamido.

"Heteroaryl" refers to a monocyclic or fused ring (i.e., rings which share an adjacent pair of atoms) group of 5 to 12 ring atoms containing one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, and, in addition, having a completely conjugated pi-electron system. Examples, without limitation, of unsubstituted heteroaryl groups are pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrimidine, quinoline, isoquinoline, purine and carbazole. The heteroaryl group may be substituted or unsubstituted. When substituted, the substituted group(s) is preferably one or more, more preferably one, two, or three, even more preferably one or two, independently selected from the group consisting of unsubstituted lower alkyl, trihaloalkyl, halo, hydroxy, unsubstituted lower alkoxy, mercapto,(unsubstituted lower alkyl)thio, cyano, acyl, thioacyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, nitro, N-sulfonamido, S-sulfonamido, $R^{18}S(O)_{-}$, $R^{18}O_{2-}$, $-C(O)OR^{18}$, $R^{18}C(O)O-$, and $-NR^{18}R^{19}$, with R^{18} and R^{19} as defined above. Preferably, the heteroaryl group is optionally substituted with one or two substituents independently selected from halo, unsubstituted lower alkyl, trihaloalkyl, hydroxy, mercapto, cyano, N-amido, mono or dialkylamino, carboxy, or N-sulfonamido.

"Heteroalicyclic" refers to a monocyclic or fused ring group having in the ring(s) of 5 to 9 ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or S(O)_n (where n is an integer from 0 to 2), the remaining ring atoms being C. The rings may also have one or more double bonds. However, the rings do not have a completely conjugated pi-electron system. Examples, without limitation, of unsubstituted heteroalicyclic groups are pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, homopiperazino, and the like. The heteroalicyclic ring may be substituted or unsubstituted. When substituted, the substituted group(s) is preferably one or more, more preferably one, two or three, even more preferably one or two, independently selected from the group consisting of unsubstituted lower alkyl, trihaloalkyl, halo, hydroxy, unsubstituted lower alkoxy, mercapto,(unsubstituted lower alkyl)thio, cyano, acyl, thioacyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, nitro, N-sulfonamido, S-sulfonamido, $R^{18}S(O)_{-}$, $R^{18}S(O)_{2-}$, $-C(O)OR^{18}$, $R^{18}C(O)O-$, and $-NR^{18}R^{19}$, with R^{18} and R^{19} as defined above. Preferably, the heteroalicyclic group is optionally substituted with one or two substituents independently selected from halo, unsubstituted lower alkyl, trihaloalkyl, hydroxy, mercapto, cyano, N-amido, mono or dialkylamino, carboxy, or N-sulfonamido.

Preferably, the heteroalicyclic group is optionally substituted with one or two substituents independently selected from halo, unsubstituted lower alkyl, trihaloalkyl, hydroxy, mercapto, cyano, N-amido, mono or dialkylamino, carboxy, or N-sulfonamido.

"Heterocycle" means a saturated cyclic radical of 3 to 8 ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or S(O)_n (where n is an integer from 0 to 2), the remaining ring atoms being C, where one or two C atoms may optionally be replaced by a carbonyl group. The heterocycl ring may be optionally substituted independently with one, two, or three substituents selected from optionally substituted lower alkyl (substituted with 1 or 2 substituents independently selected from carboxy or ester), haloalkyl, cyanoalkyl, halo, nitro, cyano, hydroxy, alkoxy, amino, monoalkylamino, dialkylamino, aralkyl, heteroaralkyl, $-COR$ (where R is alkyl) or $-COOR$ where R is (hydrogen or alkyl). More specifically the term heterocycl includes, but is not limited to, tetrahydropyran, 2,2-dimethyl-1,3-dioxolane, piperidino, N-methylpiperidin-3-yl, piperazino, N-methylpyrrolidin-3-yl, 3-pyrrolidino, morpholino, thiomorpholino, thiomorpholino-1-oxide, thiomorpholino 1,1-dioxide, 4-ethyloxycarbonylpiperazino, 3-oxopiperazino, 2-imidazolidone, 2-pyrrolidinone, 2-oxohomopiperazino, tetrahydropyrimidin-2-one, and the derivatives thereof. Preferably, the heterocycle group is optionally substituted with one or two substituents independently selected from halo, unsubstituted lower alkyl, lower alkyl substituted with carboxy, ester, hydroxy, mono or dialkylamino.

"Hydroxy" refers to an $-OH$ group.

"Alkoxy" refers to both an $-O$ -(unsubstituted alkyl) and an $-O$ -(unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, e.g., methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, and the like.

"Aryloxy" refers to both an $-O$ -aryl and an $-O$ -heteroaryl group, as defined herein. Representative examples include, but are not limited to, phenoxy,

pyridinyloxy, furanyloxy, thienyloxy, pyrimidinyloxy, pyrazinyloxy, and the like, and derivatives thereof.

“Mercapto” refers to an —SH group.

“Alkylthio” refers to both an —S-(unsubstituted alkyl) and an —S-(unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, e.g., methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, and the like.

“Arylthio” refers to both an —S-aryl and an —S-heteraryl group, as defined herein. Representative examples include, but are not limited to, phenylthio, pyridylthio, furanylthio, thienylthio, pyrimidylthio, and the like and derivatives thereof.

“Acyl” refers to a —C(O)—R" group, where R" is selected from the group consisting of hydrogen, unsubstituted lower alkyl, trihalomethyl, unsubstituted cycloalkyl, aryl optionally substituted with one or more, preferably one, two, or three substituents selected from the group consisting of unsubstituted lower alkyl, trihalomethyl, unsubstituted lower alkoxy, halo and —NR¹⁸R¹⁹ groups, heteroaryl (bonded through a ring carbon) optionally substituted with one or more, preferably one, two, or three substituents selected from the group consisting of unsubstituted lower alkyl, trihaloalkyl, unsubstituted lower alkoxy, halo and —NR¹⁸R¹⁹ groups and heteroalicyclic (bonded through a ring carbon) optionally substituted with one or more, preferably one, two, or three substituents selected from the group consisting of unsubstituted lower alkyl, trihaloalkyl, unsubstituted lower alkoxy, halo and —NR¹⁸R¹⁹ groups. Representative acy groups include, but are not limited to, acetyl, trifluoroacetyl, benzoyl, and the like.

“Aldehyde” refers to an acyl group in which R" is hydrogen.

“Thioacyl” refers to a —C(S)—R" group, with R" as defined herein.

“Ester” refers to a —C(O)O—R" group with R" as defined herein except that R" cannot be hydrogen.

“Acetyl” group refers to a —C(O)CH₃ group.

“Halo” group refers to fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.

“Trihalomethyl” group refers to a —CX₃ group wherein X is a halo group as defined herein.

“Trihalomethanesulfonyl” group refers to a X₃CS(=O)₂— groups with X as defined above.

“Cyano” refers to a —C≡N group.

“Methylenedioxy” refers to a —OCH₂O— group where the two oxygen atoms are bonded to adjacent carbon atoms.

“Ethylenedioxy” group refers to a —OCH₂CH₂O— where the two oxygen atoms are bonded to adjacent carbon atoms.

“S-sulfonamido” refers to a —S(O)₂NR¹⁸R¹⁹ group, with R¹⁸ and R¹⁹ as defined herein.

“N-sulfonamido” refers to a —NR¹⁸S(O)₂R¹⁹ group, with R¹⁸ and R¹⁹ as defined herein.

“O-carbamyl” group refers to a —OC(O)NR¹⁸R¹⁹ group with R¹⁸ and R¹⁹ as defined herein.

“N-carbamyl” refers to an R¹⁸OC(O)NR¹⁹— group, with R¹⁸ and R¹⁹ as defined herein.

“O-thiocarbamyl” refers to a —OC(S)NR¹⁸R¹⁹ group with R¹⁸ and R¹⁹ as defined herein.

“N-thiocarbamyl” refers to a R¹⁸OC(S)NR¹⁹— group, with R¹⁸ and R¹⁹ as defined herein.

“Amino” refers to an —NR¹⁸R¹⁹ group, wherein R¹⁸ and R¹⁹ are both hydrogen.

“C-amido” refers to a —C(O)NR¹⁸R¹⁹ group with R¹⁸ and R¹⁹ as defined herein.

“N-amido” refers to a R¹⁸C(O)NR¹⁹— group, with R¹⁸ and R¹⁹ as defined herein.

“Nitro” refers to a —NO₂ group.

“Haloalkyl” means an unsubstituted alkyl, preferably unsubstituted lower alkyl as defined above that is substituted with one or more same or different halo atoms, e.g., —CH₂Cl, —CF₃, —CH₂CF₃, —CH₂CCl₃, and the like.

“Aralkyl” means unsubstituted alkyl, preferably unsubstituted lower alkyl as defined above which is substituted with an aryl group as defined above, e.g., —CH₂phenyl, —(CH₂)₂phenyl, —(CH₂)₃phenyl, CH₃CH(CH₃)CH₂phenyl, and the like and derivatives thereof.

“Heteroaralkyl” group means unsubstituted alkyl, preferably unsubstituted lower alkyl as defined above which is substituted with a heteroaryl group, e.g., —CH₂pyridinyl, —(CH₂)₂pyrimidinyl, —(CH₂)₃imidazolyl, and the like, and derivatives thereof.


“Monoalkylamino” means a radical —NHR where R is an unsubstituted alkyl or unsubstituted cycloalkyl group as defined above, e.g., methylamino, (1-methylethyl)amino, cyclohexylamino, and the like.

“Dialkylamino” means a radical —NRR where each R is independently an unsubstituted alkyl or unsubstituted cycloalkyl group as defined above, e.g., dimethylamino, diethylamino, (1-methylethyl)-ethylamino, cyclohexylmethylamino, cyclopentylmethylamino, and the like.


“Cyanoalkyl” means unsubstituted alkyl, preferably unsubstituted lower alkyl as defined above, which is substituted with 1 or 2 cyano groups.

“Optional” or “optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “heterocycle group optionally substituted with an alkyl group” means that the alkyl may but need not be present, and the description includes situations where the heterocycle group is substituted with an alkyl group and situations where the heterocycle group is not substituted with the alkyl group.

The terms “2-indolinone”, “indolin-2-one” and “2-oxindole” are used interchangeably herein to refer to a molecule having the chemical structure:



The term “pyrrole” refers to a molecule having the chemical structure:



The term “pyrrole substituted 2-indolinone” and “3-pyrrolidinyl-2-indolinone” are used interchangeably herein to refer to a chemical compound having the general structure shown in Formula (I).

Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers". Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers" and those that are non-superimposable mirror images of each other are termed "enantiomers". When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".

The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. For example, if the R⁶ substituent in a compound of formula (I) is 2-hydroxyethyl, then the carbon to which the hydroxy group is attached is an asymmetric center and therefore the compound of Formula (I) can exist as an (R)- or (S)-stereoisomer. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 1992).

The compounds of Formula (I) may exhibit the phenomena of tautomerism and structural isomerism. For example, the compounds described herein may adopt an E or a Z configuration about the double bond connecting the 2-indolinone moiety to the pyrrole moiety or they may be a mixture of E and Z. This invention encompasses any tautomer or structural isomeric form and mixtures thereof which possess the ability to modulate RTK, CTK and/or STK activity and is not limited to any one tautomeric or structural isomeric form.

A "pharmaceutical composition" refers to a mixture of one or more of the compounds described herein, or physiologically/pharmaceutically acceptable salts or prodrugs thereof, with other chemical components, such as physiologically/pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

The compound of Formula (I) may also act as a prodrug. A "prodrug" refers to an agent which is converted into the parent drug *in vivo*. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water solubility is beneficial.

A further example of a prodrug might be a short polypeptide, for example, without limitation, a 2-10 amino

acid polypeptide, bonded through a terminal amino group to a carboxy group of a compound of this invention wherein the polypeptide is hydrolyzed or metabolized *in vivo* to release the active molecule. The prodrugs of a compound of Formula (I) are within the scope of this invention.

Additionally, it is contemplated that a compound of Formula (I) would be metabolized by enzymes in the body of the organism such as human being to generate a metabolite that can modulate the activity of the protein kinases. Such metabolites are within the scope of the present invention.

As used herein, a "physiologically/pharmaceutically acceptable carrier" refers to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.

An "pharmaceutically acceptable excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of a compound. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

As used herein, the term "pharmaceutically acceptable salt" refers to those salts which retain the biological effectiveness and properties of the parent compound. Such salts include:

(i) acid addition salt which is obtained by reaction of the free base of the parent compound with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, sulfuric acid, and perchloric acid and the like, or with organic acids such as acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaric acid, citric acid, succinic acid or malonic acid and the like, preferably hydrochloric acid or (L)-malic acid such as the L-malate salt of 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidinemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide; or

(2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanamine, diethanamine, triethanamine, tromethamine, N-methylglucamine, and the like.

"PK" refers to receptor protein tyrosine kinase (RTKs), non-receptor or "cellular" tyrosine kinase (CTKs) and serine-threonine kinases (STKs).

"Method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by, practitioners of the chemical, pharmaceutical, biological, biochemical and medical arts.

"Modulation" or "modulating" refers to the alteration of the catalytic activity of RTKs, CTKs and STKs. In particular, modulating refers to the activation of the catalytic activity of RTKs, CTKs and STKs, preferably the activation or inhibition of the catalytic activity of RTKs, CTKs and STKs, depending on the concentration of the compound or salt to which the RTK, CTK or STK is exposed or, more preferably, the inhibition of the catalytic activity of RTKs, CTKs and STKs.

"Catalytic activity" refers to the rate of phosphorylation of tyrosine under the influence, direct or indirect, of RTKs

15

and/or CTks or the phosphorylation of serine and threonine under the influence, direct or indirect, of STks.

“Contacting” refers to bringing a compound of this invention and a target PK together in such a manner that the compound can affect the catalytic activity of the PK, either directly, i.e., by interacting with the kinase itself, or indirectly, i.e., by interacting with another molecule on which the catalytic activity of the kinase is dependent. Such “contacting” can be accomplished “in vitro,” i.e., in a test tube, a petri dish or the like. In a test tube, contacting may involve only a compound and a PK of interest or it may involve whole cells. Cells may also be maintained or grown in cell culture dishes and contacted with a compound in that environment. In this context, the ability of a particular compound to affect a PK related disorder, i.e., the IC₅₀ of the compound, defined below, can be determined before use of the compounds in vivo with more complex living organisms is attempted. For cells outside the organism, multiple methods exist, and are well-known to those skilled in the art, to get the PKs in contact with the compounds including, but not limited to, direct cell microinjection and numerous transmembrane carrier techniques.

“In vitro” refers to procedures performed in an artificial environment such as, e.g., without limitation, in a test tube or culture medium.

“In vivo” refers to procedures performed within a living organism such as, without limitation, a mouse, rat or rabbit.

“PK related disorder,” “PK driven disorder,” and “abnormal PK activity” all refer to a condition characterized by inappropriate, i.e., under or, more commonly, over, PK catalytic activity, where the particular PK can be an RTK, a CTK or an STK. Inappropriate catalytic activity can arise as the result of either: (1) PK expression in cells which normally do not express PKs, (2) increased PK expression leading to unwanted cell proliferation, differentiation and/or growth, or, (3) decreased PK expression leading to unwanted reductions in cell proliferation, differentiation and/or growth. Over-activity of a PK refers to either amplification of the gene encoding a particular PK or production of a level of PK activity which can correlate with a cell proliferation, differentiation and/or growth disorder (that is, as the level of the PK increases, the severity of one or more of the symptoms of the cellular disorder increases). Under-activity is, of course, the converse, wherein the severity of one or more symptoms of a cellular disorder increase as the level of the PK activity decreases.

“Treat”, “treating” and “treatment” refer to a method of alleviating or abrogating a PK mediated cellular disorder and/or its attendant symptoms. With regard particularly to cancer, these terms simply mean that the life expectancy of

16

an individual affected with a cancer will be increased or that one or more of the symptoms of the disease will be reduced.

“Organism” refers to any living entity comprised of at least one cell. A living organism can be as simple as, for example, a single eukaryotic cell or as complex as a mammal, including a human being.

“Therapeutically effective amount” refers to that amount of the compound being administered which will relieve to some extent one or more of the symptoms of the disorder being treated. In reference to the treatment of cancer, a therapeutically effective amount refers to that amount which has the effect of:

- (1) reducing the size of the tumor;
- (2) inhibiting (that is, slowing to some extent, preferably stopping) tumor metastasis;
- (3) inhibiting to some extent (that is, slowing to some extent, preferably stopping) tumor growth, and/or,
- (4) relieving to some extent (or, preferably, eliminating) one or more symptoms associated with the cancer.

“Monitoring” means observing or detecting the effect of contacting a compound with a cell expressing a particular PK. The observed or detected effect can be a change in cell phenotype, in the catalytic activity of a PK or a change in the interaction of a PK with a natural binding partner. Techniques for observing or detecting such effects are well-known in the art.

The above-referenced effect is selected from a change or an absence of change in a cell phenotype, a change or absence of change in the catalytic activity of said protein kinase or a change or absence of change in the interaction of said protein kinase with a natural binding partner in a final aspect of this invention.

“Cell phenotype” refers to the outward appearance of a cell or tissue or the biological function of the cell or tissue. Examples, without limitation, of a cell phenotype are cell size, cell growth, cell proliferation, cell differentiation, cell survival, apoptosis, and nutrient uptake and use. Such phenotypic characteristics are measurable by techniques well-known in the art.

“Natural binding partner” refers to a polypeptide that binds to a particular PK in a cell. Natural binding partners can play a role in propagating a signal in a PK-mediated signal transduction process. A change in the interaction of the natural binding partner with the PK can manifest itself as an increased or decreased concentration of the PK/natural binding partner complex and, as a result, in an observable change in the ability of the PK to mediate signal transduction.

Representative compounds of the present invention are shown in Table I below.

TABLE 1

Example Structure	Name
1	4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylideneethyl)-1H-pyrole-2-carboxylic acid
2	4-Methyl-5-(1-methyl-2-oxo-1,2-dihydroindol-3-ylideneethyl)-1H-pyrole-2-carboxylic acid
3	4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylideneethyl)-1H-pyrole-2-carboxylic acid methyl ester
4	5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylideneethyl)-4-methyl-1H-pyrole-2-carboxylic acid ethyl ester

TABLE 1-continued

Example	Structure	Name
5		5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylideneethyl)-4-methyl-1H-pyrole-2-carboxylic acid
6		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-4-methyl-1H-pyrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
7		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-4-methyl-1H-pyrole-2-carboxylic acid (3-diethylaminopropyl)amide
8		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-4-methyl-1H-pyrole-2-carboxylic acid (2-diethylaminoethyl)amide

TABLE 1-continued

Example	Structure	Name
9		5-(2-Oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrole-2-carboxylic acid (2-diethylaminoethyl)amide
10		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrole-2-carboxylic acid (2-diethylaminoethyl)amide
11		5-(2-Oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrole-2-carboxylic acid (2-diethylaminoethyl)amide
12		3-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrole-2-carboxylic acid (3-diethylaminopropyl)amide

TABLE 1-continued

Example	Structure	Name
13		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-3-methyl-1H-pyrole-2-carboxylic acid (3-diethylaminopropyl)amide
14		3-Methyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylideneethyl)-1H-pyrole-2-carboxylic acid (3-diethylaminopropyl)amide
15		5-(5-Methoxy-2-oxo-1,2-dihydroindol-3-ylideneethyl)-3-methyl-1H-pyrole-2-carboxylic acid (3-diethylaminopropyl)amide
16		5-(6-Methoxy-2-oxo-1,2-dihydroindol-3-ylideneethyl)-3-methyl-1H-pyrole-2-carboxylic acid (3-diethylaminopropyl)amide

TABLE 1-continued

Example	Structure	Name
17		3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid (2-diethylaminoethyl)amide
18		3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid (3-diethylaminopropyl)amide
19		3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

TABLE 1-continued

Example	Structure	Name
20		3-(2-Oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidene)hexane-1,6-diamine
21		4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidene)hexane-3-methanamine
22		4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidene)hexane-3-methanamine

TABLE 1-continued

Example	Structure	Name
23		4-Benzoyl-3-methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
24		4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
25		4-Benzoyl-3-methyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

TABLE 1-continued

Example	Structure	Name
26		4-Benzoyl-5-(6-methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
27		4-Benzoyl-5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
28		4-Benzoyl-5-(5-methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide

TABLE 1-continued

Example	Structure	Name
29		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl)-3-methyl-1H-pyrole-2-carboxylic acid (3-diethylaminopropyl)amide
30		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl)-3-methyl-1H-pyrole-2-carboxylic acid (3-pyridin-1-ylpropyl)amide
31		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl)-3-methyl-1H-pyrole-2-carboxylic acid (3-morpholin-4-ylpropyl)amide

TABLE 1-continued

Example	Structure	Name
32		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (3-hydroxy-propyl)amide
33		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (2-hydroxy-ethyl)amide
34		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (2-morpholin-4-yl-ethyl)amide

TABLE 1-continued

Example	Structure	Name
35		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-3-methyl-1H-pyrrole-2-carboxylic acid (2-pyridin-1-yl-ethyl)amide
36		4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-3-methyl-1H-pyrrole-2-carboxylic acid [2-(4-hydroxy-phenyl)-ethyl]amide
37		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide

TABLE 1-continued




Example	Structure	Name
38		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-pyridin-1-ylpropyl)amide
39		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
40		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid [3-(4-methyl-piperazin-1-yl)propyl]amide

TABLE 1-continued

Example	Structure	Name
41		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-2-isopropyl-4-phenyl-1H-pyrole-3-carboxylic acid
42		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-2-methyl-4-phenyl-1H-pyrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
43		5-[6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylideneethyl]-2-methyl-4-phenyl-1H-pyrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide

TABLE 1-continued

Example	Structure	Name
44		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrole-3-carboxylic acid (2-dimethylaminoethyl)amide
45		5-(6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrole-3-carboxylic acid (2-dimethylamino-ethyl)amide
46		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrole-3-carboxylic acid ethyl ester

TABLE 1-continued

Example	Structure	Name
47		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl)-2-methyl-4-phenyl-1H-pyrole-3-carboxylic acid (2-dimethylaminopropyl)amide
48		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-dimethylaminooethyl)amide
49		2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidene)methyl)-1H-pyrole-3-carboxylic acid (2-dimethylaminooethyl)amide

TABLE 1-continued

Example	Structure	Name
50		5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide
51		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
52		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide

TABLE 1-continued

Example	Structure	Name
53		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide
54		5-(6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-dimethylamino-ethyl)amide
55		5-[6-(3-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-dimethylamino-ethyl)amide

TABLE 1-continued

Example	Structure	Name
56		2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylideneethyl)pyrrole-3-carboxylic acid (2-diethylaminocetyl)amide
57		2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylideneethyl)pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
58		2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylideneethyl)pyrrole-3-carboxylic acid (3-imidazol-1-yl-propyl)amide

TABLE 1-continued

Example	Structure	Name
59		2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylideneethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
60		2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylideneethyl)-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
61		2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylideneethyl)-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide

TABLE 1-continued

Example	Structure	Name
62		5-[6-(3,5-Dichlorophenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
63		2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

TABLE 1-continued

Example	Structure	Name
64		2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrole-3-carboxylic acid (2-pyridin-1-yl-ethyl)amide
65		2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrole-3-carboxylic acid (3-dimethylaminopropyl)amide

TABLE 1-continued

Example	Structure	Name
66		2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylideneethyl)-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide
67		2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylideneethyl)-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide
68		2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylideneethyl)-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide

TABLE 1-continued

Example	Structure	Name
69		3-[4-(3-Diethylaminopropylcarbamoyl)-3,5-dimethyl-2-oxo-2,3-dihydro-1H-indole-4-carboxylic acid (3-chloro-4-methoxy-phenyl)amide
70		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide
71		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylideneethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (2-diethylaminooethyl)amide

TABLE 1-continued

Example	Structure	Name
72		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylideneacetyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide
73		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylideneacetyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide
74		5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylideneacetyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (pyridin-4-ylmethyl)amide

TABLE 1-continued

Example	Structure	Name
75		5-[6-(4-Buyl-phenyl)-2-oxo-1,2-dihydroindol-3-ylidene]methyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
76		5-[6-(5-Isopropyl-2-methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidene]methyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide

TABLE 1-continued

Example	Structure	Name
77		5-[6-(4-Ethyl-phenyl)-2-oxo-1,2-dihydroindol-3-ylideneethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide
78		5-[6-(2,4-Dimethoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylideneethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide

TABLE 1-continued



Example Structure	Name
 <p>79</p>	5-[6-(3-isopropyl-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyridin-1-yl-ethyl)amide
 <p>80</p>	5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

TABLE I-continued

Example	Structure	Name
81		3-[4-(2-diethylaminocarbonyl)-3,5-dimethyl-1H-pyrrol-2-yl]methylenecarboxylic acid
82		5-(5-Dimethylsulfanoyl-2-oxo-1,2-dihydroindol-3-ylideneethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)amide

TABLE 1-continued

Example	Structure	Name
83		5-[5-(3-Chloro-phenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylideneamethyl]-2,4-dimethyl-1H-Pyrrole-3-carboxylic acid (2-pyridin-1-yl-ethyl)amide
84		2,4-Dimethyl-5-[2-oxo-5-(pyridin-3-ylsulfamoyl)-1,2-dihydroindol-3-ylideneamethyl]-1H-pyrrole-3-carboxylic acid (2-pyridin-1-yl-ethyl)amide
85		3-[3,5-Dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrrol-2-ylmethylene]-4-(2-hydroxy-ethyl)-1,3-dihydroindol-2-one

TABLE 1-continued

Example	Structure	Name
86		3-[3,5-Dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid phenylamide
87		5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylideneethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
88		5-[5-(3-Chloro-phenylsulfamoyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide]

TABLE 1-continued

Example	Structure	Name
89		3-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid (2-dimethylamino-ethyl)-amide
90		3-(2-Oxo-1,2-dihydro-indol-3-ylidene-methyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid ethyl ester
91		3-(4-Methyl-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid ethyl ester

TABLE 1-continued

Example	Structure	Name
92		3-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid ethyl ester
93		3-(3-Ethoxycarbonyl-4,5,6,7-tetrahydro-2H-isindol-1-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid
94		3-(5-Methoxy-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid ethyl ester

TABLE 1-continued

Example	Structure	Name
95		3-(2-Oxo-5-phenyl-1,2-dihydro-indol-3-ylideneethyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid ethyl ester
96		3-(2-Oxo-5-sulfamoyl-1,2-dihydro-indol-3-ylideneethyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid ethyl ester
97		3-(5-Methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylideneethyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid ethyl ester

TABLE 1-continued

Example	Structure	Name
98		3-(5-Dimethylsulfanoyl-2-oxo-1,2-dihydro-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoundole-1-carboxylic acid ethyl ester
99		3-(2-Oxo-5-phenylsulfamoyl-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoundole-1-carboxylic acid ethyl ester
100		3-(6-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoundole-1-carboxylic acid ethyl ester

TABLE 1-continued

Example	Structure	Name
101		3-(2-Oxo-6-phenyl-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid ethyl ester
102		3-(3-Ethoxycarbonyl-4,5,6,7-tetrahydro-2H-isindol-1-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid
103		3-(6-Methoxy-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isindole-1-carboxylic acid ethyl ester

TABLE 1-continued

Example	Structure	Name
104		3-(5-isopropylsulfanoyl-2-oxo-1,2-dihydro-3-ylideneethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester
105		3-(3-Methylcarbamoyl-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid
106		3-(3-Dimethylcarbamoyl-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid

TABLE 1-continued

Example	Structure	Name
107		2-Oxo-3-[3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-2H-isindol-1-ylmethylene]-2,3-dihydro-1H-indole-5-carboxylic acid
108		3-[3-(Morpholine-4-carbonyl)-4,5,6,7-tetrahydro-2H-isindol-1-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid
109		3-[3-(Morpholine-4-carbonyl)-4,5,6,7-tetrahydro-2H-isindol-1-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid

TABLE 1-continued

Example	Structure	Name
110		3-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid methylamide
111		3-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid dimethylamide
112		5-Bromo-3-[3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene]-1,3-dihydro-indol-2-one

TABLE 1-continued

Example	Structure	Name
113		5-Bromo-3-[3-(morpholine-4-carbonyl)-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene]-1,3-dihydro-indol-2-one
114		3-(3-Dimethylcarbamoyl-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid
115		4-Methyl-5-(5-methylsulfonyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrole-3-carboxylic acid

TABLE I-continued

Example	Structure	Name
116		{[4-Methyl-5-(4-methyl-5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylideneethyl)-1H-pyrole-3-carboxylic acid ethyl ester]-amino}-acetic acid ethyl ester
117		{[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylideneethyl)-1H-pyrole-3-carboxylic acid ethyl ester]-amino}-acetic acid ethyl ester
118		{[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylideneethyl)-1H-pyrole-3-carboxylic acid ethyl ester]-amino}-acetic acid ethyl ester

TABLE 1-continued

Example	Structure	Name
119		3-[3-Methyl-4-(piperidine-1-carbonyl)-1H-pyrrrol-2-yl]methylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid methylamide
120		5-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidene)methyl-1H-pyrrrole-3-carboxylic acid
121		5-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidene)methyl-1H-pyrrrole-3-carboxylic acid ethyl ester

TABLE 1-continued

Example	Structure	Name
122		2-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-5-methyl-1H-pyrrole-3-carboxylic acid ethyl ester
123		2-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-5-methyl-1H-pyrrole-3-carboxylic acid
124		2-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-5-methyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide

TABLE 1-continued

Example	Structure	Name	
125		2-(5-Bromo-2-oxo-1,2-dihydro-3-ylideneethyl)-5-methyl-3-carboxylic acid (2-diethylamino-ethyl)-anide	
133		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylideneethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-acetylamino-ethyl)-anide	399 [M - 1]
134		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylideneethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-acetylamino-ethyl)-anide	383 [M - 1]

TABLE 1-continued

Example	Structure	Name	Mass
135		2-(2-acetylaminooethyl)-5-[2-acetyl-3-methyl-2H-pyrole-1,2-dihydro-indol-3Z-ylidene]pentane-3-carboxylic acid (2-acetylaminooethyl)-amide	365 [M -]
136		5-[5-(2-acetyl-3-methyl-2H-pyrole-1,2-dihydro-indol-3Z-ylidene)pentyl]pyrimidin-1-yl)propyl]-amide	500 [M + 1] 502 [M + 1]
137		5-[5-(2-acetyl-3-methyl-2H-pyrole-1,2-dihydro-indol-3Z-ylidene)pentyl]pyrimidin-1-yl)propyl]-amide	454 [M - 1]

TABLE 1-continued

Example	Structure	Name	Mass
138		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-yldene]methyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [3-(2-oxo-tetrahydro-pyrimidin-1-yl)propyl]-amide	438 [M - 1]
139		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-yldene]methyl]-1H-pyrole-3-carboxylic acid [3-(2-oxo-tetrahydro-pyrimidin-1-yl)propyl]-amide	422 [M + 1]
140		5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-yldene]methyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [3-(2-oxo-tetrahydro-pyrimidin-1-yl)propyl]-amide	447 [M + 1]

TABLE 1-continued

Example	Structure	Name	Mass
141		Trifluoro-acetate-4-[2-[(5-[5-[5-bromo-2-oxo-1,2-dihydro-indol-(3Z)-yldenenethyl]-2,4-dimethyl-1H-pyrole-3-carboxyl]-amino)-ethyl]-2-oxo-piperazin-1-ium;	436 [M + 1] 438 [M + 1]
126		2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-(3Z)-yldenenethyl)-1H-pyrole-3-carboxylic acid (2-dimethylaminooethyl)-amide	381 [M + 1]
127		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-yldenenethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-diethylaminooethyl)-amide	415 [M + 1]

TABLE 1-continued

Example	Structure	Name	Mass
128		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)-amide	379 [M + 1]
129		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)-amide	397 [M + 1]
130		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-1H-pyrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)-amide	413 [M + 1]

TABLE 1-continued

Example Structure	Name	Mass
131	2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-yldenenethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)-amide	353 [M + 1]
132	5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-yldenenethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)-amide	371 [M + 1]
142	5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-yldenenethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide	430 [M - 1]

TABLE 1-continued

Example	Structure	Name	Mass
143		5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-yldenenethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide	470 [M + 1] 472 [M - 1]
144		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-yldenenethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide	428 [M + 1]
145		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-yldenenethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide	412 [M + 1]

TABLE I-continued

Example	Structure	Name	Mass
146		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylideneethyl]-1H-pyrole-3-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide	392 [M - 1]
147		5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylideneethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide	419 [M + 1]
148		{4-[2-((5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylideneethyl]-2,4-dimethyl-1H-pyrole-3-carbonyl)-amino)-ethyl]-piperazin-1-yl}-acetic acid ethyl ester	558 [M + 1] 560 [M + 1]

TABLE I-continued

Example	Structure	Name	Mass
149		{4-[2-((5-chloro-2-oxo-1,2-dihydro-indol-3(2H)-ylidene)methyl)-2-dimethyl-1H-pyrrole-3-carbonyl]-amino)ethyl-piperazin-1-yl]-acetic acid ethyl ester	514 [M + 1]
150		{4-[2-((5-[5-fluoro-2-oxo-1,2-dihydro-indol-3(2H)-ylidene)methyl)-2-dimethyl-1H-pyrrole-3-carbonyl]-amino)ethyl-piperazin-1-yl]-acetic acid ethyl ester	498 [M + 1]

TABLE 1-continued

Example	Structure	Name	Mass
153		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidene]methyl-1H-pyrrole-3-carboxylic acid [2-(cyanomethyl)-amino]ethyl-1-amide	362 [M - 1]
154		5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidene]methyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(2-oxo-azepan-1-yl)propyl]-amide	511 [M - 1] 513 [M - 1]
155		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidene]methyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(2-oxo-azepan-1-yl)propyl]-amide	469 [M + 1]

TABLE 1-continued

Example	Structure	Name	Mass
156		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-yldienemethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [3-(2-oxo-azepan-1-yl)-propyl]-amide	453 [M + 1]
157		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-yldienemethyl]-1H-pyrole-3-carboxylic acid [3-(2-oxo-azepan-1-yl)-propyl]-amide	435 [M + 1]
158		5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-yldienemethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [3-(2-oxo-azepan-1-yl)-propyl]-amide	460 [M + 1]

TABLE 1-continued

Example	Structure	Name	Mass
159		5-[5'-Bromo-2-oxo-1,2-dihydro-indol-1(3Z)-ylidene-methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-acetylaminooethyl)-amide	443 [M - 1] 445 [M - 1]
160		Trifluoro-acetate-4-[2-({5-[5'-fluoro-2-oxo-1,2-dihydro-indol-1(3Z)-ylidene-methyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl}amino)-ethyl]-2-oxo-piperazin-1-iium.	426 [M + 1]

TABLE I-continued

Example	Structure	Name	408 [M + 1]
161		Trifluoro-acetate-[2-((2,4-dimethyl-5-[2-oxo-1,2-dihydro-3H-indol-(3Z)-ylienenethyl]-1H-pyrole-3-carbonyl)-amino)-ethyl]-2-oxo-piperazin-1-ium;	
162		Trifluoro-acetate-[2-((5-[5-cyano-2-oxo-1,2-dihydro-3H-indol-(3Z)-ylienenethyl]-2,4-dimethyl-1H-pyrole-3-carbonyl)-amino)-ethyl]-2-oxo-piperazin-1-ium;	433 [M + 1]

TABLE 1-continued



Example	Structure	Name	Molecular Weight
163	 <p>5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-yldienemethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(2-cyanoethyl)amino]-ethyl]-amide</p>		454 [M - 1] 456 [M - 1]
164	 <p>5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-yldienemethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(2-cyanoethyl)amino]-ethyl]-amide</p>		410 [M - 1]

TABLE 1-continued



Example	Structure	Name	Mass
165		5-[5-Fluoro-2-oxo-1,2-dihydro-1H-pyridenethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(2-cyanoethylamino)-ethyl]-amide	394 [M - 1]
166		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-1H-pyridenethyl]-1H-pyrole-3-carboxylic acid [2-(2-cyanoethylamino)-ethyl]-amide	376 [M - 1]

TABLE 1-continued

Example	Structure	Name	Mass
167		5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-yldenemethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(2-cyanoethyl)amino]ethyl-amide	401 [M - 1]
168		Trifluoro-acetate-4-[2-(5-[5-chloro-2-oxo-1,2-dihydro-indol-(3Z)-yldenemethyl]-2,4-dimethyl-1H-pyrole-3-carbonyl)amino]-ethyl]-2-oxo-piperazin-1-ium;	440 [M - 1]

TABLE 1-continued

Example	Structure	Name	$[M - 1]$
168		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-1(3Z)-ylidene-methyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(4-methyl-piperazin-1-yl)-ethyl]-amide	424 [M - 1]
169		5-[5-Chloro-2-oxo-1,2-dihydro-indol-1(3Z)-ylidene-methyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(4-methyl-piperazin-1-yl)-ethyl]-amide	440 [M - 1]
170		5-[5-Bromo-2-oxo-1,2-dihydro-indol-1(3Z)-ylidene-methyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(4-methyl-piperazin-1-yl)-ethyl]-amide	484 [M - 1] 486 [M - 1]

TABLE 1-continued

Example	Structure	Name	Mass
171		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-4-(3Z)-ylideneethyl]-1H-pyrole-3-carboxylic acid [2-(4-methyl-piperazin-1-yl)-ethyl]-amide	406 [M - 1]
172		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-4-(3Z)-ylideneethyl]-1H-pyrole-3-carboxylic acid [2-(3,5-dimethyl-piperazin-1-yl)-ethyl]-amide	422 [M + 1]
173		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-4-(3Z)-ylideneethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(3,5-dimethyl-piperazin-1-yl)-ethyl]-amide	438 [M - 1]

TABLE 1-continued

Example	Structure	Name	456 [M + 1]
174		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylideneethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(3,5-dimethyl-piperazin-1-yl)-ethyl]-amide	
175		5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylideneethyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid [2-(3,5-dimethyl-piperazin-1-yl)-ethyl]-amide	498 [M - 1] 500 [M - 1]
176		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylideneethyl]-1H-pyrole-3-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide	422 [M + 1]

TABLE 1-continued

Example Structure	Name	
177	<p>5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylideneethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(4-methyl-piperazin-1-yl)propyl]-amide</p>	438 [M - 1]
178	<p>5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylideneethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(4-methyl-piperazin-1-yl)propyl]-amide</p>	454 [M - 1]
179	<p>5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylideneethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [3-(4-methyl-piperazin-1-yl)propyl]-amide</p>	498 [M - 1] 500 [M - 1]

TABLE 1-continued

Example	Structure	Name	Molecular Weight
180		2,4-Dimethyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-yldenenethyl]-1H-pyrrole-3-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-ethyl]-amide	482 [M - 1]
181		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-yldenenethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-ethyl]-amide	500 [M - 1]

TABLE 1-continued

Example	Structure	Name	Mass
182		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-ethyl]-amide	517 [M - 1]
183		5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-ethyl]-amide	560 [M - 1] 562 [M - 1]

TABLE 1-continued

Example	Structure	Name	Mass
184		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-yldene]methyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid (3-pyrolidin-1yl-2-one)-amide	480 [M + 1]
185		Trifluoroacetate 4-[2-({5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-yldene]methyl}-2,4-dimethyl-1H-pyrole-3-carboxyyl)amino]-ethyl]-2-oxo-piperazin-1-ium	440 [M - 1]
186		5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-yldene]methyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid (3-pyrolidin-1yl-2-one)-amide	

TABLE 1-continued

Example	Structure	Name
187		5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidene-methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1-yl-2-one)-amide
188		5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidene-methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1-yl-2-one)-amide
189		5-[5-chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidene-methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyridin-2-yl-ethyl)-amide

TABLE 1-continued




Example	Structure	Name
190		5-[5-fluoro-2-oxo-1,2-dihydro-indol-3(2H)-ylidene]methyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-pyridin-2-ylethyl)-amide trifluoroacetate salt
191		5-[2-oxo-1,2-dihydro-indol-3(2Z)-ylidene]methyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-pyridin-2-ylethyl)-amide hydrochloride salt
192		5-[5-bromo-2-oxo-1,2-dihydro-indol-3(2Z)-ylidene]methyl]-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-pyridin-2-ylethyl)-amide trifluoroacetate salt

TABLE 1-continued

Example	Structure	Name
193		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-4-(3Z)-ylidene]ethyl-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-ethylaminooethyl)-amide
194		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-4-(3Z)-ylidene]ethyl-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-aminoethyl)-amide
195		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-4-(3Z)-ylidene]ethyl-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-diethyl-N-oxoaminoethyl)-amide

TABLE 1-continued




Example	Structure	Name
196		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-1-(3Z)-yldene]ethyl-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-ethyl-N-hydroxyaminoethyl)amide
197		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-1-(3Z)-yldene]ethyl-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-diethylamino-2-hydroxyethyl)amide
198		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-1-(3Z)-yldene]ethyl-2,4-dimethyl-1H-pyrole-3-carboxylic acid (2-ethyl-2-(2-hydroxyethyl)aminoethyl)amide

TABLE 1-continued

Example	Structure	Name
199		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-3(Z)-ylidene-methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-ethyl-2-(1-hydroxyethyl)aminoethyl]-amide
200		5-[5-Cyano-2-oxo-1,2-dihydro-indol-3(Z)-ylidene-methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-N-acetylaminomethyl)-amide
201		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-3(Z)-ylidene-methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (carboxymethyl)-amide

TABLE 1-continued

Example	Structure	Name
202		5-[5-Fluoro-2-oxo-1,2-dihydro-indol-3(2H)-yldenemethyl]-1H-pyrrole-3-carboxylic acid [2-(2-hydroxyethylamino)ethyl]-amide
203		5-[5-Cyano-2-oxo-1,2-dihydro-indol-3(2H)-yldenemethyl]-1H-pyrrole-3-carboxylic acid (2-pyridin-2-ylethyl)-amide trifluoroacetate
204		5-[5-Bromo-2-oxo-1,2-dihydro-indol-3(2H)-yldenemethyl]-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1-yl-2-onopropyl)-amide trifluoroacetate

The compound numbers correspond to the Example numbers in the Examples section. That is, the synthesis of Compound 1 in Table 1 is described in Example 1. The compounds presented in Table 1 are exemplary only and are not to be construed as limiting the scope of this invention in any manner.

PREFERRED EMBODIMENTS

While the broadest definition is set forth in the Summary of the Invention, certain compounds of Formula (I) set forth below are preferred.

- (1) A preferred group of compounds of Formula (I) is that wherein R¹, R³, and R⁴ are hydrogen.
- (2) Another preferred group of compounds of Formula (I) is that wherein R¹, R², and R⁴ are hydrogen.
- (3) Another preferred group of compounds of Formula (I) is that wherein R¹, R², and R³ are hydrogen.
- (4) Another preferred group of compounds of Formula (I) is that wherein R², R³, and R⁴ are hydrogen.
- (5) Another preferred group of compounds of Formula (I) is that wherein R¹, R², R³ and R⁴ are hydrogen.
- (6) Yet another preferred group of compounds of Formula (I) is that wherein R⁵, R⁶ or R⁷, preferably R⁵ or R⁶, more preferably R⁶ is —COR¹⁰ wherein R¹⁰ is —NR¹¹(CH₂)_nR¹² wherein:

R¹¹ is hydrogen or lower unsubstituted alkyl, preferably hydrogen or methyl; n is 2, 3 or 4, preferably 2 or 3; and

R¹² is —NR¹³R¹⁴ wherein R¹³ and R¹⁴ are independently alkyl, more preferably lower unsubstituted lower alkyl or R¹³ and R¹⁴ combine to form a group selected from —(CH₂)₄—, —(CH₂)₅—, —(CH₂)₂—O—(CH₂)₂— or —(CH₂)₂N(CH₃)(CH₂)₂—, preferably R¹³ and R¹⁴ are independently hydrogen, methyl, ethyl, or combine to form morpholin-4-yl, pyrrolidin-1-yl, piperazin-1-yl, or 4-methylpiperazin-1-yl.

More preferably, R⁵ or R⁶ in (6) above is N-(2-dimethylaminoethyl)-aminocarbonyl, N-(2-ethylaminoethyl)-N-methylaminocarbonyl, N-(3-dimethylaminopropyl)-aminocarbonyl, N-(2-diethylaminoethyl)aminocarbonyl, N-(3-ethylaminopropyl)aminocarbonyl, N-(3-diethylaminopropyl)aminocarbonyl, 3-pyrrolidin-1-yl-propylaminocarbonyl, 3-morpholin-4-ylpropylaminocarbonyl, 2-pyrrolidin-1-ylethylaminocarbonyl, 2-morpholin-4-ylethylaminocarbonyl, 2-(4-methylpiperazin-1-yl)ethylaminocarbonyl, 2-(4-methylpiperazin-1-yl)propylaminocarbonyl, 2-(3,5-dimethylpiperazin-1-yl)ethylaminocarbonyl or 2-(3,5-dimethylpiperazin-1-yl)propylaminocarbonyl, even more preferably N-(2-diethylaminoethyl)aminocarbonyl or N-(2-ethylaminoethyl)aminocarbonyl.

(7) Yet another preferred group of compounds of Formula (I) is that wherein R⁵, R⁶ or R⁷, preferably R⁵ or R⁶, more preferably R⁶ is —COR¹⁰ wherein R¹⁰ is —NR¹³R¹⁴ wherein R¹³ is hydrogen and R¹⁴ is alkyl, preferably lower alkyl substituted with hydroxy, aryl, heteroaryl, heteroalicyclic, or carboxy, more preferably methyl, ethyl, propyl or butyl substituted with hydroxy, aryl, heteroalicyclic such as piperidine, piperazine, morpholine and the like, heteroaryl, or carboxy. Even more preferably within this group (7), R⁵ or R⁶ is 2-ethoxycarbonylmethyl-aminocarbonyl, carboxymethylamino-carbonyl, 3-hydroxypropylaminocarbonyl, 2-hydroxyethylaminocarbonyl, 3-triazin-1-ylpropylamino-carbonyl, triazin-1-ylethylaminocarbonyl,

4-hydroxyphenylethylaminocarbonyl, 3-imidazol-1-ylpropylaminocarbonyl, pyridin-4-ylmethylaminocarbonyl, 2-pyridin-2-ylethylaminocarbonyl or 2-imidazol-1-ylethylaminocarbonyl.

- (8) Yet another preferred group of compounds of Formula (I) is that wherein R⁵, R⁶ or R⁷, preferably R⁵ or R⁶, more preferably R⁶ is —COR¹⁰ wherein R¹⁰ is —NR¹¹(CH₂)_nR¹² wherein:
- R¹¹ is hydrogen or alkyl, preferably hydrogen or methyl; n is 2, 3 or 4, preferably 2 or 3; and
- R¹² is —NR¹³R¹⁴ wherein R¹³ and R¹⁴ together combine to form a heterocycle, preferably a 5, 6 or 7 membered heterocycle containing a carbonyl group and 1 or 2 nitrogen atoms. Preferably, R⁵ or R⁶ is 2-(3-ethoxycarbonylmethylpiperazin-1-yl)ethylaminocarbonyl, 2-(3-oxopiperazin-1-yl)ethylaminocarbonyl, 2-(imidazolidin-1-yl-2-one)ethylaminocarbonyl, 2-(tetrahydropyrimidin-1-yl-2-one)ethylaminocarbonyl, 2-(2-oxopyrrolidin-1-yl)ethylaminocarbonyl, 3-(4-methylpiperazin-1-yl)-propylaminocarbonyl, 3-(3-ethoxycarbonylmethylpiperazin-1-yl)-propylaminocarbonyl, 3-(3-oxopiperazin-1-yl)propylaminocarbonyl, 3-(imidazolidin-1-yl-2-one)propylaminocarbonyl, 3-(tetrahydropyrimidin-1-yl-2-one)-propylaminocarbonyl, 3-(2-oxopyrrolidin-1-yl)propylaminocarbonyl, 2-(2-oxohomopiperidin-1-yl)ethylaminocarbonyl or 3-(2-oxohomopiperidin-1-yl)propylaminocarbonyl.

(9) Yet another preferred group of compounds of Formula (I) is that wherein R⁵, R⁶ or R⁷, preferably R⁵ or R⁶, more preferably R⁶ is —COR¹⁰ wherein:

- (a) R¹⁰ is —NR¹¹(CH₂)_nR¹² wherein:
- R¹¹ is hydrogen or alkyl, preferably hydrogen or methyl; n is 2, 3 or 4, preferably 2 or 3; and
- R¹² is —NR¹³R¹⁴ wherein R¹³ is hydrogen and R¹⁴ is cyanoalkyl or —NHCOR^a where R^a is alkyl; or
- (b) R¹⁰ is —NR¹³R¹⁴ wherein R¹³ and R¹⁴ together combine to form a heterocycle not containing a carbonyl group within the ring. Preferably, R⁵ or R⁶ is 2-(2-cyanoethylamino)ethylaminocarbonyl, 2-(acetylamino)ethylaminocarbonyl, morpholinocarbonyl, piperidin-1-ylcarbonyl, 2-cyanomethylaminoethylaminocarbonyl or piperidin-1-ylcarbonyl.

- (10) Another preferred group of compounds of Formula (I) is that wherein R⁵ is —COR¹⁰ wherein R¹⁰ is —NR¹³R¹⁴ wherein R¹³ is hydrogen and R¹⁴ is lower alkyl substituted with hydroxy, lower alkyl substituted with hydroxyalkylamino, carboxy, or —NR¹⁸R¹⁹ wherein R¹⁸ and R¹⁹ are independently hydrogen or lower unsubstituted alkyl, more preferably R⁵ is 2-[diethylamino]-2-hydroxyethylaminocarbonyl, 2-(N-ethyl-N-2-hydroxyethylamino)ethylaminocarbonyl, carboxymethylamino-carbonyl, or 2-(2-hydroxyethylamino)ethylamino-carbonyl.

- (11) Yet another preferred group of compounds of Formula (I) is that wherein R⁶ is —COR¹⁰ wherein R¹⁰ is —NR¹³R¹⁴ wherein R¹³ is hydrogen and R¹⁴ is lower alkyl substituted with hydroxy, lower alkyl substituted with hydroxyalkylamino, carboxy, or —NR¹⁸R¹⁹ wherein R¹⁸ and R¹⁹ are independently hydrogen or lower unsubstituted alkyl; more preferably R⁶ is [2-(diethylamino)-2-hydroxy]ethylaminocarbonyl, 2-(N-ethyl-N-2-hydroxyethylamino)ethylaminocarbonyl, carboxymethylaminocarbonyl, or 2-(2-hydroxyethylamino)ethylamino-carbonyl.

- (12) Yet another preferred group of compounds of Formula (I) is that wherein R⁵ is —COR¹⁰ wherein R¹⁰ is —NR¹¹

(19) Another more preferred group of compounds of Formula (I) is that wherein:

R^1 and R^4 are hydrogen;

R^2 is selected from the group consisting of hydrogen, halo, lower alkoxy, $—C(O)R^{15}$ and $—S(O)_2NR^{13}R^{14}$;

R^3 is selected from the group consisting of hydrogen, lower alkoxy, $—C(O)R^{15}$, $—S(O)_2NR^{13}R^{14}$, aryl and heteroaryl;

R^5 is $—C(O)R^{10}$;

R^6 is selected from the group consisting of hydrogen and lower alkyl; and

R^7 is selected from the group consisting of hydrogen, lower alkyl and $—C(O)R^{17}$.

It is another presently preferred embodiment of this invention that, in a compound having a structure as described in (15):

R^{10} is selected from the group consisting of hydroxy, lower alkoxy and $—NR^{11}(CH_2)_nR^{12}$, wherein

n is 2 or 3;

R^{11} is selected from the group consisting of hydrogen and lower alkyl; and,

R^{12} is selected from the group consisting of aryl and $—NR^{13}R^{14}$.

It is a further presently preferred embodiment of this invention that, in a compound having a structure as described in the previous two paragraphs, R^{13} and R^{14} are independently selected from the group consisting of hydrogen, lower alkyl, and, combined, $—(CH_2)_4$ —, $—(CH_2)_5$ —, $—CH_2)_2O(CH_2)_2$ — or $—(CH_2)_2N(CH_3)(CH_2)_2$ —.

(20) Another presently preferred embodiment of this invention is a compound in which:

R^1 is selected from the group consisting of hydrogen, lower alkyl, $—(CH_2)_nR^{16}$ and $—C(O)NR^8R^9$;

R^2 is selected from the group consisting of hydrogen, halogen, aryl and $—S(O)_2NR^{13}R^{14}$;

R^3 is selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, heteroaryl and $—C(O)R^{15}$;

R^4 is hydrogen;

R^5 is selected from the group consisting of hydrogen and lower alkyl;

R^6 is $—C(O)R^{10}$;

R^7 is selected from the group consisting of hydrogen, lower alkyl and aryl;

R^{16} is selected from the group consisting of hydroxy and $—C(O)R^{15}$; and,

r is 2 or 3.

A presently preferred embodiment of this invention is a compound having as structure described in the paragraph just above in which R^3 is aryl optionally substituted with one or more groups selected from the group consisting of lower alkyl, lower alkoxy and halo.

(21) Likewise, it is a presently preferred embodiment of this invention that, in a compound in which:

R^1 is selected from the group consisting of hydrogen, lower alkyl, $—(CH_2)_nR^{16}$ and $—C(O)NR^8R^9$;

R^2 is selected from the group consisting of hydrogen, halogen, aryl and $—S(O)_2NR^{13}R^{14}$;

R^3 is selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, heteroaryl and $—C(O)R^{15}$;

R^4 is hydrogen;

R^5 is selected from the group consisting of hydrogen and lower alkyl;

R^6 is $—C(O)R^{10}$;

R^7 is selected from the group consisting of hydrogen, lower alkyl and aryl;

R^{16} is selected from the group consisting of hydroxy and $—C(O)R^{15}$; and,

r is 2 or 3,

R^{10} is selected from the group consisting of hydroxy, lower alkoxy, $—NR^{13}R^4$ and $—NR^{11}(CH_2)_nR^{12}$, wherein n is 1, 2 or 3, R^{11} is hydrogen and R^{12} is selected from the group consisting of hydroxy, lower alkoxy, $—C(O)R^{15}$, heteroaryl and $—NR^{13}R^{14}$.

(22) A further presently preferred embodiment of this invention is a compound having a structure as described in the paragraph immediately above in which R^{13} and R^{14} are independently selected from the group consisting of hydrogen, lower alkyl, heteroaryl and, combined, $—(CH_2)_4$ —, $—(CH_2)_5$ —, $—(CH_2)_2O(CH_2)_2$ —, or $—(CH_2)_2N(CH_3)(CH_2)_2$ —.

(23) Another presently preferred embodiment of this invention is a compound in which:

R^1 is $—C(O)NR^8R^9$, wherein R^8 is hydrogen and R^9 is aryl optionally substituted with one or more groups selected from the group consisting of halo, hydroxy and lower alkoxy;

R^2 is selected from the group consisting of hydrogen, halogen, aryl and $—S(O)_2NR^{13}R^{14}$;

R^3 is selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, aryl, heteroaryl and $—C(O)R^{15}$;

R^4 is hydrogen;

R^5 is selected from the group consisting of hydrogen and lower alkyl;

R^6 is $—C(O)R^{10}$;

R^7 is selected from the group consisting of hydrogen, lower alkyl and aryl;

R^{16} is selected from the group consisting of hydroxy and $—C(O)R^{15}$; and,

r is 2 or 3,

(24) A still further presently preferred embodiment of this invention is a compound in which:

R^1 is selected from the group consisting of hydrogen and lower alkyl;

R^2 is selected from the group consisting of hydrogen, halo, lower alkoxy, aryl, $—C(O)R^{15}$ and $—S(O)_2NR^{13}R^{14}$;

R^3 is selected from the group consisting of hydrogen, halo, aryl, heteroaryl and $—C(O)R^{15}$;

R^4 is hydrogen;

R^5 is $—C(O)R^{10}$; and,

R^6 and R^7 combine to form a $—(CH_2)_4$ — group.

In a compound having a structure as described in the paragraph immediately above, it is a presently preferred embodiment that R^{10} is selected from the group consisting of hydroxy, alkoxy, $—NR^{13}R^{14}$ and $—NH(CH_2)NR^{13}R^{14}$ where n is 2 or 3.

It is a presently preferred embodiment of this invention that, in a compound having a structure as described in the two paragraphs immediately above, R^{13} and R^{14} are independently selected from the group consisting of hydrogen, lower alkyl, and, combined, $—(CH_2)_4$ —, $—(CH_2)_5$ —, $—(CH_2)_2O(CH_2)_2$ — or $—(CH_2)_2N(CH_3)(CH_2)_2$ —.

Utility

The PKs whose catalytic activity is modulated by the compounds of this invention include protein tyrosine kinases of which there are two types, receptor tyrosine kinases (RTKs) and cellular tyrosine kinases (CTKs), and serine-threonine kinases (STKs). RTK mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response (e.g., cell division, metabolic effects on the extracellular microenvironment, etc.). See, Schlessinger and Ullrich, 1992, *Neuron* 9:303-391.

It has been shown that tyrosine phosphorylation sites on growth factor receptors function as high-affinity binding sites for SH2 (src homology) domains of signaling molecules. Fantl et al., 1992, *Cell* 69:413-423, Songyang et al., 1994, *Mol. Cell. Biol.* 14:2777-2785, Songyang et al., 1993, *Cell* 72:767-778, and Koch et al., 1991, *Science* 252:668-678. Several intracellular substrate proteins that associate with RTKs have been identified. They may be divided into two principal groups: (1) substrates that have a catalytic domain, and (2) substrates which lack such domain but which serve as adapters and associate with catalytically active molecules. Songyang et al., 1993, *Cell* 72:767-778. The specificity of the interactions between receptors and SH2 domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. Differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors are consistent with the observed differences in their substrate phosphorylation profiles. Songyang et al., 1993, *Cell* 72:767-778. These observations suggest that the function of each RTK is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.

STKs, being primarily cytosolic, affect the internal biochemistry of the cell, often as a down-line response to a PTK event. STKs have been implicated in the signaling process which initiates DNA synthesis and subsequent mitosis leading to cell proliferation.

Thus, PK signal transduction results in, among other responses, cell proliferation, differentiation, growth and metabolism. Abnormal cell proliferation may result in a wide array of disorders and diseases, including the development of neoplasia such as carcinoma, sarcoma, glioblastoma and hemangioma, disorders such as leukemia, psoriasis, arteriosclerosis, arthritis and diabetic retinopathy and other disorders related to uncontrolled angiogenesis and/or vasculogenesis.

A precise understanding of the mechanism by which the compounds of this invention inhibit PKs is not required in order to practice the present invention. However, while not hereby being bound to any particular mechanism or theory, it is believed that the compounds interact with the amino acids in the catalytic region of PKs. PKs typically possess a bi-lobate structure wherein ATP appears to bind in the cleft between the two lobes in a region where the amino acids are conserved among PKs. Inhibitors of PKs are believed to bind by non-covalent interactions such as hydrogen bonding, van der Waals forces and ionic interactions in the same general region where the aforesaid ATP binds to the PKs. More specifically, it is thought that the 2-indolinone component of the compounds of this invention binds in the general space normally occupied by the adenine ring of ATP. Specificity of a particular molecule for a particular PK may then arise as the result of additional interactions between the various substituents on the 2-indolinone core and the amino acid domains specific to particular PKs. Thus, different indolinone substituents may contribute to preferential binding to particular PKs. The ability to select compounds active at different ATP (or other nucleotide) binding sites makes the compounds of this invention useful for targeting any protein with such a site. The compounds disclosed herein thus have utility in in vitro assays for such proteins as well as exhibiting in vivo therapeutic effects through interaction with such proteins.

Additionally, the compounds of the present invention provide a therapeutic approach to the treatment of many kinds of solid tumors, including but not limited to carcinomas, sarcomas including Kaposi's sarcoma, erythroblastoma, glioblastoma, meningioma, astrocytoma, melanoma and myoblastoma. Treatment or prevention of non-solid tumor cancers such as leukemia are also contemplated by this invention. Indications may include, but are not limited to brain cancers, bladder cancers, ovarian cancers, 10 gastric cancers, pancreas cancers, colon cancers, blood cancers, lung cancers and bone cancers.

Further examples, without limitation, of the types of disorders related to inappropriate PK activity that the compounds described herein may be useful in preventing, treating 15 and studying, are cell proliferative disorders, fibrotic disorders and metabolic disorders.

Cell proliferative disorders, which may be prevented, treated or further studied by the present invention include cancer, blood vessel proliferative disorders and mesangial 20 cell proliferative disorders.

Blood vessel proliferative disorders refer to disorders related to abnormal vasculogenesis (blood vessel formation) and angiogenesis (spreading of blood vessels). While vasculogenesis and angiogenesis play important roles in a 25 variety of normal physiological processes such as embryonic development, corpus luteum formation, wound healing and organ regeneration, they also play a pivotal role in cancer development where they result in the formation of new capillaries needed to keep a tumor alive. Other examples of 30 blood vessel proliferation disorders include arthritis, where new capillary blood vessels invade the joint and destroy cartilage, and ocular diseases, like diabetic retinopathy, where new capillaries in the retina invade the vitreous, bleed and cause blindness.

Two structurally related RTKs have been identified to bind VEGF with high affinity: the fms-like tyrosine 1 (f1-1) receptor (Shibuya et al., 1990, *Oncogene*, 5:519-524; De Vries et al., 1992, *Science*, 255:989-991) and the KDR/FLK-1 receptor, also known as VEGF-R2. Vascular endothelial growth factor (VEGF) has been reported to be an 35 endothelial cell specific mitogen with in vitro endothelial cell growth promoting activity. Ferrara & Henzel, 1989, *Biochem. Biophys. Res. Comm.*, 161:851-858; Vaisman et al., 1990, *J. Biol. Chem.*, 265:19461-19566. Information set 40 forth in U.S. application Ser. Nos. 08/193,829, 08/038,596 and 07/975,750, strongly suggest that VEGF is not only responsible for endothelial cell proliferation, but also is the prime regulator of normal and pathological angiogenesis. See generally, Klagsburn & Soker, 1993, *Current Biology*, 3(10):699-702; Houck, et al., 1992, *J. Biol. Chem.*, 267:26031-26037.

Normal vasculogenesis and angiogenesis play important 45 roles in a variety of physiological processes such as embryonic development, wound healing, organ regeneration and 50 female reproductive processes such as follicle development in the corpus luteum during ovulation and placental growth after pregnancy. Folkman & Shing, 1992, *J. Biological Chem.*, 267(16):10931-34. Uncontrolled vasculogenesis and/or angiogenesis has been associated with diseases such 55 as diabetes as well as with malignant solid tumors that rely on vascularization for growth. Klagsburn & Soker, 1993, *Current Biology*, 3(10):699-702; Folkham, 1991, *J. Natl. Cancer Inst.*, 82:4-6; Weidner, et al., 1991, *New Engl. J. Med.*, 324:1-5.

60 The surmised role of VEGF in endothelial cell proliferation and migration during angiogenesis and vasculogenesis indicates an important role for the KDR/FLK-1 receptor in

these processes. Diseases such as diabetes mellitus (Folkman, 198, in *XIth Congress of Thrombosis and Haemostasis* (Verstraeta, et al., eds.), pp. 583-596, Leuven University Press, Leuven) and arthritis, as well as malignant tumor growth may result from uncontrolled angiogenesis. See e.g., Folkman, 1971, *N. Engl. J. Med.*, 285:1182-1186. The receptors to which VEGF specifically binds are an important and powerful therapeutic target for the regulation and modulation of vasculogenesis and/or angiogenesis and a variety of severe diseases which involve abnormal cellular growth caused by such processes. Plowman, et al., 1994, *DN&P*, 7(6):334-339. More particularly, the KDR/FLK-1 receptor's highly specific role in neovascularization make it a choice target for therapeutic approaches to the treatment of cancer and other diseases which involve the uncontrolled formation of blood vessels.

Thus, the present invention provides compounds capable of regulating and/or modulating tyrosine kinase signal transduction including KDR/FLK-1 receptor signal transduction in order to inhibit or promote angiogenesis and/or vasculogenesis, that is, compounds that inhibit, prevent, or interfere with the signal transduced by KDR/FLK-1 when activated by ligands such as VEGF. Although it is believed that the compounds of the present invention act on a receptor or other component along the tyrosine kinase signal transduction pathway, they may also act directly on the tumor cells that result from uncontrolled angiogenesis.

Although the nomenclature of the human and murine counterparts of the generic "flk-1" receptor differ, they are, in many respects, interchangeable. The murine receptor, Flk-1, and its human counterpart, KDR, share a sequence homology of 93.4% within the intracellular domain. Likewise, murine FLK-1 binds human VEGF with the same affinity as mouse VEGF, and accordingly, is activated by the ligand derived from either species. Millauer et al., 1993, *Cell*, 72:835-846; Quinn et al., 1993, *Proc. Natl. Acad. Sci. USA*, 90:7533-7537. FLK-1 also associates with and subsequently tyrosine phosphorylates human RTK substrates (e.g., PLC- γ or p85) when co-expressed in 293 cells (human embryonal kidney fibroblasts).

Models which rely upon the FLK-1 receptor therefore are directly applicable to understanding the KDR receptor. For example, use of the murine FLK-1 receptor in methods which identify compounds that regulate the murine signal transduction pathway are directly applicable to the identification of compounds which may be used to regulate the human signal transduction pathway, that is, which regulate activity related to the KDR receptor. Thus, chemical compounds identified as inhibitors of KDR/FLK-1 in vitro, can be confirmed in suitable in vivo models. Both in vivo mouse and rat animal models have been demonstrated to be of excellent value for the examination of the clinical potential of agents acting on the KDR/FLK-1 induced signal transduction pathway.

Thus, the present invention provides compounds that regulate, modulate and/or inhibit vasculogenesis and/or angiogenesis by affecting the enzymatic activity of the KDR/FLK-1 receptor and interfering with the signal transduced by KDR/FLK-1. Thus the present invention provides a therapeutic approach to the treatment of many kinds of solid tumors including, but not limited to, glioblastoma, melanoma and Kaposi's sarcoma, and ovarian, lung, mammary, prostate, pancreatic, colon and epidermoid carcinoma. In addition, data suggests the administration of compounds which inhibit the KDR/FLK-1 mediated signal transduction pathway may also be used in the treatment of hemangioma, restenosis and diabetic retinopathy.

Furthermore, this invention relates to the inhibition of vasculogenesis and angiogenesis by other receptor-mediated pathways, including the pathway comprising the flt-1 receptor.

Receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and autophosphorylation. Binding sites are thereby created for intracellular signal transduction molecules which leads to the formation of complexes with a spectrum of cytoplasmic signalling molecules that facilitate the appropriate cellular response, e.g., cell division and metabolic effects to the extracellular microenvironment. See, Schlessinger and Ullrich, 1992, *Neuron*, 9:1-20.

The close homology of the intracellular regions of KDR/FLK-1 with that of the PDGF- β receptor (50.3% homology) and/or the related flt-1 receptor indicates the induction of overlapping signal transduction pathways. For example, for the PDGF- β receptor, members of the src family (Twamley et al., 1993, *Proc. Natl. Acad. Sci. USA*, 90:7696-7700), phosphatidylinositol-3'-kinase (Hu et al., 1992, *Mol. Cell. Biol.*, 12:981-990), phospholipase cy (Kashishian & Cooper, 1993, *Mol. Cell. Biol.*, 4:49-51), ras-GTPase-activating protein, (Kashishian et al., 1992, *EMBO J.*, 11:1373-1382), PTP-ID/syp (Kazlauskas et al., 1993, *Proc. Natl. Acad. Sci. USA*, 90:6939-6943), Grb2 (Arvidsson et al., 1994, *Mol. Cell. Biol.*, 14:6715-6726), and the adapter molecules Shc and Nck (Nishimura et al., 1993, *Mol. Cell. Biol.*, 13:6889-6896), have been shown to bind to regions involving different autophosphorylation sites. See generally, Claesson-Welsh, 1994, *Prog. Growth Factor Res.*, 5:37-54. Thus, it is likely that signal transduction pathways activated by KDR/FLK-1 include the ras pathway (Rozakis et al., 1992, *Nature*, 360:689-692), the PI-3'-kinase, the src-mediated and the pcy-mediated pathways. Each of these pathways may play a critical role in the angiogenic and/or vasculogenic effect of KDR/FLK-1 in endothelial cells. Consequently, a still further aspect of this invention relates to the use of the organic compounds described herein to modulate angiogenesis and vasculogenesis as such processes are controlled by these pathways.

Conversely, disorders related to the shrinkage, contraction or closing of blood vessels, such as restenosis, are also implicated and may be treated or prevented by the methods of this invention.

Fibrotic disorders refer to the abnormal formation of extracellular matrices. Examples of fibrotic disorders include hepatic cirrhosis and mesangial cell proliferative disorders. Hepatic cirrhosis is characterized by the increase in extracellular matrix constituents resulting in the formation of a hepatic scar. An increased extracellular matrix resulting in a hepatic scar can also be caused by a viral infection such as hepatitis. Lipocytes appear to play a major role in hepatic cirrhosis. Other fibrotic disorders implicated include atherosclerosis.

Mesangial cell proliferative disorders refer to disorders brought about by abnormal proliferation of mesangial cells. Mesangial proliferative disorders include various human renal diseases such as glomerulonephritis, diabetic nephropathy and malignant nephrosclerosis as well as such disorders as thrombotic microangiopathy syndromes, transplant rejection, and glomerulopathies. The RTK PDGFR has been implicated in the maintenance of mesangial cell proliferation. Floege et al., 1993, *Kidney International* 43:47S-54S.

Many cancers are cell proliferative disorders and, as noted previously, PKs have been associated with cell proliferative

disorders. Thus, it is not surprising that PKs such as, for example, members of the RTK family have been associated with the development of cancer. Some of these receptors, like EGFR (Tuzi et al., 1991, *Br. J. Cancer* 63:227-233, Torp et al., 1992, *APMIS* 100:713-719) HER2/neu (Slamon et al., 1989, *Science* 244:707-712) and PDGF-R (Kumabe et al., 1992, *Oncogene*, 7:627-633) are over-expressed in many tumors and/or persistently activated by autocrine loops. In fact, in the most common and severe cancers these receptor over-expressions (Akbasak and Suner-Akbasak et al., 1992, *J. Neurol. Sci.*, 111:119-133, Dickson et al., 1992, *Cancer Treatment Res.* 61:249-273, Korc et al., 1992, *J. Clin. Invest.* 90:1352-1360) and autocrine loops (Lee and Donoghue, 1992, *J. Cell. Biol.*, 118:1057-1070, Korc et al., supra, Akbasak and Suner-Akbasak et al., supra) have been demonstrated. For example, EGFR has been associated with squamous cell carcinoma, astrocytoma, glioblastoma, head and neck cancer, lung cancer and bladder cancer. HER2 has been associated with breast, ovarian, gastric, lung, pancreas and bladder cancer. PDGFR has been associated with glioblastoma and melanoma as well as lung, ovarian and prostate cancer. The RTK c-met has also been associated with malignant tumor formation. For example, c-met has been associated with, among other cancers, colorectal, thyroid, pancreatic, gastric and hepatocellular carcinomas and lymphomas. Additionally c-met has been linked to leukemia. Over-expression of the c-met gene has also been detected in patients with Hodgkin's disease and Burkitt's disease.

IGF-IR, in addition to being implicated in nutritional support and in type-II diabetes, has also been associated with several types of cancers. For example, IGF-I has been implicated as an autocrine growth stimulator for several tumor types, e.g. human breast cancer carcinoma cells (Arteaga et al., 1989, *J. Clin. Invest.* 84:1418-1423) and small lung tumor cells (Macaulay et al., 1990, *Cancer Res.*, 50:2511-2517). In addition, IGF-I, while integrally involved in the normal growth and differentiation of the nervous system, also appears to be an autocrine stimulator of human gliomas. Sandberg-Nordqvist et al., 1993, *Cancer Res.* 53:2475-2478. The importance of IGF-IR and its ligands in cell proliferation is further supported by the fact that many cell types in culture (fibroblasts, epithelial cells, smooth muscle cells, T-lymphocytes, myeloid cells, chondrocytes and osteoblasts (the stem cells of the bone marrow)) are stimulated to grow by IGF-I. Goldring and Goldring, 1991, *Eukaryotic Gene Expression*, 1:301-326. Baserga and Coppola suggest that IGF-IR plays a central role in the mechanism of transformation and, as such, could be a preferred target for therapeutic interventions for a broad spectrum of human malignancies. Baserga, 1995, *Cancer Res.*, 55:249-252, Baserga, 1994, *Cell* 79:927-930, Coppola et al., 1994, *Mol. Cell. Biol.*, 14:4588-4595.

STKs have been implicated in many types of cancer including, notably, breast cancer (Cance, et al., *Int. J. Cancer*, 54:571-77 (1993)).

The association between abnormal PK activity and disease is not restricted to cancer. For example, RTKs have been associated with diseases such as psoriasis, diabetes mellitus, endometriosis, angiogenesis, atheromatous plaque development, Alzheimer's disease, restenosis, von Hippel-Lindau disease, epidermal hyperproliferation, neurodegenerative diseases, age-related macular degeneration and hemangiomas. For example, EGFR has been indicated in corneal and dermal wound healing. Defects in Insulin-R and IGF-1R are indicated in type-II diabetes mellitus. A more complete correlation between specific RTKs and their therapeutic indications is set forth in Plowman et al., 1994, *DN&P* 7:334-339.

As noted previously, not only RTKs but CTKs including, but not limited to, src, abl, fps, yes, fyn, lyn, lck, blk, bck, fgr and yrk (reviewed by Bolen et al., 1992, *FASEB J.*, 6:3403-3409) are involved in the proliferative and metabolic signal transduction pathway and thus could be expected, and have been shown, to be involved in many PTK-mediated disorders to which the present invention is directed. For example, mutated src (v-src) has been shown to be an oncogene (pp60^{v-src}) in chicken. Moreover, its cellular homolog, the proto-oncogene pp60^{c-src} transmits oncogenic signals of many receptors. Over-expression of EGFR or HER2/neu in tumors leads to the constitutive activation of pp60^{c-src}, which is characteristic of malignant cells but absent in normal cells. On the other hand, mice deficient in the expression of c-src exhibit an osteopetrosis phenotype, indicating a key participation of c-src in osteoclast function and a possible involvement in related disorders.

Similarly, Zap70 has been implicated in T-cell signaling 20 which may relate to autoimmune disorders.

STKs have been associated with inflammation, autoimmune disease, immunoresponses, and hyperproliferation disorders such as restenosis, fibrosis, psoriasis, osteoarthritis and rheumatoid arthritis.

PKs have also been implicated in embryo implantation. Thus, the compounds of this invention may provide an effective method of preventing such embryo implantation and thereby be useful as birth control agents. Additional disorders which may be treated or prevented using the 30 compounds of this invention are immunological disorders such as autoimmune disease, AIDS and cardiovascular disorders such as atherosclerosis.

Finally, both RTKs and CTKs are currently suspected as being involved in hyperimmune disorders.

Examples of the effect of a number of exemplary compounds of this invention on several PTKs are shown in Table 2 below. The compounds and data presented are not to be construed as limiting the scope of this invention in any manner whatsoever.

40 Administration and Pharmaceutical Composition

A compound of the present invention or a pharmaceutically acceptable salt thereof, can be administered as such to a human patient or can be administered in pharmaceutical compositions in which the foregoing materials are mixed with suitable carriers or excipient(s). Techniques for formulation and administration of drugs may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, Pa., latest edition.

As used herein, "administer" or "administration" refers to the delivery of a compound of Formula (I) or a pharmaceutically acceptable salt thereof or of a pharmaceutical composition containing a compound of Formula (I) or a pharmaceutically acceptable salt thereof of this invention to an organism for the purpose of prevention or treatment of a 55 PK-related disorder.

Suitable routes of administration may include, without limitation, oral, rectal, transmucosal or intestinal administration or intramuscular, subcutaneous, intramedullary, intrathecal, direct intraventricular, intravenous, intraventricular, 60 intraperitoneal, intranasal, or intraocular injections. The preferred routes of administration are oral and parenteral.

Alternatively, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into a solid tumor, often in a depot or sustained release formulation.

Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated

with tumor-specific antibody. The liposomes will be targeted to and taken up selectively by the tumor.

Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For injection, the compounds of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, lozenges, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient. Pharmaceutical preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding other suitable auxiliaries if desired, to obtain tablets or dragee cores. Useful excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol, cellulose preparations such as, for example, maize starch, wheat starch, rice starch and potato starch and other materials such as gelatin, gum tragacanth, methyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethylcellulose, and/or polyvinyl-pyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid. A salt such as sodium alginate may also be used.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with a filler such as lactose, a binder such as starch, and/or a lubricant such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. Stabilizers may be added in these formulations, also.

Pharmaceutical compositions which may also be used include hard gelatin capsules. As a non-limiting example, the active compound capsule oral drug product formulation may be as 50 and 200 mg dose strengths (formulation codes J-011248-AA-00 and J-011248-AA-01, respectively). The two dose strengths are made from the same granules by

filling into different size hard gelatin capsules, size 3 for the 50 mg capsule and size 0 for the 200 mg capsule. The composition of the formulation may be, for example, as indicated in Table 2.

TABLE 2

Ingredient Name/Grade	Concentration in Granulation (% w/w)	Amount in 50 mg Capsule (mg)	Amount in 200 mg Capsule (mg)
Formulation Code	J-011248-AA-00	J-011248-AA-01	
Active Compound NF	65.0	50.0	200.0
Mannitol NF	23.5	18.1	72.4
Croscarmellose sodium NF	6.0	4.6	18.4
Povidone K 30 NF	5.0	3.8	15.2
Magnesium stearate NF	0.5	0.38	1.52
Capsule, Swedish yellow NF		Size 3	Size 0

The capsules may be packaged into brown glass or plastic bottles to protect the active compound from light. The containers containing the active compound capsule formulation must be stored at controlled room temperature (15-30° C.).

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray using a pressurized pack or a nebulizer and a suitable propellant, e.g., without limitation, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetra-fluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be controlled by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may also be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating materials such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical compositions for parenteral administration include aqueous solutions of a water soluble form, such as, without limitation, a salt, of the active compound. Additionally, suspensions of the active compounds may be prepared in a lipophilic vehicle. Suitable lipophilic vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate and triglycerides, or materials such as liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers and/or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as depot preparations.

Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. A compound of this invention may be formulated for this route of administration with suitable polymeric or hydrophobic materials (for instance, in an emulsion with a pharmacologically acceptable oil), with ion exchange resins, or as a sparingly soluble derivative such as, without limitation, a sparingly soluble salt.

A non-limiting example of a pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer and an aqueous phase such as the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:DSW) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of such a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of Polysorbate 80, the fraction size of polyethylene glycol may be varied, other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone, and other sugars or polysaccharides may substitute for dextrose.

Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. In addition, certain organic solvents such as dimethylsulfoxide also may be employed, although often at the cost of greater toxicity.

Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

The pharmaceutical compositions herein also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

Many of the PK modulating compounds of the invention may be provided as physiologically acceptable salts wherein the claimed compound may form the negatively or the positively charged species. Examples of salts in which the compound forms the positively charged moiety include, without limitation, quaternary ammonium (defined elsewhere herein), salts such as the hydrochloride, sulfate, carbonate, lactate, tartrate, malate, maleate, succinate wherein the nitrogen atom of the quaternary ammonium group is a nitrogen of the selected compound of this invention which has reacted with the appropriate acid. Salts in which a compound of this invention forms the negatively charged species include, without limitation, the sodium, potassium, calcium and magnesium salts formed by the reaction of a carboxylic acid group in the compound with an

appropriate base (e.g. sodium hydroxide (NaOH), potassium hydroxide (KOH), Calcium hydroxide ($\text{Ca}(\text{OH})_2$), etc.).

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an amount sufficient to achieve the intended purpose, e.g., the modulation of PK activity or the treatment or prevention of a PK-related disorder.

More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.

Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

For any compound used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from cell culture assays. Then, the dosage can be formulated for use in animal models so as to achieve a circulating concentration range that includes the IC_{50} as determined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of the PK activity). Such information can then be used to more accurately determine useful doses in humans.

Toxicity and therapeutic efficacy of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the IC_{50} and the LD_{50} (both of which are discussed elsewhere herein) for a subject compound. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.1).

Dosage amount and interval may be adjusted individually to provide plasma levels of the active species which are sufficient to maintain the kinase modulating effects. These plasma levels are referred to as minimal effective concentrations (MECs). The MEC will vary for each compound but can be estimated from in vitro data, e.g., the concentration necessary to achieve 50–90% inhibition of a kinase may be ascertained using the assays described herein. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. HPLC assays or bioassays can be used to determine plasma concentrations.

Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen that maintains plasma levels above the MEC for 10–90% of the time, preferably between 30–90% and most preferably between 50–90%.

At present, the therapeutically effective amounts of compounds of Formula (I) may range from approximately 25 mg/m^2 to 1500 mg/m^2 per day; preferably about 3 mg/m^2 /day. Even more preferably 50 mg/qm qd till 400 mg/qd .

In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration and other procedures known in the art may be employed to determine the correct dosage amount and interval.

The amount of a composition administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.

The compositions may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which

may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or of human or veterinary administration. Such notice, for example, may be of the labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. Suitable conditions indicated on the label may include treatment of a tumor, inhibition of angiogenesis, treatment of fibrosis, diabetes, and the like.

It is also an aspect of this invention that a compound described herein, or its salt or prodrug, might be combined with other chemotherapeutic agents for the treatment of the diseases and disorders discussed above. For instance, a compound, salt or prodrug of this invention might be combined with alkylating agents such as fluorouracil (5-FU) alone or in further combination with leukovorin; or other alkylating agents such as, without limitation, other pyrimidine analogs such as UFT, capecitabine, gemcitabine and cytarabine, the alkyl sulfonates, e.g., busulfan (used in the treatment of chronic granulocytic leukemia), imrosulfan and piposulfan; aziridines, e.g., benzodepa, carboquone, meturedepa and uredepa; ethyleneimines and methylmelamines, e.g., altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylolmelamine; and the nitrogen mustards, e.g., chlorambucil (used in the treatment of chronic lymphocytic leukemia, primary macroglobulinemia and non-Hodgkin's lymphoma), cyclophosphamide (used in the treatment of Hodgkin's disease, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, Wilm's tumor and rhabdomyosarcoma), estramustine, ifosfamide, novembrichin, prednimustine and uracil mustard (used in the treatment of primary thrombocytosis, non-Hodgkin's lymphoma, Hodgkin's disease and ovarian cancer); and triazines, e.g., dacarbazine (used in the treatment of soft tissue sarcoma).

A compound, salt or prodrug of this invention can also be used in combination with other antimetabolite chemotherapeutic agents such as, without limitation, folic acid analogs, e.g. methotrexate (used in the treatment of acute lymphocytic leukemia, choriocarcinoma, mycosis fungoides breast cancer, head and neck cancer and osteogenic sarcoma) and pteropterin; and the purine analogs such as mercaptopurine and thioguanine which find use in the treatment of acute granulocytic, acute lymphocytic and chronic granulocytic leukemias.

It is contemplated that a compound, salt or prodrug of this invention can also be used in combination with natural product based chemotherapeutic agents such as, without limitation, the vinca alkaloids, e.g., vinblastin (used in the treatment of breast and testicular cancer), vincristine and vindesine; the epipodophylotoxins, e.g., etoposide and teniposide, both of which are useful in the treatment of testicular cancer and Kaposi's sarcoma; the antibiotic chemotherapeutic agents, e.g., daunorubicin, doxorubicin, epirubicin, mitomycin (used to treat stomach, cervix, colon, breast, bladder and pancreatic cancer), dactinomycin,

temozolomide, plicamycin, bleomycin (used in the treatment of skin, esophagus and genitourinary tract cancer); and the enzymatic chemotherapeutic agents such as L-asparaginase.

In addition to the above, a compound, salt or prodrug of this invention could also be used in combination with the platinum coordination complexes (cisplatin, etc.); substituted ureas such as hydroxyurea; methylhydrazine derivatives, e.g., procarbazine; adrenocortical suppressants, e.g., mitotane, aminoglutethimide; and hormone and hormone antagonists such as the adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate); estrogens (e.g., diethylstilbestrol); antiestrogens such as tamoxifen; androgens, e.g., testosterone propionate; and aromatase inhibitors such as anastrozole.

Finally, it is also contemplated that the combination of a compound of this invention will be effective in combination with mitoxantrone or paclitaxel for the treatment of solid tumor cancers or leukemias such as, without limitation, acute myelogenous (non-lymphocytic) leukemia.

General Synthetic Procedure

The following general methodology may be employed to prepare the compounds of this invention:

The appropriately substituted 2-oxindole (1 equiv.), the 25 appropriately substituted aldehyde (1.2 equiv.) and a base (0.1 equiv.) are mixed in a solvent (1-2 ml/mmol 2-oxindole) and the mixture is then heated for from about 2 to about 12 hours. After cooling, the precipitate that forms is filtered, washed with cold ethanol or ether and vacuum dried to give the solid product. If no precipitate forms, the reaction mixture is concentrated and the residue is triturated with dichloromethane/ether, the resulting solid is collected by filtration and then dried. The product may optionally be further purified by chromatography.

The base may be an organic or an inorganic base. If an organic base is used, preferably it is a nitrogen base. Examples of organic nitrogen bases include, but are not limited to, diisopropylamine, trimethylamine, triethylamine, aniline, pyridine, 1,8-diazabicyclo[5.4.1]undec-7-ene, pyrrolidine and piperidine.

Examples of inorganic bases are, without limitation, ammonia, alkali metal or alkaline earth hydroxides, phosphates, carbonates, bicarbonates, bisulfates and amides. The alkali metals include, lithium, sodium and potassium while the alkaline earths include calcium, magnesium and barium.

In a presently preferred embodiment of this invention, when the solvent is a protic solvent, such as water or alcohol, the base is an alkali metal or an alkaline earth inorganic base, preferably, a alkali metal or an alkaline earth hydroxide.

It will be clear to those skilled in the art, based both on known general principles of organic synthesis and on the disclosures herein which base would be most appropriate for the reaction contemplated.

The solvent in which the reaction is carried out may be a protic or an aprotic solvent, preferably it is a protic solvent. A "protic solvent" is a solvent which has hydrogen atom(s) covalently bonded to oxygen or nitrogen atoms which renders the hydrogen atoms appreciably acidic and thus capable of being "shared" with a solute through hydrogen bonding. Examples of protic solvents include, without limitation, water and alcohols.

An "aprotic solvent" may be polar or non-polar but, in either case, does not contain acidic hydrogens and therefore is not capable of hydrogen bonding with solutes. Examples, without limitation, of non-polar aprotic solvents, are pentane, hexane, benzene, toluene, methylene chloride and

carbon tetrachloride. Examples of polar aprotic solvents are chloroform, tetrahydro-furan, dimethylsulfoxide and dimethylformamide.

In a presently preferred embodiment of this invention, the solvent is a protic solvent, preferably water or an alcohol such as ethanol.

The reaction is carried out at temperatures greater than room temperature. The temperature is generally from about 30° C. to about 150° C., preferably about 80° C. to about 100° C., most preferable about 75° C. to about 85° C., which is about the boiling point of ethanol. By "about" is meant that the temperature range is preferably within 10 degrees Celcius of the indicated temperature, more preferably within 5 degrees Celcius of the indicated temperature and, most preferably, within 2 degrees Celcius of the indicated temperature. Thus, for example, by "about 75° C." is meant 75° C. ± 10° C., preferably 75° C. ± 5° C. and most preferably, 75° C. ± 2° C.

2-Oxindoles and aldehydes, may be readily synthesized using techniques well known in the chemical arts. It will be appreciated by those skilled in the art that other synthetic pathways for forming the compounds of the invention are available and that the following is offered by way of example and not limitation.

EXAMPLES

The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.

Synthetic Examples

Method A: Formylation of Pyrroles

POCl₃ (1.1 equiv.) is added dropwise to dimethylformamide (3 equiv.) at -10° C. followed by addition of the appropriate pyrrole dissolved in dimethylformamide. After stirring for two hours, the reaction mixture is diluted with H₂O and basified to pH 11 with 10 N KOH. The precipitate which forms is collected by filtration, washed with H₂O and dried in a vacuum oven to give the desired aldehyde.

Method B: Saponification of Pyrrolecarboxylic Acid Esters

A mixture of a pyrrolecarboxylic acid ester and KOH (2-4 equiv.) in EtOH is refluxed until reaction completion is indicated by thin layer chromatography (TLC). The cooled reaction mixture is acidified to pH 3 with 1 N HCl. The precipitate which forms is collected by filtration, washed with H₂O and dried in a vacuum oven to give the desired pyrrolecarboxylic acid.

Method C: Amidation

To a stirred solution of a pyrrolecarboxylic acid dissolved in dimethylformamide (0.3M) is added 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide (1.2 equiv.), 1-hydroxybenzotriazole (1.2 equiv.), and triethylamine (2 equiv.). The appropriate amine is added (1 equiv.) and the reaction stirred until completion is indicated by TLC. Ethyl acetate is then added to the reaction mixture and the solution washed with saturated NaHCO₃ and brine (with extra salt), dried over anhydrous MgSO₄ and concentrated to afford the desired amide.

Method D: Condensation of Aldehydes and Oxindoles Containing Carboxylic Acid Substituents

A mixture of the oxindole (1 equivalent), 1 equivalent of the aldehyde and 1-3 equivalents of piperidine (or

pyrrolidine) in ethanol (0.4 M) is stirred at 90-100° C. until reaction completion is indicated by TLC. The mixture is then concentrated and the residue acidified with 2N HCl. The precipitate that forms is washed with H₂O and EtOH and then dried in a vacuum oven to give the product.

Method E: Condensation of Aldehydes and Oxindoles Not Containing Carboxylic Acid Substituents

A mixture of the oxindole (1 equivalent), 1 equivalent of the aldehyde and 1-3 equivalents of piperidine (or pyrrolidine) in ethanol (0.4 M) is stirred at 90-100° C. until reaction completion is indicated by TLC. The mixture is cooled to room temperature and the solid which forms is collected by vacuum filtration, washed with ethanol and dried to give the product. If a precipitate does not form upon cooling of the reaction mixture, the mixture is concentrated and purified by column chromatography.

C. Examples of Oxindole Syntheses

The following examples of the synthesis of representative oxindoles is not to be construed as limiting the scope of this invention in any manner whatsoever. Alternate routes to the oxindoles shown as well as other oxindoles to be used to make the compounds of this invention will become apparent to those skilled in the art based on the following disclosures. Such syntheses and oxindoles are within the scope and spirit of this invention.

5-Amino-2-oxindole

5-Nitro-2-oxindole (6.3 g) was hydrogenated in methanol over 10% palladium on carbon to give 3.0 g (60% yield) of the title compound as a white solid.

5-Bromo-2-oxindole

2-Oxindole (1.3 g) in 20 mL acetonitrile was cooled to -10° C. and 2.0 g N-bromosuccinimide was slowly added with stirring. The reaction was stirred for 1 hour at -10° C. and 2 hours at 0° C. The precipitate was collected, washed with water and dried to give 1.9 g (90% yield) of the title compound.

4-Methyl-2-oxindole

Diethyl oxalate (30 mL) in 20 mL of dry ether was added with stirring to 19 g of potassium ethoxide suspended in 50 mL of dry ether. The mixture was cooled in an ice bath and 20 mL of 3-nitro-o-xylene in 20 mL of dry ether was slowly added. The thick dark red mixture was heated to reflux for 0.5 hr, concentrated to a dark red solid, and treated with 10% sodium hydroxide until almost all of the solid dissolved. The dark red mixture was treated with 30% hydrogen peroxide until the red color changed to yellow. The mixture was treated alternately with 10% sodium hydroxide and 30% hydrogen peroxide until the dark red color was no longer present. The solid was filtered off and the filtrate acidified with 6N hydrochloric acid. The resulting precipitate was collected by vacuum filtration, washed with water, and dried under vacuum to give 9.8 g (45% yield) of 2-methyl-6-nitrophenylacetic acid as an off-white solid. The solid was hydrogenated in methanol over 10% palladium on carbon to give 9.04 g of the title compound as a white solid.

7-Bromo-5-chloro-2-oxindole

5-Chloro-2-oxindole (16.8 g) and 19.6 g of N-bromosuccinimide were suspended in 140 mL of acetonitrile and refluxed for 3 hours. Thin layer chromatography (silica, ethyl acetate) at 2 hours of reflux showed 5-chloro-2-oxindole or N-bromosuccinimide (Rf 0.8), product (Rf 0.85) and a second product (Rf 0.9) whose proportions did not change after another hour of reflux. The mixture was cooled to 10° C., the precipitate was collected by vacuum filtration, washed with 25 mL of ethanol and sucked dry for

179

20 minutes in the funnel to give 14.1 g of wet product (56% yield). The solid was suspended in 200 mL of denatured ethanol and slurry-washed by stirring and refluxing for 10 minutes. The mixture was cooled in an ice bath to 10° C. The solid product was collected by vacuum filtration, washed with 25 mL of ethanol and dried under vacuum at 40° C. to give 12.7 g (51% yield) of 7-bromo-5-chloro-2-oxindole.

5-Fluoro-2-oxindole

5-Fluoroisatin (8.2 g) was dissolved in 50 mL of hydrazine hydrate and refluxed for 1.0 hr. The reaction mixtures were then poured in ice water. The precipitate was then filtered, washed with water and dried in a vacuum oven to afford the title compound.

5-Nitro-2-oxindole

2-Oxindole (6.5 g) was dissolved in 25 mL concentrated sulfuric acid and the mixture maintained at -10 to -15° C. while 2.1 mL of fuming nitric acid was added dropwise. After the addition of the nitric acid the reaction mixture was stirred at 0° C. for 0.5 hr and poured into ice-water. The precipitate was collected by filtration, washed with water and crystallized from 50% acetic acid. The crystalline product was then filtered, washed with water and dried under vacuum to give 6.3 g (70%) of 5-nitro-2-oxindole.

5-Aminosulfonyl-2-oxindole

To a 100 mL flask charged with 27 mL of chlorosulfonic acid was added slowly 13.3 g of 2-oxindole. The reaction temperature was maintained below 30° C. during the addition. After the addition, the reaction mixture was stirred at room temperature for 1.5 hr, heated to 68° C. for 1 hr, cooled, and poured into water. The precipitate was washed with water and dried in a vacuum oven to give 11.0 g of 5-chlorosulfonyl-2-oxindole (50% yield) which was used without further purification.

5-Chlorosulfonyl-2-oxindole (2.1 g) was added to 10 mL of ammonium hydroxide in 10 mL of ethanol and stirred at room temperature overnight. The mixture was concentrated and the solid collected by vacuum filtration to give 0.4 g (20% yield) of the title compound as an off-white solid.

5-Isopropylaminosulfonyl-2-oxindole

To a 100 mL flask charged with 27 mL chlorosulfonic acid was slowly added 13.3 g 2-oxindole. The reaction temperature was maintained below 30° C. during the addition. The reaction mixture was stirred at room temperature for 1.5 hour, heated to 68° C. for 1 hour, cooled, and poured into water. The precipitate which formed was filtered, washed with water and dried in a vacuum oven to give 11.0 g (50%) of 5-chlorosulfonyl-2-oxindole which was used without further purification.

A suspension of 3 g 5-chlorosulfonyl-2-oxindole, 1.15 g isopropylamine and 1.2 mL of pyridine in 50 mL of dichloromethane was stirred at room temperature for 4 hours during which time a white solid formed. The solid was collected by vacuum filtration, slurry-washed with hot ethanol, cooled, collected by vacuum filtration and dried under vacuum at 40° C. overnight to give 1.5 g (45%) of 5-isopropylaminosulfonyl-2-oxindole.

¹HNMR (360 MHz, DMSO-d6) δ 10.69 (s, br, 1H, NH), 7.63 (dd, J=2 and 8 Hz, 1H), 7.59 (d, J=2 Hz, 1H), 7.32 (d, J=7 Hz, 1H, NH—SO₂—), 6.93 (d, J=8 Hz, 1H), 3.57 (s, 2H), 3.14–3.23 (m, 1H, CH—(CH₃)₂), 0.94 (d, J=7 Hz, 6H, 2xCH₃)

5-Phenylaminosulfonyl-2-oxindole

A suspension of 5-chlorosulfonyl-2-oxindole (1.62 g, 7 mmol), aniline (0.782 mL, 8.4 mmol) and pyridine (1 mL) in dichloromethane (20 mL) was stirred at room temperature

180

for 4 hours. The reaction mixture was diluted with ethyl acetate (300 mL) and acidified with 1N hydrochloric acid (16 mL). The organic layer was washed with sodium bicarbonate and brine, dried and concentrated. The residue was washed with ethanol (3 mL) and then chromatographed on silica gel eluting with methanol/dichloromethane 1:9 to give of 5-phenylaminosulfonyl-2-oxindole.

¹HNMR (360 MHz, DMSO-d6) δ 10.71 (s, br, 1H, NH), 10.10 (s, br, 1H, NH), 7.57–7.61 (m, 2H), 7.17–7.22 (m, 2H), 7.06–7.09 (m, 2H), 6.97–7.0 (m, 1H), 6.88 (d, J=8.4 Hz, 1H), 3.52 (s, 2H).

2-Oxo-2,3-dihydro-1H-indole-5-sulfonic Acid pyridin-3-ylamide

A solution of 5-chlorosulfonyl-2-oxindole (3 g) and 3-aminopyridine (1.46 g) in pyridine (15 mL) was stirred at room temperature overnight at which time a brown solid was present. The solid was filtered, washed with ethanol and dried under vacuum to yield 1.4 g (38%) of 2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid pyridin-3-ylamide.

¹HNMR (360 MHz, DMSO-d6) δ 10.74 (s, 1H, NH), 10.39 (s, 1H, SO₂NH), 8.27–8.28 (d, 1H), 8.21–8.23 (m, 1H), 7.59–7.62 (m, 2H), 7.44–7.68 (m, 1H), 7.24–7.28 (m, 1H), 6.69–6.71 (d, 1H), 3.54 (s, 2H).

MS m/z (APCI+) 290.2.

5-Phenyloxindole

5-Bromo-2-oxindole (5 g, 23.5 mmol) was dissolved in 110 mL toluene and 110 mL ethanol with stirring and a little heat. Tetrakis(triphenylphosphine)palladium(0) (1.9 g, 1.6 mmol) was added followed by 40 mL (80 mmol) 2M aqueous sodium carbonate. To this mixture was added benzene boronic acid (3.7 g, 30.6 mmol) and the mixture was heated in a 100° C. oil bath for 12 hours. The reaction was cooled, diluted with ethyl acetate (500 mL), washed with saturated sodium bicarbonate (200 mL), water (200 mL), 1N HCl (200 mL) and brine (200 mL). The organic layer was dried over magnesium sulfate and concentrated to afford a brown solid. Trituration with dichloromethane afforded 3.8 g (77%) of 5-phenyl-2-oxindole as a tan solid.

¹HNMR (360 MHz, DMSO-d6) δ 10.4 (br s, 1H, NH), 7.57 (dd, J=1.8 and 7.2 Hz, 1H), 7.5 to 7.35 (m, 5H), 7.29 (m, 1H), 6.89 (d, J=8.2 Hz, 1H), 3.51 (s, 2H, CH₂CO).

MS m/z 209 [M⁺].

In similar fashion, the following oxindoles can be prepared:

6-(3,5-Dichlorophenyl)-1,3-dihydroindol-2-one

¹H NMR (360 MHz, DMSO-d6) δ 10.46 (br, 1H, NH), 7.64 (d, J=1.8 Hz, 2H), 7.57 (m, 1H), 7.27 (m, 2H), 7.05 (d, J=1.1 Hz, 1H), 3.5 (s, 2H).

MS-EI m/z 277/279 [M]⁺.

6-(4-Butylphenyl)-1,3-dihydroindol-2-one

¹H NMR (360 MHz, DMSO-d6) δ 10.39 (s, 1H, NH), 7.49 (d, J=8.0 Hz, 2H), 7.25 (d, J=8 Hz, 3H), 7.17 (dd, J=1.5 and 7.8 Hz, 1H), 6.99 (d, J=1.5 Hz, 1H), 3.48 (s, 2H, CH₂CO), 2.60 (t, J=7.5 Hz, 2 Hz, CH₂CH₃), 1.57 (m, 2H, CH₂), 1.32 (m, 2H, CH₂), 0.9 (t, J=7.5 Hz, 3H, CH₃).

6-(5-Isopropyl-2-methoxyphenyl)-1,3-dihydroindol-2-one

¹H NMR (360 MHz, DMSO-d6) δ 10.29 (br s, 1H, NH), 7.16–7.21 (m, 2H), 7.08 (d, J=2.4 Hz, 1H), 6.97–7.01 (m, 2H), 6.89 (d, J=0.8 Hz, 1H), 3.71 (s, 3H, OCH₃), 3.47 (s, 2H, CH₂CO), 2.86 (m, 1H, CH(CH₃)₂), 1.19 (d, J=6.8 Hz, 6H, CH(CH₃)₂).

MS-EI m/z 281 [M]⁺.

181

6-(4-Ethylphenyl)-1,3-dihydroindol-2-one

¹H NMR (360 MHz, DMSO-d6) δ 10.39 (br s, 1H, NH), 7.50 (d, J=8.2 Hz, 2H), 7.28 (d, J=8.2 Hz, 2H), 7.25 (d, J=7.5 Hz, 1H), 7.17 (dd, J=1.6 & 7.5 Hz, 1H), 6.99 (d, J=1.6 Hz, 1H), 3.48 (s, 2H, CH₂CO), 2.63 (q, J=7.6 Hz, 2H, CH₂CH₃), 1.20 (t, J=7.6 Hz, 3H, CH₂CH₃).

MS-EI m/z 237 [M]⁺.

6-(3-Isopropylphenyl)-1,3-dihydroindol-2-one

¹H NMR (360 MHz, DMSO-d6) δ 10.37 (br s, 1H, NH), 7.43 (m, 1H), 7.35-7.39 (m, 1H), 7.17-7.27 (m, 3H), 7.01 (d, J=1.8 Hz, 1H), 3.49 (s, 2H, CH₂CO), 2.95 (m, 1H, CH(CH₃)₂), 1.24 (d, J=6.8 Hz, 6H, CH(CH₃)₂).

MS-EI m/z 251 [M]⁺.

6-(2,4-Dimethoxyphenyl)-1,3-dihydroindol-2-one

¹H NMR (360 MHz, DMSO-d6) δ 10.28 (br s, 1H, NH), 7.17 (m, 2H), 6.93 (dd, J=1.6 & 7.6 Hz, 1H), 6.86 (d, J=1.6 Hz, 1H), 6.63 (d, J=2.4 Hz, 1H), 6.58 (dd, J=2.4 & 8.5 Hz, 1H), 3.79 (s, 3H, OCH₃), 3.74 (s, 3H, OCH₃), 3.45 (s, 2H, CH₂CO).

MS-EI m/z 269 [M]⁺.

6-Pyridin-3-yl-1,3-dihydroindol-2-one

¹H NMR (360 MHz, DMSO-d6) δ 10.51 (s, 1H, NH), 8.81 (d, J=2.5 Hz, 1H), 8.55 (dd, J=1.8 and 5.7 Hz, 1H), 8 (m, 1H), 7.45 (dd, J=5.7 and 9.3 Hz, 1H), 7.3 (m, 2H), 7.05 (s, 1H), 3.51 (s, 2H, CH₂CO).

MS m/z 210 [M]⁺.

2-Oxo-2,3-dihydro-1H-indole-4-carboxylic Acid (3-chloro-4-ethoxyphenyl)-amide

To a solution of 4-carboxy-2-oxindole (200 mg, 1.13 mmol) and 3-chloro-4-methoxyphenylamine (178 mg, 1.13 mmol) in dimethylformamide (15 mL) at room temperature was added benzotriazol-1-yloxytris(dimethylamino) phosphonium hexafluorophosphate (BOP reagent, 997 mg, 2.26 mmol) followed by 4-dimethylaminopyridine (206 mg, 1.69 mmol). The mixture was stirred at room temperature for 72 hours. The reaction was then diluted with ethyl acetate (300 mL), washed with saturated sodium bicarbonate (100 mL), water, 2N hydrochloric acid (100 mL), water (3×200 mL) and brine. It was then dried over magnesium sulfate and concentrated. The residue was triturated with ethyl acetate to give 2-oxo-2,3-dihydro-1H-indole-4-carboxylic acid (3-chloro-4-methoxyphenyl)-amide as a pink solid.

¹H NMR (360 MHz, DMSO-d6) δ 10.50 (s, br, 1H, NH), 10.12 (s, br, 1H, NH), 7.9 (s, J=2.5 Hz, 1H), 7.62 (dd, J=2.5 & 9 Hz, 1H), 7.38 (d, J=7.6 Hz, 1H), 7.32 (t, J=7.6 Hz, 1H), 7.13 (d, J=9 Hz, 1H), 6.98 (d, J=7.6 Hz, 1H), 3.83 (s, 3H, OCH₃), 3.69 (s, 2H, CH₂).

MS-EI m/z 316 [M]⁺.

4-Carboxy-2-oxindole

A solution of trimethylsilyldiazomethane in hexane (2 M) was added dropwise to a solution of 2.01 g 2-chloro-3-carboxy-nitrobenzene in 20 mL methanol at room temperature until no further gas evolution occurred. Acetic acid was then added to quench excess trimethylsilyldiazomethane. The reaction mixture was evaporated under vacuum and the residue was dried in an oven overnight. The 2-chloro-3-methoxycarbonylnitrobenzene obtained was pure enough for the following reaction.

Dimethyl malonate (6.0 mL) was added to an ice-cold suspension of 2.1 g sodium hydride in 15 mL DMSO. The reaction mixture was stirred at 100° C. for 1 hour and then cooled to room temperature. 2-Chloro-3-methoxycarbonylnitrobenzene (2.15 g) was added in one portion and the mixture was heated to 100° C. for 1.5 hours.

182

The reaction mixture was then cooled to room temperature, poured into ice water, acidified to pH 5 and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated to give 3.0 g of the dimethyl 2-methoxycarbonyl-6-nitrophenyl-malonate.

Dimethyl 2-methoxycarbonyl-6-nitrophenylmalonate (3.0 g) was refluxed in 50 mL of 6 N hydrochloric acid overnight. The mixture was concentrated to dryness, 20 mL ethanol and 1.1 g of tin(II) chloride were added and the mixture was refluxed for 2 hours. The mixture was filtered through Celite, concentrated and chromatographed on silica gel using ethyl acetate:hexane:acetic acid as eluent to give 0.65 g (37%) of 4-carboxy-2-oxindole as a white solid.

¹H NMR (360 MHz, DMSO-d6) δ 12.96 (s, br, 1H, COOH), 10.74 (s, br, 1H, NH), 7.53 (d, J=8 Hz, 1H), 7.39 (t, J=8 Hz, 1H), 7.12 (d, J=8 Hz, 1H), 3.67 (s, 2H).

D. Synthesis of Pyrrole Substituted 2-indolinones.

Example 1

4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic Acid

4-Methyl-2-pyrrolecarboxylic acid ethyl ester (commercially available) was formylated using method A to give (73%) of 5-formyl-4-methyl-2-pyrrolecarboxylic acid ethyl ester. It was then hydrolysed using method B to give 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (58%).

Oxindole (133 mg, 1 mmol) was condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (153 mg) using method D to give 268 mg (100%) of the title compound as an orange-red solid.

¹H NMR (360 MHz, DMSO-d6) δ 13.84 (s, br, 1H, NH), 12.84 (s, br, 1H, COOH), 10.98 (s, br, 1H, NH), 7.82 (d, J=7.5 Hz, 1H), 7.67 (s, 1H, H-vinyl), 7.18 (t, J=7.5 Hz, 1H), 7.01 (t, J=7.5 Hz, 1H), 6.88 (d, J=7.5 Hz, 1H), 6.71 (d, J=2.2 Hz, 1H), 2.32 (s, 3H, CH₃).

MS (negative mode) 266.8 [M-1]⁺.

Example 2

4-Methyl-5-(1-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic Acid

1-Methyl-1,3-dihydroindol-2-one (147 mg, 1 mmol) was condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (153 mg) using method D to give 250 mg (86%) of the title compound.

¹H NMR (360 MHz, DMSO-d6) δ 13.82 (s, br, 1H, NH), 12.88 (s, br, 1H, 7.83 (d, J=7.5 Hz, 1H), 7.65 (s, 1H, H-vinyl), 7.26 (t, J=7.5 Hz, 1H), 7.02-7.09 (m, 2H), 6.70 (d, J=2.2 Hz, 1H), 2.32 (s, 3H, CH₃).

MS m/z 283.0 [M+1]⁺.

Example 3

4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic Acid Methyl Ester

Oxindole (105 mg, 0.79 mmol) was condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid methyl ester (110 mg, 0.67 mmol) using method E to give 153.2 mg (81%) of the title compound.

¹H NMR (360 MHz, DMSO-d6) δ 13.98 (s, br, 1H, NH), 10.97 (s, br, 1H, NH), 7.82 (d, J=7.6 Hz, 1H), 7.67 (s, 1H, H-vinyl), 7.2 (dt, J=1.2 & 7.7 Hz, 1H), 7.01 (dt, J=1.2, 7.7 Hz, 1H), 6.90 (d, J=7.6 Hz, 1H), 6.77 (d, J=2 Hz, 1H).

MS (ES) m/z 283 [M⁺+1].

183

Example 4

5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic Acid Ethyl Ester

5-Chloro-1,3-dihydroindol-2-one (2.22 g, 13.2 mmol) was condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid ethyl ester (2.43 g) using method E to give 4.1 g (94%) of the title compound as an orange solid.

¹H NMR (360 MHz, DMSO-d₆) δ 13.95 (s, br, 1H, NH), 7.98 (d, J=2.2 Hz, 1H, H-4), 7.78 (s, 1H, H-vinyl), 7.18 (dd, J=2.2 & 8.3 Hz, 1H, H-6), 6.87 (d, J=8.3 Hz, 1H, H-7), 7.34 (d, J=1.8 Hz, 1H, H-3'), 4.27 (q, J=7.2 Hz, 2H, OCH₂CH₃), 2.33 (s, 3H, CH₃), 1.29 (t, J=7.2 Hz, 3H, OCH₂CH₃).

MS-EI m/z 330 [M⁺].

Example 5

5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic Acid

A mixture of 5-(5-chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic acid ethyl ester (1.3 g, 4 mmol) and potassium hydroxide in methanol (25 mL) and ethanol (25 mL) was heated to reflux for overnight. Insoluble materials were removed by filtration and the mixture was neutralized with 6N hydrochloric acid to give 0.876 g (70%) of the title compound.

¹H NMR (360 MHz, DMSO-d₆) δ 13.80 (s, br, 1H, NH), 12.90 (s, br, 1H, COOH), 11.06 (s, br, 1H, NH), 8.02 (d, J=1.8 Hz, 1H, H-4), 7.81 (s, 1H, H-vinyl), 7.20 (dd, J=1.8 & 8.3 Hz, 1H, H-6), 6.89 (d, J=8.3 Hz, 1H, H-7), 6.72 (d, J=1.8 Hz, 1H, H-3'), 2.35 (s, 3H, CH₃).

MS-EI m/z 302 [M⁺].

Example 6

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide

5-Bromo-1,3-dihydroindol-2-one (0.16 g, 0.76 mmol) was condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide (0.2 g, prepared by method C) to give 60 mg (17%) of the title compound as an orange solid.

¹H NMR (360 MHz, DMSO-d₆) δ 13.61 (s, br, 1H, NH), 11.02 (s, br, 1H, NH), 8.42 (t, J=5.8 Hz, 1H, CONHCH₂), 8.12 (d, J=1.8 Hz, 1H, H-4), 7.78 (s, 1H, H-vinyl), 7.30 (dd, J=1.8 & 8.4 Hz, 1H, H-6), 6.82 (d, J=8.4 Hz, 1H, H-7), 6.77 (d, J=2.4 Hz, 1H, H-3'), 3.22-3.31 (m, 2H, CH₂), 2.38-2.43 (m, 6H, 3xCH₂), 2.35 (s, 3H, CH₃), 1.62-1.71 (m, 6H, 3xCH₂).

MS-EI m/z 456 and 458 [M⁺-1 and M⁺+2].

Example 7

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrole-2-carboxylic Acid (3-diethylamino-propyl)amide

5-Bromo-1,3-dihydroindol-2-one (0.16 g, 0.75 mmol) was condensed with 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide (0.2 g, prepared by method C) to give 30 mg (8%) of the title compound as an orange solid.

¹H NMR (360 MHz, DMSO-d₆) δ 13.61 (s, br, 1H, NH), 11.02 (s, br, 1H, NH), 8.40 (m, 1H, CONHCH₂), 8.12 (d, J=1.5 Hz, 1H, H-4), 7.78 (s, 1H, H-vinyl), 7.30 (dd, J=1.5 & 8.2 Hz, 1H, H-6), 6.82 (d, J=8.2 Hz, 1H, H-7), 6.78 (d, J=2.4 Hz, 1H, H-3'), 3.23 (m, 2H, CH₂), 2.38-2.45 (m, 6H, CH₂

184

& N(CH₂CH₃)₂), 2.35 (s, 3H, CH₃), 1.61 (m, 2H, CH₂), 0.93 (t, J=7.1 Hz, 6H, N(CH₂CH₃)₂).

MS-EI m/z 458 and 460 [M⁺-1 and M⁺+2].

Example 8

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic Acid (2-diethylaminoethyl)amide

5-Bromo-1,3-dihydroindol-2-one (212 mg, 1 mmol) was condensed with 5-formyl-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)amide (prepared from ethyl pyrrole-2-carboxylate by method A, B and then C) to give 162 mg (38%) of the title compound.

¹H NMR (300 MHz, DMSO-d₆) δ 13.53 (s, br, 1H, NH),

11.06 (s, br, 1H, NH), 8.37 (t, 1H, CONHCH₂), 7.89 (m, 2H), 7.32 (dd, J=2.0 Hz, 1H), 6.96 (s, 1H), 6.80-6.84 (m, 2H), 3.3 (m, 2H, CH₂), 2.45-2.55 (m, 6H, N(CH₂CH₃)₂ & CH₃), 0.95 (t, J=7.2 Hz, 6H, N(CH₂CH₃)₂).

MS-EI m/z 430 and 432 [M⁺-1 and M⁺+1].

Example 9

5-(2-Oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic Acid (2-diethylaminoethyl)amide

6-Phenyl-1,3-dihydroindol-2-one (209 mg, 1 mmol) was condensed with 5-formyl-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)amide to give 182 mg (42%) of the title compound.

¹H NMR (300 MHz, DMSO-d₆) δ 13.56 (s, br, 1H, NH),

11.06 (s, br, 1H, NH), 8.36 (t, 1H, CONHCH₂), 7.77 (s, 1H, H-vinyl), 7.73 (d, J=7.8 Hz, 1H), 7.64 (d, J=7.2 Hz, 2H), 7.46 (m, 2H), 7.32 (m, 2H), 7.11 (s, 1H), 6.96 (m, 1H), 6.80 (m, 1H), 3.31-3.32 (m, 2H, CH₂), 2.46-2.53 (m, 6H, N(CH₂CH₃)₂ & CH₂), 0.96 (t, J=6.9 Hz, 6H, N(CH₂CH₃)₂).

MS-EI m/z 428 [M⁺].

Example 10

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic Acid (2-diethylaminoethyl)-methylamide

5-Bromo-1,3-dihydroindol-2-one (212 mg, 1 mmol) was condensed with 5-formyl-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)methylamide to give 246 mg (55%) of the title compound.

¹H NMR (360 MHz, DMSO-d₆) δ 13.54 (s, br, 1H, NH),

11.06 (s, br, 1H, NH), 7.90 (m, 2H), 7.33 (dd, J=1.8 & 8.4 Hz, 1H), 6.82-6.85 (m, 3H), 3.55 (s, br, 2H, CH₂), 3.25 (s, br, 3H, NCH₃), 2.57 (t, J=6.5 Hz, 2H, CH₂), 2.45 (m, 4H, N(CH₂CH₃)₂), 0.91 (m, 6H, N(CH₂CH₃)₂).

MS-EI m/z 444 and 446 [M⁺-1 and M⁺+1].

Example 11

5-(2-Oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic Acid (2-diethylaminoethyl)methylamide

6-Phenyl-1,3-dihydroindol-2-one (209 mg, 1 mmol) was condensed with 5-formyl-1H-pyrrole-2-carboxylic acid (2-diethylaminoethyl)methylamide to give 277 mg (63%) of the title compound.

¹H NMR (360 MHz, DMSO-d₆) δ 13.58 (s, br, 1H, NH),

11.04 (s, br, 1H, NH), 7.78 (s, 1H, H-vinyl), 7.73 (d, J=7.8 Hz, 1H), 7.64 (d, J=7.5 Hz, 2H), 7.46 (m, 2H), 7.33-7.36 (m, 2H), 7.11 (s, 1H), 6.84 (m, 1H), 6.78 (m, 1H), 3.55 (s, br, 2H, CH₂), 3.25 (s, br, 3H, NCH₃), 2.58 (t, 2H, CH₂), 2.44 (m, 4H, N(CH₂CH₃)₂), 0.92 (m, 6H, N(CH₂CH₃)₂).

185

Example 12

3-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic Acid (3-diethylaminopropyl)amide
 Oxindole (66.5 mg, 0.5 mmol) was condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl) amide (prepared from 3-formyl-3-methyl-1H-pyrrole-2-carboxylic acid ethyl ester by method B then C) to give 39 mg (21%) of the title compound.

¹H NMR (300 MHz, DMSO-d6) δ 13.34 (s, br, 1H, NH), 10.88 (s, br, 1H, NH), 7.62–7.67 (m, 3H), 7.17 (m, 1H), 6.99 (m, 1H), 6.87 (d, J=7.6 Hz, 1H), 6.63 (d, J=1 Hz, 1H), 3.26–3.32 (m, 2H, CH₂), 2.41–2.48 (m, 6H, CH₂ & N(CH₂CH₃)₂), 2.29 (s, 3H, CH₃), 1.63 (m, 2H, CH₂), 0.93 (t, J=7.2 Hz, 6H, N(CH₂CH₃)₂).

MS-EI m/z 380 [M⁺].

Example 13

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (3-diethylaminopropyl)amide

5-Bromo-1,3-dihydroindol-2-one (106 mg, 0.5 mmol) was condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide to give 35 mg (15%) of the title compound.

¹H NMR (300 MHz, DMSO-d6) δ 13.35 (s, br, 1H, NH), 11.00 (s, br, 1H, NH), 7.89 (d, J=1.9 Hz, 1H, H-4), 7.80 (s, 1H, H-vinyl), 7.74 (t, J=5.3 Hz, 1H, CONHCH₂), 7.31 (dd, J=1.9 & 8.4 Hz, 1H, H-6), 6.83 (d, J=8.4 Hz, 1H, H-7), 6.63 (s, 1H, H-3), 3.26 (m, 2H, CH₂), 2.41–2.48 (m, 6H, CH₂ & N(CH₂CH₃)₂), 2.29 (s, 3H, CH₃), 1.63 (m, 2H, CH₂), 0.93 (t, J=7.1 Hz, 6H, N(CH₂CH₃)₂).

MS-EI m/z 458 and 460 [M⁺-1 and M⁺+1].

Example 14

3-Methyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic Acid (3-diethylaminopropyl)amide

6-Phenyl-1,3-dihydroindol-2-one (105 mg, 0.5 mmol) was condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide to give 67.8 (30%) of the title compound.

¹H NMR (300 MHz, DMSO-d6) δ 13.37 (s, br, 1H, NH), 11.02 (s, br, 1H, NH), 7.23–7.73 (m, 11H), 3.29 (m, 2H, CH₂), 2.41–2.48 (m, 6H, CH₂ & N(CH₂CH₃)₂), 2.29 (s, 3H, CH₃), 1.64 (m, 2H, CH₂), 0.94 (t, J=7.0 Hz, 6H, N(CH₂CH₃)₂).

MS-EI m/z 456 [M⁺].

Example 15

5-(5-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (3-diethylaminopropyl)amide

5-Methoxy-1,3-dihydroindol-2-one (82.5 mg, 0.5 mmol) was condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide to give 80 mg (39%) of the title compound.

¹H NMR (300 MHz, DMSO-d6) δ 13.45 (s, br, 1H, NH), 10.70 (s, br, 1H, NH), 7.68–7.70 (m, 2H), 7.32 (d, J=1.8 Hz, 1H), 6.72–6.79 (m, 2H), 6.60 (s, 1H), 3.73 (s, 3H, OCH₃), 3.28 (m, 2H, CH₂), 2.41–2.48 (m, 6H, CH₂ & N(CH₂CH₃)₂), 2.29 (s, 3H, CH₃), 1.63 (m, 2H, CH₂), 0.93 (t, J=7.0 Hz, 6H, N(CH₂CH₃)₂).

MS m/z 410 [M⁺].

186

Example 16

5-(6-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (3-diethylaminopropyl)amide

6-Methoxy-1,3-dihydroindol-2-one (82.5 mg, 0.5 mmol) was condensed with 5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide to give 63 mg (31%) of the title compound.

¹H NMR (300 MHz, DMSO-d6) δ 13.22 (s, br, 1H, NH), 10.86 (s, br, 1H, NH), 7.39–7.63 and 6.37–6.55 (m, 6H), 3.73 (s, 3H, OCH₃), 3.3 (m, 2H, CH₂), 2.45 (m, 6H, CH₂ & N(CH₂CH₃)₂), 2.28 (s, 3H, CH₃), 1.63 (m, 2H, CH₂), 0.93 (m, 6H, N(CH₂CH₃)₂).

MS m/z 410 [M⁺].

Example 17

3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic Acid (2-diethylaminoethyl)amide

4,5,6,7-Tetrahydro-2H-isoindole-1-carboxylic acid ethyl ester (May, Donald A.; Lash, Timothy D.; *J. Org. Chem.*, 1992, 57:18, 4820–4828) was formylated using method A then B to give 3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid.

5-Bromo-1,3-dihydroindol-2-one (1.43 g, 6.8 mmol) was condensed with 3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (2-diethylaminoethyl)amide (1.97 g) to give 2.2 g (67%) of the title compound as a yellow-orange solid.

¹H NMR (360 MHz, DMSO-d6) δ 13.47 (s, 1H, NH), 11.0 (s, 1H, NH), 8.0 (d, 1H, NH), 7.70 (s, 1H, CH), 7.28 (dd, J=2.1 and 8.2 Hz, 1H, ArH), 7.16 (m, 1H, ArH), 6.8 (d, J=8.3 Hz, 1H, ArH), 3.3 (s, 2H, CONH), 2.5 (m, 6H, 3×NCH₂), 2.78 (br m, 2H, pyrrole CH₂), 2.72 (br m, 2H, pyrroleCH₂), 1.7 (br m, 4H, N(CH₂CH₃)₂), 1.74 (br s, 4H, CH₂CH₂CH₂CH₂), 0.96 (t, J=7.4 Hz, 6H, N(CH₂CH₃)₂).

MS-EI m/z 484 and 486 [M⁺-1 and M⁺+1].

Example 18

3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic Acid (3-diethylamino-propyl)amide

5-Bromo-1,3-dihydroindol-2-one (20 mg, 0.1 mmol) was condensed with 3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (3-diethylaminopropyl)amide (30 mg) to give 33 mg (46%) of the title compound as an orange solid.

¹H NMR (360 MHz, DMSO-d6) δ 10.9 (s, 1H, NH), 8.0 (m, 1H, NH), 7.68 (m, 1H, ArH), 7.4 (m, 1H, ArH), 7.29 (d, J=1.9 and 8.5 Hz, 1H, ArH), 6.8 (d, J=8 Hz, 1H, ArH), 2.7 (br m, 4H, 2×NCH₂), 2.4 (m, 8H, 4×NCH₂), 1.7 (br m, 4H, N(CH₂CH₃)₂), 1.6 (br m, 2H, CH₂CH₂CH₂), 0.93 (t, J=7.4 Hz, 6H, N(CH₂CH₃)₂).

MS-EI m/z 499 and 501 [M⁺and M⁺+2].

Example 19

3-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide

5-Bromo-1,3-dihydroindol-2-one (80 mg, 0.4 mmol) was condensed with 3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide (120 mg) to give 43 mg (22%) of the title compound as a tan-orange solid.

187

¹H NMR (360 MHz, DMSO-d6) δ 13.4 (s, 1H, NH), 10.9 (s, 1H, NH), 8.0 (m, 1H, NH), 7.69 (m, 1H, ArH), 7.49 (m, 1H, ArH), 7.28 (d, J=1.7 and 7.8 Hz, 1H, ArH), 6.8 (d, J=8 Hz, 1H, ArH), 3.3 (br m, 2H, 2xNCH₂), 2.8 (m, 4H, 2xpyrroleCH₂), 2.5 (br m, 4H, N(CH₂CH₃)₂), 1.6 (br m, 8H, 2xpyrroleCH₂CH₂, CH₂CH₂CH₂ and CONHCH₂).

MS-EI m/z 497 and 499 [M⁺ and M⁺⁺²].

Example 20

3-(2-Oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic Acid (2-diethylaminoethyl)amide

6-Pyridin-3-yl-1,3-dihydroindol-2-one (60 mg, 0.4 mmol) was condensed with 3-formyl-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic acid (2-diethylaminoethyl)amide (80 mg) to give 50 mg (38%) of the title compound as a reddish solid.

¹H NMR (360 MHz, DMSO-d6) δ 13.4 (s, 1H, NH), 11 (s, 1H, NH), 8.9 (d, 1H, NH), 8.7 (dd, 1H, ArH), 8.1 (dd, 1H, ArH), 7.9 (d, 1H, ArH), 7.6 (s, 1H, CH), 7.5 (dd, 1H, ArH), 7.3 (dd, 1H, ArH), 7.1 (m, 2H, ArH), 3.35 (m, 2H, CONHCH₂), 2.8 (m, 4H, 2xpyrroleCH₂), 2.5 (br m, 6H, N(CH₂CH₃)₂ and NCH₂), 1.75 (br s, 4H, 2xpyrroleCH₂CH₂), 0.9 (t, 6H, N(CH₂CH₃)₂).

MS-EI m/z 484 [M⁺].

Example 21

4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (3-diethylaminopropyl)amide

To a mixture of benzoyl chloride (1 equiv.) and aluminum chloride (1 equiv.) in dichloroethane at 0° C. was added ethyl 3,5-dimethyl-2-pyrrolecarboxylate (1 equiv.). The mixture was stirred at 80° C. for 4 hr. The mixture was then extracted with ethyl acetate (EtOAc) and H₂O. The combined organic extracts were washed with saturated sodium bicarbonate and brine, dried and concentrated to give (51%) of 4-benzoyl-3,5-dimethyl-1H-pyrrole-2-carboxylic acid.

A mixture of 4-benzoyl-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester (4.13 g, 15.2 mmol) and ceric ammonium nitrate (33 g, 4 equiv.) in 50 mL of tetrahydrofuran (THF):acetic acid (HOAc):H₂O 1:1:1 was refluxed overnight. The reaction mixture was then cooled, extracted with EtOAc and then basified to pH 9 with sodium carbonate. The organic layer was then washed with brine, dried (MgSO₄) and concentrated followed by column chromatography to give 3.25 g (75%) of 4-benzoyl-5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid ethyl ester as a yellow solid.

5-Bromo-1,3-dihydro-indol-2-one was condensed with 4-benzoyl-5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid using method D to give 4-benzoyl-5-(5-bromo-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic acid.

The above carboxylic acid was then coupled with N,N-diethyl-1,3-propanediamine using method C to give the title compound.

¹H NMR (360 MHz, DMSO-d6) δ 7.96 (m, 1H, CONHCH₂), 7.76 (d, J=7.0 Hz, 2H), 7.68 (t, 1H), 7.56 (m, 2H), 7.40 (s, 2H) 7.33 (dd, J=1.6 & 8.3 Hz, 1H, H-6), 6.84 (d, J=8.3 Hz, 1H, H-7), 3.33 (m, 2H, CH₂), 2.42-2.46 (m, 6H, 3xCH₂), 2.10 (s, 3H, CH₃), 1.65 (m, 2H, CH₂), 0.94 (t, J=7.0 Hz, 6H, N(CH₂CH₃)₂).

MS Electron Impact m/z 564 [M⁺⁺¹].

188

Example 22

4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (3-morpholin-4-ylpropyl)amide

¹H NMR (360 MHz, DMSO-d6) δ 14.10 (s, 1H, NH), 11.14 (br s, 1H, NH), 7.92 (m, 1H, CONHCH₂), 7.75 (m, 2H), 7.69 (t, 1H), 7.56 (m, 2H), 7.42 (m, 2H), 7.33 (dd, J=1.9 & 8.3 Hz, 1H, H-6), 6.85 (d, J=8.3 Hz, 1H, H-7), 3.56 (m, 4H, 2xCH₂), 3.33 (m, 2H, CH₂), 2.35 (m, 6H, 3xCH₂), 2.10 (s, 3H, CH₃), 1.70 (m, 2H, CH₂).

Example 23

4-Benzoyl-3-methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide

¹H NMR (300 MHz, DMSO-d6) δ 14.18 (s, 1H, NH), 11.14 (br s, 1H, NH), 8.01 (m, 1H, CONHCH₂), 7.74 (m, 1H), 7.67 (m, 1H), 7.55 (m, 1H), 7.32 (s, 1H, H-vinyl), 7.17 (m, 1H), 6.92 (m, 1H), 3.36 (m, 2H, CH₂), 2.44 (m, 6 H, 3xCH₂), 2.11 (s, 3H, CH₃), 1.65-1.75 (m, 6H, 3xCH₂).

MS Electron Impact m/z 482 [M⁺].

Example 24

4-Benzoyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide

¹H NMR (360 MHz, DMSO-d6) δ 14.01 (s, 1H, NH), 11.18 (br s, 1H, NH), 7.98 (m, 1H, CONHCH₂), 7.75 (m, 2H), 7.68 (m, 1H), 7.55 (m, 2H), 7.40 (m, 2H), 7.33 (dd, J=2.0 & 8.2 Hz, 1H, H-6), 6.84 (d, J=8.2 Hz, 1H, H-7), 3.34 (m, 2H, CH₂), 2.42-2.47 (m, 6 H, 3xCH₂), 2.09 (s, 3H, CH₃), 1.70 (m, 2H, CH₂), 1.64 (m, 4H, 2xCH₂).

Example 25

4-Benzoyl-3-methyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-2-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide

¹H NMR (300 MHz, DMSO-d6) δ 14.15 (s, 1H, NH), 11.16 (br s, 1H, NH), 7.98 (m, 1H, CONHCH₂), 7.77 (d, J=7.7 Hz, 2H), 7.69 (m, 1H), 7.53-7.63 (m, 4H), 7.44 (m, 2H), 7.33-7.37 (m, 2H), 7.24 (s, 2H), 7.12 (s, 1H), 3.36 (m, 2H, CH₂), 2.43-2.48 (m, 6 H, 3xCH₂), 2.12 (s, 3H, CH₃), 1.74 (m, 2H, CH₂), 1.69 (m, 4H, 2xCH₂).

MS Electron Impact m/z 558 [M⁺].

Example 26

4-Benzoyl-5-(6-methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide

¹H NMR (300 MHz, DMSO-d6) δ 13.99 (s, 1H, NH), 11.05 (br s, 1H, NH), 7.93 (m, 1H, CONHCH₂), 7.72 (m, 2H), 7.65 (m, 1H), 7.54 (m, 2H), 7.15 (s, 1H, H-vinyl), 7.04 (d, J=8.4 Hz, 1H, H-4), 6.51 (dd, J=2.3 & 8.4 Hz, 1H, H-5), 6.44 (d, J=2.3 Hz, 1H, H-7), 3.74 (s, 3H, OCH₃), 3.35 (m, 2H, CH₂), 2.42-2.46 (m, 6 H, 3xCH₂), 2.10 (s, 3H, CH₃), 1.72 (m, 2H, CH₂), 1.65 (m, 4H, 2xCH₂).

MS Electron Impact m/z 512 [M⁺].

Example 27

4-Benzoyl-5-(5-methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide

¹H NMR (360 MHz, DMSO-d6) δ 14.24 (s, 1H, NH), 10.90 (br s, 1H, NH), 7.97 (m, 1H, CONHCH₂), 7.75 (d,

189

J=7.2 Hz, 2H), 7.69 (m, 1H), 7.56 (m, 2H), 7.24 (s, 1H, H-vinyl), 6.79 (m, 2H), 6.66 (m, 1H), 3.67 (s, 3H, OCH₃), 3.34 (m, 2H, CH₂), 2.43–2.48 (m, 6 H, 3×CH₂), 2.14 (s, 3H, CH₃), 1.71 (m, 2H, CH₂), 1.66 (m, 4H, 2×CH₂).

MS Electron Impact m/z 512 [M⁺].

Example 28

4-Benzoyl-5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide

¹H NMR (300 MHz, DMSO-d₆) δ 14.20 (s, 1H, NH), 11.14 (br s, 1H, NH), 8.03 (m, 1H, CONHCH₂), 7.75 (m, 2H), 7.68 (m, 1H), 7.55 (m, 2H), 7.38 (s, 1H, H-vinyl), 7.08 (m, 1H), 7.01 (m, 1H), 6.87 (m, 1H), 3.34 (m, 2H, CH₂), 2.42–2.48 (m, 6 H, 3×CH₂), 2.09 (s, 3H, CH₃), 1.70 (m, 2H, CH₂), 1.65 (m, 4H, 2×CH₂).

MS Electron Impact m/z 500 [M⁺].

Example 29

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (3-diethylaminopropyl)amide

5-Bromo-1,3-dihydro-indol-2-one was condensed with 4-acetyl-5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid (3-diethylaminopropyl)amide (prepared from 4-acetyl-5-formyl-3-methyl-1H-pyrrole-2-carboxylic acid ethyl ester by method B then C) to give the title compound.

¹H NMR (300 MHz, DMSO-d₆) δ 14.19 (s, 1H, NH), 11.19 (br s, 1H, NH), 8.15 (m, 1H, CONHCH₂), 8.11 (s, 1H, H-vinyl), 7.72 (d, J=1.8 Hz, 1H, H-4), 7.38 (dd, J=1.8 & 8.2 Hz, 1H, H-6), 6.87 (d, J=8.2 Hz, 1H, H-7), 3.27 (m, 2H, CH₂), 2.57 (s, 3H, CH₃CO), 2.46 (m, 9 H, CH₃ & 3×CH₂), 1.64 (m, 2H, CH₂), 0.93 (t, J=7.1 Hz, 6H, N(CH₂CH₃)₂).

Example 30

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide

¹H NMR (300 MHz, DMSO-d₆) δ 8.14 (m, 1H, CONHCH₂), 8.10 (s, 1H, H-vinyl), 7.70 (d, 1H, H-4), 7.36 (dd, J=1.6 & 8.1 Hz, 1H, H-6), 6.85 (d, J=8.1 Hz, 1H, H-7), 3.32 (m, 2H, CH₂), 2.57 (s, 3H, CH₃CO), 2.44 (s, 3H, CH₃), 2.35–2.48 (m, 6H, 3×CH₂), 1.65–1.71 (m, 6H, 3×CH₂).

MS m/z 499 & 501 [M⁺] & [M⁺⁺²].

Example 31

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (3-morpholin-4-ylpropyl)amide

¹H NMR (300 MHz, DMSO-d₆) δ 14.20 (s, 1H, NH), 11.26 (br s, 1H, NH), 8.09 (m, 2H, H-vinyl & CONHCH₂), 7.73 (d, J=1.5 Hz, 1H, H-4), 7.38 (dd, J=1.5 & 8.3 Hz, 1H, H-6), 6.87 (d, J=8.3 Hz, 1H, H-7), 3.55 (m, 4H, 2×CH₂), 3.26 (m, 2H, CH₂), 2.57 (s, 3H, CH₃CO), 2.44 (s, 3H, CH₃), 2.35 (m, 6H, 3×CH₂), 1.68 (m, 2H, CH₂).

MS-EI m/z 514 & 516 [M⁺⁻¹] & [M⁺⁺¹]

Example 32

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (3-hydroxypropyl)amide

¹H NMR (360 MHz, DMSO-d₆) δ 14.17 (s, 1H, NH), 11.25 (br s, 1H, NH), 8.10 (s, 1H, H-vinyl), 8.03 (m, 1H,

190

CONHCH₂), 7.71 (br s, 1H, H-4), 7.37 (br d, J=8.4 Hz, 1H, H-6), 6.87 (d, J=8.4 Hz, 1H, H-7), 4.51 (br s, 1H, OH), 3.51 (br s, 2H, CH₂), 3.36 (m, 2H, CH₂), 2.57 (s, 3H, CH₃CO), 2.43 (s, 3H, CH₃), 1.70 (m, 2H, CH₂).

⁵ MS-EI m/z 445 & 447 [M⁺⁻¹] & [M⁺⁺¹].

Example 34

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (2-morpholin-4-ylethyl)amide

¹H NMR (360 MHz, DMSO-d₆) δ 14.19 (s, 1H, NH), 11.14 (br s, 1H, NH), 8.10 (s, 1H, H-vinyl), 7.84 (m, 1H, CONHCH₂), 7.71 (d, J=1.8 Hz, 1H, H-4), 7.38 (dd, J=1.8 & 8.2 Hz, 1H, H-6), 6.87 (d, J=8.2 Hz, 1H, H-7), 3.58 (m, 4H, 2×CH₂), 3.40 (m, 2H, CH₂), 2.57 (s, 3H, CH₃CO), 2.49 (m, 4H, 2×CH₂), 2.45 (m, 3H, CH₃ & CH₂).

MS-EI m/z 500 & 502 [M⁺⁻¹] & [M⁺⁺¹].

20**Example 35**

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide

¹H NMR (360 MHz, DMSO-d₆) δ 14.17 (s, 1H, NH), 11.23 (s, 1H, NH), 8.11 (s, 1H, H-vinyl), 7.91 (m, 1H, CONHCH₂), 7.73 (d, J=1.9 Hz, 1H, H-4), 7.39 (dd, J=1.9 & 8.3 Hz, 1H, H-6), 6.88 (d, J=8.3 Hz, 1H, H-7), 3.40 (m, 2H, CH₂), 2.62 (m, 2H, CH₂), 2.57 (s, 3H, CH₃CO), 2.49 (m, 4H, 2×CH₂), 2.44 (s, 3H, CH₃), 1.69 (m, 4H, 2×CH₂).

Example 36

4-Acetyl-5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-3-methyl-1H-pyrrole-2-carboxylic Acid [2-(4-hydroxyphenyl)ethyl]amide

¹H NMR (300 MHz, DMSO-d₆) δ 14.21 (s, 1H, NH), 11.18 (s, 1H, OH), 9.09 (s, 1H, NH), 8.06–8.10 (m, 2H), 7.73 (s, 1H), 7.38 (d, J=7.8 Hz, 1H), 7.04 (d, J=7.1 Hz, 2H), 6.88 (d, J=7.8 Hz, 1H), 6.67 (d, J=7.1 Hz, 2H), 3.42 (m, 2H, CH₂), 2.72 (m, 2H, CH₂), 2.56 (s, 3H, CH₃CO), 2.37 (s, 3H, CH₃).

MS-EI m/z 507 & 509 [M⁺⁻¹] & [M⁺⁺¹].

Example 37

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic Acid (3-diethylaminopropyl)amide

A mixture of 2-aminoacetophenone hydrochloride (1 equiv.), ethyl isobutyrylacetate (1.2 equiv.) and sodium acetate (2.4 equiv.) in H₂O was stirred at 100° C. for 18 hours and then cooled to room temperature. The aqueous layer was decanted off and the oil was dissolved in ethyl acetate. It was then washed with water and brine and then dried to give (93%) of 2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid ethyl ester as a red brown oil.

¹H NMR (300 MHz, DMSO-d₆) δ 11.21 (s, br, 1H, NH), 7.14–7.27 (m, 5H), 6.70 (d, J=2.7 Hz, 1H), 4.02 (q, J=7.1 Hz, 2H, OCH₂CH₃), 3.65 (m, 1H, CH(CH₃)₂), 1.22 (d, J=7.5 Hz, 6H, 2H, CH(CH₃)₂), 1.04 (t, J=7.1 Hz, 3H, OCH₂CH₃).

MS-EI m/z 257 [M⁺].

The above pyrrole was formylated using method A to give (41%) 5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid ethyl ester as a reddish solid.

¹H NMR (300 MHz, DMSO-d₆) δ 12.35 (s, br, 1H, NH), 9.14 (s, 1H, CHO), 7.36 (s, 5H), 3.96 (q, J=7.1 Hz, 2H,

191

OCH₂CH₃), 3.74 (m, 1H, CH(CH₃)₂), 1.29 (d, J=6.9 Hz, 6H, CH (CH₃)₂), 0.90 (t, J=7.1 Hz, 3H, OCH₂CH₃).

MS-EI m/z 285 [M⁺].

The pyrrolecarboxylic acid ester was hydrolysed using method B to give (57%) of 5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid as a beige solid.

¹HNMR (300 MHz, DMSO-d6) δ 12.28 (s, br, 1H, COOH), 12.02 (s, br, 1H, NH), 9.10 (s, 1H, CHO), 7.35 (s, 5H), 3.81 (m, 1H, CH(CH₃)₂), 1.28 (d, J=6.9 Hz, 6H, CH(CH₃)₂).

MS-EI m/z 257 [M⁺].

5-Bromo-1,3-dihydroindol-2-one (120 mg, 0.31 mmol) was condensed with 5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (prepared by method C) to give 120 mg (71%) of the title compound.

¹HNMR (300 MHz, DMSO-d6) δ 14.23 (s, br, 1H, NH), 11.08 (s, br, 1H, NH), 7.38–7.55 (m, 7H, Ar-H & CONHCH₂), 7.30 (s, 1H, H-vinyl), 7.26 (dd, J=1.8 & 7.8 Hz, 1H), 6.85 (d, J=8.7 Hz, 1H), 3.36 (m, 1H, CH(CH₃)₂), 3.07 (m, 2H, CH₂), 2.34 (q, J=7.1 Hz, 4H, N(CH₂CH₃)₂), 2.22 (t, J=6.9 Hz, 2H, CH₂), 1.40 (m, 2H, CH₂), 1.31 (d, J=6.9 Hz, 6H, CH(CH₃)₂), 0.86 (t, J=7.1 Hz, 6H, N(CH₂CH₃)₂).

MS m/z 565.1 [M⁺+1].

Example 38

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic Acid (3-pyrrolidin-1-ylpropyl) amide

5-(5-bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (127 mg, 0.28 mmol) was condensed with 3-pyrrolidin-1-ylpropylamine (43 mg, 0.336 mmol) to give 140 mg (66%) of the title compound.

¹HNMR (300 MHz, DMSO-d6) δ 14.40 (s, br, 1H, NH), 7.38–7.47 (m, 7H), 7.23–7.27 (m, 2H), 6.84 (d, J=8.1 Hz, 1H), 3.36 (m, 1H, CH(CH₃)₂), 3.08 (m, 2H, CH₂), 2.30 (m, 4H, 2xCH₂), 2.20 (t, J=7.0 Hz, 2H, CH₂), 1.62 (m, 4H, 2xCH₂), 1.42 (t, J=7.0 Hz, 2H, CH₂), 1.31 (d, J=7.2 Hz, 6H, CH (CH₃)₂).

MS-EI m/z 560 and 562 [M⁺–1 and M⁺+1].

Example 39

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide

5-Bromo-1,3-dihydroindol-2-one (57 µg, 0.27 mmol) was condensed with 5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (120 mg) to give 78 mg (53%) of the title compound as a yellow solid.

¹HNMR (300 MHz, DMSO-d6) δ 14.23 (s, br, 1H, NH), 11.09 (s, br, 1H, NH), 7.38–7.51 (m, 6H), 7.25–7.28 (m, 2H), 7.19 (t, 1H, CONHCH₂), 6.85 (d, J=7.8 Hz, 1H), 3.43 (m, 1H, CH(CH₃)₂), 3.11 (m, 2H, CH₂), 2.28–2.39 (m, 6H, N(CH₂CH₃)₂ & CH₂), 1.31 (d, J=6.9 Hz, CH(CH₃)₂), 0.85 (t, J=7.0 Hz, 6H, N(CH₂CH₃)₂).

MS-EI m/z 548 and 550 [M⁺–1 and M⁺+1].

192

Example 40

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic Acid [3-(4-methylpiperazin-1-yl)propyl]amide

5-Bromo-1,3-dihydroindol-2-one (53 mg, 0.25 mmol) was condensed with 5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid [3-(4-methylpiperazin-1-yl)propyl]amide (300 mg) to give 65 mg of the title compound.

¹HNMR (300 MHz, DMSO-d6) δ 14.22 (s, br, 1H, NH), 11.08 (s, br, 1H, NH), 7.23–7.50 (m, 9H), 6.85 (d, J=8.7 Hz, 1H), 3.37 (m, 1H, CH(CH₃)₂), 3.05 (m, 2H, CH₂), 2.24 (m, 8H, 4xCH₂), 2.11 (m, 5H, CH₂ & CH₃), 1.42 (m, 2H, CH₂), 1.31 (d, J=7.2 Hz, 6H, CH(CH₃)₂).

MS-EI m/z 589 and 591 [M⁺–1 and M⁺+1].

Example 41

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic Acid

5-Bromo-1,3-dihydroindol-2-one (170 mg, 0.8 mmol) was condensed with 5-formyl-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (205 mg) using method D to give 210 mg (58%) of the title compound as a yellow solid.

¹HNMR (300 MHz, DMSO-d6) δ 14.31 (s, br, 1H, NH), 11.16 (s, br, 1H, NH), 7.26–7.44 (m, 7H), 7.11 (s, 1H, H-vinyl), 6.85 (d, J=7.8 Hz, 1H), 3.78 (m, 1H, CH(CH₃)₂), 1.34 (d, J=6.9 Hz, 6H, CH(CH₃)₂).

MS-EI m/z 452 [M⁺+1].

Example 42

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide

5-Bromo-1,3-dihydroindol-2-one (44 mg, 0.21 mmol) was condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (70 mg, prepared in the same manner as the isopropyl analog, above) to give 0.03 g (27%) of the title compound as a yellow solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.87 (s, br, 1H, NH), 11.11 (s, br, 1H, NH), 7.36–7.51 (m, 6H), 7.26 (dd, J=1.8 & 8.1 Hz, 1H), 7.2 (s, 1H, H-vinyl), 7.09 (m, 1H, CONHCH₂), 6.83 (d, J=8.1 Hz, 1H), 3.17 (m, 2H, NCH₂), 2.48 (m, CH₃), 2.29–2.35 (m, 6H, 3xNCH₂), 1.59 (m, 4H, 2xCH₂).

MS-EI m/z 518 and 520 [M⁺–1 and M⁺+1].

50

Example 43

5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide

6-(2-Methoxyphenyl)-1,3-dihydroindol-2-one (50 mg, 0.21 mmol) was condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (70 mg) to give 0.04 g (35%) of the title compound as a yellow-orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.82 (s, br, 1H, NH), 11.02 (s, br, 1H, NH), 7.48 (m, 2H), 7.43 (m, 1H), 7.38 (m, 2H), 7.32 (m, 1H), 7.24 (m, 2H), 7.16 (s, 1H, H-vinyl), 7.08 (m, 2H), 7.03 (m, 1H), 7.0 (m, 2H), 3.74 (s, 3H, OCH₃), 3.19 (m, 2H, NCH₂), 2.49 (m, CH₃), 2.32–2.38 (m, 6H, 3xNCH₂), 1.59 (m, 4H, 2xCH₂).

MS-EI m/z 546 [M⁺].

193

Example 44

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic Acid (2-dimethylaminoethyl)amide

5-Bromo-1,3-dihydroindol-2-one (46 mg, 0.22 mmol) was condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide (65 mg) to give 60 mg (55%) of the title compound as a yellow solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.86 (s, br, 1H, NH), 11.09 (s, br, 1H, NH), 7.47–7.49 (m, 2H), 7.38–7.41 (m, 4H), 7.26 (dd, J=2.2 & 8.3 Hz, 1H), 7.21 (s, 1H, H-vinyl), 7.04 (m, 1H, CONHCH₂), 6.77 (d, J=8.3 Hz, 1H), 3.15 (m, 2H, NCH₂), 2.48 (m, CH₃), 2.16 (t, J=6.8 Hz, 2H, 3xNCH₂), 2.02 (s, 6H, 2xNCH₃).

MS m/z 493 and 494.8 [M⁺ and M⁺⁺²].

Example 45

5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic Acid (2-dimethylaminoethyl)amide

6-(2-Methoxyphenyl)-1,3-dihydroindol-2-one (53 mg, 0.22 mmol) was condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide (65 mg) to give 0.05 g (44%) of the title compound as an orange gum.

¹HNMR (300 MHz, DMSO-d6) δ 13.82 (s, br, 1H, NH), 11.02 (s, br, 1H, NH), 7.37–7.52 (m, 5H), 7.32 (m, 1H), 7.22–7.27 (m, 2H), 7.16 (s, 1H), 7.08 (m, 2H), 7.03 (m, 1H), 7.0 (m, 2H), 3.74 (s, 3H, OCH₃), 3.15 (m, 2H, NCH₂), 2.49 (m, CH₃), 2.16 (t, J=6.5 Hz, 2H, NCH₂), 2.02 (s, 6H, 2xNCH₃).

MS m/z 521 [M⁺⁺¹].

Example 46

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic Acid Ethyl Ester

5-Bromo-1,3-dihydroindol-2-one (60 mg, 0.29 mmol) was condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid ethyl ester (75 mg) to give 78 mg (60%) of the title compound as an orange solid.

¹HNMR (360 MHz, DMSO-d6) δ 14.01 (s, br, 1H, NH), 11.13 (s, br, 1H, NH), 7.42–7.46 (m, 3H), 7.27–7.34 (m, 4H), 7.12 (s, 1H), 6.84 (dd, J=2.2 & 8.3 Hz, 1H), 3.99–4.03 (m, 2H, OCH₂CH₃), 2.61 (s, 3H, CH₃), 0.98–1.03 (m, 3H, OCH₂CH₃).

MS-EI m/z 450 and 452 [M⁺⁺¹ and M⁺⁺²].

Example 47

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic Acid (3-diethylaminopropyl)amide

5-bromo-1,3-dihydroindol-2-one (0.47 g, 2.2 mmol) was condensed with 5-formyl-2-methyl-4-phenyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (0.75 g) to give 0.11 g (42%) of the title compound as an orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.86 (s, br, 1H, NH), 7.42–7.46 (m, 3H), 7.37–7.50 (m, 7H), 7.24–7.28 (m, 2H), 6.83 (d, J=8.1 Hz, 1H), 3.09 (m, 2H, NCH₂), 2.45 (s, 3H, CH₃), 2.38 (q, J=7.1 Hz, 4H, 2xNCH₂CH₃), 2.26 (t, J=6.9 Hz, 2H, NCH₂), 1.42 (m, 2H, NCH₂), 0.87 (t, J=7.1 Hz, 6H, 2xNCH₂CH₃).

MS-EI m/z 535.0 and 537 [M⁺ and M⁺⁺²].

194

Example 48

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-dimethylaminoethyl)amide

A mixture of tert-butyl 3-oxobutyrate and sodium nitrite (1 equiv.) in acetic acid was stirred at room temperature to give tert-butyl-2-hydroximino-3-oxobutyrate.

Ethyl-3-oxobutyrate (1 equiv.), zinc dust (3.8 equiv.) and the crude tert-butyl-2-hydroximino-3-oxobutyrate in acetic acid was stirred at 60° C. for 1 hr. The reaction mixture was poured into H₂O and the filtrate was collected to give (65%) 2-tert-butyloxycarbonyl-3,5-dimethyl-4-ethoxycarbonylpyrrole.

A mixture of 2-tert-butyloxycarbonyl-3,5-dimethyl-4-ethoxycarbonylpyrrole and triethyl orthoformate (1.5 equiv.) in trifluoroacetic acid was stirred at 15° C. for 1 hour. The reaction was concentrated and the residue was purified to give (64%) 2,4-dimethyl-3-ethoxycarbonyl-5-formylpyrrole as yellow needles.

2,4-Dimethyl-3-ethoxycarbonyl-5-formylpyrrole was hydrolyzed using method B to give (90%) 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid.

¹H NMR (360 MHz, DMSO-d6) δ 12 (br s, 2H, NH and CO₂H), 9.58 (s, 1H, CHO), 2.44 (s, 3H, CH₃), 2.40 (s, 3H, CH₃).

MS m/z 267 [M⁺].

5-Bromo-1,3-dihydroindol-2-one (0.17 g, 0.8 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide (0.2 g, prepared by method C) using method B to give 0.3 g (83%) of the title compound as a yellow solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.60 (s, br, 1H, NH), 10.94 (s, br, 1H, NH), 8.07 (d, J=1.8 Hz, 1H, H-4), 7.75 (s, 1H, H-vinyl), 7.44 (t, J=5.2 Hz, 1H, CONHCH₂), 7.24 (dd, J=1.8 & 8.4 Hz, 1H, H-6), 6.82 (d, J=8.4 Hz, 1H, H-7), 3.26–3.33 (m, 2H, NCH₂), 2.42 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 2.38 (t, J=6.7 Hz, 2H, NCH₂), 2.18 (s, 6H, N(CH₃)₂).

MS-EI m/z 430 and 432 [M⁺⁺¹ and M⁺⁺²].

Example 49

2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid (2-dimethylaminoethyl)amide

6-Phenyl-1,3-dihydroindol-2-one (0.17 g, 0.8 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide (0.2 g) to give 0.13 g (36%) of the title compound as a yellow-orange solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.59 (s, br, 1H, NH), 10.93 (s, br, 1H, NH), 7.85 (d, J=7.92 Hz, 1H, H-4), 7.63–7.65 (m, 3H), 7.40–7.47 (m, 3H), 7.32–7.36 (m, 1H, Ar—H), 7.30 (dd, J=1.6 & 7.9 Hz, 1H, H-5), 7.11 (d, J=1.6 Hz, 1H, H-7), 3.28–3.34 (m, 2H, NCH₂), 2.43 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 2.38 (t, J=6.8 Hz, 2H, NCH₂), 2.18 (s, 6H, N(CH₃)₂).

MS-EI m/z 428 [M⁺].

Example 50

5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-dimethylaminoethyl)amide

5-Chloro-1,3-dihydroindol-2-one (0.1 g, 0.6 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide (0.15 g) to give 0.22 g (90%) of the title compound as a yellow solid.

195

¹HNMR (300 MHz, DMSO-d6) δ 13.61 (s, br, 1H, NH), 10.98 (, br, 1H, NH), 7.96 (d, J=2.0 Hz, 1H, H-4), 7.75 (s, 1H, H-vinyl), 7.50 (t, J=5.5 Hz, 1H, CONHCH₂), 7.12 (dd, J=2.0 & 8.3 Hz, 1H, H-6), 6.86 (d, J=8.3 Hz, 1H, H-7), 3.26–3.31 (m, 2H, NCH₂), 2.42 (s, 3H, CH₃), 2.40 (s, 3H, CH₃), 2.36 (t, J=6.6 Hz, 2H, NCH₂), 2.17 (s, 6H, N(CH₃)₂).
MS-EI m/z 386 [M⁺].

Example 51

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide

5-Bromo-1,3-dihydroindol-2-one (0.17 g, 0.8 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (0.2 g) to give 0.09 g (26%) of the title compound as a yellow solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.61 (s, br, 1H, NH), 10.98 (, br, 1H, NH), 8.09 (d, J=1.7 Hz, 1H, H-4), 7.76 (s, 1H, H-vinyl), 7.42 (t, J=5.5 Hz, 1H, CONHCH₂), 7.24 (dd, J=1.7 & 8.0 Hz, 1H, H-6), 6.82 (d, J=8.0 Hz, 1H, H-7), 3.23–3.32 (m, 2H, NCH₂), 2.46–2.55 (m, 6H, 3×NCH₂), 2.43 (s, 3H, CH₃), 2.42 (s, 3H, CH₃), 0.96 (t, J=7.2 Hz, 6H, 2×NCH₂CH₃).

MS-EI m/z 458 and 460 [M⁺–1 and M⁺+1].

Example 52

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-yl-ethyl)amide

5-Bromo-1,3-dihydroindol-2-one (0.09 g, 0.4 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (0.1 g) to give 0.14 g (81%) of the title compound as a yellow-orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.61 (s, br, 1H, NH), 10.98 (, br, 1H, NH), 8.09 (d, J=1.9 Hz, 1H, H-4), 7.76 (s, 1H, H-vinyl), 7.53 (t, J=5.5 Hz, 1H, CONHCH₂), 7.24 (dd, J=1.9 & 8.5 Hz, 1H, H-6), 6.81 (d, J=8.5 Hz, 1H, H-7), 3.29–3.35 (m, 2H, NCH₂), 2.54 (t, J=6.9 Hz, 2H, NCH₂), 2.47 (m, under DMSO), 2.42 (s, 3H, CH₃), 2.40 (s, 3H, CH₃), 1.66–1.69 (m, 4H, 2×CH₂).

MS-EI m/z 456 and 458 [M⁺–1 and M⁺+1].

Example 53

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (3-imidazol-1-ylpropyl)amide

5-Bromo-1,3-dihydroindol-2-one (0.09 g, 0.4 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide (0.1 g) to give 0.1 g (59%) of the title compound as an orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.63 (s, br, 1H, NH), 10.99 (, br, 1H, NH), 8.09 (d, J=2.2 Hz, 1H, H-4), 7.77 (s, 1H, H-vinyl), 7.71 (t, J=5.7 Hz, 1H, CONHCH₂), 7.65 (s, 1H, Ar—H), 7.25 (dd, J=2.2 & 8.4 Hz, 1H, H-6), 7.20 (s, 1H, Ar—H), 6.89 (s, 1H, Ar—H), 6.81 (d, J=8.4 Hz, 1H, H-7), 4.02 (t, J=6.7 Hz, 2H, NCH₂), 3.18 (q, J=6.7 Hz, 2H, NCH₂), 2.43 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 1.93 (m, 2H, CH₂).

MS-EI m/z 467 and 469 [M⁺–1 and M⁺+1].

Example 54

5-[6-(2-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide

6-(2-Methoxyphenyl)-1,3-dihydroindol-2-one (30 mg, 0.13 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-

196

pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (30 mg) to give 0.06 g (100%) of the title compound as a yellow-orange gum.

¹HNMR (300 MHz, DMSO-d6) δ 13.60 (s, br, 1H, NH), 10.89 (s, br, 1H, NH), 7.79 (d, J=8.4 Hz, 1H), 7.63 (s, 1H, H-vinyl), 7.46 (t, J=5.5 Hz, 1H, CONHCH₂), 7.28–7.35 (m, 2H), 6.99–7.11 (m, 4H), 3.76 (s, 3H, OCH₃), 3.27–3.31 (m, 2H, NCH₂), 2.43 (s, 3H, CH₃), 2.39 (s, 3H, CH₃), 2.37 (m, 2H, NCH₂), 2.18 (s, 6H, N(CH₃)₂).

MS-EI m/z 458 [M⁺].

Example 55

5-[6-(3-Methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide

6-(3-Methoxyphenyl)-1,3-dihydroindol-2-one (30 mg, 0.13 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (30 mg) to give 8 mg (14%) of the title compound as a yellow-orange solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.59 (s, br, 1H, NH), 10.92 (s, br, 1H, NH), 7.84 (d, J=7.6 Hz, 1H), 7.65 (s, 1H, H-vinyl), 7.42 (m, 1H, CONHCH₂), 7.36 (d, J=7.8 Hz, 1H), 7.29 (dd, J=1.6 & 7.6 Hz, 1H), 7.20 (d, J=7.8 Hz, 1H), 7.14 (d, J=2.8 Hz, 1H), 7.11 (d, J=1.6 Hz, 1H), 6.91 (dd, J=2.8 & 7.8 Hz, 1H), 3.82 (s, 3H, OCH₃), 3.21–3.33 (m, 2H, NCH₂), 2.43 (s, 3H, CH₃), 2.40 (s, 3H, CH₃), 2.36–2.40 (m, 2H, NCH₂), 2.18 (s, 6H, N(CH₃)₂).

MS-EI m/z 458 [M⁺].

Example 56

2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide

5-Phenyl-1,3-dihydroindol-2-one (80 mg, 0.4 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (0.1 g) using method B to give 79 mg (46%) of the title compound.

¹HNMR (300 MHz, DMSO-d6) δ 13.66 (s, br, 1H, NH), 10.95 (, br, 1H, NH), 8.15 (d, J=1.2 Hz, 1H), 7.81 (s, 1H, H-vinyl), 7.71 (d, J=7.5 Hz, 1H), 7.40–7.47 (m, 4H), 7.31 (m, 1H), 6.95 (d, J=8.1 Hz, 1H), 3.2–3.31 (m, 2H, NCH₂), 2.46–2.55 (m, 6H, 3×NCH₂), 2.44 (s, 6H, 2×CH₃), 0.96 (t, J=7.4 Hz, 6H, 2×NCH₂CH₃).

MS-EI m/z 456 [M⁺].

Example 57

2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide

5-Phenyl-1,3-dihydroindol-2-one (0.04 g, 0.2 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (0.04 g) to give the title compound as a yellow-orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.65 (s, br, 1H, NH), 10.96 (, br, 1H, NH), 8.15 (d, J=1.0 Hz, 1H), 7.80 (s, 1H, H-vinyl), 7.71 (d, J=7.2 Hz, 2H), 7.49 (t, J=6.3 Hz, 1H, CONHCH₂), 7.41–7.46 (m, 3H), 7.31 (m, 1H), 6.95 (d, J=7.8 Hz, 1H), 4.08 (m, 4H, 2×NCH₂), 3.32 (m, 2H, NCH₂), 2.55 (t, J=7.1 Hz, 2H, NCH₂), 2.47 (m, under DMSO), 2.43 (s, 6H, 2×CH₃), 1.66 (m, 4H, 2×CH₂).

MS-EI m/z 454 [M⁺].

197

Example 58

2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid (3-imidazol-1-ylpropyl)amide

5-Phenyl-1,3-dihydroindol-2-one (8 mg, 0.04 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide (10 mg) to give 10 mg (59%) of the title compound as an orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.67 (s, br, 1H, NH), 10.96 (s, br, 1H, NH), 8.16 (d, J=1.2 Hz, 1H), 7.81 (s, 1H, H-vinyl), 7.65–7.72 (m, 4H), 7.44 (m, 3H), 7.31 (m, 1H, CONHCH₂), 7.21 (s, 1H, Ar—H), 4.02 (t, J=6.5 Hz, 2H, NCH₂), 3.19 (q, J=6.5 Hz, 2H, CONHCH₂), 2.44 (s, 6H, 2xCH₃), 1.93 (m, 2H, CH₂CH₂CH₂).

MS-EI m/z 465 [M⁺].

Example 59

2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide

6-Phenyl-1,3-dihydroindol-2-one (0.08 g, 0.4 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (0.1 g) to give 65 mg (38%) of the title compound as a yellow solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.61 (s, br, 1H, NH), 10.99 (s, br, 1H, NH), 7.86 (d, J=7.8 Hz, 1H), 7.62–7.66 (m, 3H), 7.40–7.47 (m, 3H), 7.28–7.36 (m, 2H), 7.10 (d, J=1.2 Hz, 1H), 3.26 (m, 2H, NCH₂), 2.46–2.55 (m, 6H, 3xNCH₂), 2.44 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 0.97 (t, J=7.2 Hz, 6H, 2xNCH₂CH₃).

MS-EI m/z 456 [M⁺].

Example 60

2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide

6-Phenyl-1,3-dihydroindol-2-one (30 mg, 0.15 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (40 mg) to give 5.9 mg (8.5%) of the title compound as a yellow-orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.60 (s, br, 1H, NH), 10.99 (s, br, 1H, NH), 7.86 (d, J=7.8 Hz, 1H), 7.63–7.66 (m, 3H), 7.51 (m, 1H, CONHCH₂), 7.45 (m, 2H), 7.28–7.36 (m, 2H), 7.10 (d, J=1.5 Hz, 1H), 3.31 (m, 6H, 3xNCH₂), 2.55 (t, J=6.6 Hz, 2H, NCH₂), 2.43 (s, 3H, CH₃), 2.40 (s, 3H, CH₃), 1.67 (m, 4H, 2xCH₂).

MS-EI m/z 454 [M⁺].

Example 61

2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid (3-imidazol-1-ylpropyl)amide

6-Phenyl-1,3-dihydroindol-2-one (8 mg, 0.04 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-imidazol-1-ylpropyl)amide (10 mg) to give 7.3 mg (43%) of the title compound as an orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.62 (s, br, 1H, NH), 10.99 (s, br, 1H, NH), 7.86 (d, J=8.2 Hz, 1H), 7.62–7.70 (m, 5H), 7.45 (m, 2H), 7.35 (m, 1H), 7.30 (dd, J=1.4 & 8.2 Hz, 1H), 7.21 (s, 1H), 7.10 (d, J=1.4 Hz, 1H), 6.89 (s, 1H), 4.02 (t, J=6.9 Hz, 2H, CH₂), 3.19 (m, 2H, NCH₂CH₂), 2.43 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 1.93 (t, J=6.9 Hz, 2H, NCH₂).

MS-EI m/z 465 [M⁺].

198

Example 62

5-[6-(3,5-Dichlorophenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide

6-(3,5-Dichlorophenyl)-1,3-dihydroindol-2-one (64 mg, 0.23 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (60 mg) to give 53 mg (44%) of the title compound as a light brown solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.62 (s, br, 1H, NH), 10.99 (s, 1H, NH), 7.89 (d, J=7.9 Hz, 1H, H-4), 7.69–7.71 (m, 3H), 7.55 (m, 1H, CONHCH₂), 7.37 (m, 2H), 7.14 (d, J=1.4 Hz, 1H, H-7), 3.27 (m, 2H, NCH₂), 2.48–2.58 (m, 6H, 3xNCH₂), 2.45 (s, 3H, CH₃), 2.42 (s, 3H, CH₃), 0.97 (t, J=6.8 Hz, 6H, 3xNCH₂CH₃).

MS m/z 526.9 [M⁺+1].

Example 63

2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide

6-Pyridin-3-yl-1,3-dihydroindol-2-one (40 mg, 0.19 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (50 mg) to give 29 mg (33%) of the title compound as a light orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.62 (s, br, 1H, NH), 11.05 (s, br, 1H, NH), 8.86 (s, br, 1H), 8.53 (d, J=5.8 Hz, 1H), 8.04 (m, 1H), 7.91 (d, J=8.1 Hz, 1H), 7.70 (s, 1H, H-vinyl), 7.40–7.48 (m, 2H), 7.35 (d, J=7.5 Hz, 1H), 7.14 (s, 1H), 3.26 (m, 2H, NCH₂), 2.48–2.55 (m, 3xNCH₂), 2.42 (s, 3H, CH₃), 2.38 (s, 3H, CH₃), 0.96 (t, J=6.9 Hz, 6H, 2xNCH₂CH₃).

MS-EI m/z 457 [M⁺].

Example 64

2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide

6-Pyridin-3-yl-1,3-dihydroindol-2-one (60 mg, 0.28 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (75 mg) to give 90 mg (71%) of the title compound as a light orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.61 (s, br, 1H, NH), 11.05 (s, br, 1H, NH), 8.86 (d, J=1.5 Hz, 1H), 8.54 (dd, J=1.5 & 4.8 Hz, 1H), 8.05 (m, 1H), 7.91 (d, J=7.8 Hz, 1H), 7.70 (s, 1H, H-vinyl), 7.44–7.53 (m, 2H), 7.36 (dd, J=1.5 & 8.1 Hz, 1H), 7.15 (d, J=1.2 Hz, 1H), 3.33 (m, 2H, NCH₂), 2.47–2.57 (m, 6H, 3xNCH₂), 2.43 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 1.67 (m, 4H, 2xCH₂).

MS-EI m/z 455 [M⁺].

Example 65

2,4-Dimethyl-5-(2-oxo-6-pyridin-3-yl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid (3-dimethylaminopropyl)amide

6-Pyridin-3-yl-1,3-dihydroindol-2-one (42 mg, 0.2 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide (50 mg) to give 67 mg (75%) of the title compound as yellow-brown solid.

199

¹HNMR (360 MHz, DMSO-d₆) δ 13.61 (s, br, 1H, NH), 11.00 (s, br, 1H, NH), 8.86 (s, br, 1H), 8.54 (s, br, 1H), 8.04 (m, 1H), 7.90 (d, J=8.0 Hz, 1H), 7.69 (s, 1H, H-vinyl), 7.63 (m, 1H), 7.45–7.48 (m, 1H), 7.35 (dd, J=1.7 & 8.0 Hz, 1H), 7.15 (d, J=1.7 Hz, 1H), 3.21–3.27 (m, 2H, NCH₂), 2.43 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 2.28 (m, 2H, NCH₂), 2.14 (s, 6H, 2×NCH₃), 1.64 (m, 2H, CH₂).

MS-EI m/z 443 [M⁺].

Example 66

2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidene methyl)-1H-pyrrole-3-carboxylic Acid (3-dimethylaminopropyl)amide

5-Phenyl-1,3-dihydroindol-2-one (67 mg, 0.32 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-dimethylaminopropyl)amide (81 mg) to give 40 mg (28%) of the title compound as an orange solid.

¹HNMR (360 MHz, DMSO-d₆) δ 13.66 (s, br, 1H, NH), 10.92 (s, br, 1H, NH), 8.14 (s, 1H), 7.79 (s, 1H), 7.71 (m, 2H), 7.62 (m, 1H), 7.44 (m, 3H), 7.32 (m, 1H), 6.95 (m, 1H), 3.33 (m, 2H, NCH₂), 2.43 (s, 6H, 2×CH₃), 2.27 (m, 2H, NCH₂), 2.13 (s, 6H, 2×NCH₃), 1.63 (m, 2H, CH₂).

MS-EI m/z 442 [M⁺].

Example 67

2,4-Dimethyl-5-(2-oxo-5-phenyl-1,2-dihydroindol-3-ylidene methyl)-1H-pyrrole-3-carboxylic Acid (3-diethylaminopropyl)amide

5-Phenyl-1,3-dihydroindol-2-one (1.5 g, 7.16 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (2 g) to give 1.3 g (40%) of the title compound as a yellow-orange solid.

¹HNMR (360 MHz, DMSO-d₆) δ 13.64 (s, 1H, NH), 10.91 (s, 1H, NH), 8.14 (d, J=1.4 Hz, 1H, ArH), 7.8 (s, 1H, ArH), 7.7 (dd, J=1.2 and 8.5 Hz, 2H, ArH), 7.6 (t, J=5.3 Hz, 1H, CONHCH₂), 7.4 (m, 3H, ArH), 7.3 (t, J=7.4 Hz, 1H, ArH), 6.9 (d, J=8.0 Hz, 1H, ArH), 3.2 (m, 2H, CONHCH₂), 2.5 (m, 12H, 3×NCH₂ and 2×CH₃), 1.61 (m, 2H, CH₂C₆H₅), 0.93 (t, J=6.7 Hz, 6H, NCH₂CH₃).

MS-EI m/z 470 [M⁺].

Example 68

2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidene methyl)-1H-pyrrole-3-carboxylic Acid (3-diethylaminopropyl)amide

5-Phenyl-1,3-dihydroindol-2-one (1.5 g, 7.16 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (2 g) to give 1.9 g (57%) of the title compound as an orange solid.

¹HNMR (360 MHz, DMSO-d₆) δ 13.58 (s, 1H, NH), 10.94 (s, 1H, NH), 7.8 (d, J=7.9 Hz, 1H, ArH), 7.6 (m, 4H, ArH), 7.4 (t, J=7.5 Hz, 2H, ArH), 7.3 (m, 2H), 7.1 (d, J=1.4 Hz, 1H, ArH), 3.2 (m, 2H, CONHCH₂), 2.5 (m, 12H, 3×NCH₂ and 2×CH₃), 1.61 (m, 2H, CH₂CH₂CH₂), 0.93 (t, J=6.7 Hz, 6H, NCH₂CH₃).

MS-EI m/z 470 [M⁺].

Example 69

3-[4-(3-Diethylaminopropylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-4-carboxylic Acid (3-chloro-4-methoxyphenyl)amide

2-Oxo-2,3-dihydro-1H-indole-4-carboxylic acid (3-chloro-4-methoxyphenyl)amide (1 g, 3.16 mmol) was

200

condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (1 g, 3.58 mmol) to give 1.7 g (85%) of the title compound as a yellow-orange solid.

MS-EI m/z 578.2 [M⁺].

Example 70

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (3-diethylaminopropyl)amide

5-Bromo-1,3-dihydroindol-2-one (0.5 g, 2.36 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (0.51 g) to give 0.84 g of the title compound as a red-orange solid.

¹HNMR (360 MHz, DMSO-d₆) δ 13.61 (s, 1H, NH), 10.99 (s, 1H, NH), 8.09 (d, J=1.8 Hz, 1H, ArH), 7.7 (m, 4H), 7.2 (dd, J=1.8 and 8.3 Hz, 2H, ArH), 6.8 (d, J=7.8 Hz, 1H, ArH), 3.3 (br s, 4H, 2×NCH₂), 3.2 (m, 2H, CONHCH₂), 2.6 (br s, 2H, NCH₂ and 2×CH₃), 2.4 (s, 6H, 2×CH₃), 1.66 (m, 2H, CH₂CH₂CH₂), 0.98 (t, J=7.1 Hz, 6H, NCH₂CH₃).

MS-EI m/z 472 and 474 [M⁺-1 and M⁺+1].

Example 71

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide

5-Bromo-1,3-dihydroindol-2-one (100 mg, 0.47 mmol) was condensed with 5-formyl-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (150 mg) to give 0.15 g (62%) of the title compound as a yellow-orange solid.

¹HNMR (300 MHz, DMSO-d₆) δ 13.97 (s, 1H, NH), 10.95 (s, 1H, NH), 8.09 (d, J=1.3 Hz, 1H, ArH), 7.84 (m, 1H), 7.79 (s, 1H), 7.23 (dd, J=1.3 and 8.1 Hz, 1H, ArH), 6.8 (d, J=8.1 Hz, 1H, ArH), 3.5 (m, 1H, CH), 3.3 (m, 3H, CH and NHCH₂), 2.5 (br m, 6H, 3×NCH₂), 1.28 (d, J=6.9 Hz, 6H, 2×CH₃), 1.23 (d, J=6.6 Hz, 6H, 2×CH₃), 0.96 (m, 6H, 2×CH₂CH₃).

MS-EI m/z 514 and 516 [M⁺-1 and M⁺+1].

Example 72

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic Acid (3-diethylaminopropyl)amide

5-Bromo-1,3-dihydroindol-2-one (90 mg, 0.42 mmol) was condensed with 5-formyl-2,4-diisopropyl-1H-pyrrole-3-carboxylic acid (3-diethylaminopropyl)amide (140 mg) to give 54 mg (25%) of the title compound as red-brown solid.

¹HNMR (300 MHz, DMSO-d₆) δ 13.98 (s, 1H, NH), 10.96 (s, 1H, NH), 8.09 (d, J=1.7 Hz, 2H), 7.78 (s, 1H, H-vinyl), 7.23 (dd, J=1.7 and 8.1 Hz, 1H, ArH), 6.82 (d, J=8.1 Hz, 1H, ArH), 3.5 (m, 1H, CH), 3.25 (m, 2H, NHCH₂), 3.15 (m, 1H, CH), 2.7 (br s, 6H, 3×NCH₂), 1.7 (br m, 2H, CH₂CH₂CH₂), 1.28 (d, J=6.9 Hz, 6H, 2×CH₃), 1.24 (d, J=5.9 Hz, 6H, 2×CH₃), 1.06 (m, 6H, 2×CH₂CH₃).

MS-EI m/z 528 and 530 [M⁺-1 and M⁺+1].

Example 73

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-diisopropyl-1H-pyrrole-3-carboxylic Acid (3-pyrrolidin-1-ylpropyl)amide

5-Bromo-1,3-dihydroindol-2-one (130 mg, 0.6 mmol) was condensed with 5-formyl-2,4-diisopropyl-1H-pyrrole-

201

3-carboxylic acid (3-pyrrolidin-1-ylpropyl)amide (150 mg, 0.45 mmol) to give 36 mg (15%) of the title compound as a tan-orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.98 (s, 1H, NH), 10.97 (s, 1H, NH), 8.10 (d, J=1.6 Hz, 2H), 7.78 (s, 1H, H-vinyl), 7.23 (dd, J=1.6 and 7.6 Hz, 1H, ArH), 6.82 (d, J=7.6 Hz, 1H, ArH), 3.5 (m, 1H, CH), 3.25 (m, 2H, NHCH₂), 3.15 (m, 1H, CH), 2.7 (br s, 6H, 3xNCH₂), 1.7 (br m, 6H, 3xNCH₂CH₂), 1.28 (d, J=5.6 Hz, 6H, 2xCH₃), 1.24 (d, J=5.7 Hz, 6H, 2xCH₃).

MS-EI m/z 526 and 528 [M⁺-1 and M⁺⁺¹].

Example 74

5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (pyridin-4-ylmethyl)amide

5-Bromo-1,3-dihydroindol-2-one (170 mg, 0.8 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (pyridin-4-ylmethyl)amide (200 mg) to give 14 mg (4%) of the title compound as a yellow solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.67 (s, 1H, NH), 11.01 (s, br, 1H, NH), 8.51 (dd, J=1.6 & 4.3 Hz, 2H), 8.23 (t, J=6.0 Hz, 1H, CONHCH₂), 8.11 (d, J=1.9 Hz, 1H), 7.78 (s, 1H, H-vinyl), 7.31 (d, J=6.0 Hz, 2H), 7.25 (dd, J=1.9 & 8.1 Hz, 1H), 6.82 (d, J=8.1 Hz, 1H), 4.45 (d, J=6.0 Hz, 2H, NCH₂), 2.46 (s, 6H, 2xCH₃).

MS-EI m/z 450 and 452 [M⁺-1 and M⁺⁺¹].

Example 75

5-[6-(4-Butylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide

5-[6-(4-Butylphenyl)]-1,3-dihydroindol-2-one (50 mg, 0.19 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (50 mg) to give 74 mg (76%) of the title compound as an orange solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.58 (s, 1H, NH), 10.93 (s, br, 1H, NH), 7.82 (d, J=7.9 Hz, 1H), 7.63 (s, 1H, H-vinyl), 7.54 (d, J=7.9 Hz, 2H), 7.46 (m, 1H, CONH), 7.26 (m, 3H), 7.09 (s, 1H), 3.30 (m, 2H, CH₂), 2.52–2.63 (m, 4H, 2xCH₂), 2.49 (m, 4H, 2xCH₂), 2.43 (s, 3H, CH₃), 2.40 (s, 3H, CH₃), 1.68 (m, 4H, 2xCH₂), 1.58 (m, 2H, CH₂), 1.34 (m, 2H, CH₂), 0.91 (t, J=7.2 Hz, 3H, CH₂CH₃).

MS-EI m/z 510 [M⁺].

Example 76

5-[6-(5-Isopropyl-2-methoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide

6-(5-Isopropyl-2-methoxyphenyl)-1,3-dihydroindol-2-one (50 mg, 0.17 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (45 mg) to give 67 mg (75%) of the title compound as an orange solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.60 (s, 1H, NH), 10.82 (s, br, 1H, NH), 7.77 (d, J=7.9 Hz, 1H), 7.61 (s, 1H, H-vinyl), 7.45 (m, 1H, CONH), 7.0–7.19 (m, 5H), 3.73 (s, 3H, OCH₃), 3.32 (m, 2H, CH₂), 2.87 (m, 1H, CH(CH₃)₂), 2.56 (m, 2H, CH₂), 2.48 (m, 4H, 2xCH₂), 2.43 (s, 3H, CH₃), 2.40 (s, 3H, CH₃), 1.68 (m, 4H, 2xCH₂), 1.21 (d, J=6.8 Hz, 6H, CH(CH₃)₂).

MS m/z 527.2 [M⁺⁺¹].

202

Example 77

5-[6-(4-Ethylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide

6-(4-Ethylphenyl)-1,3-dihydroindol-2-one (45 mg, 0.19 mmol) was condensed 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (50 mg) to give 60 mg (65%) of the title compound as a yellow-orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.59 (s, 1H, NH), 10.96 (s, br, 1H, NH), 7.83 (d, J=8.4 Hz, 1H), 7.64 (s, 1H, H-vinyl), 7.51–7.56 (m, 3H), 7.25–7.30 (m, 3H), 7.08 (d, J=1 Hz, 1H), 3.31 (m, 2H, CH₂), 2.63 (m, 2H, CH₂CH₃), 2.55 (m, 2H, CH₂), 2.49 (m, 4H, 2xCH₂), 2.42 (s, 3H, CH₃), 2.40 (s, 3H, CH₃), 1.67 (m, 4H, 2xCH₂), 1.20 (t, J=7.5 Hz, 3H, CH₂CH₃).

MS-EI m/z 482 [M⁺].

Example 78

5-[6-(2,4-Dimethoxyphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide

6-(2,4-Dimethoxyphenyl)-1,3-dihydroindol-2-one (51 mg, 0.19 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (50 mg) to give 30 mg (31%) of the title compound as an orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.59 (s, 1H, NH), 10.86 (s, br, 1H, NH), 7.75 (d, J=7.8 Hz, 1H), 7.60 (s, 1H, H-vinyl), 749 (m, 1H, CONH), 7.22 (d, J=8.4 Hz, 1H), 7.03 (m, 1H), 6.97 (s, 1H), 6.58–6.65 (m, 2H), 3.79 (s, 3H, OCH₃), 3.76 (s, 3H, OCH₃), 3.33 (m, 2H, CH₂), 2.55 (m, 2H, CH₂), 2.50 (m, 4H, 2xCH₂), 2.42 (s, 3H, CH₃), 2.39 (s, 3H, CH₃), 1.67 (m, 4H, 2xCH₂).

MS-EI m/z 514 [M⁺].

Example 79

5-[6-(3-Isopropylphenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide

6-(3-Isopropylphenyl)-1,3-dihydroindol-2-one (48 mg, 0.19 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (50 mg) to give 59 mg (63%) of the title compound as an orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.63 (s, 1H, NH), 10.97 (s, br, 1H, NH), 7.87 (d, J=7.8 Hz, 1H), 7.68 (s, 1H, H-vinyl), 7.24–7.55 (m, 6H), 7.13 (s, 1H), 3.34 (m, 2H, CH₂), 3.30 (m, 1H, CH(CH₃)₂), 2.60 (m, 2H, CH₂), 2.50 (m, 4H, 2xCH₂), 2.45 (s, 3H, CH₃), 2.43 (s, 3H, CH₃), 1.70 (m, 4H, 2xCH₂), 1.27 (d, J=6.9 Hz, 6H, CH(CH₃)₂).

MS-EI m/z 496 [M⁺].

Example 80

5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide

5-Fluoro-1,3-dihydroindol-2-one (0.54 g, 3.8 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide to give 0.83 g (55%) of the title compound as a yellow green solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.66 (s, 1H, NH), 10.83 (s, br, 1H, NH), 7.73 (dd, J=2.5 & 9.4 Hz, 1H), 7.69 (s, 1H, H-vinyl), 7.37 (t, 1H, CONHCH₂CH₂), 6.91 (m, 1H), 6.81–6.85 (m, 1H), 3.27 (m, 2H, CH₂), 2.51 (m, 6H, 3xCH₂), 2.43 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 0.96 (t, J=6.9 Hz, 6H, CH(CH₃)₂).

MS-EI m/z 398 [M⁺].

203

Example 80 (Alternative Synthesis)

5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-diethylamino-ethyl)-amide

Hydrazine hydrate (55%, 3000 mL) and 5-fluoroisatin (300 g) were heated to 100° C. An additional 5-fluoro-isatin (500 g) was added in portions (100 g) over 120 minutes with stirring. The mixture was heated to 110° C. and stirred for 4 hours. The mixture was cooled to room temperature and the solids collected by vacuum filtration to give crude (2-amino-5-fluoro-phenyl)-acetic acid hydrazide (748 g). The hydrazide was suspended in water (700 mL) and the pH of the mixture adjusted to <pH 3 with 12 N hydrochloric acid. The mixture was stirred for 12 hours at room temperature. The solids were collected by vacuum filtration and washed twice with water. The product was dried under vacuum to give 5-fluoro-1,3-dihydro-indol-2-one (600 g, 73% yield) as a brown powder. ¹H-NMR (dimethylsulfoxide-d₆) δ 3.46 (s, 2H, CH₂), 6.75, 6.95, 7.05 (3xm, 3H, aromatic), 10.35 (s, 1H, NH). MS m/z 152 [M+1].

3,5-Dimethyl-1H-pyrrole-2,4-dicarboxylic acid 2-tert-butyl ester 4-ethyl ester (2600 g) and ethanol (7800 mL) were stirred vigorously while 10 N hydrochloric acid (3650 mL) was slowly added. The temperature increased from 25° C. to 35° C. and gas evolution began. The mixture was warmed to 54° C. and stirred with further heating for one hour at which time the temperature was 67° C. The mixture was cooled to 5° C. and 32 L of ice and water were slowly added with stirring. The solid was collected by vacuum filtration and washed three times with water. The solid was air dried to constant weight to give of 2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (1418 g, 87% yield) as a pinkish solid. ¹H-NMR (dimethylsulfoxide-d₆) δ 2.10, 2.35 (2xs, 2x3H, 2xCH₃), 4.13 (q, 2H, CH₂), 6.37 (s, 1H, CH), 10.85 (s, 1H, NH). MS m/z 167 [M+1].

Dimethylformamide (322 g) and dichloromethane (3700 mL) were cooled in an ice bath to 4° C. and phosphorus oxychloride (684 g) was added with stirring. Solid 2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (670 g) was slowly added in aliquots over 15 minutes. The maximum temperature reached was 18° C. The mixture was heated to reflux for one hour, cooled to 10° C. in an ice bath and 1.6 L of ice water was rapidly added with vigorous stirring. The temperature increased to 15° C. 10 N Hydrochloric acid (1.6 L) was added with vigorous stirring. The temperature increased to 22° C. The mixture was allowed to stand for 30 minutes and the layers allowed to separate. The temperature reached a maximum of 40° C. The aqueous layer was adjusted to pH 12-13 with 10 N potassium hydroxide (3.8 L) at a rate that allowed the temperature to reach and remain at 55° C. during the addition. After the addition was complete the mixture was cooled to 10° C. and stirred for 1 hour. The solid was collected by vacuum filtration and washed four times with water to give 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (778 g, 100% yield) as a yellow solid. ¹H-NMR (DMSO-d₆) δ 1.25 (t, 3H, CH₃), 2.44, 2.48 (2xs, 2x3H, 2xCH₃), 4.16 (q, 2H, CH₂), 9.59 (s, 1H, CHO), 12.15 (br s, 1H, NH). MS m/z 195 [M+1].

5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester (806 g), potassium hydroxide (548 g), water (2400 mL) and methanol (300 mL) were refluxed for two hours with stirring and then cooled to 8° C. The mixture was extracted twice with dichloromethane. The aqueous layer was adjusted to pH 4 with 1000 mL of 10 N hydrochloric acid keeping the temperature under 15° C. Water was added

204

to facilitate stirring. The solid was collected by vacuum filtration, washed three times with water and dried under vacuum at 50° C. to give 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic (645 g, 93.5% yield) acid as a yellow solid. NMR (DMSO-d₆) δ 2.40, 2.43 (2xs, 2x3H, 2xCH₃), 9.57 (s, 1H, CHO), 12.07 (br s, 2H, NH+COOH). MS m/z 168 [M+1].

5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (1204 g) and 6020 mL of dimethylformamide were stirred at room temperature while 1-(3-dimethyl-aminopropyl-3-ethylcarbodiimide hydrochloride (2071 g), hydroxybenzotriazole (1460 g), triethylamine (2016 mL) and diethylethylenediamine (1215 mL) were added. The mixture was stirred for 20 hours at room temperature. The mixture was diluted with 3000 mL of water, 2000 mL of brine and 3000 mL of saturated sodium bicarbonate solution and the pH adjusted to greater than 10 with 10 N sodium hydroxide. The mixture was extracted twice with 5000 mL each time of 10% methanol in dichloromethane and the extracts combined, dried over anhydrous magnesium sulfate and rotary evaporated to dryness. The mixture was with diluted with 1950 mL of toluene and rotary evaporated again to dryness. The residue was triturated with 3:1 hexane:diethyl ether (4000 mL). The solids were collected by vacuum filtration, washed twice with 400 mL of ethyl acetate and dried under vacuum at 34° C. for 21 hours to give 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (819 g, 43% yield) as a light brown solid. ¹H-NMR (dimethylsulfoxide-d₆) δ 0.96 (t, 6H, 2xCH₃), 2.31, 2.38 (2xs, 2xCH₃), 2.51 (m, 6H 3xCH₂), 3.28 (m, 2H, CH₂), 7.34 (m, 1H, amide NH), 9.56 (s, 1H, CHO), 11.86 (s, 1H, pyrrole NH). MS m/z 266 [M+1].

5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide (809 g), 5-fluoro-1,3-dihydro-indol-2-one (438 g), ethanol (8000 mL) and pyrrolidine (13 mL) were heated at 78° C. for 3 hours. The mixture was cooled to room temperature and the solids collected by vacuum filtration and washed with ethanol. The solids were stirred with ethanol (5900 mL) at 72° C. for 30 minutes. The mixture was cooled to room temperature. The solids were collected by vacuum filtration, washed with ethanol and dried under vacuum at 54° C. for 130 hours to give 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide (1013 g, 88% yield) as an orange solid. ¹H-NMR (dimethylsulfoxide-d₆) δ 0.98 (t, 6H, 2xCH₃), 2.43, 2.44 (2xs, 6H, 2xCH₃), 2.50 (m, 6H, 3xCH₂), 3.28 (q, 2H, CH₂), 6.84, 6.92, 7.42, 7.71, 7.50 (5xm, 5H, aromatic, vinyl, CONH), 10.88 (s, 1H, CONH), 13.68 (s, 1H, pyrrole NH). MS m/z 397 [M-1].

Example 81

3-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic Acid

2-Oxo-2,3-dihydro-1H-indole-6-carboxylic acid (80 mg, 0.45 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide to give 210 mg (92%) of the title compound as a yellow orange solid.

¹HNMR (360 MHz, DMSO-d₆) δ 13.6 (s, 1H, NH), 7.76 (d, J=8.0 Hz, 1H), 7.66 (s, 1H, H-vinyl), 7.57 (dd, J=1.5 & 8.0 Hz, 1H), 7.40-7.42 (m, 2H), 3.28 (m, 2H, CH₂), 2.88 (m, H-piperidine), 2.54 (m, 6H, 3xCH₂), 2.44 (s, 3H, CH₃), 2.40 (s, 3H, CH₃), 1.56 (m, H-piperidine), 0.97 (t, J=6.98 Hz, 6H, N(CH₂CH₃)₂).

MS m/z 424 [M⁺].

205

Example 82

5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide (90 mg, 0.38 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (100 mg) to give 100 mg (54%) of the title compound as a yellow solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.65 (s, 1H, NH), 11.30 (s, br, 1H, NH), 8.25 (d, 1H), 7.92 (s, 1H, H-vinyl), 7.48–7.53 (m, 2H), 7.07 (d, J=8.2 Hz, 1H), 3.33 (m, 2H, CH₂), 2.61 (s, 6H, N(CH₃)₂), 2.56 (t, 2H, CH₂), 2.49 (m, 4kH, 2×CH₂), 2.45 (s, 3H, CH₃), 2.44 (s, 3H, CH₃), 1.67 (m, 4H, 2×CH₂).

MS-EI m/z 485 [M⁺].

Example 83

5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide

2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid (3-chlorophenyl)amide (120 mg, 0.38 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (100 mg) to give 150 mg (69%) of the title compound as a yellow orange solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.55 (s, 1H, NH), 11.26 (br s, 1H, NH), 10.30 (br s, 1H, NH), 8.26 (d, 1H), 7.79 (s, 1H, H-vinyl), 7.51–7.57 (m, 2H), 7.22 (t, J=8.1 Hz, 1H), 7.15 (m, 1H), 7.07 (m, 1H), 7.0 (m, 2H), 3.44 (m, 2H, CH₂), 2.57 (t, J=7.0 Hz, 2H, CH₂), 2.49 (m, 4H, 2×CH₂), 2.44 (s, 3H, CH₃), 2.43 (s, 3H, CH₃), 1.68 (m, 4H, 2×CH₂).

MS m/z 568 [M⁺].

Example 84

2,4-Dimethyl-5-[2-oxo-5-(pyridin-3-ylsulfamoyl)-1,2-dihydroindol-3-ylidenemethyl]-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)amide

2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid pyridin-3-ylamide (110 mg, 0.38 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-ylethyl)amide (100 mg) to give 150 mg (74%) of the title compound as an orange solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.58 (s, 1H, NH), 8.21 (d, J=2.0 Hz, 2H), 8.04 (m, 1H), 7.76 (s, 1H, H-vinyl), 7.49–7.54 (m, 2H), 7.41 (m, 1H), 7.14 (m, 1H), 6.94 (d, J=8.5 Hz, 1H), 33.33 (m, 2H, CH₂), 2.56 (t, J=7.06 Hz, 2H, CH₂), 2.49 (m, 4H, 2×CH₂), 2.43 (s, 6H, 2×CH₃), 1.68 (m, 4H, 2×CH₂).

MS m/z 535 [M⁺].

Example 85

3-[3,5-Dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-ylmethylene]-4-(2-hydroxyethyl)-1,3-dihydroindol-2-one

4-(2-Hydroxyethyl)-1,3-dihydroindol-2-one (71 mg, 0.4 mmol) was condensed with 3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrole-2-carbaldehyde to give 90 mg (55%) of the title compound as an orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 14.25 (s, 1H, NH), 10.88 (s, 1H, NH), 7.57 (s, 1H, H-vinyl), 7.03 (m, 1H,

206

6.75–6.82 (m, 2H), 4.86 (m, 1H, OH), 3.70 (m, 2H, CH₂), 3.04 (m, 2H, CH₂), 2.48 (m, 4H, 2×CH₂), 2.28 (br s, 7H), 2.19 (s, 3H, CH₃), 2.18 (s, 3H, CH₃).

MS m/z (+ve) 4.09.3 [M⁺].

Example 86

3-[3,5-Dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic Acid phenylamide

2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid phenylamide (110 mg, 0.4 mmol) was condensed with 3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrole-2-carbaldehyde (100 mg) to give 50 mg (24%) of the title compound as a yellow solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.52 (s, 1H, NH), 11.26 (s, 1H, NH), 10.08 (s, 1H, NH), 8.21 (d, J=1.6 Hz, 1H), 7.75 (s, 1H, H-vinyl), 7.50 (dd, J=1.6 & 8.3 Hz, 1H), 7.19 (m, 2H), 7.10 (m, 2H), 6.97 (m, 2H), 2.49 (m, 4H, 2×CH₂), 2.28 (m, 10H, 2×CH₃ & 2×CH₂), 2.18 (s, 3H, CH₃).

MS-EI m/z 519 [M⁺].

Example 87

5-(5-Dimethylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide

2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide (90 mg, 0.38 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (100 mg) to give 80 mg (43%) of the title compound as a yellow solid.

¹HNMR (300 MHz, DMSO-d6) δ 11.30 (s, 1H, NH), 8.27 (d, J=1.7 Hz, 1H), 7.94 (s, 1H, H-vinyl), 7.49 (dd, J=1.7 & 8.0 Hz, 1H), 7.44 (m, 1H, CONHCH₂CH₂), 7.07 (d, J=8.0 Hz, 1H), 3.26 (m, 2H, CH₂), 2.60 (s, 6H, N(CH₃)₂), 2.53 (m, 2H, CH₂), 2.45–2.50 (m, 10H, 2×CH₃ & N(CH₂CH₃)₂), 0.96 (t, J=7.2 Hz, 6H, N(CH₂CH₃)₂).

MS-EI m/z 487 [M⁺].

Example 88

5-[5-(3-Chlorophenylsulfamoyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide

2-Oxo-2,3-dihydro-1H-indole-5-sulfonic acid (3-chlorophenyl)amide (120 mg, 3.8 mmol) was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (100 mg) to give 80 mg (37%) of the title compound as a yellow solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.55 (s, 1H, NH), 11.24 (s, 1H, NH), 10.29 (s, 1H, NH), 8.25 (d, J=1.87 Hz, 1H), 7.79 (s, 1H, H-vinyl), 7.52 (dd, J=1.87 & 8.3 Hz, 1H), 7.42 (m, 1H, CONHCH₂CH₂), 7.22 (t, J=8.02 Hz, 1H), 7.15 (t, J=2 Hz, 1H), 7.08 (m, 1H), 7.0 (m, 2H), 3.27 (m, 2H, CH₂), 2.48–2.57 (m, 6H, 3×CH₂), 2.45 (s, 3H, CH₃), 2.44 (s, 3H, CH₃), 0.97 (t, J=7.0 Hz, 6H, N(CH₂CH₃)₂).

MS m/z 570.1 [M⁺].

Example 95

3-(2-Oxo-5-phenyl-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic Acid Ethyl Ester

¹HNMR (360 MHz, DMSO-d6) δ 13.74 (s, 1H, NH), 11.00 (s, 1H, NH), 8.13 (d, J=1.7 Hz, 1H), 7.74 (s, 1H,

207

H-vinyl), 7.70 (d, $J=7.7$ Hz, 2H), 7.49 (dd, $J=1.7$ & 8.0 Hz, 1H), 7.44 (t, $J=7.7$ Hz, 2H), 7.32 (m, 1H), 6.96 (d, $J=8.0$ Hz, 1H), 4.26 (q, $J=7.0$ Hz, 2H, OCH_2CH_3), 2.79 (m, 2H, CH_2), 2.72 (m, 2H, CH_2), 1.73 (m, 4H, $2\times\text{CH}_2$), 1.30 (t, $J=7.0$ Hz, 3H, OCH_2CH_3).

MS-EI m/z 412 [M⁺].

Example 99

3-(2-Oxo-5-phenylsulfamoyl-1,2-dihydroindol-3-ylidenemethyl)-4,5,6,7-tetrahydro-2H-isoindole-1-carboxylic Acid Ethyl Ester

¹HNMR (360 MHz, DMSO-d6) δ 13.64 (s, 1H, NH), 11.33 (s, 1H, NH), 10.07 (s, 1H, NH), 8.24 (d, $J=1.8$ Hz, 1H), 7.74 (s, 1H, H-vinyl), 7.57 (dd, $J=1.8$ & 8.0 Hz, 1H), 7.21 (t, $J=7.6$ Hz, 2H), 7.11 (d, $J=7.6$ Hz, 2H), 6.99 (d, $J=8.0$ Hz, 1H), 6.98 (d, $J=7.6$ Hz, 1H), 4.27 (q, $J=7.0$ Hz, 2H, OCH_2CH_3), 2.80 (m, 2H, CH_2), 2.73 (m, 2H, CH_2), 1.73 (m, 4H, $2\times\text{CH}_2$), 1.30 (t, $J=7.0$ Hz, 3H, OCH_2CH_3).

MS-EI m/z 491 [M⁺].

Example 109

3-[3-(Morpholine-4-carbonyl)-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic Acid

¹HNMR (360 MHz, DMSO-d6) δ 13.60 (s, 1H, NH), 12.75 (br s, 1H, COOH), 11.08 (s, 1H, NH), 7.85 (d, $J=7.8$ Hz, 1H), 7.71 (s, 1H, H-vinyl), 7.62 (dd, $J=1.4$ & 7.8 Hz, 1H), 7.41 (d, $J=1.4$ Hz, 1H), 3.65 (m, 4H, $2\times\text{CH}_2$), 3.55 (m, 4H, $2\times\text{CH}_2$), 2.81 (m, 2H, CH_2), 2.54 (m, 2H, CH_2), 1.73 (m, 4H, $2\times\text{CH}_2$).

MS-EI m/z 421 [M⁺].

Example 112

5-Bromo-3-[3-(pyrrolidine-1-carbonyl)-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene]-1,3-dihydro-indol-2-one

¹HNMR (360 MHz, DMSO-d6) δ 13.56 (s, 1H, NH), 11.00 (s, 1H, NH), 8.05 (d, $J=1.8$ Hz, 1H), 7.74 (s, 1H, H-vinyl), 7.28 (dd, $J=1.3$ & 8.3 Hz, 1H), 6.83 (d, $J=8.3$ Hz, 1H), 3.57 (m, 4H, $2\times\text{CH}_2$), 2.79 (m, 2H, CH_2), 2.65 (m, 2H, CH_2), 1.88 (m, 4H, $2\times\text{CH}_2$), 1.71 (m, 4H, $2\times\text{CH}_2$).

MS-EI m/z 439 & 441 [M⁺-1] & [M⁺+1].

Example 114

3-(3-Dimethylcarbamoyl)-4,5,6,7-tetrahydro-2H-isoindol-1-ylmethylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic Acid

¹HNMR (360 MHz, DMSO-d6) δ 13.60 (s, 1H, NH), 12.72 (br s, 1H, COOH), 11.05 (s, 1H, NH), 7.85 (d, $J=7.9$ Hz, 1H), 7.72 (s, 1H, H-vinyl), 7.62 (dd, $J=1.3$ & 7.9 Hz, 1H), 7.42 (d, $J=1.3$ Hz, 1H), 3.03 (s, 6H, $\text{N}(\text{CH}_3)_2$), 2.81 (m, 2H, CH_2), 2.55 (m, 2H, CH_2), 1.73 (m, 4H, $2\times\text{CH}_2$).

MS-EI m/z 379 [M⁺].

Example 115

4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid

¹HNMR (300 MHz, DMSO-d6) \square 13.56 (br s, 1H, NH), 8.24 (d, $J=1.5$ Hz, 1H), 7.86 (s, 1H, H-vinyl), 7.74 (d, $J=2.9$ Hz, 1H), 7.56 (dd, $J=1.5$ & 8.1 Hz, 1H), 7.20 (br m, 1H, NHCH_3), 7.03 (d, $J=8.1$ Hz, 1H), 2.57 (s, 3H, CH_3), 2.41 (s, 3H, CH_3).

MS-EI m/z 361 [M⁺].

208

Example 116

{[4-Methyl-5-(4-methyl-5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]-amino}-acetic Acid Ethyl Ester

4-Methyl-1H-pyrrole-3-carboxylic acid ethyl ester (lit. ref. D. O. Cheng, T. L. Bowman and E. LeGoff, J. Heterocyclic Chem.; 1976; 13; 1145-1147) was formylated using method A, hydrolysed using method B followed by amidation (method C) to give [(5-formyl-4-methyl-1H-pyrrole-3-carbonyl)-amino]-acetic acid ethyl ester.

4-Methylaminosulfonyl-2-oxindole (50 mg, 0.21 mmol) was condensed with [(5-formyl-4-methyl-1H-pyrrole-3-carbonyl)-amino]-acetic acid ethyl ester (100 mg, 0.42 mmol) and piperidine (0.1 mL) in ethanol (2 mL) to give 50 mg (52%) of the title compound.

¹HNMR (360 MHz, DMSO-d6) δ 13.59 (s, 1H, NH), 11.29 (v.b.r. s, 1H, NH-CO), 8.33 (t, $J=5.8$ Hz, 1H, CONHCH_2), 7.83 (d, $J=3.11$ Hz, 1H), 7.80 (s, 1H, H-vinyl), 7.71 (d, $J=8.5$ Hz, 1H), 7.34 (br m, 1H, NHCH_3), 6.89 (d, $J=8.5$ Hz, 1H), 4.11 (q, $J=7.1$ Hz, 2H, OCH_2CH_3), 3.92 (d, $J=5.8$ Hz, 2H, GlyCH_2), 2.86 (s, 3H, CH_3), 2.48 (s, 3H, CH_3), 2.42 (d, $J=4.71$ Hz, 3H, HNCH_3), 1.20 (t, $J=7.1$ Hz, 3H, OCH_2CH_3).

MS-EI m/z 460 [M⁺].

Example 117

{[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]-amino}-acetic Acid Ethyl Ester

A mixture of 5-methylaminosulfonyl-2-oxindole (0.06 g, 0.22 mmol), [(5-formyl-4-methyl-1H-pyrrole-3-carbonyl)-amino]-acetic acid ethyl ester (0.075 g, 0.27 mmol) and piperidine (2 drops) in ethanol (5 mL) was heated in a sealed tube at 90° C. for 12 hrs. After cooling, the precipitate was collected by vacuum filtration, washed with ethanol, triturated with dichloromethane/ether and dried to give 0.035 g (36%) of the title compound as a yellowish brown solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.6 (s, 1H, NH), 11 (v.b.r. s, 1H, NH-CO), 8.30 (t, $J=5.7$ Hz, 1H, CONHCH_2), 8.25 (d, $J=1.2$ Hz, 1H), 7.88 (s, 1H, H-vinyl), 7.84 (d, $J=3.3$ Hz, 1H), 7.57 (dd, $J=1.9$ & 8.5 Hz, 1H), 7.14 (br m, 1H, NHCH_3), 7.04 (d, $J=8.5$ Hz, 1H), 4.11 (q, $J=6.7$ Hz, 2H, OCH_2CH_3), 3.92 (d, $J=5.7$ Hz, 2H, GlyCH_2), 2.55 (s, 3H, CH_3), 2.41 (m, 3H, NCH_3), 1.20 (t, $J=6.7$ Hz, 3H, OCH_2CH_3).

MS m/z 446 [M⁺].

Example 118

{[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrole-3-carbonyl]-amino}-acetic Acid

A mixture of [(5-formyl-4-methyl-1H-pyrrole-3-carbonyl)-amino]-acetic acid ethyl ester (0.142 g, 0.59 mmol) and 1N NaOH (1.2 mL) in methanol (10 mL) was stirred at room temperature for 1 hr. The reaction was concentrated and the residue was condensed with 5-methylaminosulfonyl-2-oxindole (0.13 g, 0.48 mmol) and piperidine (0.12 mL) in ethanol (12 mL) to give 0.11 g (52%) of the title compound.

¹HNMR (300 MHz, DMSO-d6) δ 13.98 (br s, 1H, NH), 8.17 (s, 1H), 7.80 (s, 1H), 7.75 (d, $J=3.1$ Hz, 1H), 7.51 (dd, $J=2$ & 8.2 Hz, 1H), 7.21 (m on br s, 2H), 6.97 (d, $J=8.1$ Hz, 1H), 3.41 (d, $J=4.2$ Hz, 2H, CH_2NH), 2.54 (s, 3H, pyrrole- CH_3), 2.39 (s, 3H, ArCH_3).

MS m/z 417 [M-1]⁺.

209

Example 120

5-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid

¹HNMR (300 MHz, DMSO-d6) δ 13.77 (br s, 1H, NH), 12.49 (s, 1H, COOH), 11.07 (s, 1H, NH), 8.39 (s, 1H, H-vinyl), 7.43 (d, J=7.47 Hz, 1H), 7.20 (t, J=7.47 Hz, 1H), 7.03 (t, J=7.47 Hz, 1H), 6.91 (d, J=7.47 Hz, 1H), 6.49 (d, J=1.53 Hz, 1H), 2.34 (s, 3H, CH₃).

MS m/z 269 [M+H]⁺.

Example 121

5-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid Ethyl Ester

¹HNMR (300 MHz, DMSO-d6) δ 13.79 (s, 1H, NH), 11.08 (s, 1H, NH), 8.31 (s, 1H, H-vinyl), 7.45 (d, J=7.52 Hz, 1H), 7.20 (t, J=7.52 Hz, 1H), 7.03 (t, J=7.52 Hz, 1H), 6.91 (d, J=7.52 Hz, 1H), 6.50 (d, J=2.1 Hz, 1H), 4.26 (q, J=7.2 Hz, 2H, OCH₂CH₃), 2.33 (s, 3H, CH₃), 1.32 (t, J=7.2 Hz, 3H, OCH₂CH₃).

MS m/z 297.1 [M+H]⁺.

Example 122

2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic Acid Ethyl Ester

¹HNMR (360 MHz, DMSO-d6) δ 13.72 (s, 1H, NH), 11.16 (s, 1H, NH), 8.29 (s, 1H, H-vinyl), 7.53 (d, J=2.0 Hz, 1H), 7.35 (dd, J=2.0 & 8.05 Hz, 1H), 6.87 (t, J=8.05 Hz, 1H), 6.53 (d, J=2.4 Hz, 1H), 4.28 (q, J=7.03 Hz, 2H, OCH₂CH₃), 2.35 (s, 3H, CH₃), 1.33 (t, J=7.03 Hz, 3H, OCH₂CH₃).

MS m/z 375 & 377 [M+H]⁺.

Example 123

2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic Acid

¹HNMR (300 MHz, DMSO-d6) δ 13.72 (s, 1H, NH), 12.57 (s, 1H, COOH), 11.19 (s, 1H, NH), 8.36 (s, 1H, H-vinyl), 7.51 (d, J=1.4 Hz, 1H), 7.34 (dd, J=1.4 & 8.17 Hz, 1H), 6.87 (t, J=8.17 Hz, 1H), 6.52 (d, J=2.5 Hz, 1H), 2.35 (s, 3H, CH₃).

MS m/z 347 & 349 [M+H]⁺.

Example 124

2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ylethyl)-amide

To a solution of 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (250 mg, 1.63 mmol) in dimethylformamide (3 mL) was added 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (376 mg, 1.2 equiv.), 1-hydroxybenzotriazole (265 mg, 1.2 equiv.), triethylamine (0.45 mL, 2 equiv.) and 1-(2-aminoethyl)pyrrolidine (0.23 mL, 1.1 equiv.). After stirring at room temperature overnight, the reaction was diluted with saturated sodium bicarbonate and brine (with extra salt) and extracted with 10% methanol in dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated to give 130 mg of 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide.

A mixture of 5-bromo-2-oxindole (106 mg, 0.5 mmol), 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide (125 mg, 1 equiv.) and piperidine (0.2 mL) in ethanol (2 mL) was heated in a sealed tube at 80° C. for 1 hr and then cooled. The precipitate was collected by vacuum filtration, washed with ethanol and ethyl acetate and dried to give the title compound as an orange solid.

5-ethidine (0.2 mL) in ethanol (2 mL) was heated in a sealed tube at 80° C. for 1 hr and then cooled. The precipitate which formed was collected by vacuum filtration, washed with ethanol and ethyl acetate and dried to give the title compound as an orange solid.

¹HNMR (300 MHz, DMSO-d6) δ 13.62 (s, 1H, NH), 11.06 (br s, 1H, NH), 8.56 (s, 1H, H-vinyl), 8.15 (m, 1H, CONHCH₂), 7.48 (d, J=1.8 Hz, 1H), 7.31 (dd, J=1.8 & 7.9 Hz, 1H), 6.86 (d, J=7.9 Hz, 1H), 6.60 (d, J=2.3 Hz, 1H), 3.35 (m, 2H, HNCH₂CH₂), 2.56 (t, J=6.91 Hz, 2H, HNCH₂CH₂), 2.35 (s, 3H, CH₃), 1.67 (m, 4H, 2xCH₂).

MS m/z 443/445 [M⁺ and M⁺⁺²].

Example 125

2-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-5-methyl-1H-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)-amide

To a solution of 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (320 mg, 2.1 mmol) in dimethylformamide (3 mL) was added 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (483 mg, 1.2 equiv.), 1-hydroxybenzotriazole (340 mg, 1.2 equiv.), triethylamine (0.59 mL, 2 equiv.) and N,N-diethylethylenediamine (0.32 mL, 1.1 equiv.). After stirring at room temperature overnight, the reaction was diluted with saturated sodium bicarbonate and brine (with extra salt) and extracted with 10% methanol in dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated to give 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide.

A mixture of 5-bromo-2-oxindole (106 mg, 0.5 mmol), 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide (126 mg, 1 equiv.) and piperidine (0.2 mL) in ethanol (2 mL) was heated in a sealed tube at 80° C. for 1 hr and then cooled. The precipitate was collected by vacuum filtration, washed with ethanol and ethyl acetate and dried to give the title compound as an orange solid.

¹HNMR (360 MHz, DMSO-d6) δ 13.62 (s, 1H, NH), 11.11 (br s, 1H, NH), 8.54 (s, 1H, H-vinyl), 8.1 (m, 1H, CONHCH₂), 7.49 (d, J=2.2 Hz, 1H), 7.31 (dd, J=2.2 & 8.3 Hz, 1H), 6.86 (d, J=8.3 Hz, 1H), 6.58 (d, J=2.24 Hz, 1H), 3.31 (m, 2H, HNCH₂CH₂), 2.59 (m, 6H, 3xCH₂), 2.36 (s, 3H, CH₃), 0.99 (t, J=6.8 Hz, 6H, N(CH₂CH₃)₂).

MS m/z 445/447 [M⁺ and M⁺⁺²].

Example 126

2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid (2-diethylamino-ethyl)-amide

A mixture of 1,3-dihydro-indol-2-one (266 mg, 2 mmol), 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (530 mg, 2 mmol) and piperidine (1 drop) in ethanol was heated at 90° C. for 2 hours. The reaction was cooled to room temperature, the resulting precipitate was collected by vacuum filtration, washed with ethanol and dried to give 422 mg (55%) of the title compound as a light yellow solid.

¹HNMR (400 MHz, DMSO-d6) δ 13.7 (s, 1H, NH), 10.9 (s, 1H, NH), 7.88 (d, J=7.6 Hz, 1H), 7.64 (s, 1H, H-vinyl), 7.41 (t, J=5.4 Hz, 1H, NH), 7.13 (dt, J=1.2 & 7.6 Hz, 1H), 6.99 (dt, J=1.2 & 7.6 Hz, 1H), 6.88 (d, J=7.6 Hz, 1H), 3.28 (m, 2H), 2.48-2.55 (m, 6H), 2.44 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 0.97 (t, J=7.2 Hz, 6H, N(CH₂CH₃)₂).

MS+ve APCI 381 [M⁺⁺¹].

211

Example 127

5-(5-Chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-diethylamino-ethyl)-amide

A mixture of 5-Chloro-1,3-dihydro-indol-2-one (335 mg, 2 mmol), 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (530 mg, 2 mmol) and piperidine (1 drop) in ethanol was heated at 90° C. for 2 hours. The reaction was cooled to room temperature, the resulting precipitate was collected by vacuum filtration, washed with ethanol and dried to give 565 mg (68%) of the title compound as an orange solid.

¹H NMR (400 MHz, DMSO-d₆) δ 13.65 (s, 1H, NH), 11.0 (s, 1H, NH), 7.98 (d, J=2.1 Hz, 1H) 7.77 (s, 1H H-vinyl), 7.44 (t, NH), 7.13 (dd, J=2.1 & 8.4 Hz, 1H) 6.87 (d, J=8.4 Hz, 1H), 3.28 (g, 2H), 2.48–2.53 (m, 6H), 2.44 (s, 3H, CH₃), 2.43 (s, 3H, CH₃), 0.97 (t, J=7.0 Hz, 6H, N(CH₂CH₃)₂)
MS+ve APCI 415 [M⁺+1].

Example 128

2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-ethyl)-amide

1,3-Dihydro-indol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide to give the title compound.
MS+ve APCI 379 [M⁺+1].

Example 129

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-yl-ethyl)-amide

5-Fluoro-1,3-dihydro-indol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide to give the title compound.
MS+ve APCI 397 [M⁺+1].

Scale-Up Procedure:

5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (61 g), 5-fluoro-1,3-dihydro-indol-2-one (79 g), ethanol (300 mL) and pyrrolidine (32 mL) were refluxed for 4.5 hours. Acetic acid (24 mL) was added to the mixture and refluxing was continued for 30 minutes. The mixture was cooled to room temperature and the solids collected by vacuum filtration and washed twice with ethanol. The solids were stirred for 130 minutes in 40% acetone in water (400 mL) containing 12 N hydrochloric acid (6.5 mL). The solids were collected by vacuum filtration and washed twice with 40% acetone in water. The solids were dried under vacuum to give 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (86 g, 79% yield) as an orange solid. ¹H-NMR (dimethylsulfoxide-d₆) δ 2.48, 2.50 (2xs, 6H, 2xCH₃), 6.80, 6.88, 7.68, 7.72 (4xm, 4H, aromatic and vinyl), 10.88 (s, 1H, CONH), 12.12 (s, 1H, COOH), 13.82 (s, 1H, pyrrole NH). MS m/z 299 [M-1].

5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (100 g) and dimethylformamide (500 mL) were stirred and benzotriazol-1-yloxymethylphosphonium hexafluorophosphate (221 g), 1-(2-aminoethyl)pyrrolidine (45.6 g) and triethylamine (93 mL) were added. The mixture was stirred for 2 hours at ambient temperature. The solid product was collected by vacuum filtration and washed with

212

ethanol. The solids were slurry-washed by stirring in ethanol (500 mL) for one hour at 64° C. and cooled to room temperature. The solids were collected by vacuum filtration, washed with ethanol, and dried under vacuum to give

5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide (101.5 g, 77% yield). ¹H-NMR (dimethylsulfoxide-d₆) δ 1.60 (m, 4H, 2xCH₂), 2.40, 2.44 (2xs, 6H, 2xCH₃), 2.50 (m, 4H, 2xCH₂), 2.57, 3.35 (2xm, 10 4H, 2xCH₂), 7.53, 7.70, 7.73, 7.76 (4xm, 4H, aromatic and vinyl), 10.88 (s, 1H, CONH), 13.67 (s, 1H, pyrrole NH). MS m/z 396 [M⁺+1].

Example 130

5-(5-Chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-pyrrolidin-1-yl-ethyl)-amide

5-Chloro-1,3-dihydro-indol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide to give the title compound.
MS+ve APCI 413 [M⁺+1].

Example 131

2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic Acid (2-dimethylaminoethyl)-amide

1,3-Dihydro-indol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylamino-ethyl)amide to give the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ 13.63 (s, 1H, NH), 10.90 (s, 1H, NH), 7.78 (d, J=7.8 Hz, 1H), 7.63 (s, 1H H-vinyl), 7.48 (t, 1H, NH), 7.13 (dt, 1H), 6.98 (dt, 1H), 6.88 (d, J=7.7 Hz, 1H), 3.31 (q, J=6.6 Hz, 2H), 2.43 (s, 3H, CH₃), 2.40 (s, 3H, CH₃), 2.38 (t, J=6.6 Hz, 2H), 2.19 (s, 6H, N(CH₂CH₃)₂)
MS+ve APCI 353 [M⁺+1].

Example 132

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-dimethylaminoethyl)-amide

5-Fluoro-1,3-dihydro-indol-2-one was condensed with 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylaminoethyl)amide to give the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ 13.68 (s, 1H, NH), 10.90 (s, 1H, NH), 7.76 (dd, J=2.4 & 9.4 Hz, 1H), 7.71 (s, 1H H-vinyl), 7.51 (t, 1H, NH), 6.93 (m, 1H), 6.84 (dd, J=4.6 & 8.4 Hz, 1H), 3.31 (q, J=6.6 Hz, 2H), 2.43 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 2.38 (t, J=6.6 Hz, 2H), 2.19 (s, 6H, N(CH₂CH₃)₂)
MS+ve APCI 371 [M⁺+1].

Example 193

5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-ethylamino-ethyl)-amide

5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide (99 g), ethanol (400 mL), 5-fluoro-2-oxindole (32 g) and pyrrolidine (1.5 g) were refluxed for 3 hours with stirring. The mixture was cooled to room temperature and the solids collected by vacuum filtration. The solids were stirred in ethanol at 60° C., cooled to room temperature and collected by vacuum filtration. The product was dried under vacuum to give 5-[5-fluoro-2-oxo-

213

1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide (75 g, 95% yield). ¹H-NMR (dimethylsulfoxide-d₆) δ 1.03 (t, 3H, CH₃), 2.42, 2.44 (2xs, 6H, 2xCH₃), 2.56 (q, 2H, CH₂), 2.70, 3.30 (2xt, 4H, 2xCH₂), 6.85, 6.92, 7.58, 7.72, 7.76 (5xm, 5H, aromatic, vinyl and CONH), 10.90 (br s, 1H, CONH), 13.65 (br s, 1H, pyrrole NH). MS m/z 369 [M-1].

Example 195

5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-diethyl-N-oxoamino-ethyl)-amide

Method A:

5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (598 mg) and dichloromethane (60 mL) in an ice bath were treated with 3-chloroperbenzoic acid (336 mg) and the mixture stirred at room temperature overnight. The solvent was rotary evaporated and the residue suspended in methanol (20 mL). Water (20 mL) containing sodium hydroxide (240 mg) was added and the mixture stirred for one hour. The precipitate was collected by vacuum filtration, washed with 5 mL of water and dried under a vacuum to give 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoamino-ethyl)-amide (510 mg, 82% yield) as an orange solid. ¹H-NMR (DMSO-d₆) δ 13.72 (br s, 1H, NH), 11.02 (br s, 1H, CONH), 9.81 (br s, 1H, CONH), 7.75 (dd, 1H, aromatic), 7.70 (s, 1H, aromatic), 6.93 (td, 1H, aromatic), 6.84 (m, 1H, aromatic), 3.63 (m, 2H, CH₂), 3.29 (m, 2H, CH₂), 3.14 (m, 4H, 2xCH₂), 2.47 (s, 1H, CH₃), 2.45 (s, 3H, CH₃), 1.64 (t, 6H, 2xCH₃). MS m/z 415 [M+1].

Method B:

5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (10 g) was suspended in dichloromethane (100 mL) and cooled in an ice bath. 3-Chloro-peroxybenzoic acid (13.1 g) was added with stirring and the mixture allowed to warm to room temperature and then stirred overnight. The mixture was rotary evaporated to dryness and chromatographed on a column of silica gel eluting with 20% methanol in dichloromethane. Fractions containing product were combined and rotary evaporated to dryness to give 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoamino-ethyl)-amide (9 g, 83% yield).

5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoamino-ethyl)-amide (9 g), 5-fluoro-1,3-dihydro-indol-2-one ((9 g, 83% yield)), and pyrrolidine ((9 g, 83% yield (0.1 g) were refluxed in ethanol (30 mL) for 4 hours. The mixture was cooled in an ice bath and the precipitate collected by vacuum filtration and washed with ethanol. The solids were stirred in ethyl acetate (30 mL), collected by vacuum filtration, washed with ethyl acetate and dried under vacuum to give 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethyl-N-oxoamino-ethyl)-amide (10.3 g 80% yield) as an orange solid. ¹H-NMR (DMSO-d₆) δ 13.72 (br s, 1H, NH), 11.02 (br s, 1H, CONH), 9.81 (br s, 1H, CONH), 7.75 (dd, 1H, aromatic), 7.70 (s, 1H, aromatic), 6.93 (td, 1H, aromatic), 6.84 (m, 1H, aromatic), 3.63 (m, 2H, CH₂), 3.29 (m, 2H, CH₂), 3.14 (m, 4H, 2xCH₂), 2.47 (s, 1H, CH₃), 2.45 (s, 3H, CH₃), 1.64 (t, 6H, 2xCH₃). MS m/z 415 [M+1].

214

Example 190

5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid [2-(pyridin-1-yl)ethyl]-amide.

5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (120 mg, 0.4 mmol) was shaken with EDC, HCl (96 mg, 0.5 mmol), anhydrous 1-hydroxy-benztriazole (68 mg, 0.5 mmol), and 2-(2-aminoethyl)pyridine purchased from Aldrich in anhydrous DMF (3 mL) for 2-3 days at room temperature. The reaction mixture was diluted with 1M NaHCO₃ (1.5 mL), then with 8 mL of water. The precipitated crude product was collected by filtration, washed with water, dried and purified by crystallization or chromatography to give 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(pyridin-1-yl)-ethyl]amide.

Example 189

5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid [2-(pyridin-1-yl)ethyl]amide.

Proceeding as described in previous example but substituting 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid with 5-[5-chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (127 mg) provided 5-[5-chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(pyridin-1-yl)ethyl]amide.

Example 192

5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid [2-(pyridin-1-yl)ethyl]amide.

Proceeding as described in Example 190 above but substituting 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid with 5-[5-bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (145 mg) provided 5-[5-bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(pyridin-1-yl)ethyl]amide.

Example 191

5-[2-Oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid [2-(pyridin-1-yl)ethyl]amide

Proceeding as described in Example 190 above but substituting 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid with 5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (113 mg) provided 5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(pyridin-1-yl)ethyl]amide.

Example 203

5-[5-Cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid [2-(pyridin-1-yl)ethyl]amide

Proceeding as described in Example 190 above but substituting 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid with 5-[5-cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (123 mg) provided 5-[5-cyano-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(pyridin-1-yl)ethyl]amide.

215

Examples 142, 186, 187, 188 and 204

Proceeding as described in Examples 190, 189, 191, 192, and 203 above but substituting 2-(2-aminoethyl)pyridine with 1-(2-aminoethyl)pyrrolidine, purchased from Aldrich Chemical Company, Inc. provided the desired compounds.

Examples 143-147

Proceeding as described in Examples 190, 189, 191, 192, and 203 above but substituting 2-(2-aminoethyl)pyridine with 1-(2-aminoethyl)imidazolin-2-one (prepared by heating dimethyl carbonate with bis(2-aminoethyl) amine (2 equivalents) in a sealed flask to 150° C. for 30 min., following the procedure described in U.S. Pat. No. 2,613, 212 (1950), to Rohm & Haas Co. The crude product was purified on silica using an eluent mixture chloroform-methanol-aqueous ammonia 80:25:2) provided the desired compounds.

Examples 148-151 and 184

Proceeding as described in Examples 190, 189, 191, 192, and 203 above but substituting 2-(2-aminoethyl)pyridine with 4-(2-aminoethyl)piperazine-1-acetic acid ethyl ester (prepared as follows: Piperazine-1-acetic acid ethyl ester (11.22 g) was treated with iodoacetonitrile (5.0 mL) in the presence of potassium carbonate (6.9 g) in ethyl acetate (260 mL) at 0° C. After complete iodoacetonitrile addition (45 min), the reaction mixture was subsequently stirred at room temperature for 11 hours. The reaction mixture was filtered and the filtrates evaporated. The residue was hydrogenated in a presence of cobalt boride (prepared from CoCl₂ and sodium borohydride) at room temperature at 50 psi for 2 days in ethanol. Filtration, evaporation and chromatographic purification using an eluent mixture chloroform-methanol-aqueous ammonia 80:25:2 provided the desired amine (3.306 g) as a pale yellow oil) provided the desired compounds.

Example 152-153

Proceeding as described in Examples 190, 189, 191, 192, and 203 above but substituting 2-(2-aminoethyl)pyridine with 2-[(2-aminoethylamino)]acetonitrile (prepared as follows: A solution of iodoacetonitrile (50 mmol) in ethyl alcohol (80 ml) was added to a solution of ethylene diamine (150 ml) in ethyl alcohol (60 ml) at 0° C. over a period of 30 minutes. The stirring was continued for another 1 hr at 0° C., then at room temperature for 14 hours. 55 mmol of potassium carbonate was added, stirred for 30 minutes, filtered and the filtrate was concentrated at room temperature. The residue was purified on silica using an eluent mixture chloroform-methanol-aqueous ammonia 80:15:1.5 to give 2-[(2-aminoethylamino)]-acetonitrile (3.550 g) which was used immediately) provided the desired compounds.

Example 154-158

Proceeding as described in Examples 190, 189, 191, 192, and 203 above but substituting 2-(2-aminoethyl)pyridine with 1-(3-aminopropyl)-azepin-2-one (prepared according to the procedure in Kraft A.: J. Chem. Soc. Perkin Trans. 1, 6, 1999, 705-14, except that the hydrolysis of DBU was performed at 145° C. neat in a presence of lithium hydroxide (1 hr, 5 ml of DBU, 2 ml of water, 420 mg of lithium hydroxide hydrate). Purification of the crude product on silica using an eluent mixture chloroform-methanol-aqueous ammonia 80:40:4 provided 1-(3-aminopropyl)azepin-2-one (4.973 g, 87% yield) provide the desired compounds.

216

Examples 133-135, 159 and 200

Proceeding as described in Examples 190, 189, 191, 192, and 203 above but substituting 2-(2-aminoethyl)pyridine with N-acetyl ethylene diamine, (prepared by heating a mixture of ethyl acetate with ethylene diamine (1.5 equivalents) to 160° C. for 1 hr in a sealed vessel. The vacuum distillation provided the desired product in 56% yield. N-acetylene diamine is also available from Aldrich) provide the desired compounds.

Examples 146-140

Proceeding as described in Examples 190, 189, 191, 192, and 203 above but substituting 2-(2-aminoethyl)pyridine with 1-(3-aminopropyl)-tetrahydro-pyrimidin-2-one (prepared in the same way as 1-(3-aminopropyl)-azepin-2-one according to the procedure in Kraft A.: J. Chem. Soc. Perkin Trans. 1, 6, 1999, 705-14: Briefly, 1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2-a]pyrimidine (4.939 g), lithium hydroxide hydrate (918 mg) and 2 ml of water was heated without a solvent in a sealed vessel to 145° C. for 1 hr. The crude product was purified on a column of silica in chloroform-methanol-aqueous ammonia 80:40:4 to give pure amine (5.265 g, 94% yield).

Examples 141, 160-162 and 185

Proceeding as described in Examples 190, 189, 191, 192, and 203 above but substituting 2-(2-aminoethyl)pyridine with 1-(2-aminoethyl)-piperazine-2-one (prepared as follows: Neat tert-butylidiphenylsilyl chloride (25 mL, 97.7 mmol) was added dropwise into a solution of DBU (19.5 mL, 130 mmol) and bis(2-aminoethyl)amine (4.32 mL, 40 mmol) in anhydrous dimethyl acetamide (80 mL) at room temperature upon cooling on water bath within 5 minutes. The mixture was stirred for 5 hours. Bromoacetic acid ethyl ester (6.70 mL, 60 mmol) was added neat upon cooling to room temperature. The reaction was stirred for 25 minutes, then evaporated on high vacuum. The residue was dissolved in methanol (200 mL), KHCO₃ (10 g) and KF (12 g, 200 mmol) were added and the mixture was stirred at 60° C for 5 hours. 10 g of Na₂CO₃ was added, stirred for 10 minutes, cooled and filtered. The filtrates were evaporated. The residue was extracted with hexanes (2 times 250 mL). The hexane-insoluble material was dissolved in ethanol (60 mL), filtered and evaporated. The residue was purified on a column of silica in chloroform-methanol-aqueous ammonia 80:40:4 to give pure amine (4.245 g, 74% yield) provided the desired compounds.

Examples 163-167

Proceeding as described in Examples 190, 189, 191, 192, and 203 above but substituting 2-(2-aminoethyl)pyridine with 3-[(2-aminoethyl)amino]propionitrile (prepared from ethylene diamine (150 mmol) and acrylonitrile (50 mmol) in THF at room temperature, as described in Israel, M. et al: *J. Med Chem.* 7, 1964, 710-16., provided the desired amine (4.294 g)) provided the desired compounds.

Example 168

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylideneethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid [2-(4-methylpiperazin-1-yl)-ethyl]-amide

To a stirred yellow muddy mixture of 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylideneethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (90 mg), DMF (0.8 mL) and TEA (0.084 mL) in a 20 mL reaction tube, was added BOP

reagent (199 mg). The mixture became clear in 5 min. 2-(4-Methylpiperazin-1-yl)ethylamine¹ (51 mg) was added into the clear mixture. The resulting solution was stirred at room temperature over night. Yellow solid products precipitated from the reaction system. Thin layer chromatography (10% methanol in methylene chloride) showed that all the starting material had been converted into the product. The solid was isolated by vacuum filtration and washed once with ethanol (1 mL). The solid was sonicated in diethyl ether (2 mL) for 20 min and collected by vacuum filtration. After drying under vacuum, 5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methylpiperazin-1-yl-ethyl)-amide (79 mg, 62% yield) was obtained.

¹H NMR (DMSO-d₆) δ 2.13 (s, 3H, CH₃), 2.40, 2.42 (2xs, 6H, 2xCH₃), 2.41 (m, 2H, CH₂), 2.47 (m, 8H, 4xCH₂), 3.30 (m, 2H, CH₂), 6.82 (dd, J=4.5, 8.7 Hz, 1H), 6.91 (td, ²J=2.4, ³J=8.8 Hz, 1H), 7.43 (t, J=5.6 Hz, 1H), 7.70 (s, 1H), 7.75 (dd, J=2.8, 9.6 Hz, 1H) (aromatic and vinyl), 10.88 (s, 1H, CONH), 13.67 (s, 1H, NH). LC-MS (m/z) 424.4 (M-1).

Example 169

5-(5-Chloro-2-oxo-1,2-dihydro-indol-3-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (4-methylpiperazin-1-yl-ethyl)-amide

Following the procedure in Example 168 above but substituting 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid with 5-[5-chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (95 mg, 0.3 mmol) gave 5-(5-chloro-2-oxo-1,2-dihydro-indol-3-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methylpiperazin-1-yl-ethyl)-amide (76 mg, 58%).

¹H NMR (DMSO-d₆) δ 2.13 (s, 3H, CH₃), 2.41, 2.42 (2xs, 6H, 2xCH₃), 2.42 (m, 2H, CH₂), 2.48 (m, 8H, 4xCH₂), 3.30 (m, 2H, CH₂), 6.84 (d, J=8.0 Hz, 1H), 7.11 (dd, J=2.0, 8.0 Hz, 1H), 7.44 (t, J=5.6 Hz, 1H), 7.76 (s, 1H), 7.97 (d, J=2.0 Hz, 1H) (aromatic and vinyl), 10.98 (s, 1H, CONH), 13.62 (s, 1H, NH).

LC-MS (m/z) 440.2 (M-1).

Example 170

5-(5-Bromo-2-oxo-1,2-dihydro-indol-3-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (4-methylpiperazin-1-yl-ethyl)-amide

Following the procedure described in Example 168, but substituting 5-(5-chloro-2-oxo-1,2-dihydro-indol-3-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid with 5-(5-bromo-2-oxo-1,2-dihydro-indol-3-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid gave 5-(5-bromo-2-oxo-1,2-dihydro-indol-3-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methylpiperazin-1-yl-ethyl)-amide (39 mg, 54%) was obtained from SU011670 (54 mg, 0.15 mmol).

¹H NMR (DMSO-d₆) δ 2.14 (s, 3H, CH₃), 2.41, 2.42 (2xs, 6H, 2xCH₃), 2.42 (m, 2H, CH₂), 2.48 (m, 8H, 4xCH₂), 3.31 (m, 2H, CH₂), 6.80 (d, J=8.0 Hz, 1H), 7.23 (dd, J=2.0, 8.0 Hz, 1H), 7.44 (t, J=5.6 Hz, 1H), 7.76 (s, 1H), 8.09 (d, J=2.0 Hz, 1H) (aromatic and vinyl), 10.99 (s, 1H, CONH), 13.61 (s, 1H, NH). LC-MS (m/z) 486.6 (M).

Example 172

5-(2-Oxo-1,2-dihydro-indol-3-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (4-methylpiperazin-1-yl-ethyl)-amide

Following the procedure described in Example 168 above but substituting 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-

5-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid SU014900 with 5-(2-oxo-1,2-dihydro-indol-3-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid gave 5-(2-oxo-1,2-dihydro-indol-3-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methylpiperazin-1-yl-ethyl)-amide, SU014903 (136 mg, 84%) was obtained from SU012120 (112.8 mg, 0.4 mmol).

¹H NMR (DMSO-d₆) δ 2.13 (s, 3H, CH₃), 2.39, 2.42 (2xs, 6H, 2xCH₃), 2.42 (m, 2H, CH₂), 2.48 (m, 8H, 4xCH₂), 3.30 (t, 2H, CH₂), 6.86 (d, J=8.0 Hz, 1H), 6.96 (t, J=7.4 Hz, 1H), 7.10 (t, J=7.8 Hz, 1H), 7.41 (t, J=5.4 Hz, 1H), 7.62 (s, 1H), 7.76 (d, J=7.6 Hz, 1H) (aromatic and vinyl), 10.88 (s, 1H, CONH), 13.61 (s, 1H, NH). LC-MS (m/z) 406.6 (M-1).

Example 171

5-[2-Oxo-1,2-dihydro-indol-(3Z)-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide

To a stirred yellow muddy mixture of 5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (112.8 mg, 0.4 mmol), DMF (0.5 mL) and triethylamine (0.111 mL) in a 20 mL reaction tube, was added BOP reagent (265 mg). The mixture became clear in 5 min. 2-(2,6-dimethylpiperazin-1-yl)ethylamine (68.6 mg) (see, Tapia, L. Alonso—Cires, P. Lopez-Tudanca, R. Mosquera, L. Labeaga, A. Innerarity, A. Orjales, *J. Med. Chem.*, 1999, 42, 2870–2880) was added into the clear mixture. The resulting solution was stirred at room temperature over night. Thin layer chromatography (10% methanol in methylene chloride) showed that all the starting material had been converted into the product. The reaction mixture was evaporated to dryness and then purified by flash chromatography (CH₂Cl₂/CH₃OH=20/1–15/1) followed by recrystallization to give 5-[2-oxo-1,2-dihydro-indol-(3Z)-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide (83 mg, 50% yield).

¹H NMR (DMSO-d₆) δ 1.15, 1.16 (2xs, 6H, 2xCH₃), 1.95 (t, J=11.6 Hz, 2H, CH₂), 2.41, 2.47 (2xs, 6H, 2xCH₃), 2.50 (m, 2H, CH₂), 3.03 (d, J=10 Hz, 2H), 3.19 (m, 2H), 3.30 (m, 2H, CH₂), 6.86 (d, J=8.0 Hz, 1H), 6.97 (t, J=7.2 Hz, 1H), 7.11 (t, J=7.8 Hz, 1H), 7.48 (t, J=5.6 Hz, 1H), 7.61 (s, 1H), 7.75 (d, J=7.6 Hz, 1H) (aromatic and vinyl), 10.88 (s, 1H, CONH), 13.62 (s, 1H, NH). LC-MS (m/z) 422.2 (M+1).

Example 173

5-[5-Fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide

Following the procedure described in Example 168 above the desired compound was obtained (60 mg, 0.2 mmol).

¹H NMR (DMSO-d₆) δ 0.891, 0.907 (2xs, 6H, 2xCH₃), 1.49 (t, J=10.4 Hz, 2H), 2.40, 2.42 (2xs, 6H, 2xCH₃), 2.41 (m, 2H, CH₂), 2.74 (m, 4H), 3.30 (m, 2H), 6.82 (dd, J=4.5, 8.7 Hz, 1H), 6.90 (td, ²J=2.4, ³J=8.4 Hz, 1H), 7.42 (t, J=5.6 Hz, 1H), 7.70 (s, 1H), 7.74 (dd, J=4.6, 8.4 Hz, 1H) (aromatic and vinyl), 10.88 (s, 1H, CONH), 13.65 (s, 1H, NH). LC-MS (m/z) 438.4 (M-1).

Example 174

5-[5-Chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidene(methyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide

Following the procedure for Example 171 above the desired compound (31.2 mg, 34%) was obtained from

219

5-[5-chloro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (63 mg, 0.2 mmol).

¹H NMR (DMSO-d₆) δ 1.15, 1.16 (2xs, 6H, 2xCH₃), 1.95 (t, J=11.6 Hz, 2H, CH₂), 2.40, 2.42 (2xs, 6H, 2xCH₃), 2.50 (m, 2H, CH₂), 3.03 (d, J=11.2 Hz, 2H), 3.19 (m, 2H), 3.30 (m, 2H, CH₂), 6.85 (d, J=8.4 Hz, 1H), 7.11 (dd, J=2.0, 8.0 Hz, 1H), 7.52 (t, J=5.6 Hz, 1H), 7.76 (s, 1H), 7.97 (d, J=2.0 Hz, 1H) (aromatic and vinyl), 10.99 (s, 1H, CONH), 13.63 (s, 1H, NH). LC-MS (m/z) 456.2 (M+1).

Example 175

5-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid [2-(3,5-dimethylpiperazin-1-yl)ethyl]amide

Following the procedure described in Example 171 the desired compound (40 mg, 40%) was obtained from 5-[5-bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (74 mg, 0.2 mmol).

¹H NMR (DMSO-d₆) δ 1.15, 1.16 (2xs, 6H, 2xCH₃), 1.95 (t, J=11.6 Hz, 2H, CH₂), 2.40, 2.42 (2xs, 6H, 2xCH₃), 2.50 (m, 2H, CH₂), 3.03 (d, J=10.4 Hz, 2H), 3.19 (m, 2H), 3.30 (m, 2H, CH₂), 6.81 (d, J=8.4 Hz, 1H), 7.24 (dd, J=2.0, 8.4 Hz, 1H), 7.51 (t, J=5.6 Hz, 1H), 7.76 (s, 1H), 8.10 (d, J=2.0 Hz, 1H) (aromatic and vinyl), 10.99 (s, 1H, CONH), 13.62 (s, 1H, NH). LC-MS (m/z) 498.4 (M-1).

Biological Examples

The following assays are employed to find those compounds demonstrating the optimal degree of the desired activity.

A. Assay Procedures.

The following assays may be used to determine the level of activity and effect of the different compounds of the present invention on one or more of the PKs. Similar assays can be designed along the same lines for any PK using techniques well known in the art.

Several of the assays described herein are performed in an ELISA (Enzyme-Linked Immunosorbent Sandwich Assay) format (Voller, et al., 1980, "Enzyme-Linked Immunosorbent Assay," Manual of Clinical Immunology, 2d ed., Rose and Friedman, Am. Soc. Of Microbiology, Washington, D.C., pp. 359-371). The general procedure is as follows: a compound is introduced to cells expressing the test kinase, either naturally or recombinantly, for a selected period of time after which, if the test kinase is a receptor, a ligand known to activate the receptor is added. The cells are lysed and the lysate is transferred to the wells of an ELISA plate previously coated with a specific antibody recognizing the substrate of the enzymatic phosphorylation reaction. Non-substrate components of the cell lysate are washed away and the amount of phosphorylation on the substrate is detected with an antibody specifically recognizing phosphotyrosine compared with control cells that were not contacted with a test compound.

The presently preferred protocols for conducting the ELISA experiments for specific PKs is provided below. However, adaptation of these protocols for determining the activity of compounds against other RTKs, as well as for CTKs and STKs, is well within the scope of knowledge of those skilled in the art. Other assays described herein measure the amount of DNA made in response to activation of a test kinase, which is a general measure of a proliferative response. The general procedure for this assay is as follows: a compound is introduced to cells expressing the test kinase,

220

either naturally or recombinantly, for a selected period of time after which, if the test kinase is a receptor, a ligand known to activate the receptor is added. After incubation at least overnight, a DNA labeling reagent such as 5-bromodeoxyuridine (BrdU) or H³-thymidine is added. The amount of labeled DNA is detected with either an anti-BrdU antibody or by measuring radioactivity and is compared to control cells not contacted with a test compound.

GST-FLK-1 BIOASSAY

This assay analyzes the tyrosine kinase activity of GST-Flk1 on poly(glutamyl) peptides.

Materials and Reagents:

1. Corning 96-well ELISA plates (Corning Catalog No. 5805-96).
2. poly(glutamyl) 4:1, lyophilized (Sigma Catalog #P0275).
3. Preparation of poly(glutamyl)(pEY) coated assay plates: Coat 2 μg/well of poly(glutamyl)(pEY) in 100 μl PBS, hold at room temperature for 2 hours or at 4°C overnight. Cover plates well to prevent evaporation.
4. PBS Buffer: for 1 L, mix 0.2 g KH₂PO₄, 1.15 g Na₂HPO₄, 0.2 g KCl and 8 g NaCl in approx. 900 ml dH₂O. When all reagents have dissolved, adjust the pH to 7.2 with HCl. Bring total volume to 1 L with dH₂O.
5. PBST Buffer: to 1 L of PBS Buffer, add 1.0 ml Tween-20.
6. TBB—Blocking Buffer: for 1 L, mix 1.21 g TRIS, 8.77 g NaCl, 1 ml TWEEN-20 in approximately 900 ml dH₂O. Adjust pH to 7.2 with HCl. Add 10 g BSA, stir to dissolve. Bring total volume to 1 L with dH₂O. Filter to remove particulate matter.
7. 1% BSA in PBS: To make a 1xworking solution, add 10 g BSA to approx. 990 ml PBS buffer, stir to dissolve. Adjust total volume to 1 L with PBS buffer, filter to remove particulate matter.
8. 50 mM Hepes pH 7.5.
9. GST-Flk1cd purified from sf9 recombinant baculovirus transformation (SUGEN, Inc.).
10. 4% DMSO in dH₂O.
11. 10 mM ATP in dH₂O.
12. 40 mM MnCl₂
13. Kinase Dilution Buffer (KDB): mix 10 ml Hepes (pH 7.5), 1 ml 5M NaCl, 40 μL 100 mM sodium orthovanadate and 0.4 ml of 5% BSA in dH₂O with 88.56 ml dH₂O.
14. NUNC 96-well V bottom polypropylene plates, Applied Scientific Catalog #AS-72092
15. EDTA: mix 14.12 g ethylenediaminetetraacetic acid (EDTA) to approx. 70 ml dH₂O. Add 10 N NaOH until EDTA dissolves. Adjust pH to 8.0. Adjust total volume to 100 ml with dH₂O.
16. 1° Antibody Dilution Buffer: mix 10 ml of 5% BSA in PBS buffer with 89.5 ml TBST.
17. Anti-phosphotyrosine monoclonal antibody conjugated to horseradish peroxidase (PY99 HRP, Santa Cruz Biotech).
18. 2,2'-Azinobis(3-ethylbenzthiazoline-6-sulfonic acid (ABTS, Moss, Cat. No. ABST).
19. 10% SDS.
- Procedure:
1. Coat Corning 96-well ELISA plates with 2 μg of polyEY peptide in sterile PBS as described in step 3 of Materials and Reagents.
2. Remove unbound liquid from wells by inverting plate. Wash once with TBST. Pat the plate on a paper towel to remove excess liquid.

221

3. Add 100 μ l of 1% BSA in PBS to each well. Incubate, with shaking, for 1 hr. at room temperature.
4. Repeat step 2.
5. Soak wells with 50 mM HEPES (pH 7.5) (150 μ l/well).
6. Dilute test compound with dH₂O/4% DMSO to 4 times the desired final assay concentration in 96-well polypropylene plates.
7. Add 25 μ l diluted test compound to ELISA plate. In control wells, place 25 μ l of dH₂O/4% DMSO.
8. Add 25 μ l of 40 mM MnCl₂ with 4 \times ATP (2 μ M) to each well.
9. Add 25 μ l 0.5M EDTA to negative control wells.
10. Dilute GST-Flk1 to 0.005 μ g (5 ng)/well with KDB.
11. Add 50 μ l of diluted enzyme to each well.
12. Incubate, with shaking, for 15 minutes at room temperature.
13. Stop reaction by adding 50 μ l of 250 mM EDTA (pH 8.0).
14. Wash 3 \times with TBST and pat plate on paper towel to remove excess liquid.
15. Add 100 μ l per well anti-phosphotyrosine HRP conjugate, 1:5,000 dilution in antibody dilution buffer. Incubate, with shaking, for 90 min. at room temperature.
16. Wash as in step 14.
17. Add 100 μ l of room temperature ABTS solution to each well.
18. Incubate, with shaking, for 10 to 15 minutes. Remove any bubbles.
19. Stop reaction by adding 20 μ l of 10% SDS to each well.
20. Read results on Dynatech MR7000 ELISA reader with test filter at 410 nM and reference filter at 630 nM.
21. PYK2 Bioassay
This assay is used to measure the in vitro kinase activity of HA epitope-tagged full length pyk2 (FL.pyk2-HA) in an ELISA assay.
22. Materials and reagents:
 1. Corning 96-well Elisa plates.
 2. 12CA5 monoclonal anti-HA antibody (SUGEN, Inc.)
 3. PBS (Dulbecco's Phosphate-Buffered Saline (Gibco Catalog #450-1300EB))
 4. TBST Buffer: for 1 L, mix 8.766 g NaCl, 6.057 g TRIS and 1 ml of 0.1% Triton X-100 in approx. 900 ml dH₂O. Adjust pH to 7.2, bring volume to 1 L.
 5. Blocking Buffer: for 1 L, mix 100 g 10% BSA, 12.1 g 100 mM TRIS, 58.44 g 1M NaCl and 10 mL of 1% TWEEN-20.
 6. FL.pyk2-HA from sf9 cell lysates (SUGEN, Inc.).
 7. 4% DMSO in MilliQue H₂O.
 8. 10 mM ATP in dH₂O.
 9. 1M MnCl₂.
 10. 1M MgCl₂.
 11. 1M Dithiothreitol (DTT).
 12. 10 \times Kinase buffer phosphorylation: mix 5.0 ml 1M Hepes (pH 7.5), 0.2 ml 1M MnCl₂, 1.0 ml 1 M MgCl₂, 1.0 ml 10% Triton X-100 in 2.8 ml dH₂O. Just prior to use, add 0.1 ml 1M DTT.
 13. NUNC 96-well V bottom polypropylene plates.
 14. 500 mM EDTA in dH₂O.
 15. Antibody dilution buffer: for 100 mL, 1 mL 5% BSA/PBS and 1 mL 10% Tween-20 in 88 mL TBS.

222

16. HRP-conjugated anti-Ptyr PY99), Santa Cruz Biotech Cat. No. SC-7020.
17. ABTS, Moss, Cat. No. ABST-2000.
18. 10% SDS.
- Procedure:
 1. Coat Corning 96 well ELISA plates with 0.5 μ g per well 12CA5 anti-HA antibody in 100 μ l PBS. Store overnight at 4° C.
 2. Remove unbound HA antibody from wells by inverting plate. Wash plate with dH₂O. Pat the plate on a paper towel to remove excess liquid.
 3. Add 150 μ l Blocking Buffer to each well. Incubate, with shaking, for 30 min at room temperature.
 4. Wash plate 4 \times with TBS-T.
 5. Dilute lysate in PBS (1.5 μ g lysate/100 μ l PBS).
 6. Add 100 μ l of diluted lysate to each well. Shake at room temperature for 1 hr.
 7. Wash as in step 4.
 8. Add 50 μ l of 2 \times kinase Buffer to ELISA plate containing captured pyk2-HA.
 9. Add 25 μ L of 400 μ M test compound in 4% DMSO to each well. For control wells use 4% DMSO alone.
 10. Add 25 μ L of 0.5 M EDTA to negative control wells.
 11. Add 25 μ l of 20 μ M ATP to all wells. Incubate, with shaking, for 10 minutes.
 12. Stop reaction by adding 25 μ l 500 mM EDTA (pH 8.0) to all wells.
 13. Wash as in step 4.
 14. Add 100 μ L HRP conjugated anti-Ptyr diluted 1:6000 in Antibody Dilution Buffer to each well. Incubate, with shaking, for 1 hr. at room temperature.
 15. Wash plate 3 \times with TBST and 1 \times with PBS.
 16. Add 100 μ L of ABST solution to each well.
 17. If necessary, stop the development reaction by adding 20 μ L 10% SDS to each well.
 18. Read plate on ELISA reader with test filter at 410 nM and reference filter at 630 nM.
- FGFR1 Bioassay
This assay is used to measure the in vitro kinase activity of FGFR1-R in an ELISA assay.
- Materials and Reagents:
 1. Costar 96-well Elisa plates (Corning Catalog #3369).
 2. Poly(Glu-Tyr) (Sigma Catalog #PO275).
 3. PBS (Gibco Catalog #450-1300EB)
 4. 50 mM Hepes Buffer Solution.
 5. Blocking Buffer (5% BSA/PBS).
 6. Purified GST-FGFR1 (SUGEN, Inc.)
 7. Kinase Dilution Buffer.
Mix 500 μ l 1M Hepes (GIBCO), 20 μ l 5% BSA/PBS, 10 μ l 100 mM sodium orthovanadate and 50 μ l 5M NaCl.
 8. 10 mM ATP
 9. ATP/MnCl₂ phosphorylation mix: mix 20 μ L ATP, 400 μ L 1M MnCl₂ and 9.56 ml dH₂O.
 10. NUNC 96-well V bottom polypropylene plates (Applied Scientific Catalog #AS-72092).
 11. 0.5M EDTA
 12. 0.05% TBST
Add 500 μ L TWEEN to 1 liter TBS.
 13. Rabbit polyclonal anti-phosphotyrosine serum (SUGEN, Inc.).

223

14. Goat anti-rabbit IgG peroxidase conjugate (Biosource, Catalog #ALI0404).

15. ABTS Solution.

16. ABTS/H₂O₂ solution.

Procedure:

1. Coat Costar 96 well ELISA plates with 1 μ g per well Poly(Glu,Tyr) in 100 μ l PBS. Store overnight at 4° C.
2. Wash coated plates once with PBS.
3. Add 150 μ L of 5% BSA/PBS Blocking Buffer to each well. Incubate, with shaking, for 1 hr. room temperature.
4. Wash plate 2xwith PBS, then once with 50 mM Hepes. Pat plates on a paper towel to remove excess liquid and bubbles.
5. Add 25 μ L of 0.4 mM test compound in 4% DMSO or 4% DMSO alone (controls) to plate.
6. Dilute purified GST-FGFR1 in Kinase Dilution Buffer (5 ng kinase/50 μ l KDB/well).
7. Add 50 μ L of diluted kinase to each well.
8. Start kinase reaction by adding 25 μ l/well of freshly prepared ATP/Mn⁺⁺ (0.4 ml 1M MnCl₂, 40 μ L 10 mM ATP, 9.56 ml dH₂O), freshly prepared).
9. This is a fast kinase reaction and must be stopped with 25 μ L of 0.5M EDTA in a manner similar to the addition of ATP.
10. Wash plate 4xwith fresh TBST.
11. Make up Antibody Dilution Buffer: Per 50 ml: Mix 5 ml of 5% BSA, 250 μ l of 5% milk and 50 μ l of 100 mM sodium vanadate, bring to final volume with 0.05% TBST.
12. Add 100 μ l per well of anti-phosphotyrosine (1:10000 dilution in ADB). Incubate, with shaking for 1 hr. at room temperature.
13. Wash as in step 10.
14. Add 100 μ l per well of Biosource Goat anti-rabbit IgG peroxidase conjugate (1:6000 dilution in ADB). Incubate, with shaking for 1 hr. at room temperature.
15. Wash as in step 10 and then with PBS to remove bubbles and excess TWEEN.
16. Add 100 μ l of ABTS/H₂O₂ solution to each well.
17. Incubate, with shaking, for 10 to 20 minutes. Remove any bubbles.
18. Read assay on Dynatech MR7000 elisa reader: test filter at 410 nM, reference filtrate 630 nM.

EGFR Bioassay

This assay is used to the in vitro kinase activity of 50 FGFR1 in an ELISA assay.

Materials and Reagents:

1. Corning 96-well Elisa plates.
2. SUMO1 monoclonal anti-EGFR antibody (SUGEN, Inc.).
3. PBS
4. TBST Buffer
5. Blocking Buffer: for 100 ml, mix 5.0 g Carnation Instant Non-fat Milk® with 100 ml of PBS.
6. A431 cell lysate (SUGEN, Inc.).
7. TBS Buffer:
8. TBS+10% DMSO: for 1L, mix 1.514 g TRIS, 2.192 g NaCl and 25 ml DMSO; bring to 1 liter total volume with dH₂O.
9. ATP (Adenosine-5'-triphosphate, from Equine muscle, Sigma Cat. No. A-5394), 1.0 mM solution in dH₂O.

224

This reagent should be made up immediately prior to use and kept on ice.

10. 1.0 mM MnCl₂.
11. ATP/MnCl₂ phosphorylation mix: to make 10 ml, mix 300 μ l of 1 mM ATP, 500 μ l MnCl₂ and 9.2 ml dH₂O. Prepare just prior to use, keep on ice.
12. NUNC 96-well V bottom polypropylene plates.
13. EDTA.
14. Rabbit polyclonal anti-phosphotyrosine serum (SUGEN, Inc.).
15. Goat anti-rabbit IgG peroxidase conjugate (Biosource Cat. No. ALI0404).
16. ABTS.
17. 30% Hydrogen peroxide.
18. ABTS/H₂O₂.
19. 0.2 M HCl.

Procedure:

1. Coat Corning 96 well ELISA plates with 0.5 μ g SUMO1 in 100 μ l PBS per well, store overnight at 4° C.
2. Remove unbound SUMO1 from wells by inverting plate to remove liquid. Wash 1xwith dH₂O. Pat the plate on a paper towel to remove excess liquid.
3. Add 150 μ l of Blocking Buffer to each well. Incubate, with shaking, for 30 min. at room temperature.
4. Wash plate 3xwith deionized water, then once with TBST. Pat plate on a paper towel to remove excess liquid and bubbles.
5. Dilute lysate in PBS (7 μ g lysate/100 μ l PBS).
6. Add 100 μ l of diluted lysate to each well. Shake at room temperature for 1 hr.
7. Wash plates as in 4, above.
8. Add 120 μ l TBS to ELISA plate containing captured EGFR.
9. Dilute test compound 1:10 in TBS, place in well
10. Add 13.5 μ l diluted test compound to ELISA plate. To control wells, add 13.5 μ l TBS in 10% DMSO.
11. Incubate, with shaking, for 30 minutes at room temperature.
12. Add 15 μ l phosphorylation mix to all wells except negative control well. Final well volume should be approximately 150 μ l with 3 μ M ATP/5 mM MnCl₂ final concentration in each well. Incubate with shaking for 5 minutes.
13. Stop reaction by adding 16.5 μ l of EDTA solution while shaking. Shake for additional 1 min.
14. Wash 4xwith deionized water, 2xwith TBST.
15. Add 100 μ l anti-phosphotyrosine (1:3000 dilution in TBST) per well. Incubate, with shaking, for 30–45 min. at room temperature.
16. Wash as in 4, above.
17. Add 100 μ l Biosource Goat anti-rabbit IgG peroxidase conjugate (1:2000 dilution in TBST) to each well. Incubate with shaking for 30 min. at room temperature.
18. Wash as in 4, above.
19. Add 100 μ l of ABTS/H₂O₂ solution to each well.
20. Incubate 5 to 10 minutes with shaking. Remove any bubbles.
21. If necessary, stop reaction by adding 100 μ l 0.2 M HCl per well.
22. Read assay on Dynatech MR7000 ELISA reader: test filter at 410 nM, reference filter at 630 nM.

PDGFR Bioassay
This assay is used to the in vitro kinase activity of FGF1-R in an ELISA assay.

Materials and Reagents:

1. Corning 96-well Elisa plates 5
2. 28D4C10 monoclonal anti-PDGFR antibody (SUGEN, Inc.).
3. PBS.
4. TBST Buffer.
5. Blocking Buffer (same as for EGFR bioassay). 10
6. PDGFR- β expressing NIH 3T3 cell lysate (SUGEN, Inc.).
7. TBS Buffer.
8. TBS+10% DMSO. 15
9. ATP.
10. MnCl₂.
11. Kinase buffer phosphorylation mix: for 10 ml, mix 250 μ l 1M TRIS, 200 μ l 5M NaCl, 100 μ l 1M MnCl₂ 20 and 50 μ l 100 mM Triton X-100 in enough dH₂O to make 10 ml.
12. NUNC 96-well V bottom polypropylene plates.
13. EDTA.
14. Rabbit polyclonal anti-phosphotyrosine serum 25 (SUGEN, Inc.).
15. Goat anti-rabbit IgG peroxidase conjugate (Biosource Cat. No. ALI0404).
16. ABTS.
17. Hydrogen peroxide, 30% solution. 30
18. ABTS/H₂O₂.
19. 0.2 M HCl.

Procedure:

1. Coat Corning 96 well ELISA plates with 0.5 μ g 35 28D4C10 in 100 μ l PBS per well, store overnight at 4° C.
2. Remove unbound 28D4C10 from wells by inverting plate to remove liquid. Wash 1x with dH₂O. Pat the plate on a paper towel to remove excess liquid. 40
3. Add 150 μ l of Blocking Buffer to each well. Incubate for 30 min. at room temperature with shaking.
4. Wash plate 3x with deionized water, then once with TBST. Pat plate on a paper towel to remove excess liquid and bubbles. 45
5. Dilute lysate in HNTG (10 μ g lysate/100 μ l HNTG).
6. Add 100 μ l of diluted lysate to each well. Shake at room temperature for 60 min.
7. Wash plates as described in Step 4. 50
8. Add 80 μ l working kinase buffer mix to ELISA plate containing captured PDGFR.
9. Dilute test compound 1:10 in TBS in 96-well polypropylene plates.
10. Add 10 μ l diluted test compound to ELISA plate. To 55 control wells, add 10 μ l TBS+10% DMSO. Incubate with shaking for 30 minutes at room temperature.
11. Add 10 μ l ATP directly to all wells except negative control well (final well volume should be approximately 100 μ l with 20 μ M ATP in each well.) Incubate 60 30 minutes with shaking.
12. Stop reaction by adding 10 μ l of EDTA solution to each well.
13. Wash 4x with deionized water, twice with TBST.
14. Add 100 μ l anti-phosphotyrosine (1:3000 dilution in 65 TBST) per well. Incubate with shaking for 30-45 min. at room temperature.

15. Wash as in Step 4.

16. Add 100 μ l Biosource Goat anti-rabbit IgG peroxidase conjugate (1:2000 dilution in TBST) to each well. Incubate with shaking for 30 min. at room temperature.
17. Wash as in Step 4.
18. Add 100 μ l of ABTS/H₂O₂ solution to each well.
19. Incubate 10 to 30 minutes with shaking. Remove any bubbles.
20. If necessary stop reaction with the addition of 100 μ l 0.2 M HCl per well.

21. Read assay on Dynatech MR7000 ELISA reader with test filter at 410 nM and reference filter at 630 nM.

Cellular HER-2 Kinase Assay

This assay is used to measure HER-2 kinase activity in whole cells in an ELISA format.

Materials and Reagents:

1. DMEM (GIBCO Catalog #11965-092).
2. Fetal Bovine Serum (FBS, GIBCO Catalog #16000-044), heat inactivated in a water bath for 30 min. at 56° C.
3. Trypsin (GIBCO Catalog #25200-056).
4. L-Glutamine (GIBCO Catalog #25030-081)
5. HEPES (GIBCO Catalog #15630-080).
6. Growth Media
Mix 500 ml DMEM, 55 ml heat inactivated FBS, 10 ml HEPES and 5.5 ml L-Glutamine.
7. Starve Media
Mix 500 ml DMEM, 2.5 ml heat inactivated FBS, 10 ml HEPES and 5.5 ml L-Glutamine.
8. PBS.
9. Flat Bottom 96-well Tissue Culture Micro Titer Plates (Corning Catalog #25860).
10. 15 cm Tissue Culture Dishes (Corning Catalog #08757148).
11. Corning 96-well ELISA Plates.
12. NUNC 96-well V bottom polypropylene plates.
13. Costar Transfer Cartridges for the Transtar 96 (Costar Catalog #7610).
14. SUMO 1: monoclonal anti-EGFR antibody (SUGEN, Inc.).
15. TBST Buffer.
16. Blocking Buffer: 5% Carnation Instant Milk® in PBS.
17. EGF Ligand: EGF-201, Shinko American, Japan.
Suspend powder in 100 μ L of 10 mM HCl. Add 100 μ L 10 mM NaOH. Add 800 μ L PBS and transfer to an Eppendorf tube, store at -20° C. until ready to use.
18. HNTG Lysis Buffer
For Stock 5xHNTG, mix 23.83 g Hepes, 43.83 g NaCl, 500 ml glycerol and 100 ml Triton X-100 and enough dH₂O to make 1 L of total solution.
For 1xHNTG*, mix 2 ml HNTG, 100 μ L 0.1M Na₃VO₄, 250 μ L 0.2M Na₄P₂O₇ and 100 μ L EDTA.
19. EDTA.
20. Na₃VO₄. To make stock solution, mix 1.84 g Na₃VO₄ with 90 ml dH₂O. Adjust pH to 10. Boil in microwave for one minute (solution becomes clear). Cool to room temperature. Adjust pH to 10. Repeat heating/cooling cycle until pH remains at 10.
21. 200 mM Na₄P₂O₇.
22. Rabbit polyclonal antiserum specific for phosphotyrosine (anti-Ptyr antibody, SUGEN, Inc.).
23. Affinity purified antiserum, goat anti-rabbit IgG antibody, peroxidase conjugate (Biosource Cat #ALI0404).

24. ABTS Solution.
25. 30% Hydrogen peroxide solution.
26. ABTS/H₂O₂.
27. 0.2 M HCl.

Procedure:

1. Coat Corning 96 well ELISA plates with SUMO1 at 1.0 ⁵ μ g per well in PBS, 100 μ l final volume/well. Store overnight at 4° C.
2. On day of use, remove coating buffer and wash plate ¹⁰ 3 times with dH₂O and once with TBST buffer. All washes in this assay should be done in this manner, unless otherwise specified.
3. Add 100 μ l of Blocking Buffer to each well. Incubate ¹⁵ plate, with shaking, for 30 min. at room temperature. Just prior to use, wash plate.
4. Use EGFr/HER-2 chimera/3T3-C7 cell line for this assay.
5. Choose dishes having 80–90% confluence. Collect ²⁰ cells by trypsinization and centrifuge at 1000 rpm at room temperature for 5 min.
6. Resuspend cells in starve medium and count with ²⁵ trypan blue. Viability above 90% is required. Seed cells in starve medium at a density of 2,500 cells per well, 90 μ l per well, in a 96 well microtiter plate. Incubate seeded cells overnight at 37° under 5% CO₂.
7. Start the assay two days after seeding.
8. Test compounds are dissolved in 4% DMSO. Samples ³⁰ are then further diluted directly on plates with starve-DMEM. Typically, this dilution will be 1:10 or greater. All wells are then transferred to the cell plate at a further 1:10 dilution (10 μ l sample and media into 90 μ l of starve media. The final DMSO concentration should be 1% or lower. A standard serial dilution may also be ³⁵ used.
9. Incubate under 5% CO₂ at 37° C. for 2 hours.
10. Prepare EGF ligand by diluting stock EGF (16.5 μ M) ⁴⁰ in warm DMEM to 150 nM.
11. Prepare fresh HNTG* sufficient for 100 μ l per well; place on ice.
12. After 2 hour incubation with test compound, add ⁴⁵ prepared EGF ligand to cells, 50 μ l per well, for a final concentration of 50 nM. Positive control wells receive the same amount of EGF. Negative controls do not receive EGF. Incubate at 37° C. for 10 min.
13. Remove test compound, EGF, and DMEM. Wash cells once with PBS.
14. Transfer HNTG* to cells, 100 μ l per well. Place on ice ⁵⁰ for 5 minutes. Meanwhile, remove blocking buffer from ELISA plate and wash.
15. Scrape cells from plate with a micropipettor and homogenize cell material by repeatedly aspirating and dispensing the HNTG* lysis buffer. Transfer lysate to a ⁵⁵ coated, blocked, washed ELISA plate. Or, use a Costar transfer cartridge to transfer lysate to the plate.
16. Incubate, with shaking, at room temperature for 1 hr.
17. Remove lysate, wash. Transfer freshly diluted anti-Ptyr antibody (1:3000 in TBST) to ELISA plate, 100 μ l ⁶⁰ per well.
18. Incubate, with shaking, at room temperature, for 30 min.
19. Remove anti-Ptyr antibody, wash. Transfer freshly ⁶⁵ diluted BIOSOURCE antibody to ELISA plate (1:8000 in TBST, 100 μ l per well).

20. Incubate, with shaking, at room temperature for 30 min.
21. Remove BIOSOURCE antibody, wash. Transfer freshly prepared ABTS/H₂O₂ solution to ELISA plate, 100 μ l per well.

22. Incubate, with shaking, for 5–10 minutes. Remove any bubbles.
23. Stop reaction with the addition of 100 μ l of 0.2M HCl per well.

24. Read assay on Dynatech MR7000 ELISA reader with test filter set at 410 nM and reference filter at 630 nM. CDK2/Cyclin A Assay

This assay is used to measure the in vitro serine/threonine kinase activity of human cdk2/cyclin A in a Scintillation Proximity Assay (SPA).

Materials and Reagents.

1. Wallac 96-well polyethylene terephthalate (flexi) plates (Wallac Catalog #1450-401).
2. Amersham Redivue [γ ³³P] ATP (Amersham catalog #AH 9968).
3. Amersham streptavidin coated polyvinyltoluene SPA beads (Amersham catalog #RPNQ0007). The beads should be reconstituted in PBS without magnesium or calcium, at 20 mg/ml.
4. Activated cdk2/cyclin A enzyme complex purified from SF9 cells (SUGEN, Inc.).
5. Biotinylated peptide substrate (Debtide). Peptide biotin-X-PKTPKKAKKL is dissolved in dH₂O at a concentration of 5 mg/ml.
6. Peptide/ATP Mixture: for 10 ml, mix 9.979 ml dH₂O, 0.00125 ml “cold” ATP, 0.010 ml Debtide and 0.010 ml γ ³³P ATP. The ultimate concentration per well will be 0.5 μ M “cold” ATP, 0.1 μ g Debtide and 0.2 μ Ci γ ³³P ATP.
7. Kinase buffer: for 10 ml, mix 8.85 ml dH₂O, 0.625 ml TRIS(pH 7.4), 0.25 ml 1M MgCl₂, 0.25 ml 10% NP40 and 0.025 ml 1M DTT, added fresh just prior to use.
8. 10 mM ATP in dH₂O.
9. 1M Tris, pH adjusted to 7.4 with HCl.
10. 1M MgCl₂.
11. 1M DTT.
12. PBS (Gibco Catalog #14190-144).
13. 0.5M EDTA.
14. Stop solution: For 10 ml, mix 9.25 ml PBS, 0.005 ml 100 mM ATP, 0.1 ml 0.5 M EDTA, 0.1 ml 10% Triton X-100 and 1.25 ml of 20 mg/ml SPA beads.

Procedure:

1. Prepare solutions of test compounds at 5× the desired final concentration in 5% DMSO. Add 10 μ l to each well. For negative controls, use 10 μ l 5% DMSO alone in wells.
2. Dilute 5 μ l of cdk2/cyclin A solution with 2.1 ml 2×kinase buffer.
3. Add 20 μ l enzyme to each well.
4. Add 10 μ l of 0.5 M EDTA to the negative control wells.
5. To start kinase reaction, add 20 μ l of peptide/ATP mixture to each well. Incubate for 1 hr. without shaking.
6. Add 200 μ l stop solution to each well.
7. Hold at least 10 min.
8. Spin plate at approx. 2300 rpm for 3–5 min.
9. Count plate using Trilux or similar reader.

229

Met Transphosphorylation Assay

This assay is used to measure phosphotyrosine levels on a poly(glutamic acid:tyrosine (4:1)) substrate as a means for identifying agonists/antagonists of met transphosphorylation of the substrate.

Materials and Reagents:

1. Corning 96-well Elisa plates, Corning Catalog #25805-96.
2. Poly(glu, tyr) 4:1, Sigma, Cat. No; P 0275.
3. PBS, Gibco Catalog #450-1300EB
4. 50 mM HEPES
5. Blocking Buffer: Dissolve 25 g Bovine Serum Albumin, Sigma Cat. No A-7888, in 500 ml PBS, filter through a 4 μ m filter.
6. Purified GST fusion protein containing the Met kinase domain, Sugen, Inc.
7. TBST Buffer.
8. 10% aqueous (MilliQue H₂O) DMSO.
9. 10 mM aqueous (dH₂O) Adenosine-5'-triphosphate, Sigma Cat. No. A-5394.
10. 2xKinase Dilution Buffer: for 100 mL, mix 10 mL 1M HEPES at pH 7.5 with 0.4 mL 5% BSA/PBS, 0.2 mL 0.1 M sodium orthovanadate and 1 mL 5M sodium chloride in 88.4 mL dH₂O.
11. 4xATP Reaction Mixture: for 10 mL, mix 0.4 mL 1 M manganese chloride and 0.02 mL 0.1 M ATP in 9.56 mL dH₂O.
12. 4xNegative Controls Mixture: for 10 mL, mix 0.4 mL 1 M manganese chloride in 9.6 mL dH₂O.
13. NUNC 96-well V bottom polypropylene plates, Applied Scientific Catalog #S-72092
14. 500 mM EDTA.
15. Antibody Dilution Buffer: for 100 mL, mix 10 mL 5% BSA/PBS, 0.5 mL 5% Carnation Instant Milk® in PBS and 0.1 mL 0.1 M sodium orthovanadate in 88.4 mL TBST.
16. Rabbit polyclonal antophosphotyrosine antibody, Sugen, Inc.
17. Goat anti-rabbit horseradish peroxidase conjugated antibody, Biosource, Inc.
18. ABTS Solution: for 1 L, mix 19.21 g citric acid, 35.49 g Na₂HPO₄ and 500 mg ABTS with sufficient dH₂O to make 1 L.
19. ABTS/H₂O: mix 15 mL ABST solution with 2 μ L H₂O₂ five minutes before use.
20. 0.2 M HCl

Procedure:

1. Coat ELISA plates with 2 μ g Poly(Glu-Tyr) in 100 μ L PBS, store overnight at 4° C.
2. Block plate with 150 μ L of 5% BSA/PBS for 60 min.
3. Wash plate twice with PBS, once with 50 mM Hepes buffer pH 7.4.
4. Add 50 μ L of the diluted kinase to all wells. (Purified kinase is diluted with Kinase Dilution Buffer. Final concentration should be 10 ng/well.)
5. Add 25 μ L of the test compound (in 4% DMSO) or DMSO alone (4% in dH₂O) for controls to plate.
6. Incubate the kinase/compound mixture for 15 minutes.
7. Add 25 μ L of 40 mM MnCl₂ to the negative control wells.
8. Add 25 μ L ATP/MnCl₂ mixture to the all other wells (except the negative controls). Incubate for 5 min.

230

9. Add 25 μ L 500 mM EDTA to stop reaction.

10. Wash plate 3xwith TBST.
11. Add 100 μ L rabbit polyclonal anti-Ptyr diluted 1:10, 000 in Antibody Dilution Buffer to each well. Incubate, with shaking, at room temperature for one hour.
12. Wash plate 3xwith TBST.
13. Dilute Biosource HRP conjugated anti-rabbit antibody 1:6,000 in Antibody Dilution buffer. Add 100 μ L per well and incubate at room temperature, with shaking, for one hour.
14. Wash plate 1xwith PBS.
15. Add 100 μ L of ABTS/H₂O₂ solution to each well.
16. If necessary, stop the development reaction with the addition of 100 μ L of 0.2M HCl per well.
17. Read plate on Dynatech MR7000 elisa reader with the test filter at 410 nM and the reference filter at 630 nM.

IGF-1 Transphosphorylation Assay

This assay is used to measure the phosphotyrosine level in poly(glutamic acid:tyrosine)(4:1) for the identification of agonists/antagonists of gsf-IGF-1 transphosphorylation of a substrate.

Materials and Reagents:

1. Corning 96-well Elisa plates.
2. Poly (Glu-tyr) (4:1), Sigma Cat. No. P 0275.
3. PBS, Gibco Catalog #450-1300EB.
4. 50 mM HEPES
5. TBB Blocking Buffer: for 1 L, mix 100 g BSA, 12.1 gTRIS (pH 7.5), 58.44 g sodium chloride and 10 mL 1% TWEEN-20.
6. Purified GST fusion protein containing the IGF-1 kinase domain (Sugen, Inc.)
7. TBST Buffer: for 1 L, mix 6.057 g Tris, 8.766 g sodium chloride and 0.5 ml TWEEN-20 with enough dH₂O to make 1 liter.
8. 4% DMSO in Milli-Q H₂O.
9. 10 mM ATP in dH₂O.
10. 2xKinase Dilution Buffer: for 100 mL, mix 10 mL 1 M HEPES (pH 7.5), 0.4 mL 5% BSA in dH₂O, 0.2 mL 0.1 M sodium orthovanadate and 1 mL 5 M sodium chloride with enough dH₂O to make 100 mL.
11. 4xATP Reaction Mixture: for 10 mL, mix 0.4 mL 1 M MnCl₂ and 0.008 mL 0.01 M ATP and 9.56 mL dH₂O.
12. 4xNegative Controls Mixture: mix 0.4 mL 1 M manganese chloride in 9.60 mL dH₂O.
13. NUNC 96-well V bottom polypropylene plates.
14. 500 mM EDTA in dH₂O.
15. Antibody Dilution Buffer: for 100 mL, mix 10 mL 5% BSA in PBS, 0.5 mL 5% Carnation Instant Non-fat Milk® in PBS and 0.1 mL 0.1 M sodium orthovanadate in 88.4 mL TBST.
16. Rabbit Polyclonal antiphosphotyrosine antibody, Sugen, Inc.
17. Goat anti-rabbit HRP conjugated antibody, Biosource.
18. ABTS Solution.
19. ABTS/H₂O: mix 15 mL ABTS with 2 μ L H₂O₂ 5 minutes before using.
20. 0.2 M HCl in dH₂O.

Procedure:

1. Coat ELISA plate with 2.0 μ g/well Poly(Glu, Tyr) 4:1 (Sigma P0275) in 100 μ L PBS. Store plate overnight at 4° C.
2. ash plate once with PBS.

231

3. Add 100 μ l of TBB Blocking Buffer to each well. Incubate plate for 1 hour with shaking at room temperature.
4. Wash plate once with PBS, then twice with 50 mM Hepes buffer pH 7.5.
5. Add 25 μ L of test compound in 4% DMSO (obtained by diluting a stock solution of 10 mM test compound in 100% DMSO with dH₂O) to plate.
6. Add 10.0 ng of gsf-IGF-1 kinase in 50 μ l Kinase Dilution Buffer) to all wells.
7. Start kinase reaction by adding 25 μ l 4xATP Reaction Mixture to all test wells and positive control wells. Add 25 μ l 4xNegative Controls Mixture to all negative control wells. Incubates for 10 minutes with shaking at room temperature.
8. Add 25 μ l 0.5M EDTA (pH 8.0) to all wells.
9. Wash plate 4xwith TBST Buffer.
10. Add rabbit polyclonal anti-phosphotyrosine antisera at a dilution of 1:10,000 in 100 μ l Antibody Dilution Buffer to all wells. Incubate, with shaking, at room temperature for 1 hour.
11. Wash plate as in step 9.
12. Add 100 μ L Biosource anti-rabbit HRP at a dilution of 1:10,000 in Antibody dilution buffer to all wells. Incubate, with shaking, at room temperature for 1 hour.
13. Wash plate as in step 9, follow with one wash with PBS to reduce bubbles and excess Tween-20.
14. Develop by adding 100 μ l/well ABTS/H₂O₂ to each well.
15. After about 5 minutes, read on ELISA reader with test filter at 410 nm and referenced filter at 630 nm.

BRDU Incorporation Assays

The following assays use cells engineered to express a selected receptor and then evaluate the effect of a compound of interest on the activity of ligand-induced DNA synthesis by determining BrdU incorporation into the DNA.

The following materials, reagents and procedure are general to each of the following BrdU incorporation assays.

Variances in specific assays are noted.

Materials and Reagents:

1. The appropriate ligand.
2. The appropriate engineered cells.
3. BrdU Labeling Reagent: 10 mM, in PBS (pH 7.4) (Boehringer Mannheim, Germany).
4. FixDenat: fixation solution (ready to use)(Boehringer Mannheim, Germany).
5. Anti-BrdU-POD: mouse monoclonal antibody conjugated with peroxidase (Boehringer Mannheim, Germany).
6. TMB Substrate Solution: tetramethylbenzidine (TMB, Boehringer Mannheim, Germany).
7. PBS Washing Solution: 1xPBS, pH 7.4.
8. Albumin, Bovine (BSA), fraction V powder (Sigma Chemical Co., USA).

General Procedure:

1. Cells are seeded at 8000 cells/well in 10% CS, 2 mM Gln in DMEM, in a 96 well plate. Cells are incubated overnight at 37° C. in 5% CO₂.
2. After 24 hours, the cells are washed with PBS, and then are serum-starved in serum free medium (0% CS DMEM with 0.1% BSA) for 24 hours.
3. On day 3, the appropriate ligand and the test compound are added to the cells simultaneously. The negative

232

control wells receive serum free DMEM with 0.1% BSA only; the positive control cells receive the ligand but no test compound. Test compounds are prepared in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.

4. After 18 hours of ligand activation, diluted BrdU labeling reagent (1:100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration=10 μ M) for 1.5 hours.
5. After incubation with labeling reagent, the medium is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added (50 μ l/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.
6. The FixDenat solution is thoroughly removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 μ l/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on a plate shaker.
7. The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:200 dilution in PBS, 1% BSA) is added (50 μ l/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.
8. The antibody conjugate is thoroughly removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on a paper towel.
9. TMB substrate solution is added (100 μ l/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.
10. The absorbance of the samples are measured at 410 nm (in "dual wavelength" mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

EGF-Induced BrdU Incorporation Assay

Materials and Reagents:

1. Mouse EGF, 201 (Toyobo Co., Ltd., Japan).
2. 3T3/EGFRc7.

EGF-Induced Her-2-driven BrdU Incorporation Assay

Materials and Reagents:

1. Mouse EGF, 201 (Toyobo Co., Ltd., Japan).
2. 3T3/EGFr/Her2/EGFr (EGFr with a Her-2 kinase domain).

EGF-Induced Her-4-Driven BrdU Incorporation Assay

Materials and Reagents:

1. Mouse EGF, 201 (Toyobo Co., Ltd., Japan).
2. 3T3/EGFr/Her4/EGFr (EGFr with a Her-4 kinase domain).

PDGF-Induced BrdU Incorporation Assay

Materials and Reagents:

1. Human PDGF B/B (Boehringer Mannheim, Germany).
2. 3T3/EGFRc7.

FGF-Induced BrdU Incorporation Assay

Materials and Reagents:

1. Human FGF2/bFGF (Gibco BRL, USA).
2. 3T3c7/EGFr

IGF1-Induced BrdU Incorporation Assay

Materials and Reagents:

1. Human, recombinant (G511, Promega Corp., USA)
2. 3T3/IGF1r.

233

Insulin-Induced BrdU Incorporation Assay
Materials and Reagents:

1. Insulin, crystalline, bovine, Zinc (13007, Gibco BRL, USA).

5
2. 3T3/H25.

HGF-Induced BrdU Incorporation Assay

Materials and Reagents:

1. Recombinant human HGF (Cat. No. 249-HG, R&D Systems, Inc. USA).

10
2. BxPC-3 cells (ATCC CRL-1687).

Procedure:

1. Cells are seeded at 9000 cells/well in RPMI 10% FBS in a 96 well plate. Cells are incubated overnight at 37° C. in 5% CO₂.
2. After 24 hours, the cells are washed with PBS, and then are serum starved in 100 μ l serum-free medium (RPMI with 0.1% BSA) for 24 hours.
3. On day 3, 25 μ l containing ligand (prepared at 1 μ g/ml in RPMI with 0.1% BSA; final HGF conc. is 200 ng/ml) and test compounds are added to the cells. The negative control wells receive 25 μ l serum-free RPMI with 0.1% BSA only; the positive control cells receive the ligand (HGF) but no test compound. Test compounds are prepared at 5 times their final concentration in serum-free RPMI with ligand in a 96 well plate, and serially diluted to give 7 test concentrations. Typically, the highest final concentration of test compound is 100 μ M, and 1:3 dilutions are used (i.e. final test compound concentration range is 0.137–100 μ M).
4. After 18 hours of ligand activation, 12.5 μ l of diluted BrdU labeling reagent (1:100 in RPMI, 0.1% BSA) is added to each well and the cells are incubated with BrdU (final concentration is 10 μ M) for 1 hour.

35
5. Same as General Procedure.

6. Same as General Procedure.

7. The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1:100 dilution in PBS, 1% BSA) is added (100 μ l/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.

8. Same as General Procedure.

9. Same as General Procedure.

45
10. Same as General Procedure.

HTV-EC—C Assay

This assay is used to measure a compound's activity against PDGF-R, FGF-R, VEGF, aFGF or Flk-1/KDR, all of which are naturally expressed by HUV-EC cells.

50
Day 0

1. Wash and trypsinize HUV-EC—C cells (human umbilical vein endothelial cells, (American Type Culture Collection, catalogue no. 1730 CRL). Wash with Dulbecco's phosphate-buffered saline (D-PBS, obtained from Gibco BRL, catalogue no. 14190-029) 2 times at about 1 ml/10 cm² of tissue culture flask. Trypsinize with 0.05% trypsin-EDTA in non-enzymatic cell dissociation solution (Sigma Chemical Company, catalogue no. C-1544). The 0.05% trypsin is made by diluting 0.25% trypsin/1 mM EDTA (Gibco, catalogue no. 25200-049) in the cell dissociation solution. Trypsinize with about 1 ml/25–30 cm² of tissue culture flask for about 5 minutes at 37° C. After cells have detached from the flask, add an equal volume of assay medium and transfer to a 50 ml sterile centrifuge tube (Fisher Scientific, catalogue no. 05-539-6).

234

2. Wash the cells with about 35 ml assay medium in the 50 ml sterile centrifuge tube by adding the assay medium, centrifuge for 10 minutes at approximately 200xg, aspirate the supernatant, and resuspend with 35 ml D-PBS. Repeat the wash two more times with D-PBS, resuspend the cells in about 1 ml assay medium/15 cm² of tissue culture flask. Assay medium consists of F12K medium (Gibco BRL, catalogue no. 21127-014) and 0.5% heat-inactivated fetal bovine serum. Count the cells with a Coulter Counter® (Coulter Electronics, Inc.) and add assay medium to the cells to obtain a concentration of 0.8–1.0 $\times 10^5$ cells/ml.
3. Add cells to 96-well flat-bottom plates at 100 μ l/well or 0.8–1.0 $\times 10^4$ cells/well, incubate ~24 h at 37° C., 5% CO₂.

15
Day 1

1. Make up two-fold test compound titrations in separate 96-well plates, generally 50 μ M on down to 0 μ M. Use the same assay medium as mentioned in day 0, step 2 above. Titrations are made by adding 90 μ l/well of test compound at 200 μ M (4 \times the final well concentration) to the top well of a particular plate column. Since the stock test compound is usually 20 mM in DMSO, the 200 μ M drug concentration contains 2% DMSO.

A diluent made up to 2% DMSO in assay medium (F12K+0.5% fetal bovine serum) is used as diluent for the test compound titrations in order to dilute the test compound but keep the DMSO concentration constant. Add this diluent to the remaining wells in the column at 60 μ l/well. Take 60 μ l from the 120 μ l of 200 μ M test compound dilution in the top well of the column and mix with the 60 μ l in the second well of the column. Take 60 μ l from this well and mix with the 60 μ l in the third well of the column, and so on until two-fold titrations are completed. When the next-to-the-last well is mixed, take 60 μ l of the 120 μ l in this well and discard it. Leave the last well with 60 μ l of DMSO/media diluent as a non-test compound-containing control. Make 9 columns of titrated test compound, enough for triplicate wells each for:

- (1) VEGF (obtained from Pepro Tech Inc., catalogue no. 100-200, (2) endothelial cell growth factor (ECGF) (also known as acidic fibroblast growth factor, or aFGF) (obtained from Boehringer Mannheim Biochemica, catalogue no. 1439 600), or, (3) human PDGF B/B (1276-956, Boehringer Mannheim, Germany) and assay media control. ECGF comes as a preparation with sodium heparin.

2. Transfer 50 μ l/well of the test compound dilutions to the 96-well assay plates containing the 0.8–1.0 $\times 10^4$ cells/100 μ l/well of the HUV-EC—C cells from day 0 and incubate ~2 h at 37° C., 5% CO₂.

3. In triplicate, add 50 μ l/well of 80 μ g/ml VEGF, 20 ng/ml ECGF, or media control to each test compound condition. As with the test compounds, the growth factor concentrations are 4 \times the desired final concentration. Use the assay media from day 0 step 2 to make the concentrations of growth factors. Incubate approximately 24 hours at 37° C., 5% CO₂. Each well will have 50 μ l test compound dilution, 50 μ l growth factor or media, and 100 μ l cells, which calculates to 200 μ l/well total. Thus the 4 \times concentrations of test compound and growth factors become 1 \times once everything has been added to the wells.

Day 2

1. Add ³H-thymidine (Amersham, catalogue no. TRK-686) at 1 μ Ci/well (10 μ l/well of 100 μ Ci/ml solution made up in RPMI media+10% heat-inactivated fetal bovine serum) and incubate ~24 h at 37° C., 5% CO₂. RPMI is obtained from Gibco BRL, catalogue no. 11875-051.

Day 3

1. Freeze plates overnight at -20° C.

Day 4

Thaw plates and harvest with a 96-well plate harvester (Tomtec Harvester 96®) onto filter mats (Wallac, catalogue no. 1205-401), read counts on a Wallac Betaplate™ liquid scintillation counter.

TABLE 3 shows the results of biological testing of some exemplary compounds of this invention. The results are

reported in terms of IC_{50} , the micromolar (μM) concentration of the compound being tested which causes a 50% change in the activity of the target PTK compared to the activity of the PTK in a control to which no test compound has been added. Specifically, the results shown indicate the concentration of a test compound needed to cause a 50% reduction of the activity of the target PTK. Bioassays which have been or can be used to evaluate compounds are described in detail below.

TABLE 3

Example	bio flkGST IC50 (μM)	bio PGFR1 IC50 (μM)	bio PDGF IC50 (μM)	bio EGF IC50 (μM)	cell EGF IC50 (μM)	Her2 Kinase IC50 (μM)	cdk2spa C50 (μM)	bio pylk2 IC50 (μM)
1	57.68	15.16	>100	>100	>100			>100
2	>100		>100	>100	>100			
3	9.85	9.62	>100	>100	>100			
4	3.57	>20	>100	>100	>100	>100		
5	8.3	16.06	>100	>100	>100	>100		
6	4.04		>100	3.26	7.82	2.43		
7	7.74		>100	5.07	9.8	4.24		
8	12.1		>100	51.34	20.08	5.5		
9	0.96		>100	>100	>100	16.38		
10	5.72		>100	94.04	15.86	8.06		
11	9.77		>100	>100	>100	>100		
12	>20		21.46	>100		27.73		
13	>20		81.92	8.17		2.66		
14	13.01			42.41	>100		66.02	
15	>20			>100	>100		98.61	
16	>20			98.06	>100		23.32	
17	8.25	2.47	94.35	0.83	11.47	15.94	>10	
18	2.67				2.57	9.23	4.99	
19	7.5				6.86	34.18	8.37	
20	11.53				>100	41.16	8	
21	7.18				40.34		27.69	
22	>20				>100		87.67	
23	>20				>100		4.05	
24					>100		5.31	
25	12.55				>100		7.9	
26	16.03				66.87	34.67	10.04	
27					>100		3.91	
28	4.5				71.27	53.66	2.67	
29	10.12				>100	26.72	3.98	
30	9.4				>100	18.69	4.1	
31	>50				>100	9.83	47.19	
32	45.74				5.94	>100		>100
34	>50				>100	>100		
35	>20				>100	80.4		54.14
36	>20				>100	>100		
37	0.22				3.06	10.78	9.84	1.4
38	4.17				3.06	6.04	8.97	2.16
39	3.38				4.69	3.67	14.54	3.53
40	4.5				7.9	6.52		6.27
42	0.1				0.12	11.95	74.55	20.43
43	1.12				8.38	>100	37.33	53.37
44	<0.05				0.02	20.73	67.46	6.99
45	1.71				>100	>100		>100
46	30.62				6.18	>100	>100	
47	0.08	1.56			0.06	11.42	41.54	8.4
48	0.006	0.3			<0.78	17.88	21.58	7.93
49					<0.78	>100	43.86	>100
50					<0.78	>100	20.34	>100
51	0.006	1.66			0.01	18.1	21.61	23.24
52	0.08	1.26			<0.78	12.53	>100	>100
53					<0.78	>100	>100	
54	1.98				<0.78	23.88	9.76	7.02
55	0.27				0.53	6.03	35.99	77.82
56	2.32				3.19	>100	10.03	7.11
57	0.06				7.98	>100	9.97	6.94
58						21.14	>100	>100
59						<0.78	>100	>100
60						<0.78	>100	>100
61						<0.78	>100	>100
62	8.00					8.32	>100	>100
63	0.21					<0.78	8.59	>100

TABLE 3-continued

Example	bio flkGST IC50 (μM)	bio PGFR1 IC50 (μM)	bio PDGF IC50 (μM)	bio EGF IC50 (μM)	cell EGF IC50 (μM)	Her2 Kinase IC50 (μM)	cdk2spa CS0 (μM)	bio pyk2 IC50 (μM)
64	0.55		<0.78	30.49	>100	>100		
65	0.37		<0.05	>100	74.36	15.97		
66	<0.05			>100	11.84	2.76		
67	0.39		24.77	31.38	19.79	2.56		
68	1.16		0.03	>100	23.52	34.13		
69	0.3		56.55	>100	97.54	>100		
70	0.09	1.50	0.0030	10.57	6.42	7.99	12.62	0.63
71	15.21		22.5	>100		9.91		
72	6.06		10.54	>100	39.94	9.65		
73	5.95		14.12	>100	39.5	8.59		
74	1.2		0.09	46.75		>100		
75	2.7		61.55	>100		>100		
76	3.33		19.18	5.11		3.01		
77	0.49		25.01	>100		>100		
78	1.94		70.62	9.33		4.25		
79	1.49		>100	27.39		>100		
80	0.13	4.29	0.001	>100		50.19	17.19	0.28
81	0.21		0.18	>100		>100		
82	2.03	7.69	6.88	>100		>100		0.31
83	0.34	0.41	9.46	2.18		86.9	0.008	
84	1.38		12.51	67.2		5.86	0.006	
85	0.2	0.8	2.59	>100		3.76		
86	1.45	1.3	19.6	41.8		>100		3.58
87	3.27	7.56	6.46	>100		9.1	0.17	
88	0.35	1.18	8.06	2.36		>100	0.09	
89	7.84		47.58	8.53	9.67	15.97		
115	7.3		7.48	>100		>100	0.006	
116	>20		>100	>100		>100	<0.0005	
117	0.91		12.9	>100		>100	0.006	
118	1.93		1.2	>100		>100	0.002	
119	1.38		61.63	>100		>100	<0.0005	

In vivo Animal Models

Xenograft Animal Models

The ability of human tumors to grow as xenografts in athymic mice (e.g., Balb/c, nu/nu) provides a useful in vivo model for studying the biological response to therapies for human tumors. Since the first successful xenotransplantation of human tumors into athymic mice, (Rygaard and Poulsen, 1969, *Acta Pathol. Microbiol. Scand.* 77:758-760), many different human tumor cell lines (e.g., mammary, lung, genitourinary, gastro-intestinal, head and neck, glioblastoma, bone, and malignant melanomas) have been transplanted and successfully grown in nude mice. The following assays may be used to determine the level of activity, specificity and effect of the different compounds of the present invention. Three general types of assays are useful for evaluating compounds: cellular/catalytic, cellular/biological and in vivo. The object of the cellular/catalytic assays is to determine the effect of a compound on the ability of a TK to phosphorylate tyrosines on a known substrate in a cell. The object of the cellular/biological assays is to determine the effect of a compound on the biological response stimulated by a TK in a cell. The object of the in vivo assays is to determine the effect of a compound in an animal model of a particular disorder such as cancer.

Suitable cell lines for subcutaneous xenograft experiments include C6 cells (glioma, ATCC #CCL 107), A375 cells (melanoma, ATCC #CRL 1619), A431 cells (epidermoid carcinoma, ATCC #CRL 1555), Calu 6 cells (lung, ATCC #HTB 56), PC3 cells (prostate, ATCC #CRL 1435), SKOV3TP5 cells and NIH 3T3 fibroblasts genetically engineered to overexpress EGFR, PDGFR, IGF-1R or any other test kinase. The following protocol can be used to perform xenograft experiments:

Female athymic mice (BALB/c, nu/nu) are obtained from Simonsen Laboratories (Gilroy, Calif.). All animals are

35 maintained under clean-room conditions in Micro-isolator cages with Alpha-dri bedding. They receive sterile rodent chow and water ad libitum.

Cell lines are grown in appropriate medium (for example, MEM, DMEM, Ham's F10, or Ham's F12 plus 5%-10% fetal bovine serum (FBS) and 2 mM glutamine (GLN)). All 40 cell culture media, glutamine, and fetal bovine serum are purchased from Gibco Life Technologies (Grand Island, N.Y.) unless otherwise specified. All cells are grown in a humid atmosphere of 90-95% air and 5-10% CO₂ at 37° C. All cell lines are routinely subcultured twice a week and are negative for mycoplasma as determined by the Mycotect method (Gibco).

Cells are harvested at or near confluence with 0.05% Trypsin-EDTA and pelleted at 450×g for 10 min. Pellets are resuspended in sterile PBS or media (without FBS) to a 50 particular concentration and the cells are implanted into the hindflank of the mice (8-10 mice per group, 2-10×10⁶ cells/animal). Tumor growth is measured over 3 to 6 weeks using vernier calipers. Tumor volumes are calculated as a product of length×width×height unless otherwise indicated.

55 P values are calculated using the Students t-test. Test compounds in 50-100 μL excipient (DMSO, or VPD:D5W) can be delivered by IP injection at different concentrations generally starting at day one after implantation.

Tumor Invasion Model

60 The following tumor invasion model has been developed and may be used for the evaluation of therapeutic value and efficacy of the compounds identified to selectively inhibit KDR/FLK-1 receptor.

Procedure

65 8 week old nude mice (female) (Simonsen Inc.) are used as experimental animals. Implantation of tumor cells can be performed in a laminar flow hood. For anesthesia, Xylazine/

239

Ketamine Cocktail (100 mg/kg ketamine and 5 mg/kg Xylazine) are administered intraperitoneally. A midline incision is done to expose the abdominal cavity (approximately 1.5 cm in length) to inject 10^7 tumor cells in a volume of 100 μ l medium. The cells are injected either into the duodenal lobe of the pancreas or under the serosa of the colon. The peritoneum and muscles are closed with a 6-0 silk continuous suture and the skin is closed by using wound clips. Animals are observed daily.

Analysis

After 2-6 weeks, depending on gross observations of the animals, the mice are sacrificed, and the local tumor metastases to various organs (lung, liver, brain, stomach, spleen, heart, muscle) are excised and analyzed (measurement of tumor size, grade of invasion, immunochemistry, *in situ* hybridization determination, etc.).

C-Kit Assay

This assay is used to detect the level of c-kit tyrosine phosphorylation.

MO7E (human acute myeloid leukemia) cells were serum starved overnight in 0.1% serum. Cells were pre-treated with the compound (concurrent with serum starvation), prior to ligand stimulation. Cells were stimulated with 250 ng/ml rh-SCF for 15 minutes. Following stimulation, cells were lysed and immunoprecipitated with an anti-c-kit antibody. Phosphotyrosine and protein levels were determined by Western blotting.

MTT Proliferation Assay

MO7E cells were serum starved and pre-treated with compound as described for the phosphorylation experiments. Cells were plated @4 \times 10⁵ cells/well in a 96 well dish, in 100 μ l RPMI+10% serum. rh-SCF (100 ng/mL) was added and the plate was incubated for 48 hours. After 48 hours, 10 μ l of 5 mg/ml MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] was added and allowed to incubate for 4 hours. Acid isopropanol (100 μ l of 0.04N HCl in isopropanol) was added and the optical density was measured at a wavelength of 550 nm.

Apoptosis Assay

MO7E cells were incubated +/- SCF and +/- compound in 10% FBS with rh-GM-CSF (10 ng/mL) and rh-IL-3 (10 ng/mL). Samples were assayed at 24 and 48 hours. To measure activated caspase-3, samples were washed with PBS and permeabilized with ice-cold 70% ethanol. The cells were then stained with PE-conjugated polyclonal rabbit anti-active caspase-3 and analyzed by FACS. To measure cleaved PARP, samples were lysed and analyzed by western blotting with an anti-PARP antibody.

Additional Assays

Additional assays which may be used to evaluate the compounds of this invention include, without limitation, a bio-flk-1 assay, an EGF receptor-HER2 chimeric receptor assay in whole cells, a bio-src assay, a bio-lck assay and an assay measuring the phosphorylation function of raf. The protocols for each of these assays may be found in U.S. application Ser. No. 09/099,842, which is incorporated by reference, including any drawings, herein.

Measurement of Cell Toxicity

Therapeutic compounds should be more potent in inhibiting receptor tyrosine kinase activity than in exerting a cytotoxic effect. A measure of the effectiveness and cell toxicity of a compound can be obtained by determining the therapeutic index, i.e., IC_{50}/LD_{50} . IC_{50} , the dose required to achieve 50% inhibition, can be measured using standard techniques such as those described herein. LD_{50} , the dosage which results in 50% toxicity, can also be measured by standard techniques as well (Mossman, 1983, *J. Immunol.*

240

Methods, 65:55-63), by measuring the amount of LDH released (Korzeniewski and Callewaert, 1983, *J. Immunol. Methods*, 64:313, Decker and Lohmann-Matthes, 1988, *J. Immunol. Methods*, 115:61), or by measuring the lethal dose in animal models. Compounds with a large therapeutic index are preferred. The therapeutic index should be greater than 2, preferably at least 10, more preferably at least 50.

B. Example of Cellular Assay Results Using 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-diethylamino-ethyl)amide.

To confirm the potency of 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) detected in biochemical assays (vide infra), the ability of said compound to inhibit ligand-dependent RTK phosphorylation was evaluated in cell-based assays using NIH-3T3 mouse cells engineered to overexpress Flk-1 or human PDGFR β . 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) inhibited VEGF-dependent Flk-1 tyrosine phosphorylation with an IC_{50} value of approximately 0.03 μ M. This value is similar to the 0.009 μ M K_i value determined for inhibition of Flk-1 by 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) determined in biochemical assays. This indicates that 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) readily penetrates into cells. Consistent with the biochemical data (vide infra) indicating that 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) had comparable activity against Flk-1 and PDGFR β , it was also found that it inhibited PDGF-dependent receptor phosphorylation in cells with an IC_{50} value of approximately 0.03 μ M. The ability of 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) to inhibit c-kit, a closely related RTK that binds stem cell factor (SCF), was determined using MO7E cells that express this receptor. In these cells, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) inhibited SCF-dependent c-kit phosphorylation with an IC_{50} value of 0.01-0.1 μ M. This compound also inhibited SCF-stimulated c-kit phosphorylation in acute myeloid leukemia (AML) blasts isolated from the peripheral blood of patients.

In addition to testing the ability of 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) to inhibit ligand-dependent receptor phosphorylation in cells, its effect on ligand-dependent proliferative response of cells was also examined *in vitro* (see Table 4). In these studies, cells quiesced by overnight serum starvation were induced to undergo DNA synthesis upon addition of the appropriate mitogenic ligand. As shown in Table 4, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) inhibited the PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFR β or PDGFR α with IC_{50} values 0.031 and 0.069 μ M, respectively, and the SCF-induced proliferation of MO7E cells with an IC_{50} value of 0.007 μ M.

TABLE 4

Receptor	Cellular IC ₅₀		
	Biochemical K _i ¹ (μM)	Receptor Phosphorylation (μM)	Ligand-dependent Proliferation (μM)
Flk-1/KDR	0.009	0.03 ²	0.004 ³
PDGFRα	0.008	0.03 ⁴	0.031 ⁴
PDGFRβ	ND	ND	0.069 ⁵
FGFR	0.83	ND	0.7 ³
c-kit	ND	0.01-0.1 ⁶	0.007 ⁶

ND = Not Determined

¹Determined using recombinant enzyme²Determined using serum-starved NIH-3T3 cells expressing Flk-1³Determined using serum-starved HUVECs⁴Determined using serum-starved NIH-3T3 cells expressing PDGFRα⁵Determined using serum-starved NIH-3T3 cells expressing PDGFRβ⁶Determined using serum-starved MO7E cells

As shown in Table 4, there is a general agreement between the biochemical and cellular activities of 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) supporting the conclusion that this compound crosses cellular membranes. Further, it can be concluded that the cellular responses are a result of the activity of compound 80 against the indicated target. In contrast, when tested in the presence of complete growth medium in vitro, substantially higher concentrations of 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) (>10 μM) were required to inhibit the growth of a variety of human tumor cells (see Table 5). This indicates that the compound did not directly inhibit the growth of these cells at concentrations required to inhibit ligand-dependent receptor phosphorylation and cell proliferation.

TABLE 5

Cell Line	Origin	IC ₅₀ (μM)	LD ₅₀ (μM)
HT29	Colon carcinoma	10	22
A549	Lung carcinoma	9.5	22
NCI-H460	NSC lung carcinoma	8.9	20
SF767T	Glioma	7.9	14
A431	Epidermoid carcinoma	6.0	18

Briefly, the results shown in Table 5 were obtained by incubating cells for 48 hr in complete growth medium in the presence of serial dilutions 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide. At the end of the growth period, the relative number of cells was determined. IC₅₀ values were calculated as the concentration of compound that inhibited the growth of cells by 50% relative to untreated cells. LD₅₀ values were calculated as the concentration of compound that caused a 50% reduction in the number of cells relative to those at the start of the experiment.

A more relevant cell-based assay in which to evaluate the anti-angiogenic potential of 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) is the in vitro mitogenesis assay using human umbilical vein endothelial cells (HUVECs) as a model system for the

endothelial cell proliferation critical to the angiogenic process. In this assay, a mitogenic response, measured as an increase in DNA synthesis, is induced in serum-starved HUVECs upon addition of VEGF or FGF. In these cells, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) inhibited the VEGF- and FGF-induced mitogenic response in a dose-dependent manner with IC₅₀ values of 0.004 μM and 0.7 μM, respectively, when compound was present throughout the 48-hr assay.

Briefly, the aforementioned results were obtained using Serum-starved HUVECs that were incubated with mitogenic concentrations of VEGF (100 ng/ml) or FGF (30 ng/ml) in the presence of serial dilutions of 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) for 24 hrs. The mitogenic response during the following 24 hrs. in the presence of ligand and inhibitor was quantitated by measurement of DNA synthesis based on incorporation of bromodeoxyuridine into cellular DNA.

In separate experiments, compound 80 inhibited the VEGF-dependent phosphorylation of ERK ½ (p42/44MAP kinase), an early downstream target of Flk-1/KDR, in a dose-dependent manner. The inhibitory activity of compound 80 was also shown to be long-lasting in this system; inhibiting VEGF-dependent phosphorylation of ERK ½ for as long as 48 hours after removal of 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) from the medium following a short (2 hr) exposure to micromolar concentrations of the compound.

VEGF has been recognized to be an important survival factor for endothelial cells. Since 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) inhibits the VEGF-dependent mitogenic response of HUVECs, the effect of the compound on HUVEC survival was investigated. In these experiments, cleavage of the caspase 3 substrate poly-ADP-ribosyl polymerase (PARP) was used as a readout for apoptosis. HUVECs cultured in serum-free conditions for 24 hours exhibited substantial levels of PARP cleavage, as detected by the accumulation of the 23 kDa PARP cleavage fragment. This was largely prevented by the addition of VEGF to the cell medium, indicating that VEGF acts as a survival factor in this assay. 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) has been shown to inhibit KDR signaling. Accordingly, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) inhibited VEGF-mediated HUVEC survival in a dose-dependent manner. Thus, these data indicate that compound 80 induced apoptosis in endothelial cells in culture in the presence of VEGF.

C. In vivo Efficacy Studies

i. Efficacy Against Established Tumor Xenografts

The in vivo efficacy of 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) was studied in subcutaneous (SC) xenograft models using human tumor cells implanted into the hindflank region of athymic mice. Following implantation, tumors were allowed to become established to a size of 100-550 mm³ prior to starting oral treatment with the compound.

Daily oral administration of compound 80 caused a dose-dependent inhibition of A431 tumor growth when treatment was initiated after tumors had grown to a size of 400 mm³. Statistically significant (P<0.05) inhibition of tumor growth was seen at doses of 40 mg/kg/day (74% inhibition) and 80 mg/kg/day (84% inhibition) (see Table 6). In preliminary experiments, a higher (160 mg/kg/day) dose of the compound was not more efficacious against established A431 tumors than the 80 mg/kg/day dose. In addition, mice treated at the 160 mg/kg/day dose of the compound lost body weight, indicating that the higher dose was not as well tolerated. Similar results were obtained in an experiment in which A431 tumors were only allowed to reach 100 mm³ in size (see Table 5). In this second experiment, complete regression of the tumors occurred in six of the eight animals treated at the 80 mg/kg/day for 21 days. In these six animals, the tumors did not regrow during a 110-day observation period following the end of treatment. In the two animals in which the tumors regrew to a large size (2000–3000 mm³), the tumors regressed in response to a second round of treatment with compound 80. Importantly, in all efficacy experiments, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) at 80 mg/kg/day has been well tolerated, even when dosed continuously for more than 100 days.

TABLE 6

Initial Tumor Volume (mm ³)	Compound ¹ (mg/kg/day)	% Inhibition (day)	P-Value
400	80	84 (36)	0.001
	40	74 (36)	0.003
	20	51 (36)	0.130
	80	93 (40)	0.002
	40	75 (40)	0.015
	10	61 (40)	0.059

¹Compound 80.

Briefly, the results shown in Table 6 were obtained using A431 cells (0.5×10⁶ cells/mouse) which were implanted SC into the hindflank region of athymic mice. Daily oral administration of 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) in a Cremophore-based vehicle or vehicle control began when tumors reached the indicated average volume. Tumors were measured using vernier calipers and tumor volume was calculated as the product of length×width×height. P-values were calculated by comparing the size of the tumors for animals that were treated with compound 80 (n=8) to those of animals that were treated with a vehicle (n=16) on the last day of the experiment, using the two-tailed Student's t-test.

The efficacy compound 80 against established human tumors of different origins was determined using Colo205 (colon carcinoma), SF763T (glioma), and NCI-H460 (non-small cell lung carcinoma) xenografts (see Table 7). These experiments were conducted using 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) administered orally at 80 mg/kg/day; a dose that was effective and well tolerated.

TABLE 7

	Tumor Type	Initial Tumor Volume (mm ³)	% Inhibition (day)	P-Value
5	A431 ¹	Epidermoid	100	93 (40)
	A431 ¹	Epidermoid	400	84 (36)
	Colo205	Colon	370	77 (54)
	NCI-H460	Lung	300	61 (54)
	SF763T	Glioma	550	53 (30)
				0.001

¹Data are from experiment reported in Table 5.

In the abovementioned experiments, compound 80 was administered once daily at 80 mg/kg in a Cremophor-based vehicle once tumors reached the indicated size. Percent inhibition compared to the vehicle-treated control group was calculated at termination of the experiments. P-values were calculated by comparing tumor sizes of the animals that had been treated with the compound to tumor sizes of those animals that had been treated with the vehicle, using the two-tailed Student's t-test.

Although 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide (Compound 80) inhibited the growth of all the tumor types shown in Table 7, there was a difference in the response of the different xenograft models. Specifically, the growth of NCI-H460 and SF763T tumors was arrested or greatly slowed whereas the Colo205 tumors, like A431 tumors, regressed when treated with 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide.

In order to determine the molecular basis for the difference in response between xenograft models, the SF763T tumors were studied. Therefore, SF763T tumors, which were less responsive to treatment with 5-(5-Fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)amide, have been evaluated at the molecular level using immunohistological techniques to determine the effect of treatment with the compound. These studies were initially conducted in this tumor type because SF763T tumors are highly vascularized with microvessels that strongly express the endothelial cell marker CD31 and are hence well suited for studies of tumor microvessel density (MVD). Immunohistological evaluation of SF763T tumors indicated that tumors from treated animals had reduced MVD relative to vehicle-treated controls, consistent with an anti-angiogenic mechanism of action for compound 80; MVD was 24.2±4.1 in animals treated with compound 80, compared to 39.3±5.7 for those that were treated with just the vehicle. As anticipated from the associated tumor growth arrest, a pronounced inhibition of tumor cell proliferation was evident in tumors that were treated with compound 80. These tumors had half the mitotic index of those in vehicle-treated tumors (data not shown). The effect compound 80 on MVD and tumor cell proliferation indicates that the compound has profound anti-angiogenic and anti-tumor effects, even under conditions in which tumors do not regress.

The ability of compound 80 to inhibit PDGFR phosphorylation and subsequent signaling in vivo was also evaluated in the SF763T tumors, which express high levels of PDGFR β . Treatment of the SF763T tumors with compound 80 strongly inhibited PDGFR β tyrosine phosphorylation in established SF763T tumors. Compound 80 also reduced the levels of phosphorylated (activated) phospholipase C gamma (PLC- γ), an immediate downstream indicator of

245

PDGFR activation. These data demonstrate that oral administration of compound 80 causes a direct effect on target (PDGFR) activity in tumors *in vivo*.

Based on the demonstration that the ability of compound 80 to inhibit VEGF-dependent signaling in HUVECs *in vitro* was long-lasting (vide supra), the efficacy of the compound was evaluated when the compound was administered infrequently in the Colo205 tumor model. As shown in Table 8, 80 mg/kg (91% inhibition) and 40 mg/kg (84% inhibition) were efficacious when administered daily, but not when administered twice weekly. In contrast, a higher dose of compound 80 (160 mg/kg) did inhibit (52% inhibition) the growth of established Colo205 tumors when administered twice weekly, suggesting that this compound can demonstrate efficacy when administered infrequently at a higher dose. It should be noted that dosing regimens may be determined by those with ordinary skill in the art without undue experimentation.

TABLE 8

Dose (mg/kg)	Frequency	% Inhibition	P-Value
160	Twice weekly	52	0.085
	Once weekly	17	NS
80	Daily	91	0.039
	Twice weekly	19	NS
40	Once weekly	0	NS
	Daily	84	0.028
	Twice weekly	36	NS

NS: not significant (P > 0.05)

Briefly, the results shown in Table 8 were obtained using Colo205 cells (0.5×10^6 cells/mouse) that had been implanted SC into the hindflank region of athymic mice. Oral administration of compound 80 according to the indicated schedule began when tumors reached 400 mm^3 . Tumors were measured using vernier calipers and tumor volume was calculated as the product of length \times width \times height. P-values were calculated by comparing the size of the tumors for animals that were treated with compound 80 to those of animals that were treated with a vehicle on the last day of the experiment, using the two-tailed Student's t-test.

ii. Efficacy of Compound 80 in a Model of Disseminated Disease

In addition to supporting the sustained growth of solid primary tumors, angiogenesis is also an essential component supporting the development of disseminated disease due to metastasis from the primary tumor. The effect of compound 80 on the development of disseminated disease was examined in the B16-F1 mouse melanoma lung colonization model. In this model, B16-F1 cells inoculated intravenously via the tail vein of athymic mice colonize the lungs and form tumors. As shown in Table 8, oral administration of compound 80 at 80 mg/kg/day effectively reduced the burden of B16-F1 cells in the lung as evaluated by measurements of total lung weight. These data suggest that compound 80 can inhibit disseminated disease *in vivo*.

TABLE 9

	Lung Weight (g)	% Inhibition	P-Value
Vehicle	0.83 \pm 0.07	—	—
Compound ¹	0.41 \pm 0.04	50	<0.001

¹Compound 80

Briefly, the results shown in Table 9 were obtained using athymic mice that had been inoculated with B16-F1 tumor

246

cells (5×10^5 cells/mouse) via the tail vein. Mice were treated daily with orally administered compound 80 at 80 mg/kg/day (n=10) or vehicle (n=18) for 24 days after tumor cell inoculation. At the end of the treatment period, the mice were sacrificed and their lungs removed and weighed. Percent inhibition was calculated by comparing the lung weight of those animals that had been treated with compound 80, with the lung weight of the animals that had only been treated with vehicle. P-values were determined using the two-tailed Student's t-test.

D. Examples of Biological Activity.

Examples of the *in vitro* potency of compounds of this invention are shown in Table 2.

CONCLUSION

In studies to investigate the pharmacokinetic characteristics of the compounds of the preferred embodiments of the present invention it has been demonstrated that oral administration of a single dose of said compounds resulted in high oral bioavailability in mice. The good oral bioavailability and linear pharmacokinetics indicate that the compounds of the preferred embodiments of the present have favorable pharmacokinetic characteristics.

In addition, the compounds of the preferred embodiments of the present invention are potent inhibitor of the tyrosine kinase activity of the split-kinase domain RTKs Flk-1/KDR and PDGFR, which are involved in angiogenesis, and the RTK c-kit, a receptor for stem cell factor (SCF), that is involved in certain hematologic cancers. At higher concentrations, the compounds of the preferred embodiments of the present invention also inhibit the tyrosine kinase activity of FGFR-1, a third RTK involved in angiogenesis. Consistent with their biochemical activity, the compounds of the preferred embodiments of the present invention inhibit the ligand-dependent tyrosine phosphorylation of target RTKs and the *in vitro* mitogenic response of human umbilical vein endothelial cells (HUVECs) stimulated with VEGF or FGF, of PDGFR-expressing NIH-3T3 cells stimulated with PDGF, and of MO7E o acute myeloid leukemia cells stimulated with SCF. In contrast, the compounds of the preferred embodiments of the present invention do not directly inhibit the proliferation of tumor cells in complete growth medium except at concentrations 2 to 3 orders of magnitude higher than those required to inhibit the ligand-dependent mitogenic responses. In mouse xenograft studies, the compounds of the preferred embodiments of the present invention inhibited the growth of established human tumors of various origins in a dose-dependent manner and at concentrations that were well tolerated even upon extended (>100 days) dosing. At 80 mg/kg/day, the compounds of the preferred embodiments of the present invention induced regression of large established A431 and Colo205 tumors, and caused substantial growth inhibition or stasis of SF763T and NCI-H460 tumors. In mice bearing SF763T tumors, the compounds of the preferred embodiments of the present invention caused reductions in microvessel density, phosphorylation of PDGFR in the tumors, and mitotic index in the tumor cells. At this dose, the compounds of the preferred embodiments of the present invention also inhibited lung colonization by B16-F1 tumor cells in a model of tumor metastasis. Regimen studies demonstrated that the compounds of the preferred embodiments of the present invention are most efficacious when administered daily. Direct evidence of the anti-angiogenic activity of the compounds of

the preferred embodiments of the present invention was detected in SF763T tumors in which microvessel density was reduced. Direct evidence that the compounds of the preferred embodiments of the present invention inhibit PDGFR phosphorylation and signaling in vivo was also obtained in SF763T tumors.

Taken together, these data support the notion that orally administered compounds of the preferred embodiments of the present invention are anti-angiogenic agents for the treatment of cancers, including solid tumors and hematological malignancies in which angiogenesis and/or signaling through c-kit are important in the disease pathology.

It will be appreciated that the compounds, methods and pharmaceutical compositions of the present invention are effective in modulating PK activity and therefore are expected to be effective as therapeutic agents against RTK, CTK-, and STK-related disorders.

One skilled in the art would also readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent herein. The molecular complexes and the methods, procedures, treatments, molecules, specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention are defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of" and "consisting of" may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.


In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group. For example, if X is described as selected from the group consisting of bromine, chlorine, and

iodine, claims for X being bromine and claims for X being chlorine and bromine are fully described.

Other embodiments are within the following claims.

What is claimed:

1. A compound of Formula (I):



wherein:

R¹ is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, -(CO)R¹⁵, -NR¹³R¹⁴, -(CH₂)_nR¹⁶ and -C(O)NR⁸R⁹;

R² is selected from the group consisting of hydrogen, halo, alkyl, trihalomethyl, hydroxy, alkoxy, cyano, -NR¹³R¹⁴, -NR¹³C(O)R¹⁴, -C(O)R¹⁵, aryl, heteroaryl, and -S(O)₂NR¹³R¹⁴;

R³ is selected from the group consisting of hydrogen, halogen, alkyl, trihalomethyl, hydroxy, alkoxy, -(CO)R¹⁵, -NR¹³R¹⁴, aryl, heteroaryl, -NR¹³S(O)₂R¹⁴, -S(O)₂NR¹³R¹⁴, -NR¹³C(O)R¹⁴, -NR¹³C(O)OR¹⁴ and -SO₂R²⁰ (wherein R²⁰ is alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl);

R⁴ is selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy and -NR¹³R¹⁴;

R⁵ is selected from the group consisting of hydrogen and alkyl;

R⁶ is -C(O)R¹⁰ wherein R¹⁰ is -NR¹¹(CH₂)_nR¹² wherein:

R¹¹ is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and

R¹² is -NR¹³R¹⁴ or -N^{+(O)R¹³R¹⁴}

R⁷ is selected from the group consisting of hydrogen, alkyl, aryl and heteroaryl;

R⁸ and R⁹ are independently selected from the group consisting of hydrogen, alkyl and aryl;

R¹³ and R¹⁴ are independently selected from the group consisting of hydrogen, alkyl, lower alkyl substituted with hydroxy, alkylamino, cyanoalkyl, cycloalkyl, aryl and heteroaryl; or

R¹³ and R¹⁴ may combine to form a heterocyclo group;

R¹⁵ is selected from the group consisting of hydrogen, hydroxy, alkoxy and aryloxy;

R¹⁶ is selected from the group consisting of hydroxy, -C(O)R¹⁵, -NR¹³R¹⁴ and -C(O)NR¹³R¹⁴, and

r is 1, 2, 3, or 4;

or a pharmaceutically acceptable salt thereof.

2. The compound or salt of claim 1 wherein:

R⁶ is -C(O)R¹⁰ wherein R¹⁰ is -NR¹¹(CH₂)_nR¹² wherein:

R¹¹ is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and

R¹² is -NR¹³R¹⁴ wherein R¹³ and R¹⁴ are independently unsubstituted lower alkyl; and

R⁷ is selected from the group consisting of hydrogen, alkyl, aryl and heteroaryl.








3. The compound or salt of claim 1 wherein R⁶ is N-(2-dimethylaminoethyl)aminocarbonyl, N-(2-

249

diethylaminoethyl)N-methylaminocarbonyl, N-(3-dimethylaminopropyl)aminocarbonyl, N-(2-diethylaminoethyl)aminocarbonyl, N-(2-ethylaminoethyl)aminocarbonyl, N-(3-ethylaminopropyl)aminocarbonyl, or N-(3-diethylaminopropyl)aminocarbonyl.


4. The compound or salt of claim 1 wherein R^6 is N-(2-diethylaminoethyl)aminocarbonyl or N-(2-ethylaminoethyl)aminocarbonyl.

5. The compound or salt of claim 1, wherein the compound is selected from the group consisting of:




250

-continued




; and



or an L-malate salt thereof.

6. A compound of Formula (I):



wherein:

 R^1 is hydrogen; R^2 is chloro, fluoro, or bromo; R^3 is hydrogen; R^4 is hydrogen; R^5 is methyl; R^6 is $-\text{C}(\text{O})\text{R}^{10}$ wherein R^{10} is $-\text{NR}^{11}(\text{CH}_2)_n\text{R}^{12}$ wherein: R^{11} is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and R^{12} is $-\text{NR}^{13}\text{R}^{14}$ wherein R^{13} and R^{14} are independently unsubstituted lower alkyl; and R^7 is methyl.7. The compound or salt of claim 1 wherein R^6 is $-\text{COR}_{10}$ wherein R_{10} is $-\text{NR}^{11}(\text{CH}_2)_n\text{R}^{12}$ wherein: R^{11} is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and R^{12} is $-\text{NR}^{13}\text{R}^{14}$ wherein R^{13} and R^{14} combine to form a group selected from $-(\text{CH}_2)_4-$, $-(\text{CH}_2)_5-$, $-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-$ and $-(\text{CH}_2)_2\text{N}(\text{CH}_3)(\text{CH}_2)_2-$.8. The compound or salt of claim 1 wherein R_6 is 3-pyrrolidin-1-ylpropylaminocarbonyl, 3-morpholin-4-

251

ylpropylamino-carbonyl, 2-pyrrolidin-1-ylethylamino-carbonyl, 2-morpholin-4-ylethylaminocarbonyl, 2-(4-methylpiperazin-1-yl)ethyl-aminocarbonyl, 2-(3,5-dimethylpiperazin-1-yl)ethyl-aminocarbonyl, 3-(4-methylpiperazin-1-yl)propylamino-carbonyl or 3-(3,5-dimethylpiperazin-1-yl)propylamino-carbonyl.

9. The compound or salt of claim 1 wherein R_6 is $-\text{COR}^{10}$ wherein R_{10} is $-\text{NR}_{13}\text{R}_{14}$ wherein R_{13} is hydrogen and R_{14} is lower alkyl substituted with hydroxy, aryl, heteroalicyclic, heteroaryl, or carboxy.

10. The compound or salt of claim 1 wherein R^6 is $-\text{COR}^{10}$ wherein R^{10} is $-\text{NR}^{11}(\text{CH}_2)_n\text{R}^{12}$ wherein:

R^{11} is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and

R^{12} is $-\text{NR}^{13}\text{R}^{14}$ wherein R^{13} and R^{14} together combine to form a heterocycle.

11. The compound or salt of claim 1 wherein R^6 is $-\text{COR}^{10}$ wherein R^{10} is $-\text{NR}^{11}(\text{CH}_2)_n\text{R}^{12}$ wherein:

R^{11} is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and

R^{12} is $-\text{NR}^{13}\text{R}^{14}$ wherein R^{13} and R^{14} together combine to form a 5, 6 or 7 atom heterocycle containing a carbonyl group and one or two nitrogen atoms within the ring.

12. The compound or salt of claim 1 wherein R^6 is 2-(3-oxopiperazin-1-yl)ethylaminocarbonyl, 2-(imidazolidin-1-yl-2-one)ethylaminocarbonyl, 2-(tetrahydropyrimidin-1-yl-2-one)ethylaminocarbonyl, 2-(2-oxopyrrolidin-1-yl)-ethylaminocarbonyl, 3-(3-oxopiperazin-1-yl)propylaminocarbonyl, 3-(imidazolidin-1-yl-2-one)propyl-aminocarbonyl, 3-(tetrahydropyrimidin-1-yl-2-one)-propylaminocarbonyl, or 3-(2-oxopyrrolidin-1-yl)propyl-aminocarbonyl.

13. The compound or salt of claim 1 wherein:

R^1 is hydrogen;

R^2 is hydrogen, cyano, fluoro, chloro, or bromo;

R^3 is phenyl; and

R^4 is hydrogen.

14. The compound or salt of claim 1 wherein:

R^1 is hydrogen, unsubstituted lower alkyl, $-\text{C}(\text{O})\text{NR}^8\text{R}^9$, unsubstituted cycloalkyl or aryl;

R^2 is hydrogen, halo, lower alkoxy, cyano, aryl or $-\text{S}(\text{O})_2\text{NR}^{13}\text{R}^{14}$ wherein R^{13} is hydrogen and R^{14} is hydrogen, aryl or alkyl;

R^3 is selected from the group consisting of hydrogen, lower alkoxy, $-\text{C}(\text{O})\text{R}^{15}$, $-\text{NR}^{13}\text{C}(\text{O})\text{R}^{14}$, aryl, and heteroaryl; and

R^4 is hydrogen.

15. The compound of claim 1 wherein R^6 is $-\text{COR}^{10}$ wherein R^{10} is $-\text{NR}^{11}(\text{CH}_2)_n\text{R}^{12}$ wherein R^{12} is $-\text{N}^+(\text{O}^-)\text{R}^{13}\text{R}^{14}$ wherein R^{13} and R^{14} are independently selected from the group consisting of unsubstituted lower alkyl.

16. The compound of claim 1 wherein R^6 is 2-[$\text{N}^+(\text{O}^-)(\text{C}_2\text{H}_5)_2$]ethyl-aminocarbonyl.

17. The compound or salt of claim 1 wherein:

R^5 is selected from the group consisting of hydrogen, or methyl; and

252

R^7 is selected from the group consisting of methyl, hydrogen or phenyl.

18. The compound or salt of claim 1 wherein:

R^1 is hydrogen;

R^2 is hydrogen, cyano, chloro, fluoro, or bromo;

R^3 hydrogen; and

R^4 is hydrogen.

19. The compound or salt of claim 1 wherein:

R^1 is hydrogen;

R^2 is cyano, chloro, fluoro, or bromo;

R^3 is hydrogen; and

R^4 is hydrogen.

20. A pharmaceutical composition, comprising a compound or salt of claim 1 and, a pharmaceutically acceptable carrier or excipient.

21. A pharmaceutical composition, comprising a compound or salt of claim 5 and, a pharmaceutically acceptable carrier or excipient.

22. A method for the modulation of the catalytic activity of a protein kinase, comprising contacting said protein kinase with a compound or salt of claim 1 or 5.

23. The method of claim 22 wherein said protein kinase is selected from the group consisting of a receptor tyrosine kinase, a non-receptor tyrosine kinase and a serine-threonine kinase.

24. A method for treating or preventing a protein kinase related disorder in an organism comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound or salt of claim 20 or claim 21 and, a pharmaceutically acceptable carrier or excipient to said organism.

25. The method of claim 24 wherein said protein kinase related disorder is selected from the group consisting of a receptor tyrosine kinase related disorder, a non-receptor tyrosine kinase related disorder and a serine-threonine kinase related disorder.

26. The method of claim 24 wherein said protein kinase related disorder is selected from the group consisting of an EGFR related disorder, a PDGFR related disorder, an IGFR related disorder and a flk related disorder.

27. The method of claim 24 wherein said protein kinase related disorder is a cancer selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer.

28. The method of claim 24 wherein said protein kinase related disorder is selected from the group consisting of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, von Heppel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.

29. The method of claim 24 wherein said organism is a human.

* * * * *



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)[Assignments on the Web](#) > [Patent Query](#)**Patent Assignment Abstract of Title**

**NOTE: Results display only for issued patents and published applications.
For pending or abandoned applications please consult USPTO staff.**

Total Assignments: 1

Patent #:	6573293	Issue Dt:	06/03/2003	Application #:	09783264	Filing Dt:	02/15/2001
Publication #:	20020156292	Pub Dt:	10/24/2002				

Inventors: Peng Cho Tang, Todd A. Miller, Xiaoyuan Li, Li Sun, Shahrzad Shirazian, Chung Chen Wei et al

Title: PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS

Assignment: 1

Reel/Frame:	012310/0844	Recorded:	11/15/2001	Pages:	6
-------------	-------------	-----------	------------	--------	---

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: TANG, PENG, CHO	Exec Dt: 10/28/2001
MILLER, TODD A.	Exec Dt: 10/23/2001
LI, XIAOYUAN	Exec Dt: 10/30/2001
SUN, LI	Exec Dt: 10/22/2001
WEI, CHUNG, CHUN	Exec Dt: 10/29/2001
SHIRAZIAN, SHAHRZAD	Exec Dt: 10/30/2001
LIANG, CONGXIN	Exec Dt: 10/29/2001
VOJKOVSKY, TOMAS	Exec Dt: 10/30/2001
NEMATALLA, ASAAD S.	Exec Dt: 10/29/2001
HAWLEY, MICHAEL	Exec Dt: 10/26/2001

Assignees: SUGEN, INC.
230 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CALIFORNIA 94080
PHARMACIA & UPJOHN COMPANY
301 HENRIETTA STREET
KALAMAZOO, MICHIGAN 49001

Correspondent: FOLEY & LARDNER
BETH A. BURROUS
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-5109

Search Results as of: 07/10/2009 09:59 AM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350.
Web interface last modified: October 18, 2008 v.2.0.2

[HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)

[Assignments on the Web](#) > [Patent Query](#)

Patent Assignment Details

NOTE: Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Reel/Frame: 012310/0844

Pages: 6

Recorded: 11/15/2001

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Total properties: 1

1	Patent #: 6573293	Issue Dt: 06/03/2003	Application #: 09783264	Filing Dt: 02/15/2001
	Publication #: US20020156292	Pub Dt: 10/24/2002		

Title: PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS

Assignors

1	TANG, PENG CHO	Exec Dt: 10/28/2001
2	MILLER, TODD A.	Exec Dt: 10/23/2001
3	LI, XIAOYUAN	Exec Dt: 10/30/2001
4	SUN, LI	Exec Dt: 10/22/2001
5	WEI, CHUNG CHUN	Exec Dt: 10/29/2001
6	SHIRAZIAN, SHAHRZAD	Exec Dt: 10/30/2001
7	LIANG, CONGXIN	Exec Dt: 10/29/2001
8	VOJKOVSKY, TOMAS	Exec Dt: 10/30/2001
9	NEMATALLA, ASAAD S.	Exec Dt: 10/29/2001
10	HAWLEY, MICHAEL	Exec Dt: 10/26/2001

Assignees

1	SUGEN, INC. 230 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CALIFORNIA 94080
2	PHARMACIA & UPJOHN COMPANY 301 HENRIETTA STREET KALAMAZOO, MICHIGAN 49001

Correspondence name and address


FOLEY & LARDNER
BETH A. BURROUS
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-5109

Search Results as of: 07/10/2009 10:00 AM

If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350.

Web interface last modified: October 18, 2008 v.2.0.2

[HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)



JANUARY 16, 2002

PTAS

Under Secretary of Commerce For Intellectual Property and
Director of the United States Patent and Trademark Office
Washington, DC 20231
www.uspto.gov

FOLEY & LARDNER
BETH A. BURROUS
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 500
WASHINGTON, D.C. 20007-5109



101899927A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF
THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS
AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER
REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE
INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA
PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD
FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY
CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723.
PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE,
ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY,
SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 11/15/2001

REEL/FRAME: 012310/0844
NUMBER OF PAGES: 6

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

TANG, PENG CHO

DOC DATE: 10/28/2001

ASSIGNOR:

MILLER, TODD A.

DOC DATE: 10/23/2001

ASSIGNOR:

LI, XIAOYUAN

DOC DATE: 10/30/2001

ASSIGNOR:

SUN, LI

DOC DATE: 10/22/2001

ASSIGNOR:

WEI, CHUNG CHUN

DOC DATE: 10/29/2001

ASSIGNOR:

SHIRAZIAN, SHAHZAD

DOC DATE: 10/30/2001

ASSIGNOR:

LIANG, CONGXIN

DOC DATE: 10/29/2001

012310/0844 PAGE 2

ASSIGNOR:
VOJKOVSKY, TOMAS

DOC DATE: 10/30/2001

ASSIGNOR:
NEMATALLA, ASAAD S.

DOC DATE: 10/29/2001

ASSIGNOR:
HAWLEY, MICHAEL

DOC DATE: 10/26/2001

ASSIGNEE:
SUGEN, INC.
230 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CALIFORNIA

94080-4811

ASSIGNEE:
PHARMACIA & UPJOHN COMPANY
301 HENRIETTA STREET
KALAMAZOO, MICHIGAN 49001

SERIAL NUMBER: 09783264
PATENT NUMBER:

FILING DATE: 02/15/2001
ISSUE DATE:

PEARLENE FOSTER, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

11-21-2001

Atty. Dkt. No. 038602-1086

FORM PTO-1595 (modified)

(Rev. 6-93)

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

FIR SHEET

101899927

To the Director of the United States Patent and Trademark Office: Please record the attached original documents or copies thereof.

1. Name of conveying party(ies):

Peng Cho Tang 10/28/01
 Todd A. Miller 10/23/01
 Xiaoyuan Li 10/30/01
 Li Sun 10/22/01
 Chung Chun Wei 10/29/01
 Shahrzad Shirazian 10/30/01
 Congxin Liang 10/29/01
 Tomas Vojkovsky 10/30/01
 Asaad S. Nematalla 10/29/01
 Michael Hawley 10/26/01

Additional conveying party(ies) NO

NOV 15 2001
PATENT & TRADEMARK OFFICE

2. Name and address of receiving party(ies):

11/15/01

SUGEN, Inc.
 230 East Grand Avenue
 South San Francisco, CA 94080-4811

Pharmacia & Upjohn Company
 301 Henrietta Street
 Kalamazoo, MI 49001

3. Nature of conveyance:

ASSIGNMENT

Execution Date: Listed Above

Additional name(s) & address(es) attached? NO

4. Application number(s) or patent number(s):

If this is being filed together with a new application, the execution date of the application is:

A. Patent Application Number(s):

09/783,264

B. Patent Number(s):

Additional numbers attached? NO

5. Name and address of party to whom correspondence concerning document should be mailed:

Beth A. Burrous
 FOLEY & LARDNER
 Washington Harbour
 3000 K Street, N.W., Suite 500
 Washington, D.C. 20007-5109

6. Total number of applications/patents involved: 1

7. Total fee (37 C.F.R. § 3.41): \$40.00

 Check Enclosed

Charge to deposit account

8. Deposit account number: 19-0741

DO NOT USE THIS SPACE

9. Statement and signature:

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. The Commissioner is hereby authorized to charge any additional recordation fees which may be required in this matter to the above identified deposit account.

Beth A. Burrous

Name of person signing

Signature

Date

11/18/01

Total number of pages including cover sheet, attachments, and document: 5

11/16/2001 BMGUYEN1 00000044 09783264

03 FC:581

40.00 0P

002.664064.1

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor has sold and assigned, and by these presents hereby sells and assigns, unto

SUGEN, INC.
230 East Grand Avenue
South San Francisco, California 94080-4811

its successors and assigns, the entire right, title and interest, so far as concerns the United States and the Territories and Possessions thereof and all foreign countries in and to the invention in







PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS









as set forth in this United States Patent Application

- executed concurrently herewith
- executed on _____
- Serial No. 09/783,264 filed February 15, 2001

said application for United States Letters Patent, including all divisional, renewal, substitute, continuation and Convention applications based in whole or in part upon said inventions or upon said applications, and any and all Letters Patent and reissues and extensions of Letters Patent granted for said inventions or upon said applications and every priority right that is or may be predicated upon or arise from said inventions, said applications, and said Letters Patent; said Assignee being hereby authorized to file patent applications in any or all countries on any or all said inventions in the name of the undersigned or in the name of said Assignee or otherwise as said Assignee may deem advisable, under the International Convention or otherwise; the Commissioner of Patents and Trademarks of the United States of America being hereby authorized to issue or transfer all said Letters Patent to said Assignee in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the undersigned, but also that such assigned right is not encumbered by any grant, license, or other right theretofore given, and that the undersigned will do all acts reasonably serving to ensure that the said inventions, patent applications and Letters Patent shall be held and enjoyed by said Assignee as fully and entirely as the same could have been held and enjoyed by the undersigned if this assignment had not been made, and particularly to execute and deliver to said Assignee all lawful documents including petitions, specifications, oaths, assignments, invention disclaimers, and lawful affidavits in form and substance which may be requested by said Assignee, to furnish said Assignee with all facts relating to said inventions or the history thereof and any and all documents, photographs, models, samples or other physical exhibits which may be of said inventions, and to testify in any proceedings relating to said inventions, patent applications and Letters Patent.

The undersigned hereby grant the firm of FOLEY & LARDNER the power to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.




NAMES AND SIGNATURES OF INVENTORS		
Name: Peng Cho TANG	Signature: 	Date: 10/28/01
Name: Todd A. MILLER	Signature:	Date:
Name: Xiaoyuan LI	Signature: 	Date: 10/30/01
Name: Li SUN	Signature: 	Date: 10/22/01
Name: Chung Chen WEI	Signature: 	Date: 10/29/01
Name: Shahrzad SHIRAZIAN	Signature: 	Date: 10/30/01
Name: Congxin LIANG	Signature: 	Date: 10/29/01
Name: Tomas VOJKOVSKY	Signature: 	Date: 10/30/01
Name: Asaad S. NEMATALLA	Signature: 	Date: 10/29/01
Name:	Signature:	Date:

NAMES AND SIGNATURES OF WITNESSES		
Name: MARYJANE NICOLAS-CARRION	Signature: 	Date: 10/25/01
Name:	Signature:	Date:
Name: MARYJANE NICOLAS-CARRION	Signature: 	Date: 10/30/01
Name: MARYJANE NICOLAS-CARRION	Signature: 	Date: 10/22/01
Name: MARYJANE NICOLAS-CARRION	Signature: 	Date: 10/29/01
Name: MARYJANE NICOLAS-CARRION	Signature: 	Date: 10/30/01
Name: MARYJANE NICOLAS-CARRION	Signature: 	Date: 10/29/01
Name: MARYJANE NICOLAS-CARRION	Signature: 	Date: 10/30/01
Name: MARYJANE NICOLAS-CARRION	Signature: 	Date: 10/29/01
Name:	Signature:	Date:

Note: *Prima facie evidence of execution may optionally be obtained by execution of this document before a U.S. Consul or before a local officer authorized to administer oaths whose authority is proved by a certificate from a U.S. Consul.*

IPT-407:4/90(1)(modified)

The undersigned hereby grant the firm of FOLEY & LARDNER the power to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

NAMES AND SIGNATURES OF INVENTORS		
Name: Peng Cho TANG	Signature: 	Date:
Name: Todd A. MILLER	Signature: 	Date: 10/23/01
Name: Xiaoyuan LI	Signature:	Date:
Name: Li SUN	Signature:	Date:
Name: Chung Chen WEI	Signature:	Date:
Name: Shahrzad SHIRAZIAN	Signature:	Date:
Name: Congxin LIANG	Signature:	Date:
Name: Tomas VOJKOVSKY	Signature:	Date:
Name: Asaad S. NEMATALLA	Signature:	Date:
Name:	Signature:	Date:
NAMES AND SIGNATURES OF WITNESSES		
Name:	Signature:	Date:
Name: <u>Timothy Alexander</u>	Signature: 	Date: 10/23/01
Name:	Signature:	Date:

Note: Prima facie evidence of execution may optionally be obtained by execution of this document before a U.S. Consul or before a local officer authorized to administer oaths whose authority is proved by a certificate from a U.S. Consul.

IPT-407:4/90(1)(modified)

ASSIGNMENT - WORLDWIDE

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor has sold and assigned, and by these presents hereby sells and assigns, unto

Pharmacia & Upjohn Company
301 Henrietta Street
Kalamazoo, Michigan 49001

its successors and assigns, the entire right, title and interest, so far as concerns the United States and the Territories and Possessions thereof and all foreign countries in and to the invention in



PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS

as set forth in this United States Patent Application

- executed concurrently herewith
- executed on _____
- Serial No. 09/783,264 filed February 15, 2001

said application for United States Letters Patent, including all divisional, renewal, substitute, continuation and Convention applications based in whole or in part upon said inventions or upon said applications, and any and all Letters Patent and reissues and extensions of Letters Patent granted for said inventions or upon said applications and every priority right that is or may be predicated upon or arise from said inventions, said applications, and said Letters Patent; said Assignee being hereby authorized to file patent applications in any or all countries on any or all said inventions in the name of the undersigned or in the name of said Assignee or otherwise as said Assignee may deem advisable, under the International Convention or otherwise; the Commissioner of Patents and Trademarks of the United States of America being hereby authorized to issue or transfer all said Letters Patent to said Assignee in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the undersigned, but also that such assigned right is not encumbered by any grant, license, or other right theretofore given, and that the undersigned will do all acts reasonably serving to ensure that the said inventions, patent applications and Letters Patent shall be held and enjoyed by said Assignee as fully and entirely as the same could have been held and enjoyed by the undersigned if this assignment had not been made, and particularly to execute and deliver to said Assignee all lawful documents including petitions, specifications, oaths, assignments, invention disclaimers, and lawful affidavits in form and substance which may be requested by said Assignee, to furnish said Assignee with all facts relating to said inventions or the history thereof and any and all documents, photographs, models, samples or other physical exhibits which may be of said inventions, and to testify in any proceedings relating to said inventions, patent applications and Letters Patent.

The undersigned hereby grant the firm of FOLEY & LARDNER the power to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

NAMES AND SIGNATURES OF INVENTORS		
Name: Michael HAWLEY	Signature: 	Date: 24 October 2001
Name:	Signature:	Date:
NAMES AND SIGNATURES OF WITNESSES		
Name: Debra J. Marquette	Signature: 	Date: 26 October, 2001
Name:	Signature:	Date:

Note: Prima facie evidence of execution may optionally be obtained by execution of this document before a U.S. Consul or before a local officer authorized to administer oaths whose authority is proved by a certificate from a U.S. Consul.


IPT-407:4/90(1)(modified)

Delaware

C
PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE DO HEREBY CERTIFY THAT THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF CONVERSION OF A DELAWARE CORPORATION UNDER THE NAME OF "PHARMACIA & UPJOHN COMPANY" TO A DELAWARE LIMITED LIABILITY COMPANY, CHANGING ITS NAME FROM "PHARMACIA & UPJOHN COMPANY" TO "PHARMACIA & UPJOHN COMPANY LLC", FILED IN THIS OFFICE ON THE THIRTEENTH DAY OF AUGUST, A.D. 2004, AT 12:48 O'CLOCK P.M.



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

0527510 8100V
040594300

AUTHENTICATION: 3294450

DATE: 08-13-04

CERTIFICATE OF CONVERSION

OF

PHARMACIA & UPJOHN COMPANY

**FROM A DELAWARE CORPORATION TO A
DELAWARE LIMITED LIABILITY COMPANY**

**PURSUANT TO SECTION 18-214 OF THE DELAWARE
LIMITED LIABILITY COMPANY ACT AND SECTION 266 OF THE DELAWARE
GENERAL CORPORATION LAW**

This Certificate of Conversion of Pharmacia & Upjohn Company (the "Company") is being duly executed and filed by Charles F. Raeburn, as an authorized person.

1. The date on which the Company was first formed in the State of Delaware is September 5, 1958.
2. The name of the Company under which it was originally incorporated was The Upjohn Company of Delaware, Inc., and its name immediately prior to filing this Certificate of Conversion is Pharmacia & Upjohn Company.
3. The name of the Company as set forth in its Certificate of Formation filed concurrently herewith is Pharmacia & Upjohn Company LLC.
4. The conversion has been approved in accordance with the provisions of Section 18-214(h) of the Delaware Limited Liability Company Act and Section 266(b) of the Delaware General Corporation Law.

/s/ Charles F. Raeburn

Name: Charles F. Raeburn
Vice President

Dated: August 13, 2004

PFIZER INC.


ASSISTANT SECRETARY'S CERTIFICATE

I, Rosemary Kenney, Assistant Secretary of Pfizer Inc., a corporation organized and existing under the laws of the State of Delaware, U.S.A., (the "Corporation") DO HEREBY CERTIFY that as such I am authorized to execute and deliver this Certificate on behalf of the Corporation, and do further certify that the following companies are indirectly wholly-owned subsidiaries of Pfizer Inc.:

Sugen, Inc.
Pharmacia & Upjohn Company LLC

IN WITNESS WHEREOF, I have executed this Certificate on behalf of the Corporation on this 14 day of July, 2009.


PFIZER INC.


Rosemary Kenney
Assistant Secretary

Country of U.S.A.
State of New York)
County of New York) ss.:

Sworn to and subscribed before me
This 14 day of July, 2009

Susan E. Grant
Notary





UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Customer No 000000

1STMT

DATE PRINTED
07/10/2009

PFIZER INC
10555 SCIENCE CENTER DRIVE
SAN DIEGO CA 92121

MAINTENANCE FEE STATEMENT

According to the records of the U.S. Patent and Trademark Office (USPTO), the maintenance fee and any necessary surcharge have been timely paid for the patent listed below. The "PYMT DATE" column indicates the payment date (i.e., the date the payment was filed).

The payment shown below is subject to actual collection. If the payment is refused or charged back by a financial institution, the payment will be void and the maintenance fee and any necessary surcharge unpaid.

Direct any questions about this statement to: Mail Stop M Correspondence, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT NUMBER	FEE AMT	SUR CHARGE	PYMT DATE	U.S. APPLICATION NUMBER	PATENT ISSUE DATE	APPL. FILING DATE	PAYMENT YEAR	SMALL ENTITY?	ATTY DKT NUMBER
6,573,293	\$900.00	\$0.00	11/16/06	09/783,264	06/03/03	02/15/01	04	NO	PC23522A

Patent Bibliographic Data		07/10/2009 11:00 AM		
Patent Number:	6573293	Application Number:	09783264	
Issue Date:	06/03/2003	Filing Date:	02/15/2001	
Title:	PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS			
Status:	8th year fee window opens: 06/03/2010		Entity:	Large
Window Opens:	06/03/2010	Surcharge Date:	12/06/2010	Expiration:
Fee Amt Due:	Window not open	Surchg Amt Due:	Window not open	Total Amt Due: Window not open
Fee Code:	1552	MAINTENANCE FEE DUE AT 7.5 YEARS		
Surcharge Fee Code:				
Most recent events (up to 7):	11/16/2006	Payment of Maintenance Fee, 4th Year, Large Entity. --- End of Maintenance History ---		
Address for fee purposes:	PFIZER INC 10555 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121			

Chronology of Review of PALLADIA (toceranib phosphate) Tablets File for Dogs (INAD 10-910; NADA 141-295):

File Section	Source	Date	Description	Time Lapse (Days)
INAD Request				
INAD	P&U	8/27/2001	Original request to open INAD	
INAD	CVM A0000, Z0001	11/23/2001	CVM assigned file numbers for INAD	88
Development Plan Concurrence				
DP	P&U	9/21/2001	Sponsor's Request for Meeting	
DP	CVM A000 Z0001	11/23/2001	CVM's MOC of 15 October 2001 meeting	63
DP	P&U	10/18/2005	Submission of meeting request to discuss current status of development of PHA-291639E	
DP	CVM Z0130	12/25/2005	CVM provides MOC of meeting from 18 NOV2005 concerning the development of PHA-291639E	68
Safety				
TAS Margin of Safety	P&U	12/20/2005	Submission of a meeting request to discuss TAS study protocol	
TAS Margin of Safety	P&U	1/10/2006	Submission of an amended meeting request to review TAS study protocol outline and obtain CVM concurrence on the study design	

TAS MOS	CVM Z-0132	3/16/2006	CVM provides MOC summarizing the meeting held on 09 February 2006 regarding the basic study design and duration of the TAS (MOS) study	86
TAS MOS	P&U	4/11/2006	P&U submits request for a review of Pivotal TAS, MOS protocol (1462N-60-05-725)	
TAS MOS	CVM E-0135	6/15/2006	CVM does not concur with MOS protocol (1462N-60-05-725)	65
TAS MOS	P&U	6/21/2006	Submission of the Revised MOS Protocol (1462N-60-05-725)	
TAS MOS	CVM E-0137	8/3/2006	CVM provides concurrence on the MOS protocol (1462N-60-05-725)	43
Safety (Technical Section)	11/21/2007	P&U	P&U Submission of Target Animal Safety Technical Section for Dogs	
Safety (Technical Section)	5/16/2008	CVM P-0150-TS	CVM considers the TAS Technical Section to be complete for the purpose of recommending approval of a New Animal Drug Application	177
Efficacy				
Efficacy Clinical Field Trial Protocol	P&U	6/28/2002	Request review of the FSE protocol (2060-8625-O-PBM-2002-001)	
Efficacy Clinical Field Trial Protocol	P&U	10/15/2002	Submission of an amendment to the FSE protocol (2060-8625-O-PBM-2002-001)	
Efficacy Clinical Field Trial Protocol	CVM E0006	11/18/2002	CVM does not concur with submitted FSE protocol and provides comments	143

Efficacy Clinical Field Trial Protocol	P&U	2/20/2003	Request review of the Revised FSE Pivotal Clinical Trial Protocol 2060-8625-O-PBM-2002-001).	
Efficacy Clinical Field Trial Protocol	CVM-	3/06/2003	CVM informs P&U that they will file protocol without review as trial has begun	14
Efficacy Technical Section	P&U	3/2/2007	Submission of Effectiveness Technical Section for Palladia	
Efficacy Technical Section	CVM/ P-0142	9/17/2007	CVM completes the Effectiveness Technical Section for the treatment of Mast Cell Tumors in dogs	199
CMC				
CMC	7/21/2006	P&U	Submission of a Meeting Request for a meeting on 29 August 2006 to discuss CMC development plans	
CMC	10/6/2006	CVM Z-0138	CVM provides their MOC summarizing the meeting held on 30 August 2006 to discuss the CMC registration plan and requirement of the bioequivalence waiver for PHA-291,639E tablets for treatment of mast cell tumors in dogs	77
CMC	11/13/2006	P&U	Submission of a Response to CVM MOC dated 06OCT2006 to clarify API Registration Plan and Tablet Registration Plan	
CMC	12/12/2006	CVM Y-0140	CVM provides a revised MOC summarizing the meeting of 30August2006 where the CMC registration plan and requirements of the bioequivalence waiver was discussed	29

CMC	2/29/2008	P&U	Submission of the CMC Technical Section	
CMC	8/19/2008	CVM P-0156-MC	CVM incompletes the CMC Technical Section	172
CMC	10/31/2008	P&U	Response to CMC Technical Section incomplete letter dated 19August2008	
CMC	12/12/2008	P&U	Amendment to CMC Technical Section (Drug Product Process Validation Plan)	
CMC	2/9/2009	P&U	Amendment to CMC Technical Section (dissolution assay paddle speed)	
CMC	2/26/2009	P&U	Amendment to CMC Technical Section (physical integrity of tablets)	
CMC	3/5/2009	P&U	Amendment to CMC Technical Section (residual solvents)	
CMC	4/15/2009	CVM P-0212-MC	CVM completes CMC Technical Section for Palladia.	166
Environmental Assessment				
Environmental Assessment	Pfizer	1/17/2003	Submission requesting categorical exclusion from the requirement to prepare an Environmental Assessment (EA) or Environmental Impact Statement (EIS) for the INAD and NADA	
Environmental Assessment	CVM G0017	3/6/2003	CVM grants categorical exclusion and considers Environmental Technical Section complete.	48
All Other Information				
AOI	Pf&U	8/7/2008	P&U submits AOI minor technical section for review	

AOI	CVM M-0183-AO	8/29/2008	CVM halts review of AOI minor technical section due to incompletion of CMC TS	22
AOI	P&U	11/4/2008	Submission of updated All Other Information minor technical section	
AOI	CVM	4/29/2009	CVM considers the All Other Information Technical Section for Palladia in dogs, to be complete	176
Labeling				
Labeling	P&U	7/29/2008	Submission of Label Technical Section	
Labeling	CVM M-0181-LB	8/29/2008	CVM stops review of Labeling Technical Section because CMC is incompletely completed.	31
Labeling	P&U	7/14/2008	G submission of Human Safety section of label for review	
Labeling	CVM G-0175-OT	9/5/2008	CVM comments to the package insert and owner information sheet submitted by Pfizer on 14 July 2008	53
Labeling	P&U	11/5/2008	Submission of Label Technical Section	
Labeling	P&U	11/18/2008	Submission of an amendment to the Label Technical Section	
Labeling	P&U	3/30/2009	Submission of an amendment to the Label Technical Section	
Labeling	P&U	4/6/2009	P&U contacts CVM to inform of minor change to product outsert for the purpose of conforming distribution statement and issue date across product information	

section and client information section				
Labeling	CVM M-0215-LB	4/17/2009	CVM considers Labeling Technical Section to be complete.	163
Administrative NADA				
NADA	Pfizer	4/22/2009	Submission of original administrative NADA	
NADA	CVM 141-295-A-0000-OT	5/22/2009	CVM approves an original new animal drug application (NADA) for PALLADIA for the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs	30